US20040043052A1 - Compositions and methods for coating medical implants - Google Patents

Compositions and methods for coating medical implants Download PDF

Info

Publication number
US20040043052A1
US20040043052A1 US10/447,309 US44730903A US2004043052A1 US 20040043052 A1 US20040043052 A1 US 20040043052A1 US 44730903 A US44730903 A US 44730903A US 2004043052 A1 US2004043052 A1 US 2004043052A1
Authority
US
United States
Prior art keywords
drug
polymer
fluorouracil
doxorubicin
fluoropyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/447,309
Inventor
William Hunter
David Gravett
Philip Toleikis
Richard Liggins
Troy Loss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiotech International AG
Original Assignee
Angiotech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29584566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040043052(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/447,309 priority Critical patent/US20040043052A1/en
Application filed by Angiotech Pharmaceuticals Inc filed Critical Angiotech Pharmaceuticals Inc
Assigned to ANGIOTECH PHARMACEUTICALS, INC. reassignment ANGIOTECH PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRAVETT, DAVID M., HUNTER, WILLIAM L., LIGGINS, RICHARD T., LOSS, TROY A. E., TOLEIKIS, PHILIP M.
Assigned to ANGIOTECH INTERNATIONAL GMBH reassignment ANGIOTECH INTERNATIONAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANGIOTECH PHARMACEUTICALS, INC.
Publication of US20040043052A1 publication Critical patent/US20040043052A1/en
Assigned to ANGIOTECH INTERNATIONAL AG reassignment ANGIOTECH INTERNATIONAL AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ANGIOTECH INTERNATIONAL GMBH
Assigned to ANGIOTECH INTERNATIONAL AG reassignment ANGIOTECH INTERNATIONAL AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ANGIOTECH INTERNATIONAL GMBH
Assigned to ANGIOTECH INTERNATIONAL AG reassignment ANGIOTECH INTERNATIONAL AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANGIOTECH PHARMACEUTICALS, INC.
Priority to US11/343,714 priority patent/US20060127438A1/en
Priority to US11/888,624 priority patent/US20080113000A1/en
Priority to US11/888,674 priority patent/US20080089952A1/en
Priority to US11/888,511 priority patent/US20070270447A1/en
Priority to US11/888,615 priority patent/US20080145514A1/en
Priority to US12/035,772 priority patent/US20080241217A1/en
Priority to US12/107,629 priority patent/US8313760B2/en
Priority to US12/553,744 priority patent/US8372420B2/en
Priority to US12/939,565 priority patent/US8425927B2/en
Priority to US13/663,254 priority patent/US20130115263A1/en
Priority to US13/846,396 priority patent/US20130224276A1/en
Priority to US14/334,326 priority patent/US20140328891A1/en
Assigned to CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT reassignment CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANGIOTECH PHARMACEUTICALS, INC.
Assigned to ANGIOTECH PHARMACEUTICALS, INC. reassignment ANGIOTECH PHARMACEUTICALS, INC. RELEASE OF SECURITY INTEREST : RECORDED AT REEL/FRAME - 049288/0184 Assignors: CAPITAL ONE, NATIONAL ASSOCIATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/085Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Definitions

  • the present invention relates generally to pharmaceutical compositions, methods, and devices, and more specifically, to compositions and methods which reduce the likelihood of an infection associated with a medical implant.
  • Infections associated with medical implants represent a major healthcare problem. For example, 5% of patients admitted to an acute care facility develop a hospital acquired infection. Hospital acquired infections (nosocomial infections) are the 11 th leading cause of death in the US and cost over $2 billion annually. Nosocomial infections directly cause 19,000 deaths per year in the US and contribute to over 58,000 others.
  • nosocomial infections The four most common causes of nosocomial infections are: urinary tract infection (28%); surgical site infection (19%); respiratory tract infection (17%); and bloodstream infection (16% and rising). A significant percentage of these infections are related to bacterial colonization of implanted medical implants such as Foley catheters (urinary tract infections); surgical drains, meshes, sutures, artificial joints, vascular grafts (wound infections); endotracheal and tracheostomy tubes (respiratory tract infection); and vascular infusion catheters (bloodstream infections). Although any infectious agent can infect medical implant, Staphylococci ( S. aureus, S. epidermidis, S. pyogenes ), Enterococci ( E.
  • Staphylococci S. aureus, S. epidermidis, S. pyogenes
  • Enterococci E.
  • One difficulty with these devices is that they can become colonized by bacteria resistant to the antibiotic coating. This can result in at least two distinct clinical problems.
  • the device serves as a source of infection in the body with the resulting development of a local or disseminated infection.
  • an infection develops, it cannot be treated with the antibiotic(s) used in the device coating.
  • the development of antibiotic-resistant strains of microbes remains a significant healthcare problem, not just for the infected patient, but also for the healthcare institution in which it develops.
  • FIG. 1 shows the effect of palmitic acid on the release profile of 5-fluorouracil from a polyurethane sample.
  • the present invention provides compositions and methods for preventing, reducing or inhibiting the likelihood of infections associated with medical implants. More specifically, within one aspect of the invention medical implants or devices are provided which release a chemotherapeutic agent, wherein the chemotherapeutic agent reduces, inhibits, or prevents the growth or transmission of foreign organisms (e.g., bacteria, fungi, or viruses) which are on or are associated with the medical device or implant. For example, within one aspect of the invention medical implant or devices are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. Within various embodiments, the implant is coated in whole or in part with a composition comprising an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • a composition comprising an anthracycline, fluoropyrimidine, folic
  • kits for making medical implants comprising adapting a medical implant (e.g., coating the implant) with an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • a medical implant e.g., coating the implant
  • an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex e.g., the desired therapeutic agent is coated on and/or released from the medical implant at a dosage and/or concentration which is less than the typical dosage and/or concentration of the agent when used in the treatment of cancer.
  • a wide variety of medical implants can be generated using the methods provided herein, including for example, catheters (e.g., vascular and dialysis catheters), heart valves, cardiac pacemakers, implantable cardioverter defibrillators, grafts (e.g., vascular grafts), ear, nose, or throat implants, urological implants, endotracheal or tracheostomy tubes, CNS shunts, orthopedic implants, and ocular implants.
  • catheters e.g., vascular and dialysis catheters
  • cardiac pacemakers implantable cardioverter defibrillators
  • grafts e.g., vascular grafts
  • ear, nose, or throat implants urological implants
  • endotracheal or tracheostomy tubes e.g., vascular grafts
  • CNS shunts e.g., vascular and dialysis catheters
  • orthopedic implants e.g., ocular implants.
  • the catheter e.g., vascular and dialysis catheters
  • heart valve cardiac pacemaker
  • implantable cardioverter defibrillator graft (e.g., vascular grafts), ear, nose, or throat implant
  • urological implant endotracheal or tracheostomy tube
  • CNS shunt orthopedic implant
  • ocular implant releases a fluoropyrimide (e.g., 5-FU) at a dosage and/or concentration which is less than a typical dosage and/or concentration which is used for the treatment of cancer.
  • fluoropyrimide e.g., 5-FU
  • a catheter which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the catheter releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the catheter further comprises a polymer wherein the agent is released from a polymer on the catheter.
  • the catheter has a polymer that is polyurethane or poly(lactide-co-glycolide) (PLG).
  • the catheter is a vascular catheter or a dialysis catheter.
  • the catheter relaeases an agent that is present on the catheter at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a heart valve which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the heart valve releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the heart valve further comprises a polymer wherein the agent is released from a polymer on the heart valve.
  • the heart valve has a polymer that is polyurethane or PLG.
  • the heart valve is a prosthetic heart valve.
  • the heart valve relaeases an agent that is present on the heart valve at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a cardiac pacemaker which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the cardiac pacemaker releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the cardiac pacemaker further comprises a polymer wherein the agent is released from a polymer on the cardiac pacemaker.
  • the cardiac pacemaker has a polymer that is polyurethane or PLG.
  • the cardiac pacemaker relaeases an agent that is present on the cardiac pacemaker at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a implantable cardioverter defibrillator which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the implantable cardioverter defibrillator releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the implantable cardioverter defibrillator further comprises a polymer wherein the agent is released from a polymer on the implantable cardioverter defibrillator.
  • the implantable cardioverter defibrillator has a polymer that is polyurethane or PLG. In still other embodiments, the implantable cardioverter defibrillator relaeases an agent that is present on the implantable cardioverter defibrillator at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a graft which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the graft releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the graft further comprises a polymer wherein the agent is released from a polymer on the graft.
  • the graft has a polymer that is polyurethane or PLG.
  • the graft is a vascular graft or a hemodialysis access graft.
  • the graft relaeases an agent that is present on the graft at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a ear, nose, or throat implant which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the ear, nose, or throat implant releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the ear, nose, or throat implant further comprises a polymer wherein the agent is released from a polymer on the ear, nose, or throat implant.
  • the ear, nose, or throat implant has a polymer that is polyurethane or PLG.
  • the ear, nose, or throat implant is a tympanostomy tube or a sinus stent.
  • the ear, nose, or throat implant relaeases an agent that is present on the ear, nose, or throat implant at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a urological implant which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the urological implant releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the urological implant further comprises a polymer wherein the agent is released from a polymer on the urological implant.
  • the urological implant has a polymer that is polyurethane or PLG.
  • the urological implant is a urinary catheter, ureteral stent, urethral stent, bladder sphincter, or penile implant.
  • the urological implant relaeases an agent that is present on the urological implant at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a endotracheal or tracheostomy tube which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the endotracheal or tracheostomy tube releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the endotracheal or tracheostomy tube further comprises a polymer wherein the agent is released from a polymer on the endotracheal or tracheostomy tube.
  • the endotracheal or tracheostomy tube has a polymer that is polyurethane or PLG.
  • the endotracheal or tracheostomy tube relaeases an agent that is present on the endotracheal or tracheostomy tube at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a CNS shunt which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the CNS shunt releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the CNS shunt further comprises a polymer wherein the agent is released from a polymer on the CNS shunt.
  • the CNS shunt has a polymer that is polyurethane or PLG.
  • the CNS shunt is a ventriculopleural shunt, a VA shunt, or a VP shunt.
  • the CNS shunt relaeases an agent that is present on the CNS shunt at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a orthopedic implant which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the orthopedic implant releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the orthopedic implant further comprises a polymer wherein the agent is released from a polymer on the orthopedic implant.
  • the orthopedic implant has a polymer that is polyurethane or PLG.
  • the orthopedic implant is a prosthetic joint or fixation device.
  • the orthopedic implant relaeases an agent that is present on the orthopedic implant at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • a ocular implant which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the ocular implant releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU.
  • the ocular implant further comprises a polymer wherein the agent is released from a polymer on the ocular implant.
  • the ocular implant has a polymer that is polyurethane or PLG.
  • the ocular implant is an intraocular lens or a contact lens.
  • the ocular implant relaeases an agent that is present on the ocular implant at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer.
  • compositions comprising a polymer and an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex, wherein said anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex is present in said composition at a concentration of less than any one of 10 ⁇ 4 M, 10 ⁇ 5 M, 10 ⁇ 6 M, or, 10 ⁇ 7 M.
  • Also provided methods for reducing or inhibiting infection associated with a medical implant comprising the step of introducing a medical implant into a patient which has been coated with an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
  • the anthracycline is doxorubicin or mitoxantrone
  • the fluoropyrimidine is 5-fluorouracil
  • the folic acid antagonist is methotrexate
  • the podophylotoxin is etoposide.
  • the composition further comprises a polymer.
  • Medical implant refers to devices or objects that are implanted or inserted into a body. Representative examples include vascular catheters, prosthetic heart valves, cardiac pacemakers, implantable cardioverter defibrillators, vascular grafts, ear, nose, or throat implants, urological implants, endotracheal or tracheostomy tubes, dialysis catheters, CNS shunts, orthopedic implants, and ocular implants.
  • the term “about” or “consists essentially of” refers to ⁇ 15% of any indicated structure, value, or range. Any numerical ranges recited herein are to be understood to include any integer within the range and, where applicable (e.g., concentrations), fractions thereof, such as one tenth and one hundredth of an integer (unless otherwise indicated).
  • the present invention discloses medical implants (as well as compositions and methods for making medical implants) which reduce the likelihood of infections in medical implants. More specifically, as noted above, infection is a common complication of the implantation of foreign bodies such as medical devices. Foreign materials provide an ideal site for micro-organisms to attach and colonize. It is also hypothesized that there is an impairment of host defenses to infection in the microenvironment surrounding a foreign material. These factors make medical implants particularly susceptible to infection and make eradication of such an infection difficult, if not impossible, in most cases.
  • agents also referred to herein as ‘therapeutic agents’ or ‘drugs’
  • a carrier e.g., a polymer; see section II below.
  • Anthracyclines e.g., doxorubicin and mitoxantrone
  • B Fluoropyrimidines (e.g., 5-FU)
  • C Folic acid antagonists (e.g., methotrexate)
  • D Podophylotoxins (e.g., etoposide)
  • E Camptothecins
  • F Hydroxyureas
  • G Platinum complexes (e.g., cisplatin).
  • Anthracyclines have the following general structure, where the R groups may be a variety of organic groups:
  • R 1 is CH 3 or CH 2 OH
  • R 2 is daunosamine or H
  • R 3 and R 4 are independently one of OH, NO 2 , NH 2 , F, Cl, Br, I, CN, H or groups derived from these
  • R 5 is hydrogen, hydroxy, or methoxy
  • R 6-8 are all hydrogen.
  • R 5 and R 6 are hydrogen and R 7 and R 8 are alkyl or halogen, or vice versa.
  • R 1 may be a conjugated peptide.
  • R 5 may be an ether linked alkyl group.
  • R 5 may be OH or an ether linked alkyl group.
  • R 1 may also be linked to the anthracycline ring by a group other than C(O), such as an alkyl or branched alkyl group having the C(O) linking moiety at its end, such as —CH 2 CH(CH 2 —X)C(O)—R 1 , wherein X is H or an alkyl group (see, e.g., U.S.
  • R 2 may alternately be a group linked by the functional group ⁇ N—NHC(O)—Y, where Y is a group such as a phenyl or substituted phenyl ring.
  • R 3 may have the following structure:
  • R 9 is OH either in or out of the plane of the ring, or is a second sugar moiety such as R 3 .
  • R 10 may be H or form a secondary amine with a group such as an aromatic group, saturated or partially saturated 5 or 6 membered heterocyclic having at least one ring nitrogen (see U.S. Pat. No. 5,843,903).
  • R 10 may be derived from an amino acid, having the structure —C(O)CH(NHR 11 )(R 12 ), in which R 11 is H, or forms a C 3-4 membered alkylene with R 12 .
  • R 12 may be H, alkyl, aminoalkyl, amino, hydroxy, mercapto, phenyl, benzyl or methylthio (see U.S. Pat. No. 4,296,105).
  • anthracyclines are Doxorubicin, Daunorubicin, Idarubicin, Epirubicin, Pirarubicin, Zorubicin, and Carubicin.
  • Suitable compounds have the structures: R 1 R 2 R 3 Doxorubicin: OCH 3 C(O)CH 2 OH OH out of ring plane Epirubicin: (4′ epimer of OCH 3 C(O)CH 2 OH OH in ring plane doxorubicin) Daunorubicin: OCH 3 C(O)CH 3 OH out of ring plane Idarubicin: H C(O)CH 3 OH out of ring plane Pirarubicin: OCH 3 C(O)CH 2 OH Zorubicin: OCH 3 C(CH 3 )( ⁇ N)NHC(O)C 6 H 5 OH Carubicin: OH C(O)CH 3 OH out of ring plane
  • anthracyclines are Anthramycin, Mitoxantrone, Menogaril, Nogalamycin, Aclacinomycin A, Olivomycin A, Chromomycin A 3 , and Plicamycin having the structures: R 1 R 2 R 3 Menogaril Nogallamycin H O-sugar sugar OCH 3 H H COOCH 3 R 1 R 2 R 3 R 4 Olivomycin A COCH(CH 3 ) 2 CH 3 COCH 3 H Chromomycin A 3 COCH 3 CH 3 COCH 3 CH 3 Plamycin H H H CH 3
  • anthracyclines include, FCE 23762 doxorubicin derivative (Quaglia et al., J. Liq. Chromatogr 17(18):3911-3923, 1994), annamycin (Zou et al., J. Pharm. Sci. 82(11):1151-1154, 1993), ruboxyl (Rapoport et al., J. Controlled Release 58(2): 153-162, 1999), anthracycline disaccharide doxorubicin analogue (Pratesi et al., Clin. Cancer Res.
  • deoxydihydroiodooxorubicin EPA 275966
  • adriblastin Kalishevskaya et al., Vestn. Mosk. Univ., 16(Biol. 1):21-7, 1988
  • 4′-deoxydoxorubicin Schoelzel et al., Leuk. Res. 10(12):1455-9, 1986
  • 4-demethyoxy-4′-o-methyldoxorubicin (Giuliani et al., Proc. Int. Congr. Chemother.
  • the therapeutic agent is a fluoropyrimidine analog, such as 5-fluorouracil, or an analog or derivative thereof, including Carmofur, Doxifluridine, Emitefur, Tegafur, and Floxuridine.
  • fluoropyrimidine analog such as 5-fluorouracil
  • Exemplary compounds have the structures: R 1 R 2 5-Fluorouracil H H Carmofur C(O)NH(CH 2 ) 5 CH 3 H Doxifluridine A 1 H Floxuridine A 2 H Emitefur CH 2 OCH 2 CH 3 B Tegafur C H B C
  • fluoropyrimidine analogs include 5-FudR (5-fluoro-deoxyuridine), or an analog or derivative thereof, including 5-iododeoxyuridine (5-ludR), 5-bromodeoxyuridine (5-BudR), Fluorouridine triphosphate (5-FUTP), and Fluorodeoxyuridine monophosphate (5-dFUMP).
  • 5-fluoro-deoxyuridine or an analog or derivative thereof, including 5-iododeoxyuridine (5-ludR), 5-bromodeoxyuridine (5-BudR), Fluorouridine triphosphate (5-FUTP), and Fluorodeoxyuridine monophosphate (5-dFUMP).
  • Exemplary compounds have the structures:
  • fluoropyrimidine analogs include N3-alkylated analogues of 5-fluorouracil (Kozai et al., J. Chem. Soc., Perkin Trans. 1(19):3145-3146, 1998), 5-fluorouracil derivatives with 1,4-oxaheteroepane moieties (Gomez et al., Tetrahedron 54(43):13295-13312, 1998), 5-fluorouracil and nucleoside analogues (Li, Anticancer Res.
  • the therapeutic agent is a folio acid antagonist, such as Methotrexate or derivatives or analogs thereof, including Edatrexate, Trimetrexate, Raltitrexed, Piritrexim, Denopterin, Tomudex, and Pteropterin.
  • Methotrexate analogs have the following general structure:
  • R group may be selected from organic groups, particularly those groups set forth in U.S. Pat. Nos. 5,166,149 and 5,382,582.
  • R 1 may be N
  • R 2 may be N or C(CH 3 )
  • R 3 and R 3 ′ may H or alkyl, e.g., CH 3
  • R 4 may be a single bond or NR, where R is H or alkyl group.
  • R 5,6,8 may be H, OCH 3 , or alternately they can be halogens or hydro groups.
  • R 7 is a side chain of the general structure:
  • the carboxyl groups in the side chain may be esterified or form a salt such as a Zn 2+ salt.
  • R 9 and R 10 can be NH 2 or may be alkyl substituted.
  • N-( ⁇ -aminoacyl) methotrexate derivatives Cheung et al., Pteridines 3(1-2):101-2, 1992
  • biotin methotrexate derivatives Fean et al., Pteridines 3(1-2): 131-2, 1992
  • D-glutamic acid or D-erythrou threo-4-fluoroglutamic acid methotrexate analogues
  • Pteridines Folic Acid Deriv, 1154-7, 1989)-, N-(L- ⁇ -aminoacyl) methotrexate derivatives (Cheung et al., Heterocycles 28(2):751-8, 1989), meta and ortho isomers of aminopterin (Rosowsky et al., J. Med. Chem. 32(12):2582, 1989), hydroxymethylmethotrexate (DE 267495), ⁇ -fluoromethotrexate (McGuire et al., Cancer Res. 49(16):4517-25, 1989), polyglutamyl methotrexate derivatives (Kumar et al., Cancer Res.
  • the therapeutic agent is a. Podophyllotoxin, or a derivative or an analog thereof.
  • exemplary compounds of this type are Etoposide or Teniposide, which have the following structures:
  • podophyllotoxins include Cu(II)-VP-16 (etoposide) complex (Tawa et al., Bioorg. Med. Chem. 6(7):1003-1008, 1998), pyrrolecarboxamidino-bearing etoposide analogues (Ji et al., Bioorg. Med. Chem. Lett, 7(5):607-612, 1997), 4 ⁇ -amino etoposide analogues (Hu, University of North Carolina Dissertation, 1992), ⁇ -lactone ring-modified arylamino etoposide analogues (Zhou et al., J. Med. Chem.
  • the therapeutic agent is Camptothecin, or an analog or derivative thereof.
  • Camptothecins have the following general structure.
  • X is typically O, but can be other groups, e.g., NH in the case of 21-lactam derivatives.
  • R 1 is typically H or OH, but may be other groups, e.g., a terminally hydroxylated C 1-3 alkane.
  • R 2 is typically H or an amino containing group such as (CH 3 ) 2 NHCH 2 , but may be other groups e.g., NO 2 ; NH 2 , halogen (as disclosed in, e.g., U.S. Pat. No. 5,552,156) or a short alkane containing these groups.
  • R 3 is typically H or a short alkyl such as C 2 H 5 .
  • R 4 is typically H but may be other groups, e.g., a methylenedioxy group with R 1 .
  • camptothecin compounds include topotecan, irinotecan (CPT-11), 9-aminocamptothecin, 21 -lactam-20(S)-camptothecin, 10,11-methylenedioxycamptothecin, SN-38, 9-nitrocamptothecin, 10-hydroxycamptothecin.
  • Exemplary compounds have the structures: R 1 R 2 R 3 Camptothecin: H H H Topotecan: OH (CH 3 ) 2 NHCH 2 H SN-38: OH H C 2 H 5
  • Camptothecins have the five rings shown here.
  • the ring labeled E must be intact (the lactone rather than carboxylate form) for maximum activity and minimum toxicity.
  • Camptothecins are believed to function as Topoisomerase I Inhibitors and/or DNA cleavage agents.
  • the therapeutic agent of the present invention may be a hydroxyurea.
  • Hydroxyureas have the following general structure:
  • Suitable hydroxyureas are disclosed in, for example, U.S. Pat. No. 6,080,874, wherein R 1 is:
  • R 2 is an alkyl group having 1-4 carbons and R 3 is one of H, acyl, methyl, ethyl, and mixtures thereof, such as a methylether.
  • R 1 is a cycloalkenyl group, for example N-[3-[5-(4-fluorophenylthio)-furyl]-2-cyclopenten-1-yl]N-hydroxyurea
  • R 2 is H or an alkyl group having 1 to 4 carbons and R 3 is H
  • X is H or a cation.
  • n is 0-2 and Y is an alkyl group.
  • the hydroxyurea has the structure:
  • the therapeutic agent is a platinum compound.
  • suitable platinum complexes may be of Pt(lI) or Pt(IV) and have this basic structure:
  • X and Y are anionic leaving groups such as sulfate, phosphate, carboxylate, and halogen; R 1 and R 2 are alkyl, amine, amino alkyl any may be further substituted, and are basically inert or bridging groups.
  • R 1 and R 2 are alkyl, amine, amino alkyl any may be further substituted, and are basically inert or bridging groups.
  • Z 1 and Z 2 are non-existent.
  • Z 1 and Z 2 may be anionic groups such as halogen, hydroxy, carboxylate, ester, sulfate or phosphate. See, e.g., U.S. Pat. Nos. 4,588,831 and 4,250,189.
  • Suitable platinum complexes may contain multiple Pt atoms. See, e.g., U.S. Pat. Nos. 5,409,915 and 5,380,897.
  • Exemplary platinum compounds are Cisplatin, Carboplatin, Oxaliplatin, and Miboplatin having the structures:
  • platinum compounds include (CPA) 2 Pt[DOLYM] and (DACH)Pt[DOLYM] cisplatin (Choi et al., Arch. Pharmacal Res. 22(2):151-156, 1999), Cis-[PtCl 2 (4,7-H-5-methyl-7-oxo]1,2,4[triazolo[1,5-a]pyrimidine) 2 ] (Navarro et al., J. Med. Chem. 41(3):332-338, 1998), [Pt(cis-1,4-DACH)(trans-Cl 2 )(CBDCA)] ⁇ 1 ⁇ 2MeOH cisplatin (Shamsuddin et al., Inorg. Chem.
  • therapeutic agents described herein may be formulated in a variety of manners, and thus may additionally comprise a carrier.
  • a wide variety of carriers may be selected of either polymeric or non-polymeric origin.
  • the polymers and non-polymer based carriers and formulations which are discussed in more detail below are provided merely by way of example, not by way of limitation.
  • biodegradable compositions include albumin, collagen, gelatin, chitosan, hyaluronic acid, starch, cellulose and derivatives thereof (e.g., methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate), alginates, casein, dextrans, polysaccharides, fibrinogen, poly(L-lactide), poly(D,L lactide), poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide), poly(glycolide), poly(trimethylene carbonate), poly(hydroxyvalerate), poly(hydroxybutyrate), pbly
  • nondegradable polymers include poly(ethylene-co-vinyl acetate) (“EVA”) copolymers, silicone rubber, acrylic polymers (e.g., polyacrylic acid, polymethylacrylic acid, poly(hydroxyethylmethacrylate), polymethylmethacrylate, polyalkylcyanoacrylate), polyethylene, polyproplene, polyamides (e.g., nylon 6,6), polyurethane (e.g., poly(ester urethanes), poly(ether urethanes), poly(ester-urea), poly(carbonate urethanes)), polyethers (e.g., poly(ethylene oxide), poly(propylene oxide), Pluronics and poly(tetramethylene glycol)) and vinyl polymers [e.g., polyvinylpyrrolidone, poly(vinyl alcohol), poly(vinyl acetate phthalate)].
  • EVA ethylene-co-vinyl acetate
  • silicone rubber e.g., silicone rubber, acrylic
  • Polymers may also be developed which are either anionic (e.g., alginate, carrageenin, carboxymethyl cellulose and poly(acrylic acid), or cationic (e.g., chitosan, poly-L-lysine, polyethylenimine, and poly (allyl amine)) (see generally, Dunn et al., J. Applied Polymer Sci. 50:353-365, 1993; Cascone et al., J. Materials Sci.: Materials in Medicine 5:770-774, 1994; Shiraishi et al., Biol. Pharm. Bull. 16(11):1164-1168, 1993; Thacharodi and Rao, Int'l J. Pharm.
  • anionic e.g., alginate, carrageenin, carboxymethyl cellulose and poly(acrylic acid
  • cationic e.g., chitosan, poly-L-lysine, polyethylenimine, and poly (allyl amine)
  • Particularly preferred polymeric carriers include poly(ethylene-co-vinyl acetate), polyurethane, acid, poly(caprolactone), poly(valerolactone), polyanhydrides, copolymers of poly(caprolactone) or poly(lactic acid) with a polyethylene glycol (e.g., MePEG), and blends thereof.
  • polyethylene glycol e.g., MePEG
  • Other representative polymers include carboxylic polymers, polyacetates, polyacrylamides, polycarbonates, polyethers, polyesters, polyethylenes, polyvinylbutyrals, polysilanes, polyureas, polyurethanes, polyoxides, polystyrenes, polysulfides, polysulfones, polysulfonides, polyvinylhalides, pyrrolidones, rubbers, thermal-setting polymers, cross-linkable acrylic and methacrylic polymers, ethylene acrylic acid copolymers, styrene acrylic copolymers, vinyl acetate polymers and copolymers, vinyl acetal polymers and copolymers, epoxy, melamine, other amino resins, phenolic polymers, and copolymers thereof, water-insoluble cellulose ester polymers (including cellulose acetate propionate, cellulose acetate, cellulose acetate butyrate, cellulose nitrate, cellulose acetate phthalate), water-
  • Polymers can be fashioned in a variety of forms, with desired release characteristics and/or with specific desired properties.
  • polymers can be fashioned to release a therapeutic agent upon exposure to a specific triggering event such as pH (see, e.g., Heller et al., “Chemically Self-Regulated Drug Delivery Systems,” in Polymers in Medicine III , Elsevier Science.Publishers B.V., Amsterdam, 1988, pp. 175-188; Kang et al., J. Applied Polymer Sci. 48:343-354, 1993; Dong et al., J. Controlled Release 19:171-178, 1992; Dong and Hoffman, J.
  • a specific triggering event such as pH (see, e.g., Heller et al., “Chemically Self-Regulated Drug Delivery Systems,” in Polymers in Medicine III , Elsevier Science.Publishers B.V., Amsterdam, 1988, pp. 175-188; Kang et al., J. Applied
  • pH-sensitive polymers include poly(acrylic acid)-based polymers and derivatives (including, for example, homopolymers such as poly(aminocarboxylic acid), poly(acrylic acid), poly(methyl acrylic acid), copolymers of such homopolymers, and copolymers of poly(acrylic acid) and acrylmonomers such as those discussed above).
  • pH sensitive polymers include polysaccharides such as carboxymethyl cellulose, hydroxypropylmethylcellulose phthalate, hydroxypropyl-methylcellu lose acetate succinate, cellulose acetate trimellilate, chitosan and alginates.
  • pH sensitive polymers include any mixture of a pH sensitive polymer and a water soluble polymer.
  • polymers can be fashioned which are temperature sensitive (see, e.g., Chen et al., “Novel Hydrogels of a Temperature-Sensitive Pluronic Grafted to a Bioadhesive Polyacrylic Acid Backbone for Vaginal Drug Delivery,” in Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22:167-168, Controlled Release Society, Inc., 1995; Okano, “Molecular Design of Stimuli-Responsive Hydrogels for Temporal Controlled Drug Delivery,” in Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22:111-112, Controlled Release Society, Inc., 1995; Johnston et al., Pharm. Res.
  • thermogelling polymers include homopolymers such as poly(N-methyl-N-n-propylacrylamide), poly(N-n-propylacrylamide), poly(N-methyl-N-isopropylacrylamide), poly(N-n-propylmethacrylamide), poly(N-isopropylacrylamide), poly(N,n-diethylacrylamide), poly(N-isopropylmethacrylamide), poly(N-cyclopropylacrylam ide), poly(N-ethylmethyacrylamide), poly(N-methyl-N-ethylacrylam ide), poly(N-cyclopropylmethacrylamide) and poly(N-ethylacrylamide).
  • homopolymers such as poly(N-methyl-N-n-propylacrylamide), poly(N-n-propylacrylamide), poly(N-methyl-N-isopropylacrylamide), poly(N-n-propylmethacrylamide), poly(N-isopropy
  • thermogelling polymers may be made by preparing copolymers between (among) monomers of the above, or by combining such homopolymers with other water soluble polymers such as acrylmonomers (e.g., acrylic acid and derivatives thereof such as methylacrylic acid, acrylate and derivatives thereof such as butyl methacrylate, acrylamide, and N-n-butyl acrylamide).
  • acrylmonomers e.g., acrylic acid and derivatives thereof such as methylacrylic acid, acrylate and derivatives thereof such as butyl methacrylate, acrylamide, and N-n-butyl acrylamide.
  • thermogelling cellulose ether derivatives such as hydroxypropyl cellulose, methyl cellulose, hydroxypropylmethyl cellulose, ethylhydroxyethyl cellulose, and Pluronics, such as F-127.
  • a wide variety of forms may be fashioned by the polymers of the present invention, including for example, rod-shaped devices, pellets, slabs, particulates, micelles, films, molds, sutures, threads, gels, creams, ointments, sprays or capsules (see, e.g., Goodell et al., Am. J. Hosp. Pharm. 43:1454-1461, 1986; Langer et al., “Controlled release of macromolecules from polymers”, in Biomedical Polymers, Polymeric Materials and Pharmaceuticals for Biomedical Use , Goldberg, E. P., Nakagim, A. (eds.) Academic Press, pp.113-137, 1980; Rhine et al, J.
  • Agents may be incorporated by dissolution in the polymer, occlusion in the matrices of the polymer, bound by covalent linkages, or encapsulated in microcapsules.
  • therapeutic compositions are provided in non-capsular formulations, such as coatings microspheres (ranging from nanometers to micrometers in size), pastes, threads or sutures of various size, films and sprays.
  • vitamin-based compositions e.g., based on vitamins A, D, E and/or K, see, e.g., PCT publication Nos. WO 98/30205 and WO 00/71163
  • liposomes see, U.S. Pat. Nos. 5,534,499, 5,683,715, 5,776,485, 5,882,679, 6,143,321, 6,146,659, 6,200,598, and PCT Publication Nos.
  • therapeutic compositions of the present invention are fashioned in a manner appropriate to the intended use.
  • the therapeutic composition should be biocompatible, and release one or more agents over a period of several days to months.
  • therapeutic compositions of the present invention should preferably be stable for several months and capable of being produced, and maintained under sterile conditions.
  • compositions may be fashioned in any size ranging from 50 nm to 500 ⁇ m, depending upon the particular use.
  • such compositions may also be readily applied as a “spray” which solidifies into a film or coating.
  • Such sprays may be prepared from microspheres of a wide array of sizes, including for example, from 0.1 ⁇ m to 9 ⁇ m, from 10 ⁇ m to 30 ⁇ m and from 30 ⁇ m to 100 ⁇ m.
  • compositions of the present invention may also be prepared in a variety of “paste” or gel forms.
  • therapeutic compositions are provided which are liquid at one temperature (e.g., temperature greater than 37° C.) and solid or semi-solid at another temperature (e.g., ambient body temperature, or any temperature lower than 37° C.).
  • polymers such as Pluronic F-127, which are liquid at a low temperature (e.g., 4° C.) and a gel at body temperature.
  • Such “thermopastes” may be readily made given the disclosure provided herein.
  • the therapeutic compositions of the present invention may be formed as a film.
  • films are generally less than 5, 4, 3, 2 or 1 mm thick, more preferably less than 0.75 mm or 0.5 mm thick, and most preferably less than 500 ⁇ m.
  • Such films are preferably flexible with a good tensile strength (e.g., greater than 50, preferably greater than 100, and more preferably greater than 150 or 200 N/cm 2 ), good adhesive properties (i.e., readily adheres to moist or wet surfaces), and have controlled permeability.
  • the therapeutic compositions can also comprise additional ingredients such as surfactants (e.g., Pluronics such as F-127, L-122, L-92, L-81, and L-61).
  • surfactants e.g., Pluronics such as F-127, L-122, L-92, L-81, and L-61).
  • polymers which are adapted to contain and release a hydrophobic compound, the carrier containing the hydrophobic compound in combination with a carbohydrate, protein or polypeptide.
  • the polymeric carrier contains or comprises regions, pockets or granules of one or more hydrophobic compounds.
  • hydrophobic compounds may be incorporated within a matrix which contains the hydrophobic compound, followed by incorporation of the matrix within the polymeric carrier.
  • matrices can be utilized in this regard, including for example, carbohydrates and polysaccharides, such as starch, cellulose, dextran, methylcellulose, and hyaluronic acid, proteins or polypeptides such as albumin, collagen and gelatin.
  • hydrophobic compounds may be contained within a hydrophobic core, and this core contained within a hydrophilic shell.
  • Other carriers that may likewise be utilized to contain and deliver the agents described herein include: hydroxypropyl ⁇ -cyclodextrin (Cserhati and Hollo, Int. J. Pharm. 108:69-75, 1994), liposomes (see, e.g., Sharma et al., Cancer Res. 53:5877-5881, 1993; Sharma and Straubinger, Pharm. Res. 11(60):889-896, 1994; WO 93/18751; U.S. Pat. No. 5,242,073), liposome/gel (WO 94/26254), nanocapsules (Bartoli et al., J.
  • the agents provided herein can also be formulated as a sterile composition (e.g., by treating the composition with ethylene oxide or by irradiation), packaged with preservatives or other suitable excipients suitable for administration to humans.
  • the devices provided herein e.g., coated catheter
  • a wide variety of implants or devices can be coated with or otherwise constructed to contain and/or release the therapeutic agents provided herein.
  • Representative examples include cardiovascular devices (e.g., implantable venous catheters, venous ports, tunneled venous catheters, chronic infusion lines or ports, including hepatic artery infusion catheters, pacemakers and pacesmaker leads (see, e.g., U.S. Pat. Nos. 4,662,382, 4,782,836, 4,856,521, 4,860,751, 5,101,824, 5,261,419, 5,284,491, 6,055,454, 6,370,434, and 6,370,434), implantable defibrillators (see, e.g., U.S. Pat. Nos.
  • neurologic/neurosurgical devices e.g., ventricular peritoneal shunts, ventricular atrial shunts, nerve stimulator devices, dural patches and implants to prevent epidural fibrosis post-laminectomy, devices for continuous subarachnoid infusions
  • gastrointestinal devices e.g., chronic indwelling catheters, feeding tubes, portosystemic shunts, shunts for ascites, peritoneal implants for drug delivery, peritoneal dialysis catheters, and suspensions or solid implants to prevent surgical adhesions
  • genitourinary devices e.g., uterine implants, including intrauterine devices (IUDs) and devices to prevent endometrial hyperplasia, fallopian tubal implants, including revers
  • vascular grafts see, e.g. 3,096,560, 3,805,301, 3,945,052, 4,140,126, 4,323,525, 4,355,426, 4,475,972, 4,530,113, 4,550,447, 4,562,596, 4,601,718, 4,647,416, 4,878,908, 5,024,671, 5,104,399, 5,116,360, 5,151,105, 5,197,977, 5,282,824, 5,405,379, 5,609,624, 5,693,088, and 5,910,168), ophthalmologic implants (e.g., multino implants and other implants for neovascular glaucoma, drug eluting contact lenses for pterygiums, splints for failed dacrocystalrhinostomy, drug eluti
  • ophthalmologic implants e.g., multino implants and other implants for neovascular glaucoma, drug eluting contact lenses for pterygium
  • Implants and other surgical or medical devices may be covered, coated, contacted, combined, loaded, filled, associated with, or otherwise adapted to release therapeutic agents compositions of the present invention in a variety of manners, including for example: (a) by directly affixing to the implant or device a therapeutic agent or composition (e.g., by either spraying the implant or device with a polymer/drug film, or by dipping the implant or device into a polymer/drug solution, or by other covalent or noncovalent means); (b) by coating the implant or device with a substance, such as a hydrogel, which will in turn absorb the therapeutic composition (or therapeutic factor above); (c) by interweaving therapeutic composition coated thread (or the polymer itself formed into a thread) into the implant or device; (d) by inserting the implant or device into a sleeve or mesh which is comprised of or coated with a therapeutic composition; (e) constructing the implant or device itself with a therapeutic agent or composition; or (f) by otherwise adapting the implant
  • the composition should firmly adhere to the implant or device during storage and at the time of insertion.
  • the therapeutic agent or composition should also preferably not degrade during storage, prior to insertion, or when warmed to body temperature after insertion inside the body (if this is required).
  • it should preferably coat or cover the desired areas of the implant or device smoothly and evenly, with a uniform distribution of therapeutic agent.
  • the therapeutic agent or composition should provide a uniform, predictable, prolonged release of the therapeutic factor into the tissue surrounding the implant or device once it has been deployed.
  • the composition should not render the stent thrombogenic (causing blood clots to form), or cause significant turbulence in blood flow (more than the stent itself would be expected to cause if it was uncoated).
  • a therapeutic agent can be deposited directly onto all or a portion of the device (see, e.g., U.S. Pat. Nos. 6,096,070 and 6,299,604), or admixed with a delivery system or carrier (e.g., a polymer, liposome, or vitamin as discussed above) which is applied to all or a portion of the device (see the patents, patent applications, and references listed above under “Compositions and Formulations.”
  • a delivery system or carrier e.g., a polymer, liposome, or vitamin as discussed above
  • therapeutic agents can be attached to a medical implant using non-covalent attachments.
  • the compound can be dissolved in an organic solvent a specified concentration. The solvent chosen for this application would not result in dissolution or swelling of the polymeric device surface.
  • the medical implant can then be dipped into the solution, withdrawn and then dried (air dry and/or vacuum dry).
  • this drug solution can be sprayed onto the surface of the implant. This can be accomplished using current spray coating technology. The release duration for this method of coating would be relatively short and would be a function of the solubility of the drug in the body fluid in which it was placed.
  • a therapeutic agent can be dissolved in a solvent that has the ability to swell or partially dissolve the surface of a polymeric implant.
  • the implant could be dipped into the drug solution for a period of time such that the drug can diffuse into the surface layer of the polymeric device.
  • the drug solution can be sprayed onto all or a part of the surface of the implant. The release profile of the drug depends upon the solubility of the drug in the surface polymeric layer. Using this approach, one would ensure that the solvent does not result in a significant distortion or dimensional change of the medical implant.
  • the implant is composed of materials that do not allow incorporation of a therapeutic agent into the surface layer using the above solvent method
  • a plasma polymerization method such that a thin polymeric layer is deposited onto the device surface.
  • Examples of such methods include parylene coating of devices, and the use of various monomers such hydrocyclosiloxane monomers, acrylic acid, acrylate monomers, methacrylic acid or methacrylate monomers.
  • therapeutic agents that have some degree of water solubility the retention of these compounds on a device are relatively short-term.
  • therapeutic agents that contain ionic groups it is possible to tonically complex these agents to oppositely charged compounds that have a hydrophobic component.
  • therapeutic agents containing amine groups can be complexed with compounds such as sodium dodecyl sulfate (SDS).
  • SDS sodium dodecyl sulfate
  • Compounds containing carboxylic groups can be complexed with tridodecymethyammonium chloride (TDMAC).
  • TDMAC tridodecymethyammonium chloride
  • Mitoxantrone for example, has two secondary amine groups and comes as a chloride salt. This compound can be added to sodium dodecyl sulfate in order to form a complex.
  • This complex can be dissolved in an organic solvent which can then be dip coated or spray coated.
  • Doxorubicin has an amine group and could thus also be complexed with SDS.
  • This complex could then be applied to the device by dip coating or spray coating methods.
  • Methotrexate for example contains 2 carboxylic acid groups and could thus be complexed with TDMAC and then coated onto the medical implant.
  • the release of these agents from the device can be modified by the use of organic compounds that have the ability to form ionic or hydrogen bonds with the therapeutic agent.
  • organic compounds that have the ability to form ionic or hydrogen bonds with the therapeutic agent.
  • a complex between the ionically charged therapeutic agent and an oppositely charged hydrophobic compound can be prepared prior to application of this complex to the medical implant.
  • a compound that has the ability to form ionic or hydrogen bond interactions with the therapeutic agent can be incorporated into the implant during the manufacture process, or during the coating process.
  • this compound can be incorporated into a coating polymer that is applied to the implant or during the process of loading the therapeutic agent into or onto the implant.
  • These agents can include fatty acids (e.g., palmitic acid, stearic acid, lauric acid), aliphatic acids, aromatic acids (e.g., benzoic acid, salicylic acid), cylcoaliphatic acids, aliphatic (stearyl alcohol, lauryl alcohol, cetyl alcohol) and aromatic alcohols alco multifunctional alcohols (e.g., citric acid, tartaric acid, pentaerithratol), lipids (e.g., phosphatidyl choline, phosphatidylethanolamine), carbohydrates, sugars, spermine, spermidine, aliphatic and aromatic amines, natural and synthetic amino acids, peptides or proteins.
  • a fatty acid such as palmitic acid can be used to modulate the release of 5-Fluoruracil from the implant.
  • therapeutic agents that have the ability to form ionic complexes or hydrogen bonds can be modified by the use of polymers that have the ability to form ionic or hydrogen bonds with the therapeutic agent.
  • therapeutic agents containing amine groups can form ionic complexes with sulfonic or carboxylic pendant groups or end-groups of a polymer.
  • polymers that can be used for this application include, but are not limited to polymers and copolymers that are prepared using acrylic acid, methacrylic acid, sodium styrene sulfonate, styrene sulfonic acid, maleic acid or 2-acrylamido-2-methyl propane sulfonic acid.
  • Polymers that have been modified by sulfonation post-polymerization can also be used in this application.
  • the medical implant for example, can be coated with, or prepared with, a polymer that comprises nafion, a sulfonated fluoropolymer. This medical device can then be dipped into a solution that comprises the amine-containing therapeutic agent.
  • the amine-containing therapeutic agent can also be applied by a spray coating process.
  • Methotrexate and doxorubicin are examples of therapeutic agents that can be used in this application.
  • Therapeutic agents with available functional groups can be covalently attached to the medical implant surface using several chemical methods. If the polymeric material used to manufacture the implant has available surface functional groups then these can be used for covalent attachment of the agent. For example, if the implant surface contains carboxylic acid groups, these groups can be converted to activated carboxylic acid groups (e.g acid chlorides, succinimidyl derivatives, 4-nitrophenyl ester derivatives etc). These activated carboxylic acid groups can then be reacted with amine functional groups that are present on the therapeutic agent (e.g., methotrexate, mitoxantrone).
  • activated carboxylic acid groups e.g acid chlorides, succinimidyl derivatives, 4-nitrophenyl ester derivatives etc.
  • these groups can be introduced to the polymer surface via a plasma treatment regime.
  • carboxylic acid groups can be introduced via a plasma treatment process process (e.g., the use of O 2 and/or CO 2 as a component in the feed gas mixture).
  • the carboxylic acid groups can also be introduced using acrylic acid or methacrylic acid in the gas stream.
  • These carboxylic acid groups can then be converted to activated carboxylic acid groups (e;g., acid chlorides, succinimidyl derivatives, 4-nitrophenyl ester derivatives, etc.) that can subsequently be reacted with amine functional groups that are present on the therapeutic agent.
  • the therapeutic agents with available functional groups can be covalently attached to the medical implant via a linker.
  • linkers can be degradable or non-degradable. Linkers that are hydrolytically or enzymatically cleaved are preferred. These linkers can comprise azo, ester, amide, thioester, anhydride, or phosphoester bonds.
  • portions of or the entire medical implant may be further coated with a polymer.
  • the polymer coating can comprise the polymers described above.
  • the polymer coating can be applied by a dip coating process, a spray coating process or a plasma deposition process. This coating can, if desired, be further crosslinked using thermal, chemical, or radiation (e.g., visible light, ultraviolet light, e-beam, gamma radiation, x-ray radiation) techniques in order to further modulate the release of the therapeutic agent from the medical implant.
  • This polymer coating can further contain agents that can increase the flexibility (e.g., plasticizer—glycerol, triethyl citrate), lubricity (e.g., hyaluronic acid), biocompatibility or hemocompatability,(e.g., heparin) of the coating.
  • plasticizer glycerol, triethyl citrate
  • lubricity e.g., hyaluronic acid
  • biocompatibility or hemocompatability e.g., heparin
  • Agents that can be used include, but are not limited to silver compounds (e.g., silver chloride, silver nitrate, silver oxide), silver ions, silver particles, iodine, povidone/iodine, chlorhexidine, 2-p-sulfanilyanilinoethanol, 4,4′-sulfinyldianiline, 4-sulfanilamidosalicylic acid, acediasulfone, acetosulfone, amikacin, amoxicillin, amphotericin B, ampicillin, apalcillin, apicycline, apramycin, arbekacin, aspoxicillin, azidamfenicol, azithromycin, aztreonam, bacitracin, bambermycin(s), biapenem, brodimoprim, butirosin, capreomycin, carbenicillin, carbomycin, carumonam, cefadroxil, cefamandole, cefatrizine, cefbupera
  • methods for preventing, reducing, and/or inhibiting an infection associated with a medical device or implant, comprising the step of introducing into a patient a medical implant which releases a chemotherapeutic agent, wherein the chemotherapeutic agent reduces, inhibits, or prevents the growth or transmission of foreign organisms (e.g., bacteria, fungi, or viruses).
  • foreign organisms e.g., bacteria, fungi, or viruses
  • agents that reduce, inhibit, or prevent the growth or transmission of foreign organisms in a patient means that the growth or transmission of a foreign organism is reduced, inhibited, or prevented in a statistically significant manner in at least one clinical outcome, or by any measure routinely used by persons of ordinary skill in the art as a diagnostic criterion in determining the same.
  • the medical implant has been covered or coated with an anthracycline (e.g., doxorubicin and mitoxantrone), fluoropyrimidine (e.g., 5-FU), folic acid antagonist (e.g., methotrexate), podophylotoxin (e.g., etoposide), camptothecin, hydroxyurea, and/or a platinum complexe (e.g., cisplatin).
  • anthracycline e.g., doxorubicin and mitoxantrone
  • fluoropyrimidine e.g., 5-FU
  • folic acid antagonist e.g., methotrexate
  • podophylotoxin e.g., etoposide
  • camptothecin hydroxyurea
  • platinum complexe e.g., cisplatin
  • Particularly preferred agents which are utilized within the context of the present invention should have an MIC of less than or equal to any one of 10 ⁇ 4 M, 10 ⁇ 5 M, 10 ⁇ 6 M, or, 10 ⁇ 7 M. Furthermore, particularly preferred agents are suitable for use at concentrations less than that 10%, 5%, or even 1% of the concentration-typically used in chemotherapeutic applications (Goodman and Gilman's The Pharmacological Basis of Therapeutics. Editors J. G. Hardman, L. L. Limbird. Consulting editor A. Goodman Gilman Tenth Edition. McGraw-Hill Medical publishing division. 10th edition, 2001, 2148 pp.). Finally, the devices should preferably be provided sterile, and suitable for use in humans.
  • vascular catheters More than 30 million patients receive infusion therapy annually in the United States. In fact, 30% of all hospitalized patients have at least one vascular catheter in place during their stay in hospital.
  • a variety of medical devices are used for infusion therapy including, but not restricted to, peripheral intravenous catheters, central venous catheters, total parenteral nutrition catheters, peripherally inserted central venous catheters (PIC lines), totally implanted intravascular access devices, flow-directed balloon-tipped pulmonary artery catheters, arterial lines, and long-term central venous access catheters (Hickman lines, Broviac catheters).
  • vascular access catheters are prone to infection by a variety of bacteria and are a common cause of bloodstream infection.
  • 100,000 bloodstream infections in US hospitals each year many are related to the presence of an intravascular device.
  • 55,000 cases of bloodstream infections are caused by central venous catheters, while a significant percentage of the remaining cases are related to peripheral intravenous catheters and arterial lines.
  • Bacteremia related to the presence of intravascular devices is not a trivial clinical concern: 50% of all patients developing this type of infection will die as a result (over 23,000 deaths per year) and in those who survive, their hospitalization will be prolonged by an average of 24 days.
  • Complications related to bloodstream infections include cellulites, the formation of abscesses, septic thrombophlebitis, and infective endocarditis. Therefore, there is a tremendous clinical need to reduce the morbidity and mortality associated with intravascular catheter infections.
  • the most common point of entry for the infection-causing bacteria is tracking along the device from the insertion site in the skin. Skin flora spread along the outside of the device to ultimately gain access to the bloodstream. Other possible sources of infection include a contaminated infusate, contamination of the catheter hub-infusion tubing junction, and hospital personnel. The incidence of infection increases the longer the catheter remains in place and any device remaining in situ for more than 72 hours is particularly susceptible.
  • the most common infectious agents include common skin flora such as coagulase-negative staphylococci ( S. epidermidis, S. saprophyticus ) and Staphylococcus aureus (particularly MRSA—methicillin—resistant S. aureus ) which account for 2 ⁇ 3 of all infections.
  • Coagulase-negative staphylococci is the most commonly isolated organism from the blood of hospitalized patients. CNS infections tend to be indolent; often occurring after a long latent period between contamination (i.e. exposure of the medical device to CNS bacteria from the skin during implantation) and the onset of clinical illness. Unfortunately, most clinically significant CNS infections are caused by bacterial strains that are resistant to multiple antibiotics, making them particularly difficult to treat. Other organisms known to cause vascular access catheter-related infections include Enterococci (e.g. E.
  • An ideal therapeutic coating would have one or more of the following characteristics: (a) the ability to kill, prevent, or inhibit colonization of a wide array of potential infectious agents including most or all of the species listed above; (b) the ability to kill, prevent, or inhibit colonization of bacteria (such as CNS and VRE) that are resistant to multiple antibiotics; (c) utilize a therapeutic agent unlikely to be used in the treatment of a bloodstream infection should one develop (i.e., one would not want to coat the device with a broad-acting antibiotic, for if a strain of bacteria resistant to the antibiotic were to develop on the device it would jeopardize systemic treatment of the patient since the infecting agent would be resistant to a potentially useful therapeutic).
  • anticancer agents are particularly suitable for incorporation into coatings for vascular catheters, namely, anthracyclines (e.g., doxorubicin and mitoxantrone), fluoropyrimidines (e.g., 5-FU), folic acid antagonists (e.g., methotrexate), and podophylotoxins (e.g., etoposide).
  • anthracyclines e.g., doxorubicin and mitoxantrone
  • fluoropyrimidines e.g., 5-FU
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • Particularly preferred agents are doxorubicin, mitoxantrone, 5-fluorouracil and analogues and derivatives thereof which also have activity against Escheridia coli and Pseudomonas aeruginosa . It is important to note that not all anticancer agents are suitable for the practice of the present invention as several agents, including 2-mercaptopurine, 6-mercaptopurine, hydroxyurea, cytarabine, cisplatinum, tubercidin, paclitaxel, and camptothecin did not have antibacterial activity against the organisms known to cause vascular access catheter-related infections.
  • Central Venous Catheters should be understood to include any catheter or line that is used to deliver fluids to the large (central) veins of the body (e.g., jugular, pulmary, femoral, iliac, inferior vena cava, superior vena cava, axillary etc.).
  • catheters include central venous catheters, total parenteral nutrition catheters, peripherally inserted central venous catheters, flow-directed balloon-tipped pulmonary artery catheters, long-term central venous access catheters (such as Hickman lines and Broviac catheters). Representative examples of such catheters are described in U.S. Pat. Nos.
  • An effective therapy would reduce the incidence of device infection, reduce the incidence of bloodstream infection, reduce the mortality rate, reduce the incidence of complications (such as endocarditis or suppurative phlebitis), prolong the effectiveness of the central venous catheter and/or reduce the need to replace the catheter. This would result in lower mortality and morbidity for patients with central venous catheters in place.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the vascular catheter.
  • the drug(s) can be applied to the central venous catheter system in several manners: (a) as a coating applied to the exterior surface of the intravascular portion of the catheter and/or the segment of the catheter that traverses the skin; (b) as a coating applied to the interior and exterior surface of the intravascular portion of the catheter and/or the segment of the catheter that traverses the skin; (c) incorporated into the polymers which comprise the intravascular portion of the catheter; (d) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the catheter; (e) in solution in the infusate; (e incorporated into, or applied as a coating to, the catheter hub, junctions and/or infusion tubing; and (g) any combination of the aforementioned.
  • Drug-coating of, or drug incorporation into, the central venous catheter will allow bacteriocidal drug levels to be achieved locally on the catheter surface, thus reducing the incidence of bacterial colonization of the vascular catheter (and subsequent development of blood borne infection), while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the catheter surface, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g., poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g., poly(ethylene-co-vinyl acetate)) as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g., poly(ethylene
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the device, or applied without a polymer carrier, the total dose of doxorubicin applied to the central venous catheter (and the other components of the infusion system) should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied to the central venous catheter (and the other components of the infusion system) should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area of the device i.e.
  • the amount of drug as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • doxorubicin should be applied to the device surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the device surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the device surface.
  • doxorubicin is released from the surface of the device such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-30 days.
  • analogues and derivatives.of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • the total dose of mitoxantrone applied to the central venous catheter (and the other components of the infusion system) should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg).
  • the total amount of drug applied to the central venous catheter (and the other components of the infusion system) should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area of the device i.e.
  • the amount of drug as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-20 ⁇ g per mm 2 of surface area.
  • mitoxantrone should be applied to the device surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the device surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained on the device surface.
  • mitoxantrone is released from the surface of the device such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-30 days.
  • analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • the total dose of 5-fluorouracil applied to the central venous catheter (and the other components of the infusion system) should not exceed 250 mg (range of 1.0 ⁇ g to 250 mg).
  • the total amount of drug applied to the central venous catheter (and the other components of the infusion system) should be in the range of 10 ⁇ g to 25 mg.
  • the dose per unit area of the device i.e.
  • the amount of drug as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the device surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the device surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained on the device surface.
  • 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the surface of the device such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-30 days.
  • analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • the total dose of etoposide applied to the central venous catheter (and the other components of the infusion system) should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg).
  • the total amount of drug applied to the central venous catheter (and the other components of the infusion system) should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area of the device i.e.
  • the amount of drug as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • etoposide should be applied to the device surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the device surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained on the device surface.
  • etoposide is released from the surface of the device such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-30 days.
  • analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • anthracycline e.g., doxorubicin or mitoxantrone
  • fluoropyrimidine e.g., 5-fluorouracil
  • folic acid antagonist e.g., methotrexate
  • podophylotoxin e.g., etoposide
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate and/or podophylotoxins (e.g., etoposide
  • antithrombotic and/or antiplatelet agents for example, heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinase
  • antithrombotic and/or antiplatelet agents for example, heparin,
  • Peripheral Venous Catheters should be understood to include any catheter or line that is used to deliver fluids to the smaller (peripheral) superficial veins of the body.
  • Peripheral venous catheters have a much lower rate of infection than do central venous catheters, particularly if they are in place for less than 72 hours.
  • peripheral catheters inserted into the femoral vein which have a significantly higher rate of infection.
  • the organisms that cause infections in a peripheral venous catheter are identical to those described above (for central venous catheters).
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the peripheral vascular catheter.
  • the drug(s) can be applied to the peripheral venous catheter system in several manners: (a) as a coating applied to the exterior and/or interior surface of the intravascular portion of the catheter and/or the segment of the catheter that traverses the skin; (b) incorporated into the polymers which comprise the intravascular portion of the catheter; (c) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the catheter; (e) in solution in the infusate; (f incorporated into, or applied as a coating to, the catheter hub, junctions and/or infusion tubing; and (g) any combination of the aforementioned.
  • Arterial lines are used to draw arterial blood gasses, obtain accurate blood pressure readings and to deliver fluids. They are placed in a peripheral artery (typically the radial artery) and often remain in place for several days. Arterial lines have a very high rate of infection (12-20% of arterial lines become infected) and the causative organisms are identical to those described above (for central venous catheters).
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the arterial line in several manners: (a) as a coating applied to the exterior and/or interior surface of the intravascular portion of the catheter and/or the segment of the catheter that traverses the skin; (b) incorporated into the polymers which comprise the intravascular portion of the catheter; (c) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the catheter; (e) in solution in the infusate; (f) incorporated into, or applied as a coating to, the catheter hub, junctions and/or infusion tubing; and (g) any combination of the aforementioned.
  • Prosthetic heart valves mechanical and bioprosthetic, are at a significant risk for developing an infection.
  • 3-6% of patients develop valvular infection within 5 years of valve replacement surgery and prosthetic valve endocarditis accounts for up to 15% of all cases of endocarditis.
  • the risk of developing an infection is not uniform—the risk is greatest in the first year following surgery with a peak incidence between the second and third month postoperatively.
  • Mechanical valves in particular are susceptible to infection in the 3 months following surgery and the microbiology is suggestive of nosocomial infection. Therefore, a drug coating designed to prevent colonization and infection of the valves in the months following surgery could be of great benefit in the prevention of this important medical problem.
  • the incidence of prosthetic valve endocarditis has not changed in the last 40 years despite significant advances in surgical and sterilization technique.
  • prosthetic heart valves include those described in U.S. Pat. Nos. 3,656,185, 4,106,129, 4,892,540, 5,528,023, 5,772,694, 6,096,075, 6,176,877, 6,358,278, and 6,371,983
  • PVE PVE of bioprosthetic valves is largely confined to the leaflets (and rarely the annulus), whereas the annulus is involved in the majority of cases of PVE in mechanical valves (82%).
  • prosthetic valve endocarditis Other complications of prosthetic valve endocarditis include valve malfunction (stenosis, regurgitation), abscess formation, embolic complications (such as stroke, CNS hemorrhage, cerebritis), conduction abnormalities, and death (55-75% of patients who develop an infection in the first 2 months after surgery).
  • An effective therapeutic valve coating would reduce the incidence of prosthetic valve endocarditis, reduce the mortality rate, reduce the incidence of complications, prolong the effectiveness of the prosthetic valve and/or reduce the need to replace the valve. This would result in lower mortality and morbidity for patients with prosthetic heart valves.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the bioprosthetic or mechanical valve.
  • the drug(s) can be applied to the prosthetic valve in several manners: (a) as a coating applied to the surface of the annular ring (particularly mechanical valves); (b) as a coating applied to the surface of the valve leaflets (particularly bioprosthetic valves); (c) incorporated into the polymers which comprise the annular ring; and/or (d) any combination of the aforementioned.
  • Drug-coating of, or drug incorporation into prosthetic heart valves will allow bacteriocidal drug levels to be achieved locally on the valvular surface, thus reducing the incidence of bacterial colonization and subsequent development of PVE, while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the valve annular ring and/or leaflets, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g., nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g., poly(ethylene-co-vinyl acetate)), as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g. poly(ethylene-
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the prosthetic heart valve, or applied without a carrier polymer, the total dose of doxorubicin applied to the prosthetic heart valve should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied to the prosthetic heart valve should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area of the valve i.e., the amount of drug as a function of the surface area of the portion of the valve to which drug is applied and/or incorporated
  • doxorubicin should be applied to the valve surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the valve surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface.
  • doxorubicin is released from the surface of the valve such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-6 months.
  • analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • the total dose of mitoxantrone applied to the prosthetic heart valve should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg).
  • the total amount of drug applied to the prosthetic heart valve should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area of the valve i.e. the amount of drug as a function of the surface area of the portion of the valve to which drug is applied and/or incorporated
  • mitoxantrone should be applied to the valve surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the valve surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained on the valve surface. It is necessary to insure that drug concentrations on the valve surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • mitoxantrone is released from the surface of the valve such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-6 months.
  • the total dose of 5-fluorouracil applied to the prosthetic heart valve should not exceed 250 mg (range of 1.0 ⁇ g to 250 mg). In a particularly preferred embodiment, the total amount of drug applied to the prosthetic heart valve should be in the range of 10 ⁇ g to 25 mg.
  • the dose per unit area of the valve i.e.
  • the amount of drug as a function of the surface area of the portion of the valve to which drug is applied and/or incorporated) should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the valve surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the valve surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained on the valve surface.
  • 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the surface of the valve such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-6 months.
  • analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • the total dose of etoposide applied to the prosthetic heart valve should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied to the prosthetic heart valve should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area of the valve i.e., the amount of drug as a function of the surface area of the portion of the valve to which drug is applied and/or incorporated
  • etoposide should be applied to the prosthetic heart valve surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the valve surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained on the valve surface.
  • etoposide is released from the surface of the valve such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-6 months.
  • analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate and/or podophylotoxins (e.g., etoposide)
  • traditional antibiotic and/or antifungal agents to enhance efficacy.
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate and/or podophylotoxins (e.g., etoposide
  • antithrombotic and/or antiplatelet agents for example, heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinas
  • antithrombotic and/or antiplatelet agents for example, heparin, de
  • pacemakers are subject to infection in two general manners: (a) infections involving the pulse generator pocket and/or subcutaneous portion of the lead, and (b) infections involving the transvenous intravascular electrode and/or the generator unit.
  • Representative examples of patents which describe pacemakers and pacemaker leads include U.S. Pat. Nos. 4,662,382, 4,782,836, 4,856,521, 4,860,751, 5,101,824, 5,261,419, 5,284,491, 6,055,454, 6,370,434, and 6,370,434.
  • pacemaker infection involves the subcutaneous generator unit or lead wires in the period shortly after placement. This type of infection is thought to be the result of contamination of the surgical site by skin flora at the time of placement. Staphylococcus epidermidis (65-75% of cases), Stapylococcus aureus , Streptococci, Corynebacterium, Proprionibacterium acnes , Enterobacteriaceae and Candida species are frequent causes of this type of infection. Treatment of the infection at this point is relatively straightforward, the infected portion of the device is removed, the patient is treated with antibiotics and a new pacemaker is inserted at a different site. Unfortunately, infections of the generator pocket can subsequently spread to the epicardial electrodes causing more severe complications such pericarditis, mediastinitis and bacteremia.
  • Infection of the intravascular portion of the tranvenous electrode poses a more significant clinical problem. This infection is thought to be caused by infection of the subcutaneous portion of the pacing apparatus that tracks along the device into the intravascular and intracardiac portions of the device. This infection tends to present at a later time (1-6 months post-procedure) and can result in sepsis, endocarditis, pneumonia, bronchitis, pulmonary embolism, cardiac vegetations and even death.
  • Coagulase Negative Staphylococci (56% of infections), Staphylococcus aureus (27%), Enterobacteriaceae (6%), Pseudomonas arugenosa (3%) and Candida albicans (2%) are the most common cause of this serious form of pacemaker infection. Treatment of this form of infection is more complex. The generator and electrodes must be removed (often surgically), antibiotics are required for prolonged periods and an entire new pacemaker system must be inserted. Mortality rates associated with this condition can be quite high—41% if treated with antibiotics alone, 20% if treated with electrode removal and antibiotics.
  • An effective cardiac pacemaker coating would reduce the incidence of subcutaneous infection and subsequent tracking of infection to the pericardial and endocardial surfaces of the heart. Clinically, this would result in a reduction in the overall rate of infection and reduce the incidence of more severe complications such as sepsis, endocarditis, pneumonia, bronchitis, pulmonary embolism, cardiac vegetations and even death. An effective coating could also prolong the effectiveness of the pacemaker and decrease the number of pacemakers requiring replacement, resulting in lower mortality and morbidity for patients with these implants.
  • an anthracycline e.g., doxorubicin and mitoxantrone
  • fluoropyrimidine e.g., 5-FU
  • folic acid antagonist e.g., methotrexate
  • podophylotoxin e.g., etoposide
  • the drug(s) can be applied to the pacemaker in several manners: (a) as a coating applied to the surface of the generator unit; (b) as a coating applied to the surface of the subcutaneous portion of the lead wires; (c) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the subcutaneous insertion site; (d) as a coating applied to the surface of the epicardial electrodes; (e) as a coating applied to the surface of the transvenous electrode; and/or (f) any combination of the aforementioned.
  • polymeric carriers are not required for attachment of the drug to the generator unit, leads and electrodes, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g.
  • cellulose-derived polymers e.g. nitrocellulose. Cellulose Acetate Butyrate, Cellulose acetate propionate
  • acrylate and methacrylate copolymers e.g. poly(ethylene-co-vinyl acetate) as well as blends thereof.
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the pacemaker components, or applied without a carrier polymer, the total dose of doxorubicin applied to the pacemaker should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the pacemaker to which drug is applied and/or incorporated
  • doxorubicin should be applied to the pacemaker surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the pacemaker surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower concentrations are sufficient).
  • doxorubicin is released from the surface of the pacemaker such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg).
  • the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the pacemaker to which drug is applied and/or incorporated
  • mitoxantrone should be applied to the pacemaker surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the pacemaker surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the pacemaker surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • mitoxantrone is released from the surface of the pacemaker such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 ⁇ g to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 ⁇ g to 25 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the pacemaker to which drug is applied and/or incorporated should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the pacemaker surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the pacemaker surface such that a minimum concentration of 10 4 -10 ⁇ 7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the pacemaker surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the pacemaker to which drug is applied and/or incorporated should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • etoposide should be applied to the pacemaker surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the pacemaker surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • etoposide is released from the surface of the pacemaker such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate and/or podophylotoxins (e.g., etoposide).
  • traditional antibiotic and/or antifungal agents to enhance efficacy.
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate and/or podophylotoxins (e.g., etoposide
  • antithrombotic and/or antiplatelet agents for example heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin,, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, str
  • ICD Implantable Cardioverter-Defibrillators
  • implantable cardioverter-defibrillators become infected following implantation (the rate is highest if surgical placement is required). Like cardiac pacemakers, implantable defibrillators are subject to infection in two general manners: (a) infections involving the subcutaneous portion of the device (subcutaneous electrodes and pulse generator unit, and (b) infections involving the intrathoracic components (rate sensing electrode, SVC coil electrode and epicardial electrodes). Representative examples of ICD's and associated components are described in U.S. Pat. Nos. 3,614,954, 3,614,955, 4,375,817, 5,314,430, 5,405,363, 5,607,385, 5,697,953, 5,776,165, 6,067,471, 6,169,923, and 6,152,955.
  • An effective ICD coating would reduce the incidence of infection-related side effects such subcutaneous infection, sepsis and pericarditis. An effective coating could also prolong the effectiveness of the ICD and decrease the number of patients requiring replacement, resulting in lower mortality and morbidity associated with these implants.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the ICD.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the surface of the pulse generator unit; (b) as a coating applied to the surface of the subcutaneous portion of the lead wires; (c) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the subcutaneous insertion site; (d) as a coating applied to the surface of the SVC coil electrode; (e) as a coating applied to the surface of the epicardial electrode; and/or (f) any combination of the aforementioned.
  • Drug-coating of, or drug incorporation into prosthetic heart valves will allow bacteriocidal drug levels to be achieved locally on the ICD surface, thus reducing the incidence of bacterial colonization and subsequent development of infectious complications, while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the generator unit, leads and electrodes, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g. poly(ethylene-co-
  • implantable cardioverter-defibrillators have many design features similar to those found in cardiac pacemakers, the dosing guidelines for doxorubicin, mitoxantrone, 5-fluorouracil and etoposide in coating ICDs are identical to those described above for cardiac pacemakers.
  • Infection rates for synthetic vascular grafts range from 1-5% and are highest in grafts that traverse the inguinal region (such as aorto-femoral grafts and femoral-popliteal grafts).
  • infection can result from extension of an infection from an adjacent contaminated tissue or hematogenous seeding, the most common cause of infection is intraoperative contamination. In fact, more than half of all cases present within the first 3 months after surgery..
  • the most common causes of infection include Staphylococcus aureus (25-35% of cases), Enterobacteriaceae, Pseudomonas aerugenosa , and Coagulase Negative Staphylococci.
  • Complications arising from vascular graft infection include sepsis, subcutaneous infection, false aneurysm formation, graft thrombosis, haemorrhage, septic or thrombotic emboli and graft thrombosis.
  • Treatment requires removal of the graft in virtually all cases combined with systemic antibiotics.
  • the surgery must be performed in a staged manner (complete resection of the infected graft, debridement of adjacent infected tissues, development of a healthy arterial stump, reperfusion through an uninfected pathway) further adding to the morbidity and mortality associated with this condition. For example, if an aortic graft becomes infected there is a 37% mortality rate and a 21% rate of leg amputation in survivors; for infrainguinal grafts the rates are 18% and 40% respectively.
  • vascular grafts are described in U.S. Pat. Nos. 3,096,560, 3,805,301, 3,945,052, 4,140,126, 4,323,525, 4,355,426, 4,475,972, 4,530,113, 4,550,447, 4,562,596, 4,601,718, 4,647,416, 4,878,908, 5,024,671, 5,104,399, 5,116,360, 5,151,105, 5,197,977, 5,282,824, 5,405,379, 5,609,624, 5,693,088, and 5,910,168.
  • An effective vascular graft coating would reduce the incidence of complications such as sepsis, haemorrhage, thrombosis, embolism, amputation and even death. An effective coating would also decrease the number of vascular grafts requiring replacement, resulting in lower mortality and morbidity for patients with these implants.
  • an anthracycline e.g., doxorubicin and mitoxantrone
  • fluoropyrimidine e.g., 5-FU
  • folic acid antagonist e.g., methotrexate
  • podophylotoxin e.g., etoposide
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the graft; (b) as a coating applied to the internal (luminal) surface of the graft; and/or (c) as a coating applied to all or parts of both surfaces.
  • polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM (CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomateriais]), acrylic or methacrylic copolymers (e.g.
  • cellulose-derived polymers e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate
  • acrylate and methacrylate copolymers e.g. poly(ethylene-co-vinyl acetate) collagen as well as blends thereof.
  • vascular grafts are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the graft coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the vascular graft, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines:
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the vascular graft components (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the vascular graft to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • doxorubicin should be applied to the vascular graft surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the vascular graft surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface.
  • doxorubicin is released from the surface of the vascular graft such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg).
  • the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the vascular graft to which drug is applied and/or incorporated
  • mitoxantrone should be applied to the vascular graft surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the vascular graft surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • mitoxantrone is released from the vascular graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • the amount of drug as a function of the surface area of the portion of the vascular graft to which drug is applied and/or incorporated) should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the vascular graft surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the vascular graft surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained.
  • 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the vascular graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the vascular graft to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • etoposide should be applied to the vascular graft surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the vascular graft surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained.
  • etoposide is released from the surface of the vascular graft such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate and/or podophylotoxins (e.g., etoposide)
  • traditional antibiotic and/or antifungal agents to enhance efficacy.
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate and/or podophylotoxins (e.g., etoposide
  • antithrombotic and/or antiplatelet agents for example heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinas
  • antithrombotic and/or antiplatelet agents for example heparin, dextran
  • Bacterial infections involving the ear, nose and throat are common occurrences in both children and adults.
  • the use of implanted medical tubes is a frequent form of treatment. Specifically, chronic otitis media is often treated with the surgical implantation of tympanostomy tubes and chronic sinusitis is frequently treated with surgical drainage and the placement of a sinus stent.
  • Acute otitis media is the most common bacterial infection, the most frequent indication for surgical therapy, the leading cause of hearing loss and a common cause of impaired language development in children.
  • the cost of treating this condition in children under the age of five is estimated at $5 billion annually in the United States alone. In fact, 85% of all children will have at least one episode of otitis media and 600,000 will require surgical therapy annually.
  • the prevalence of otitis media is increasing and for severe cases surgical therapy is more cost effective than conservative management.
  • Acute otitis media (bacterial infection of the middle ear) is characterized by Eustachian tube dysfunction leading to failure of the middle ear clearance mechanism.
  • the most common causes of otitis media are Streptococcus pneumoniae (30%), Haemophilus influenza (20%), Branhamella catarrhalis (12%), Streptococcus pyogenes (3%), and Staphylococcus aureus (1.5%).
  • the end result is the accumulation of bacteria, white blood cells and fluid which, in the absence of an ability to drain through the Eustachian tube, results in increased pressure in the middle ear.
  • antibiotic therapy is sufficient treatment and the condition resolves. However, for a significant number of patients the condition becomes frequently recurrent or does not resolve completely.
  • Surgical placement of tympanostomy tubes is the most widely used treatment for chronic otitis media because, although not curative, it improves hearing (which in turn improves language development) and reduces the incidence of acute otitis media.
  • Tympanostomy tube placement is one of the most common surgical procedures in the United States with 1.3 million surgical placements per year. Nearly all younger children and a large percentage of older children require general anaesthesia for placement. Since general anaesthesia has a higher incidence of significant side effects in children (and represents the single greatest risk and cost associated with the procedure), it is desirable to limit the number of anaesthetics that the child is exposed to.
  • tympanostomy tube insertion Common complications of tympanostomy tube insertion include chronic otorrhea (often due to infection by S. pneumoniae, H. influenza, Pseudomonas aerugenosa, S.aureus , or Candida), foreign body reaction with the formation of granulation tissue and infection, plugging (usually obstructed by granulation tissue, bacteria and/or clot), tympanic membrane perforation, myringosclerosis, tympanic membrane atrophy (retraction, atelectasis), and cholesteatoma.
  • An effective tympanostomy tube coating would allow easy insertion, remain in place for as long as is required, be easily removed in the office without anaesthesia, resist infection and prevent the formation of granulation tissue in the tube (which can not only lead to obstruction, but also “tack down” the tube such that surgical removal of the tube under anaesthetic becomes necessary).
  • An effective tympanostomy tube would also reduce the incidence of complications such as chronic otorrhea (often due to infection by S. pneumoniae, H. influenza, Pseudomonas aerugenosa, S.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the tympanostomy tube.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the tympanostomy tube; (b) as a coating applied to the internal (luminal) surface of the tympanostomy tube; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the tympanostomy tube.
  • Drug-coating of, or drug incorporation into, the tympanostomy tube will allow bacteriocidal drug levels to be achieved locally on the tube surface, thus reducing the incidence of bacterial colonization (and subsequent development of middle ear infection), while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the tympanostomy tube surface, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g. poly(ethylene-co-
  • tympanostomy tubes There are two general designs of tympanostomy tubes: grommet-shaped tubes, which tend to stay in place for less than 1 year but have a low incidence of permanent perforation of the tympanic membrane (1%), and T-tubes, which stay in place for several years but have a higher rate of permanent perforation (5%).
  • tympanostomy tubes are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the tympanostomy tube, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines:
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the tympanostomy tube components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the tympanostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • doxorubicin should be applied to the tympanostomy tube surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the tympanostomy tube surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower concentrations are sufficient).
  • doxorubicin is released from the surface of the tympanostomy tube such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg).
  • the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the tympanostomy tube to which drug is applied and/or incorporated
  • mitoxantrone should be applied to the tympanostomy tube surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the tympanostomy tube surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e.
  • mitoxantrone is released from the tympanostomy tube surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • the amount of drug as a function of the surface area of the portion of the tympanostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the tympanostomy tube surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the tympanostomy tube surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained.
  • 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the tympanostomy tube surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the tympanostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • etoposide should be applied to the tympanostomy tube surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the tympanostomy tube surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained.
  • etoposide is released from the surface of the tympanostomy tube such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • the sinuses are four pairs of hollow regions contained in the bones of the skull named after the bones in which they are located (ethmoid, maxillary, frontal and sphenoid). All are lined by respiratory mucosa which is directly attached to the bone. Following an inflammatory insult such as an upper respiratory tract infection or allergic rhinitis, a purulent form of sinusitis can develop. Occasionally secretions can be retained in the sinus due to altered ciliary function or obstruction of the opening (ostea) that drains the sinus.
  • Incomplete drainage makes the sinus prone to infection typically with Haemophilus influenza, Streptococcus pneumoniae, Moraxella catarrhalis , Veillonella, Peptococcus, Corynebacterium acnes and certain species of fungi.
  • the stents can become infected or overgrown by granulation tissue that renders them ineffective.
  • An effective sinus stent coating would allow easy insertion, remain in place for as long as is required, be easily removed in the office without anaesthesia, resist infection and prevent the formation of granulation tissue in the stent (which can not only lead to obstruction, but also “tack down” the stent such that surgical removal becomes necessary). Therefore, development of a sinus stent which does not become obstructed by granulation tissue, does not scar in place and is less prone to infection would be beneficial.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the sinus stent.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the sinus stent; (b) as a coating applied to the internal (luminal) surface of the sinus stent; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the sinus stent.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640 TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640 TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g. poly(ethylene-
  • Implanted medical devices are used in the urinary tract with greater frequency than in any other body system and have some of the highest rates of infection. In fact, the great majority of urinary devices become infected if they remain in place for a prolonged period of time and are the most common cause of nosocomial infection.
  • An effective urinary catheter coating would allow easy insertion into the bladder, resist infection and prevent the formation of biofilm in the catheter.
  • An effective coating would prevent or reduce the incidence of urinary tract infection, pyelonephritis, and/or sepsis.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the urinary catheter.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the urinary catheter; (b) as a coating applied to the internal (luminal) surface of the urinary catheter; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the urinary catheter.
  • Drug-coating of, or drug incorporation into, the urinary catheter will allow bacteriocidal drug levels to be achieved locally on the catheter surface, thus reducing the incidence of bacterial colonization (and subsequent development of urinary tract infection and bacteremia), while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the urinary catheter surface, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g. poly(ethylene-co-
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the urinary catheter components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the urinary catheter to which drug is applied and/or incorporated
  • doxorubicin should be applied to the urinary catheter surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary catheter surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower concentrations are sufficient).
  • doxorubicin is released from the surface of the urinary catheter such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 hour-1 month.
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg).
  • the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the urinary catheter to which drug is applied and/or incorporated
  • mitoxantrone should be applied to the urinary catheter surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary catheter surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • mitoxantrone is released from the urinary catheter surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 hour-1 month.
  • the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 ⁇ g to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 ⁇ g to 25 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the urinary catheter to which drug is applied and/or incorporated
  • 5-fluorouracil should be applied to the urinary catheter surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary catheter surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the urinary catheter surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 hour-1 month.
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the urinary catheter to which drug is applied and/or incorporated
  • etoposide should be applied to the urinary catheter surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary catheter surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • etoposide is released from the surface of the urinary catheter such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 hour-1 month.
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • Ureteral stents are hollow tubes with holes along the sides and coils at either end to prevent migration. Ureteral stents are used to relieve obstructions (caused by stones or malignancy), to facilitate the passage of stones, or to allow healing of ureteral anastomoses or leaks following surgery or trauma. They are placed endoscopically via the bladder or percutaneously via the kidney. A microbial biofilm forms on up to 90% of ureteral stents and 30% develop significant bacteruria with the incidence increasing the longer the stent is in place. Pseudomonas aeruginosa is the most common pathogen, but Enterococci, Staphylococcus aureus and Candida also cause infection. Effective treatment frequently requires stent removal in addition to antibiotic therapy.
  • ureteral stents can become infected or encrusted with urinary salts that render them ineffective.
  • An effective ureteral stent coating would allow easy insertion, remain in place for as long as is required, be easily removed, resist infection and prevent the formation of urinary salts. Therefore, development of a ureteral stent which does not become obstructed by granulation tissue, does not scar in place and is less prone to infection would be beneficial.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the ureteral stent.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the ureteral stent; (b) as a coating applied to the internal (luminal) surface of the ureteral stent; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the ureteral stent.
  • Drug-coating of, or drug incorporation into, the ureteral stent will allow bacteriocidal drug levels to be achieved locally on the stent surface, thus reducing the incidence of bacterial colonization (and subsequent development of pyelonephritis and/or bacteremia), while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the ureteral stent surface, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g. poly(ethylene-co-
  • Urethral stents are used for the treatment of recurrent urethral strictures, detruso-external sphincter dyssynergia and bladder outlet obstruction due to benign prostatic hypertrophy.
  • the stents are typically self-expanding and composed of metal superalloy, titanium, stainless steel or polyurethane. Infections are most often due to Coagulase Negative Staphylococci, Pseudomonas aeruginosa , Enterococci, Staphylococcus aureus , Serratia and Candida. Treatment of infected stents frequently requires systemic antibiotic therapy and removal of the device.
  • An effective urethral stent coating would allow easy insertion, remain in place for as long as is required, be easily removed, resist infection and prevent the formation of urinary salts. Therefore, development of a urethral stent which does not become obstructed by granulation tissue, does not scar in place and is less prone to infection would be beneficial.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the urethral stent.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the urethral stent; (b) as a coating applied to the internal (luminal) surface of the urethral stent; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the urethral stent.
  • Drug-coating of, or drug incorporation into, the urethral stent will allow bacteriocidal drug levels to be achieved locally on the stent surface, thus reducing the incidence of bacterial colonization (and subsequent development of pyelonephritis and/or bacteremia), while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the ureteral stent surface, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g. poly(ethylene-co-
  • Prosthetic bladder sphincters are used to treat incontinence and generally consist of a periurethral implant.
  • the placement of prosthetic bladder sphincters can be complicated by infection (usually in the first 6 months after surgery) with Coagulase Negative Staphylococci (including Staphylococcus epidermidis ), Staphylococcus aureus, Pseudomonas aeruginosa , Enterococci, Serratia and Candida. Infection is characterized by fever, erythema, induration and purulent drainage from the operative site. The usual route of infection is through the incision at the time of surgery and up to 3% of prosthetic bladder sphincters become infected despite the best sterile surgical technique. To help combat this, intraoperative irrigation with antibiotic solutions is often employed.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the prosthetic bladder sphincter.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the prosthetic bladder sphincter; and/or (b) incorporated into the polymers which comprise the prosthetic bladder sphincter.
  • Drug-coating of, or drug incorporation into, the prosthetic bladder sphincter will allow bacteriocidal drug levels to be achieved locally, thus reducing the incidence of bacterial colonization (and subsequent development of urethritis and/or wound infection), while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the prosthetic bladder sphincter surface, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g. poly(ethylene-co-
  • prosthetic bladder sphincters are prone to infections caused by the same bacteria as occur with urinary catheters
  • the dosing guidelines for doxorubicin, mitoxantrone, 5-fluorouracil and etoposide in coating prosthetic bladder sphincters are identical to those described above for urinary catheters.
  • drug release should occur over a 2 to 24 week period.
  • Penile implants are used to treat erectile dysfunction and are generally flexible rods, hinged rods or inflatable devices with a pump.
  • the placement of penile implants can be complicated by infection (usually in the first 6 months after surgery) with Coagulase Negative Staphylococci (including Staphylococcus epidermidis ), Staphylococcus aureus, Pseudomonas aeruginosa , Enterococci, Serratia and Candida.
  • the type of device or route of insertion does not affect the incidence of infection. Infection is characterized by fever, erythema, induration and purulent drainage from the operative site.
  • the usual route of infection is through the incision at the time of surgery and up to 3% of penile implants become infected despite the best sterile surgical technique. To help combat this, intraoperative irrigation with antibiotic solutions is often employed.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the penile implant.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the penile implant; and/or (b) incorporated into the polymers which comprise the penile implant.
  • Drug-coating of, or drug incorporation into, the penile implant will allow bacteriocidal drug levels to be achieved locally, thus reducing the incidence of bacterial colonization (and subsequent development of local infection and device failure), while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the penile implant surface, several polymeric carriers are particularly suitable for use in this embodiment.
  • Endotracheal tubes and tracheostomy tubes are used to maintain the airway when ventilatory assistance is required. Endotracheal tubes tend to be used to establish an airway in the acute setting, while tracheostomy tubes are used when prolonged ventilation is required or when there is a fixed obstruction in the upper airway.
  • nosocomial pneumonia occurs 300,000 times per year and is the second most common cause of hospital-acquired infection (after urinary tract infection) and the most common infection in ICU patients.
  • nosocomial pneumonia is a frequent cause death with fatality rates over 50%. Survivors spend on average 2 weeks longer in hospital and the annual cost of treatment is close to $2 billion.
  • Bacterial pneumonia is the most common cause of excess morbidity and mortality in patients who require intubation. In patients who are intubated electively (i.e. for elective surgery), less than 1% will develop a nosocomial pneumonia. However, patients who are severely ill with ARDS (Adult Respiratory Distress Syndrome) have a greater than 50% chance of developing a nosocomial pneumonia. It is thought that new organisms colonize the oropharynx in intubated patients, are swallowed to contaminate the stomach, are aspirated to inoculate the lower airway and eventually contaminate the endotracheal tube.
  • ARDS Adult Respiratory Distress Syndrome
  • An effective endotracheal tube or tracheostomy tube coating would resist infection and prevent the formation of biofilm in the tube.
  • An effective coating would prevent or reduce the incidence of pneumonia, sepsis and death.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the endotracheal tube or tracheostomy tube. Due to its activity against Klebsiella pneumoniae , methotrexate can also be useful for this embobiment. As cisplatin and hydroxyurea have some activity against Pseudomonas aeruginosa , they can also be of some utility in the practice of this embodiment.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the endotracheal tube or tracheostomy tube; (b) as a coating applied to the internal (luminal) surface of the endotracheal tube or tracheostomy tube; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the endotracheal tube or tracheostomy tube.
  • Drug-coating of, or drug incorporation into, the endotracheal tube or tracheostomy tube will allow bacteriocidal drug levels to be achieved locally on the catheter surface, thus reducing the incidence of bacterial colonization (and subsequent development of pneumonia and sepsis), while producing negligible systemic exposure to the drugs.
  • polymeric carriers are not required for attachment of the drug to the endotracheal tube or tracheostomy tube surface, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof.
  • polyurethanes e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]
  • acrylic or methacrylic copolymers e.g. poly(ethylene-co-
  • endotracheal tube and tracheostomy tubes are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the endotracheal tube or tracheostomy tube, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines:
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the endotracheal tube or tracheostomy tube components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg. The dose per unit area (i.e.
  • the amount of drug as a function of the surface area of the portion of the endotracheal tube or tracheostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • doxorubicin should be applied to the endotracheal tube or tracheostomy tube surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the endotracheal tube or tracheostomy tube surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower concentrations are sufficient).
  • doxorubicin is released from the surface of the endotracheal tube or tracheostomy tube such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations from the endotracheal tube for a period ranging from 1 hour to 1 month, while release from a tracheostomy tube would range from 1 day to 3 months.
  • analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the endotracheal tube or tracheostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-20 ⁇ g per mm 2 of surface area.
  • mitoxantrone should be applied to the endotracheal tube or tracheostomy tube surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the endotracheal tube or tracheostomy tube surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • mitoxantrone is released from the endotracheal tube or tracheostomy tube surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations from the endotracheal tube for a period ranging from 1 hour to 1 month, while release from a tracheostomy tube would range from 1 day to 3 months.
  • analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • the amount of drug as a function of the surface area of the portion of the endotracheal tube or tracheostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the endotracheal tube or tracheostomy tube surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the endotracheal tube or tracheostomy tube surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e. are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the endotracheal tube or tracheostomy tube surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations from the endotracheal tube for a period ranging from 1 hour to 1 month, while release from a tracheostomy tube would range from 1 day to 3 months.
  • analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the endotracheal tube or tracheostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • etoposide should be applied to the endotracheal tube or tracheostomy tube surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the endotracheal tube or tracheostomy tube surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of ptoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • etoposide is released from the surface of the endotracheal tube or tracheostomy tube such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations from the endotracheal tube for a period ranging from 1 hour to 1 month, while release from a tracheostomy tube would range from 1 day to 3 months.
  • analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • Kidney failure patients have a dysfunctional immune response that makes them particularly susceptible to infection.
  • Infections of hemodialysis access grafts are characterized as either being early (within month; thought to be a complication of surgery) and late (after 1 month; thought to be related to access care). Over a 2 year period, approximately 2% of AVF's become infected while 11-16% of PTFE grafts will become infected on at least one occasion.
  • infection can result from extension of an infection from an adjacent contaminated tissue or hematogenous seeding, the most common cause of infection is intraoperative contamination. The most common causes of infection include Staphylococcus aureus , Enterobacteriaceae, Pseudomonas aerugenosa , and Coagulase Negative Staphylococci.
  • Complications arising from hemodialysis access graft infection include sepsis, subcutaneous infection, false aneurysm formation, endocarditis, osteomyelitis, septic arthritis, haemorrhage, septic or thrombotic emboli, graft thrombosis and septic dealth (2-4% of all infections). Treatment often requires removal of part or all of the graft combined with systemic antibiotics.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the synthetic hemodialysis access graft.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the graft; (b) as a coating applied to the internal (luminal) surface of the graft; and/or (c) as a coating applied to all or parts of both surfaces.
  • the drug would be formulated into a surgical implant placed around the outside of the fistula at the time of surgery.
  • polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g.
  • cellulose-derived polymers e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate
  • acrylate and methacrylate copolymers e.g. poly(ethylene-co-vinyl acetate)
  • An effective hemodialysis access graft coating would reduce the incidence of complications such as sepsis, haemorrhage, thrombosis, embolism, endocarditis, osteomyelitis and even death. An effective coating would also decrease the number of hemodialysis access grafts requiring replacement, resulting in lower mortality and morbidity for patients with these implants.
  • hemodialysis access grafts are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the graft coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the hemodialysis access graft, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines:
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the hemodialysis access graft components (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the hemodialysis access graft to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • doxorubicin should be applied to the hemodialysis access graft surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the hemodialysis access graft surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower concentrations are sufficient).
  • doxorubicin is released from the surface of the hemodialysis access graft such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the hemodialysis access graft (such as Dacron or Teflon), or applied without a carrier polymer
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the hemodialysis access graft to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-20 ⁇ g per mm 2 of surface area.
  • mitoxantrone should be applied to the hemodialysis access graft surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the hemodialysis access graft surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained.
  • mitoxantrone is released from the hemodialysis access graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • the amount of drug as a function of the surface area of the portion of the hemodialysis access graft to which drug is applied and/or incorporated) should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the hemodialysis access graft surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the hemodialysis access graft surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained.
  • 5-fluorouracil is released from the hemodialysis access graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the hemodialysis access graft to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • etoposide should be applied to the hemodialysis access graft surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the hemodialysis access graft surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained.
  • etoposide is released from the surface of the hemodialysis access graft such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • antithrombotic and/or antiplatelet agents for example heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, strept
  • antithrombotic and/or antiplatelet agents for example heparin, dextran sulphate,
  • a variety of central venous catheters are available for use in hemodialysis including, but not restricted to, catheters which are totally implanted such as the Lifesite (Vasca Inc., Tewksbury, Mass.) and the Dialock (Biolink Corp., Middleboro, Mass.). Central venous catheters are, prone to infection and embodiments for that purpose are described above.
  • Peritoneal dialysis catheters are typically double-cuffed and tunnelled catheters that provide access to the peritoneum.
  • the most common peritoneal dialysis catheter designs are the Tenckhoff catheter, the Swan Neck Missouri catheter and the Toronto Western catheter.
  • the peritoneum acts as a semipermeable membrane across which solutes can be exchanged down a concentration gradient.
  • Peritoneal dialysis infections are typically classified as either peritonitis or exit-site/tunnel infections (i.e. catheter infections). Exit-site/tunnel infections are characterized by redness, induration or purulent discharge from the exit site or subcutaneous portions of the catheter. Peritonitis is more a severe infection that causes abdominal pain, nausea, fever and systemic evidence of infection. Unfortunately, the peritoneal dialysis catheter likely plays a role in both types of infection. In exit-site/tunnel infections, the catheter itself becomes infected.
  • Peritoneal catheter-related infections are typically caused by Staphylococcus aureus , Coagulase Negative Staphylococci, Escherichia coli, Viridans group streptococci , Enterobacteriacae, Corynebacterium, Branhamella, Actinobacter, Serratia, Proteus, Pseudomonas aeruginosa and Fungi.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the synthetic peritoneal dialysis graft.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the graft; (b) as a coating applied to the internal (luminal) surface of the graft; (c) as a coating applied to the superficial cuff; (d) as a coating applied to the deep cuff; (e) incorporated into the polymers that comprise the graft; and/or (f) as a coating applied to a combination of these surfaces.
  • polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g.
  • cellulose-derived polymers e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate
  • acrylate and methacrylate copolymers e.g. poly(ethylene-co-vinyl acetate) as well as blends thereof.
  • An effective peritoneal dialysis graft coating would reduce the incidence of complications such as hospitalization, peritonoitis, sepsis, and even death. An effective coating would also decrease the number of peritoneal dialysis grafts requiring replacement, resulting in lower mortality and morbidity for patients with these implants.
  • peritoneal dialysis grafts are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the graft coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the peritoneal dialysis graft, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines:
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the peritoneal dialysis graft components (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the peritoneal dialysis graft to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • doxorubicin should be applied to the peritoneal dialysis graft surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the peritoneal dialysis graft surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower concentrations are sufficient).
  • doxorubicin is released from the surface of the peritoneal dialysis graft such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the peritoneal dialysis graft (such as Dacron or Teflon), or applied without a carrier polymer
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the peritoneal dialysis graft to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-20 ⁇ g per mm 2 of surface area.
  • mitoxantrone should be applied to the peritoneal dialysis graft surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the peritoneal dialysis graft surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • mitoxantrone is released from the peritoneal dialysis graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • the amount of drug as a function of the surface area of the portion of the peritoneal dialysis graft to which drug is applied and/or incorporated) should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the peritoneal dialysis graft surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the peritoneal dialysis graft surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the peritoneal dialysis graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the peritoneal dialysis graft to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • etoposide should be applied to the peritoneal dialysis graft surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the peritoneal dialysis graft surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • etoposide is released from the surface of the peritoneal dialysis graft such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1 week-6 months.
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • CSF cerebrospinal fluid
  • Ventricular CSF is diverted via a prosthetic shunt to a number of drainage locations including the pleura (ventriculopleural shunt), jugular vein, vena cava (VA shunt), gallbladder and peritoneum (VP shunt; most common).
  • pleura ventilation shunt
  • VA shunt vena cava
  • VP shunt peritoneum
  • CSF shunts are relatively prone to developing infection, although the incidence has declined from 25% twenty years ago to 10% at present as a result of improved surgical technique. Approximately 25% of all shunt complications are due to the development of infection of the shunt and these can lead to significant clinical problems such as ventriculitis, ventricular compartmentalization, meningitis, subdural empyema, nephritis (with VA shunts), seizures, cortical mantle thinning, mental retardation or death. Most infections present with fever, nausea, vomiting, malaise, or signs of increased intracranial pressure such as headache or altered consciousness.
  • CNS shunt infections are Coagulase Negative Staphylococci (67%; Staphylococcus epidermidis is the most frequently isolated organism), Staphylococcus aureus (10-20%), viridans streptococci, Streptococcus pyogenes, Enterococcus, Corynebacterium, Escherichia coli , Klebsiella, Proteus and Pseudomonas aeruginosa . It is thought that the majority of infections are due to inoculation of the organism during surgery, or during manipulation of the shunt in the postoperative period. As a result, most infections present clinically in the first few weeks following surgery.
  • An effective CNS shunt coating would reduce the incidence of complications such as ventriculitis, ventricular compartmentalization, meningitis, subdural empyema, nephritis (with VA shunts), seizures, cortical mantle thinning, mental retardation or death.
  • An effective coating would also decrease the number of CNS shunts requiring replacement, resulting in lower mortality and morbidity for patients with these implants.
  • an anthracycline e.g., doxorubicin and mitoxantrone
  • fluoropyrimidine e.g., 5-FU
  • folic acid antagonist e.g., methotrexate
  • podophylotoxin e.g., etoposide
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the shunt; (b) as a coating applied to the internal (luminal) surface of the shunt; and/or (c) as a coating applied to all or parts of both surfaces.
  • polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g.
  • cellulose-derived polymers e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate
  • acrylate and methacrylate copolymers e.g. poly(ethylene-co-vinyl acetate) as well as blends thereof.
  • CNS shunts are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the shunt coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the CNS shunt, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines:
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the CNS shunt components (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the CNS shunt to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • doxorubicin should be applied to the CNS shunt surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the CNS shunt surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface.
  • doxorubicin is released from the surface of the CNS shunt such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-12 weeks.
  • analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the CNS shunt to which drug is applied and/or incorporated should fall within the range of 0.01 ⁇ g-20 ⁇ g per mm 2 of surface area.
  • mitoxantrone should be applied to the CNS shunt surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the CNS shunt surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • mitoxantrone is released from the CNS shunt surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-12 weeks.
  • the amount of drug as a function of the surface area of the portion of the CNS shunt to which drug is applied and/or incorporated) should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the CNS shunt surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the CNS shunt surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained.
  • 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the CNS shunt surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-12 weeks.
  • analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e.
  • the amount of drug as a function of the surface area of the portion of the CNS shunt to which drug is applied and/or incorporated) should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • etoposide should be applied to the CNS shunt surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the CNS shunt surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained.
  • etoposide is released from the surface of the CNS shunt such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-12 weeks.
  • analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • EMD External Ventricular Drainage
  • ICP Intracranial Pressure
  • EVD and ICP monitoring devices are also used in the management of hydrocephalus.
  • the therapeutic agents, doses, coatings and release kinetics for the development of drug-coated EVD's and drug-coated ICP monitoring devices are identical to those described for CNS shunts.
  • Implanted orthopedic devices such as prosthetic joints such as hip, knee, elbow, shoulder, wrist, metacarpal, and metatarsal prosthetics are subject to complications as a result of infection of the implant.
  • Orthopedic implant infection has a variety of sequela including pain, immobility, failure of the prosthetic itself, loss/removal the of prosthetic, reoperation, loss of the affected limb or even death.
  • the cost of treating each infection exceeds the cost of the primary joint arthroplasty itself by 3 or 4-fold (in excess of $50,000/case).
  • Other orthopedic implant hardware such as internal and external fixation devices, plates and screws are also subject to such infection and infection-related complications.
  • the present treatment includes multiple operations to remove infected prosthetics, with its own inherent risks, combined with antibiotic use.
  • the rate of orthopedic prosthetic infection is highest in the first month post operatively then declines continuously there after.
  • the combined incidence of rate of prosthetic joint infection for 2 years is approximately 5.9% per 1,000 joints; the rate then drops to 2.3% per 1,000 joints from year 2 to 10.
  • the rate of infection also varies depending on the joint. Knee prosthetics are infected twice as frequently as hips. Shoulder prosthetic infections range from 0.5% to 3%, elbows up to 12%, wrists 1.5% to 5.0% and ankles 1.4% to 2.4%.
  • Risk factors are multiple.
  • the host may be compromised as a result of a systemic condition, an illness, a local condition, or as a result of medications that decrease the host defence capability.
  • Repeat surgical procedures increase the likelihood of infection as there is a reported 8-fold elevated risk of infection as compared to the primary prosthetic replacement procedure.
  • the presence of a deep infection increases the risk of prosthetic infection 6-fold.
  • Various diseases also increase the risk of infection.
  • rheumatoid arthritis patients have a higher risk of infection possibly as a result of medications that compromising their immunocompetency, while psoriatic patients have a higher rate possibly mediated by a compromised skin barrier that allows entry of microbes.
  • Different implant materials have their own inherent rate of infection.
  • a metal-to-metal hinged prosthetic knee has 20-times the risk of infection of a metal-to-plastic knee.
  • prosthetic joint infections are caused by gram positive cocci, ( Staphylococcus aureus , Coagulase Negative Staphylococci, Beta-Hemolytic Streptococcus, Viridans Group Streptococci) and enterococci. Often multiple strains of staphylococcus can be present in a single prosthetic infection. Other organisms include aerobic gram negative bacilli, Enterobacteriacea, Pseudomonas aeruginosa and Anaerobes (such as Peptostreptococcus and Bacteroides species). Polymicrobial infections account for 12% of infections.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the orthopedic implant.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external intraosseous surface of the prosthesis; (b) as a coating applied to the external (articular) surface of the prosthesis; (c) as a coating applied to all or parts of both surfaces; (d) as a coating applied to the surface of the orthopedic hardware (plates, screws, etc); (e) incorporated into the polymers which comprise the prosthetic joints (e.g. articular surfaces and other surface coatings) and hardware (e.g. polylactic acid screws and plates); and/or (f) incorporated into the components of the cements used to secure the orthopedic implants in place.
  • polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g.
  • cellulose-derived polymers e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate
  • acrylate and methacrylate copolymers e.g. poly(ethylene-co-vinyl acetate) as well as blends thereof.
  • the drugs of interest can also be incorporated into calcium phosphate or hydroxyapatite coatings on the medical devices.
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the orthopedic implant components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the orthopedic implant to which drug is applied and/or incorporated
  • doxorubicin should be applied to the orthopedic implant surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the orthopedic implant surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria. and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower concentrations are sufficient).
  • doxorubicin is released from the surface of the orthopedic implant such that anti-infective activity is maintained for a period ranging from several hours to several months. As described previously, the risk of infectious contamination of the implant is greatest over the first 3 days. Therefore, in a particularly preferred embodiment, the majority (or all) of the drug is released over the first 72 hours to prevent infection while allowing normal healing to occur thereafter.
  • analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg).
  • the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the orthopedic implant to which drug is applied and/or incorporated
  • mitoxantrone should be applied to the orthopedic implant surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the orthopedic implant surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • mitoxantrone is released from the orthopedic implant surface such that anti-infective activity is maintained for a period ranging from several hours to several months. As described previously, the risk of infectious contamination of the implant is greatest over the first 3 days. Therefore, in one embodiment, the majority (or all) of the drug is released over the first 72 hours to prevent infection while allowing normal healing to occur thereafter. It should be readily evident based upon the discussion provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 ⁇ g to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 ⁇ g to 25 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the orthopedic implant to which drug is applied and/or incorporated should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the orthopedic implant surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the orthopedic implant surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (ie., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the orthopedic implant surface such that anti-infective activity is maintained for a period ranging from several hours to several months. As described previously, the risk of infectious contamination of the implant is greatest over the first 3 days. Therefore, in a particularly preferred embodiment, the majority (or all) of the drug is released over the first 72 hours to prevent infection while allowing normal healing to occur thereafter.
  • analogues and derivatives of 5-fluorouracil as described previously
  • the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the orthopedic implant to which drug is applied and/or incorporated should fall within the range of 0.01 ⁇ g-100 ⁇ g per mm 2 of surface area.
  • etoposide should be applied to the orthopedic implant surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the orthopedic implant surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • etoposide is released from the surface of the orthopedic implant such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the risk of infectious contamination of the implant is greatest over the first 3 days. Therefore, in a particularly preferred embodiment, the majority (or all) of the drug is released over the first 72 hours to prevent infection while allowing normal healing to occur thereafter.
  • analogues and derivatives of etoposide with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • anthracyclines e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • Implants are commonly used in the practice of medicine and surgery for a wide variety of purposes. These include implants such as drainage tubes, biliary T-tubes, clips, sutures, meshes, barriers (for the prevention of adhesions), anastomotic devices, conduits, irrigation fluids, packing agents, stents, staples, inferior vena cava filters, embolization agents, pumps (for the delivery of therapeutics), hemostatic implants (sponges), tissue fillers, cosmetic implants (breast implants, facial implants, prostheses), bone grafts, skin grafts, intrauterine devices (IUD), ligatures, titanium implants (particularly in dentistry), chest tubes, nasogastric tubes, percutaneous feeding tubes, colostomy devices, bone wax, and Penrose drains, hair plugs, ear rings, nose rings, and other piercing-associated implants, as well as anaesthetic solutions to name a few. Any foreign body when placed into the body is at risk for developing an infection—particularly
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide can be added to solutions used in medicine (storage solutions, irrigation fluids, saline, mannitol, glucose solutions, lipids, nutritional fluids, and anaesthetic solutions) to prevent infection transmitted via infected solutions/fluids used in patient management.
  • doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the intraocular lens.
  • the drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the lens; (b) as a coating applied to the internal (luminal) surface of the lens; (c) as a coating applied to all or parts of both surfaces of the lens; and/or (d) incorporated into the polymers which comprise the lens.
  • polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment.
  • polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640TM [CT Biomaterials], HYDROSLIP CTM [CT Biomaterials], HYDROTHANETM [CT Biomaterials]), acrylic or methacrylic copolymers (e.g.
  • cellulose-derived polymers e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate
  • acrylate and methacrylate copolymers e.g. poly(ethylene-co-vinyl acetate) as well as blends thereof.
  • the exact dose administered will vary with lens size, surface area, design and portions of the lens coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the lens being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the intraocular lens, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines:
  • anthracyclines Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the intraocular lens components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the intraocular lens to which drug is applied and/or incorporated
  • doxorubicin should be applied to the intraocular lens surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the intraocular lens surface such that a minimum concentration of 10 ⁇ 7 -10 ⁇ 4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower concentrations are sufficient).
  • doxorubicin is released from the surface of the intraocular lens such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-12 weeks.
  • the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 ⁇ g to 5 mg).
  • the total amount of drug applied should be in the range of 0.1 ⁇ g to 1 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the intraocular lens to which drug is applied and/or incorporated
  • mitoxantrone should be applied to the intraocular lens surface at a dose of 0.05 ⁇ g/mm 2 -3 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the intraocular lens surface such that a minimum concentration of 10 ⁇ 5 -10 ⁇ 6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • mitoxantrone is released from the intraocular lens surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-12 weeks.
  • the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 ⁇ g to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 ⁇ g to 25 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the intraocular lens to which drug is applied and/or incorporated should fall within the range of 0.1 ⁇ g-1 mg per mm 2 of surface area.
  • 5-fluorouracil should be applied to the intraocular lens surface at a dose of 1.0 ⁇ g/mm 2 -50 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the intraocular lens surface such that a minimum concentration of 10 ⁇ 4 -10 ⁇ 7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10 ⁇ 4 M; although for some embodiments lower drug levels will be sufficient).
  • 5-fluorouracil is released from the intraocular lens surface such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-12 weeks.
  • the total dose of etoposide applied should not exceed 25 mg (range of 0.1 ⁇ g to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 ⁇ g to 5 mg.
  • the dose per unit area i.e. the amount of drug as a function of the surface area of the portion of the intraocular lens to which drug is applied and/or incorporated
  • etoposide should be applied to the intraocular lens surface at a dose of 0.1 ⁇ g/mm 2 -10 ⁇ g/mm 2 .
  • the above dosing parameters should be utilized in combination with the release rate of the drug from the intraocular lens surface such that a concentration of 10 ⁇ 5 -10 ⁇ 6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10 ⁇ 5 M; although for some embodiments lower drug levels will be sufficient).
  • etoposide is released from the surface of the intraocular lens such that anti-infective activity is maintained for a period ranging from several hours to several months.
  • the drug is released in effective concentrations for a period ranging from 1-12 weeks.
  • anthracyclihes e.g., doxorubicin or mitoxantrone
  • fluoropyrimidines e.g., 5-fluorouracil
  • folic acid antagonists e.g., methotrexate
  • podophylotoxins e.g., etoposide
  • Contact lenses are primarily used for the correction of refractive errors, but are also used after cataract surgery (Aphakie lenses) and “bandage” lenses are used following corneal trauma. Over 24 million people wear contact lenses and many of them will suffer from ulcerative keratitis resulting from contact lens-associated infection. These infections are typically bacterial in nature, are secondary to corneal damage/defects, and are caused primarily by Gram Positive Cocci and Pseudomonas aeruginosa.
  • doxorubicin mitoxantrone
  • 5-fluorouracil 5-fluorouracil
  • etoposide can be added to contact lens storage solution to prevent infection transmitted via infected cleaning/storage solutions.
  • MIC assays were conducted essentially as described by Amsterdam, D. 1996. Susceptibility testing of antimicrobials in liquid media, p.52-111. In Loman, V., ed. Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, Md. Briefly, a variety of compounds were tested for antibacterial activity against isolates of P. aeruginosa, K. pneumoniae, E. coli. S. epidermidus and S. aureus in the MIC (minimum inhibitory concentration assay under aerobic conditions using 96 well polystyrene microtitre plates (Falcon 1177), and Mueller Hinton broth at 37° C. incubated for 24 h.
  • Compounds which showed inhibition of growth included: mitoxantrone (both strains), methotrexate (vancomycin resistant pediococcus), 5-fluorouracil (both strains), etoposide (both strains), and 2-mercaptopurine (vancomycin resistant pediococcus).
  • a coating solution is prepared by dissolving 20 g ChronoFlex Al 85A (CT Biomaterials) in 100 mL DMAC:THF (40:60) at 50° C. with stirring. Once dissolved, the polymer solution is cooled to room temperature. 20 mg mitoxantrone is added to 2 mL of the polyurethane solution. The solution is stirred until a homogenious mixture is obtained. Polyurethane 7 French tubing is dipped into the polymer/drug solution and then withdrawn. The coated tube is air dried (80° C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • a coating solution is prepared by dissolving 2 g PLG (50:50) in 10 mL dichloromethane:methanol (70:30). Once dissolved, 20mg mitoxantrone is added to the polymer solution. Once the solution is a homogeneous solution, polyurethane 7 French tubing is dipped into the solution and then withdrawn. The coated tube is air dried. The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • a coating solution is prepared by dissolving 20 g ChronoFlex Al 85A (CT Biomaterials) in 100 mL DMAC:THF (50:50) at 50° C. with stirring. Once dissolved, the polymer solution is cooled to room temperature. 20 mg mitoxantrone is added to 2 mL of the polyurethane solution. The solution is stirred until a homogenious mixture is obtained. A stainless steel tympanostomy tube is dipped into the polymer/drug solution and then withdrawn. The coated tube is air dried (80° C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • a coating solution is prepared by dissolving 20 g ChronoFlex Al 85A (CT Biomaterials) in 100 mL THF at 50° C. with stirring. Once dissolved, the polymer solution is cooled to room temperature. 20 mg etoposide is added to 2 mL of the polyurethane solution. The solution is stirred until a homogenious mixture is obtained. Polyurethane 7 French tubing is dipped into the polymer/drug solution and then withdrawn. The coated tube is air dried (80 C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • CT Biomaterials ChronoFlex Al 85A
  • a coating solution is prepared by dissolving 2 g PLG (50:50) in 10 mL dichloromethane:methanol (70:30). Once dissolved, 20 mg etoposide is added to the polymer solution. Once the solution is a homogeneous solution, polyurethane 7 French tubing is dipped into the solution and then withdrawn. The coated tube is air dried. The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • a coating solution is prepared by dissolving 20 g ChronoFlex Al 85A (CT Biomaterials) in 100 mL DMAC:THF (50:50) at 50° C. with stirring. Once dissolved, the polymer solution is cooled to room temperature. 20 mg etoposide is added to 2 mL of the polyurethane solution. The solution is stirred until a homogenious mixture is obtained. A stainless steel tympanostomy tube is dipped into the polymer/drug solution and then withdrawn. The coated tube is air dried (80° C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • EDC 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
  • a piece of polyurethane 7 French tubing that has undergone a oxygen plasma pretreatment step is dipped into a water:methanol (30:70) solution that contained 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 20 mg/mL Doxorubicin. After various times (15 min, 30 min, 60 min 120 min) the tubing is removed from the solution and dried at 60° C. for 2 hours followed by vacuum drying for 24 hours.
  • EDC 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
  • a solution was prepared by dissolving 100 mg of 5-Fluorouracil into 20 ml anhydrous methanol. Polyurethane catheter tubing was immersed in this solution for 16 hours. The catheter tubing was vacuum dried at 50° C. for 16 hours.
  • a solution was prepared by dissolving 20 mg of Mitoxantrone-2HCl into 20 ml anhydrous methanol. Polyurethane catheter tubing was immersed in this solution for 16 hours. The catheter tubing was vacuum dried at 50° C. for 16 hours.
  • a solution was prepared by dissolving 20 mg of Doxorubicin-HCl into 20 ml anhydrous methanol. Polyurethane catheter tubing was immersed in this solution for 16 hours. The catheter tubing was vacuum dried at 50° C. for 16 hours.
  • a solution was prepared by dissolving 125 mg 5-Fluorouracil and 2.5 g of Chronoflex AL85A (CT Biomaterials) in 50 ml of THF at 55° C. The solution was cooled to room temperature. Polyurethane catheters were weighted at one end and dipped in solution and then removed immediately. This process was repeated three times with 1 minute drying time interval between each dipping process. The catheter tubing was vacuum dried at 50° C. for 16 hours.
  • a solution was prepared by dissolving 125 mg 5-Fluorouracil, 62.5 mg of palmitic acid, and 2.437 g of ChronoflexAL85A (CT Biomaterials) in 50 ml of THF at 55° C. The solution was cooled to room temperature. Polyurethane catheters were weighted at one end and dipped in solution and then removed immediately. This process was repeated three times with a 1 minute drying time interval between each dipping process. The catheter tubing was vacuum dried at 50° C. for 16 hours.
  • Catheters are weighted at one end and dipped into 5% Nafion solution (Dupont) and then removed immediately. This process was repeated three times with a 1 minute drying time interval between each dipping process.
  • the catheter tubing was dried at room temperature for 2 hours.
  • a solution was prepared with 1 mg of mitoxantrone-2HCl in 40 ml of deionized water. The catheter tubing was immersed in the solution for 5 minutes, and then was washed with deionized water and dried at room temperature.
  • Catheters are weighted at one end and dipped into 5% Nafion solution (Dupont) and then removed immediately. This process was repeated three times with a 1 minute drying time interval between each dipping process.
  • the catheter tubing was dried at room temperature for 2 hours.
  • a solution was prepared with 1 mg of doxorubicin-HCl in 40 ml of deionized water. The catheter tubing was immersed in the solution for 5 minutes, and then was washed with deionized water and dried at room temperature.
  • the release buffer was prepared by adding 8.22 g sodium chloride, 0.32 g sodium phosphate monobasic (monohydrate) and 2.60 g sodium phosphate dibasic (anhydrous) to a beaker. 1 L HPLC grade water was added and the solution was stirred until all the salts were dissolved. If required, the pH of the solution was adjusted to pH 7.4 ⁇ 0.2 using either 0.1N NaOH or 0.1N phosphoric acid.
  • a sample of the therapeutic agent-loaded catheter was placed in a 15 mL culture tube.
  • 15 mL release buffer (Example 21) was added to the culture tube.
  • the tube was sealed with a Teflon lined screw cap and was placed on a rotating wheel in a 37° C. oven.
  • the buffer is withdrawn from the culture tube and is replaced with fresh buffer.
  • the withdrawn buffer is then analysed for the amount of therapeutic agent contained in this buffer solution.
  • FIG. 1 show the effect of palmitic acid on the release profile of 5-fluorouracil.
  • An overnight bacterial culture was diluted 1 to 5 to a final volume of 5 mls fresh Mueller Hinton broth. Then 100 ⁇ l of the diluted bacterial culture were spread onto Mueller Hinton agar plates.
  • a test material e.g., catheter tubing
  • catheters are typically 1 cm long and about 3 mm in diameter (which may be made of polyurethane, silicon or other suitable material) and are loaded with drug either through dip-coating or through use of a drug-impregnated coating. The plates were incubated at 37° C. for 16-18 hours.
  • the zone of clearing around a test material was then measured (e.g., the distance from the catheter to where bacterial growth is inhibited), which indicated the degree of bacterial growth prevention.
  • Various bacterial strains that may be tested include, but are not limited to, the following: E. coli C498 UB1005, P. aeruginosa H187, S. aureus C622 ATCC 25923, and S. epidermidis C621.

Abstract

Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0001]
  • The present invention relates generally to pharmaceutical compositions, methods, and devices, and more specifically, to compositions and methods which reduce the likelihood of an infection associated with a medical implant. [0002]
  • 2. Description of the Related Art [0003]
  • Infections associated with medical implants represent a major healthcare problem. For example, 5% of patients admitted to an acute care facility develop a hospital acquired infection. Hospital acquired infections (nosocomial infections) are the 11[0004] th leading cause of death in the US and cost over $2 billion annually. Nosocomial infections directly cause 19,000 deaths per year in the US and contribute to over 58,000 others.
  • The four most common causes of nosocomial infections are: urinary tract infection (28%); surgical site infection (19%); respiratory tract infection (17%); and bloodstream infection (16% and rising). A significant percentage of these infections are related to bacterial colonization of implanted medical implants such as Foley catheters (urinary tract infections); surgical drains, meshes, sutures, artificial joints, vascular grafts (wound infections); endotracheal and tracheostomy tubes (respiratory tract infection); and vascular infusion catheters (bloodstream infections). Although any infectious agent can infect medical implant, Staphylococci ([0005] S. aureus, S. epidermidis, S. pyogenes), Enterococci (E. coli), Gram Negative Aerobic Bacilli, and Pseudomonas aeruginosa are common causes. Once a medical implant becomes colonized by bacteria, it must frequently be replaced resulting in increased morbidity for the patient and increased cost to the healthcare system. Often the infected device serves as a source for a disseminated infection which can lead to significant morbidity or even death.
  • In an attempt to combat this important clinical problem, devices have been coated with antimicrobial drugs. Representative examples include U.S. Pat. No. 5,520,664 (“Catheter Having a Long-Lasting Antimicrobial Surface Treatment”), U.S. Pat. No. 5,709,672 (“Silastic and Polymer-Based Catheters with Improved Antimicrobial/Antifungal Properties”), U.S. Pat. No. 6,361,526 (“Antimicrobial Tympanostomy Tubes”), U.S. Pat. No. 6,261,271 (“Anti-infective and antithrombogenic medical articles and method for their preparation”), U.S. Pat. No. 5,902,283 (“Antimicrobial impregnated catheters and other medical implants”) U.S. Pat. No. 5,624,704 (“Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent”) and U.S. Pat. No. 5,709,672 (“Silastic and Polymer-Based Catheters with Improved Antimicrobial/Antifungal Properties”). [0006]
  • One difficulty with these devices, however, is that they can become colonized by bacteria resistant to the antibiotic coating. This can result in at least two distinct clinical problems. First, the device serves as a source of infection in the body with the resulting development of a local or disseminated infection. Secondly, if an infection develops, it cannot be treated with the antibiotic(s) used in the device coating. The development of antibiotic-resistant strains of microbes remains a significant healthcare problem, not just for the infected patient, but also for the healthcare institution in which it develops. [0007]
  • Thus, there is a need in the art for medical implants which have a reduced likelihood of an associated infection. The present invention discloses such devices (as well as compositions and methods for making such devices) which reduce the likelihood of infections in medical implants, and further, provides other, related advantages. [0008]
  • BRIEF DESCRIPTION OF THE DRAWING
  • FIG. 1 shows the effect of palmitic acid on the release profile of 5-fluorouracil from a polyurethane sample.[0009]
  • BRIEF SUMMARY OF THE INVENTION
  • Briefly stated, the present invention provides compositions and methods for preventing, reducing or inhibiting the likelihood of infections associated with medical implants. More specifically, within one aspect of the invention medical implants or devices are provided which release a chemotherapeutic agent, wherein the chemotherapeutic agent reduces, inhibits, or prevents the growth or transmission of foreign organisms (e.g., bacteria, fungi, or viruses) which are on or are associated with the medical device or implant. For example, within one aspect of the invention medical implant or devices are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. Within various embodiments, the implant is coated in whole or in part with a composition comprising an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. [0010]
  • Other aspects of the present invention provide methods for making medical implants, comhprising adapting a medical implant (e.g., coating the implant) with an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. Within certain embodiments, the desired therapeutic agent is coated on and/or released from the medical implant at a dosage and/or concentration which is less than the typical dosage and/or concentration of the agent when used in the treatment of cancer. [0011]
  • A wide variety of medical implants can be generated using the methods provided herein, including for example, catheters (e.g., vascular and dialysis catheters), heart valves, cardiac pacemakers, implantable cardioverter defibrillators, grafts (e.g., vascular grafts), ear, nose, or throat implants, urological implants, endotracheal or tracheostomy tubes, CNS shunts, orthopedic implants, and ocular implants. Within certain embodiments, the catheter (e.g., vascular and dialysis catheters), heart valve, cardiac pacemaker, implantable cardioverter defibrillator, graft (e.g., vascular grafts), ear, nose, or throat implant, urological implant, endotracheal or tracheostomy tube, CNS shunt, orthopedic implant, or ocular implant releases a fluoropyrimide (e.g., 5-FU) at a dosage and/or concentration which is less than a typical dosage and/or concentration which is used for the treatment of cancer. [0012]
  • Within further aspects of the invention, there is provided a catheter which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the catheter releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the catheter further comprises a polymer wherein the agent is released from a polymer on the catheter. In certain embodiments, the catheter has a polymer that is polyurethane or poly(lactide-co-glycolide) (PLG). In related embodiments, the catheter is a vascular catheter or a dialysis catheter. In still other embodiments, the catheter relaeases an agent that is present on the catheter at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0013]
  • Within further aspects of the invention, there is provided a heart valve which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the heart valve releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the heart valve further comprises a polymer wherein the agent is released from a polymer on the heart valve. In certain embodiments, the heart valve has a polymer that is polyurethane or PLG. In related embodiments, the heart valve is a prosthetic heart valve. In still other embodiments, the heart valve relaeases an agent that is present on the heart valve at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0014]
  • Within further aspects of the invention, there is provided a cardiac pacemaker which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the cardiac pacemaker releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the cardiac pacemaker further comprises a polymer wherein the agent is released from a polymer on the cardiac pacemaker. In certain embodiments, the cardiac pacemaker has a polymer that is polyurethane or PLG. In still other embodiments, the cardiac pacemaker relaeases an agent that is present on the cardiac pacemaker at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0015]
  • Within further aspects of the invention, there is provided a implantable cardioverter defibrillator which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the implantable cardioverter defibrillator releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the implantable cardioverter defibrillator further comprises a polymer wherein the agent is released from a polymer on the implantable cardioverter defibrillator. In certain embodiments, the implantable cardioverter defibrillator has a polymer that is polyurethane or PLG. In still other embodiments, the implantable cardioverter defibrillator relaeases an agent that is present on the implantable cardioverter defibrillator at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0016]
  • Within further aspects of the invention, there is provided a graft which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the graft releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the graft further comprises a polymer wherein the agent is released from a polymer on the graft. In certain embodiments, the graft has a polymer that is polyurethane or PLG. In related embodiments, the graft is a vascular graft or a hemodialysis access graft. In still other embodiments, the graft relaeases an agent that is present on the graft at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0017]
  • Within further aspects of the invention, there is provided a ear, nose, or throat implant which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the ear, nose, or throat implant releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the ear, nose, or throat implant further comprises a polymer wherein the agent is released from a polymer on the ear, nose, or throat implant. In certain embodiments, the ear, nose, or throat implant has a polymer that is polyurethane or PLG. In related embodiments, the ear, nose, or throat implant is a tympanostomy tube or a sinus stent. In still other embodiments, the ear, nose, or throat implant relaeases an agent that is present on the ear, nose, or throat implant at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0018]
  • Within further aspects of the invention, there is provided a urological implant which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the urological implant releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the urological implant further comprises a polymer wherein the agent is released from a polymer on the urological implant. In certain embodiments, the urological implant has a polymer that is polyurethane or PLG. In related embodiments, the urological implant is a urinary catheter, ureteral stent, urethral stent, bladder sphincter, or penile implant. In still other embodiments, the urological implant relaeases an agent that is present on the urological implant at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0019]
  • Within further aspects of the invention, there is provided a endotracheal or tracheostomy tube which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the endotracheal or tracheostomy tube releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the endotracheal or tracheostomy tube further comprises a polymer wherein the agent is released from a polymer on the endotracheal or tracheostomy tube. In certain embodiments, the endotracheal or tracheostomy tube has a polymer that is polyurethane or PLG. In still other embodiments, the endotracheal or tracheostomy tube relaeases an agent that is present on the endotracheal or tracheostomy tube at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0020]
  • Within further aspects of the invention, there is provided a CNS shunt which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the CNS shunt releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the CNS shunt further comprises a polymer wherein the agent is released from a polymer on the CNS shunt. In certain embodiments, the CNS shunt has a polymer that is polyurethane or PLG. In related embodiments, the CNS shunt is a ventriculopleural shunt, a VA shunt, or a VP shunt. In still other embodiments, the CNS shunt relaeases an agent that is present on the CNS shunt at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0021]
  • Within further aspects of the invention, there is provided a orthopedic implant which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the orthopedic implant releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the orthopedic implant further comprises a polymer wherein the agent is released from a polymer on the orthopedic implant. In certain embodiments, the orthopedic implant has a polymer that is polyurethane or PLG. In related embodiments, the orthopedic implant is a prosthetic joint or fixation device. In still other embodiments, the orthopedic implant relaeases an agent that is present on the orthopedic implant at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0022]
  • Within further aspects of the invention, there is provided a ocular implant which releases an agent selected from the group consisting of an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. In one embodiment, the ocular implant releases a fluoropyrimidine and in still another embodiment the fluoropyrimidine is 5-FU. In other embodiments, the ocular implant further comprises a polymer wherein the agent is released from a polymer on the ocular implant. In certain embodiments, the ocular implant has a polymer that is polyurethane or PLG. In related embodiments, the ocular implant is an intraocular lens or a contact lens. In still other embodiments, the ocular implant relaeases an agent that is present on the ocular implant at a concentration which is less than the typical dosage and/or concentration that is used in the treatment of cancer. [0023]
  • Within other aspects of the invention, compositions are provided comprising a polymer and an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex, wherein said anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex is present in said composition at a concentration of less than any one of 10[0024] −4 M, 10−5 M, 10−6 M, or, 10−7 M.
  • Also provided methods for reducing or inhibiting infection associated with a medical implant, comprising the step of introducing a medical implant into a patient which has been coated with an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex. [0025]
  • Within various embodiments of the above, the anthracycline is doxorubicin or mitoxantrone, the fluoropyrimidine is 5-fluorouracil, the folic acid antagonist is methotrexate, and the podophylotoxin is etoposide. Within further embodiments the composition further comprises a polymer. [0026]
  • These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (e.g., compounds or agents and methods for making such compounds or agents, etc.), and are therefore incorporated by reference in their entirety. When PCT applications are referred to it is also understood that the underlying or cited U.S. applications are also incorporated by reference herein in their entirety. [0027]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms that will be used hereinafter. [0028]
  • “Medical implant” refers to devices or objects that are implanted or inserted into a body. Representative examples include vascular catheters, prosthetic heart valves, cardiac pacemakers, implantable cardioverter defibrillators, vascular grafts, ear, nose, or throat implants, urological implants, endotracheal or tracheostomy tubes, dialysis catheters, CNS shunts, orthopedic implants, and ocular implants. [0029]
  • As used herein, the term “about” or “consists essentially of” refers to ±15% of any indicated structure, value, or range. Any numerical ranges recited herein are to be understood to include any integer within the range and, where applicable (e.g., concentrations), fractions thereof, such as one tenth and one hundredth of an integer (unless otherwise indicated). [0030]
  • Briefly, as noted above, the present invention discloses medical implants (as well as compositions and methods for making medical implants) which reduce the likelihood of infections in medical implants. More specifically, as noted above, infection is a common complication of the implantation of foreign bodies such as medical devices. Foreign materials provide an ideal site for micro-organisms to attach and colonize. It is also hypothesized that there is an impairment of host defenses to infection in the microenvironment surrounding a foreign material. These factors make medical implants particularly susceptible to infection and make eradication of such an infection difficult, if not impossible, in most cases. [0031]
  • Medical implant failure as a result of infection, with or without the need to replace the implant, results in significant morbidity, mortality and cost to the healthcare system. Since there is a wide array of infectious agents capable of causing medical implant infections, there exists a significant unmet need for therapies capable of inhibiting the growth of a diverse spectrum of bacteria and fungi on implantable devices. The present invention meets this need by providing drugs that can be released from an implantable device, and which have potent antimicrobial activity at extremely low doses. Further, these agents have the added advantage that should resistance develop to the chemotherapeutic agent, the drug utilized in the coating would not be one which would be used to combat the subsequent infection (i.e., if bacterial resistance developed it would be to an agent that is not used as an antibiotic). [0032]
  • Discussed in more detail below are (I) Agents; (II) Compositions and Formulations; (III) Devices, and (IV) Clinical Applications. [0033]
  • I. AGENTS
  • Briefly, a wide variety of agents (also referred to herein as ‘therapeutic agents’ or ‘drugs’) can be utilized within the context of the present invention, either with or without a carrier (e.g., a polymer; see section II below). Discussed in more detail below are (A) Anthracyclines (e.g., doxorubicin and mitoxantrone), (B) Fluoropyrimidines (e.g., 5-FU), (C) Folic acid antagonists (e.g., methotrexate), (D) Podophylotoxins (e.g., etoposide), (E) Camptothecins, (F) Hydroxyureas, and (G) Platinum complexes (e.g., cisplatin). [0034]
  • A. Anthracyclines
  • Anthracyclines have the following general structure, where the R groups may be a variety of organic groups: [0035]
    Figure US20040043052A1-20040304-C00001
  • According to U.S. Pat. No. 5,594,158, suitable R groups are as follows: R[0036] 1 is CH3 or CH2OH; R2 is daunosamine or H; R3 and R4 are independently one of OH, NO2, NH2, F, Cl, Br, I, CN, H or groups derived from these; R5 is hydrogen, hydroxy, or methoxy; and R6-8 are all hydrogen. Alternatively, R5 and R6 are hydrogen and R7 and R8 are alkyl or halogen, or vice versa.
  • According to U.S. Pat. No. 5,843,903, R[0037] 1 may be a conjugated peptide. According to U.S. Pat. No. 4,296,105, R5 may be an ether linked alkyl group. According to U.S. Pat. No. 4,215,062, R5 may be OH or an ether linked alkyl group. R1 may also be linked to the anthracycline ring by a group other than C(O), such as an alkyl or branched alkyl group having the C(O) linking moiety at its end, such as —CH2CH(CH2—X)C(O)—R1, wherein X is H or an alkyl group (see, e.g., U.S. Pat. No. 4,215,062). R2 may alternately be a group linked by the functional group ═N—NHC(O)—Y, where Y is a group such as a phenyl or substituted phenyl ring. Alternately R3 may have the following structure:
    Figure US20040043052A1-20040304-C00002
  • in which R[0038] 9 is OH either in or out of the plane of the ring, or is a second sugar moiety such as R3. R10 may be H or form a secondary amine with a group such as an aromatic group, saturated or partially saturated 5 or 6 membered heterocyclic having at least one ring nitrogen (see U.S. Pat. No. 5,843,903). Alternately, R10 may be derived from an amino acid, having the structure —C(O)CH(NHR11)(R12), in which R11 is H, or forms a C3-4 membered alkylene with R12. R12 may be H, alkyl, aminoalkyl, amino, hydroxy, mercapto, phenyl, benzyl or methylthio (see U.S. Pat. No. 4,296,105).
  • Exemplary anthracyclines are Doxorubicin, Daunorubicin, Idarubicin, Epirubicin, Pirarubicin, Zorubicin, and Carubicin. Suitable compounds have the structures: [0039]
    Figure US20040043052A1-20040304-C00003
    R1 R2 R3
    Doxorubicin: OCH3 C(O)CH2OH OH out of ring plane
    Epirubicin:
    (4′ epimer of OCH3 C(O)CH2OH OH in ring plane
    doxorubicin)
    Daunorubicin: OCH3 C(O)CH3 OH out of ring plane
    Idarubicin: H C(O)CH3 OH out of ring plane
    Pirarubicin: OCH3 C(O)CH2OH
    Figure US20040043052A1-20040304-C00004
    Zorubicin: OCH3 C(CH3)(═N)NHC(O)C6H5 OH
    Carubicin: OH C(O)CH3 OH out of ring plane
  • Other suitable anthracyclines are Anthramycin, Mitoxantrone, Menogaril, Nogalamycin, Aclacinomycin A, Olivomycin A, Chromomycin A[0040] 3, and Plicamycin having the structures:
    Figure US20040043052A1-20040304-C00005
    R1 R2 R3
    Menogaril Nogallamycin H O-sugar sugar
    Figure US20040043052A1-20040304-C00006
    OCH3H H COOCH3
    Figure US20040043052A1-20040304-C00007
    R1 R2 R3 R4
    Olivomycin A COCH(CH3)2 CH3 COCH3 H
    Chromomycin A3 COCH3 CH3 COCH3 CH3
    Plamycin H H H CH3
    Figure US20040043052A1-20040304-C00008
  • Other representative anthracyclines include, FCE 23762 doxorubicin derivative (Quaglia et al., [0041] J. Liq. Chromatogr 17(18):3911-3923, 1994), annamycin (Zou et al., J. Pharm. Sci. 82(11):1151-1154, 1993), ruboxyl (Rapoport et al., J. Controlled Release 58(2): 153-162, 1999), anthracycline disaccharide doxorubicin analogue (Pratesi et al., Clin. Cancer Res. 4(11):2833-2839, 1998), N-(trifluoroacetyl)doxorubicin and 4′-O-acetyl-N-(trifluoroacetyl)doxorubicin (Berube & Lepage, Synth. Commun. 28(6):1109-1116, 1998), 2-pyrrolinodoxorubicin (Nagy et al., Proc. Nat'l Acad. Sci. U.S.A. 95(4):1794-1799, 1998), disaccharide doxorubicin analogues (Arcamone et al., J. Nat'l Cancer Inst. 89(16):1217-1223, 1997), 4-demethoxy-7-O-[2,6-dideoxy-4-O-(2,3,6-trideoxy-3-amino-α-L-lyxo-hexopyranosyl)-α-L-lyxo-hexopyranosyl]adriamicinone doxorubicin disaccharide analog (Monteagudo et al., Carbohydr. Res. 300(1):11-16, 1997), 2-pyrrolinodoxorubicin (Nagy et al., Proc. Nat'l Acad. Sci. U.S.A. 94(2):652-656, 1997), morpholinyl doxorubicin analogues (Duran et al., Cancer Chemother Pharmacol. 38(3):210-216, 1996), enaminomalonyl-β-alanine doxorubicin derivatives (Seitz et al., Tetrahedron Lett. 36(9):1413-16, 1995), cephalosporin doxorubicin derivatives (Vrudhula et al., J. Med. Chem. 38(8):1380-5, 1995), hydroxyrubicin (Solary et al., Int. J. Cancer 58(1):85-94, 1994), methoxymorpholino doxorubicin derivative (Kuhl et al., Cancer Chemother. Pharmacol. 33(1):10-16, 1993), (6-maleimidocaproyl)hydrazone doxorubicin derivative (Willner et al., Bioconjugate Chem. 4(6):521-7, 1993), N-(5,5-diacetoxypent-1-yl) doxorubicin (Cherif & Farquhar, J. Med. Chem. 35(17):3208-14, 1992), FCE 23762 methoxymorpholinyl doxorubicin derivative (Ripamonti et al., Br. J. Cancer 65(5):703-7, 1992), N-hydroxysuccinimide ester doxorubicin derivatives (Demant et al., Biochim. Biophys. Acta 1118(1):83-90, 1991), polydeoxynucleotide doxorubicin derivatives (Ruggiero et al., Biochim. Biophys. Acta 1129(3):294-302, 1991), morpholinyl doxorubicin derivatives (EPA 434960), mitoxantrone doxorubicin analogue (Krapcho et al., J. Med. Chem. 34(8):2373-80. 1991), AD198 doxorubicin analogue (Traganos et al., Cancer Res. 51(14):3682-9, 1991), 4-demethoxy-3′-N-trifluoroacetyldoxorubicin (Horton et al., Drug Des. Delivery 6(2):123-9, 1990), 4′-epidoxorubicin (Drzewoski et al., Pol. J. Pharmacol. Pharm. 40(2):159-65, 1988; Weenen et al., Eur. J. Cancer Clin. Oncol 20(7):919-26, 1984), alkylating cyanomorpholino doxorubicin derivative (Scudder et al., J. Nat'l Cancer Inst. 80(16):1294-8, 1988), deoxydihydroiodooxorubicin (EPA 275966), adriblastin (Kalishevskaya et al., Vestn. Mosk. Univ., 16(Biol. 1):21-7, 1988), 4′-deoxydoxorubicin (Schoelzel et al., Leuk. Res. 10(12):1455-9, 1986), 4-demethyoxy-4′-o-methyldoxorubicin (Giuliani et al., Proc. Int. Congr. Chemother. 16:285-70-285-77, 1983), 3′-deamino-3′-hydroxydoxorubicin (Horton et al., J. Antibiot. 37(8):853-8, 1984), 4-demethyoxy doxorubicin analogues (Barbieri et al., Drugs Exp. Clin. Res. 10(2):85-90, 1984), N-L-leucyl doxorubicin derivatives (Trouet et al., Anthracyclines (Proc. Int. Symp. Tumor Pharmacother.), 179-81, 1983), 3′-deamino-3′-(4-methoxy-1-piperidinyl) doxorubicin derivatives (U.S. Pat. No. 4,314,054), 3′-deamino-3′-(4-mortholinyl) doxorubicin derivatives (U.S. Pat. No. 4,301,277), 4′-deoxydoxorubicin and 4′-o-methyldoxorubicin (Giuliani et al., Int. J. Cancer 27(1):5-13, 1981), aglycone doxorubicin derivatives (Chan & Watson, J. Pharm. Sci. 67(12):1748-52, 1978), SM 5887 (Pharma Japan 1468:20, 1995), MX-2 (Pharma Japan 1420:19, 1994), 4′-deoxy-13(S)-dihydro-4′-iododoxorubicin (EP 275966), morpholinyl doxorubicin derivatives (EPA 434960), 3′-deamino-3′-(4-methoxy-1-piperidinyl) doxorubicin derivatives (U.S. Pat. No. 4,314,054), doxorubicin-14-valerate, morpholinodoxorubicin (U.S. Pat. No. 5,004,606), 3′-deamino-3′-(3″-cyano-4″-morpholinyl doxorubicin; 3′-deamino-3′-(3″-cyano-4″-morpholinyl)-13-dihydoxorubicin; (3′-deamino-3′-(3″-cyano-4″-morpholinyl) daunorubicin; 3′-deamino-3′-(3″-cyano-4″-morpholinyl)-3-dihydrodaunorubicin; and 3′-deamino-3′-(4″-morpholinyl-5-iminodoxorubicin and derivatives (U.S. Pat. No. 4,585,859), 3′-deamino-3′-(4-methoxy-1-piperidinyl) doxorubicin derivatives (U.S. Pat. No. 4,314,054) and 3-deamino-3-(4-morpholinyl) doxorubicin derivatives (U.S. Pat. No. 4,301,277).
  • B. Fluoropyrimidine Analogs
  • In another aspect, the therapeutic agent is a fluoropyrimidine analog, such as 5-fluorouracil, or an analog or derivative thereof, including Carmofur, Doxifluridine, Emitefur, Tegafur, and Floxuridine. Exemplary compounds have the structures: [0042]
    Figure US20040043052A1-20040304-C00009
    R1 R2
    5-Fluorouracil H H
    Carmofur C(O)NH(CH2)5CH3 H
    Doxifluridine A1 H
    Floxuridine A2 H
    Emitefur CH2OCH2CH3 B
    Tegafur C H
    B
    Figure US20040043052A1-20040304-C00010
    C
    Figure US20040043052A1-20040304-C00011
  • Other suitable fluoropyrimidine analogs include 5-FudR (5-fluoro-deoxyuridine), or an analog or derivative thereof, including 5-iododeoxyuridine (5-ludR), 5-bromodeoxyuridine (5-BudR), Fluorouridine triphosphate (5-FUTP), and Fluorodeoxyuridine monophosphate (5-dFUMP). Exemplary compounds have the structures: [0043]
    Figure US20040043052A1-20040304-C00012
  • 5-Fluoro-2′-deoxyuridine: R═F [0044]
  • 5-Bromo-2′-deoxyuridine: R═Br [0045]
  • 5-Iodo-2′-deoxyuridine: R═I [0046]
  • Other representative examples of fluoropyrimidine analogs include N3-alkylated analogues of 5-fluorouracil (Kozai et al., [0047] J. Chem. Soc., Perkin Trans. 1(19):3145-3146, 1998), 5-fluorouracil derivatives with 1,4-oxaheteroepane moieties (Gomez et al., Tetrahedron 54(43):13295-13312, 1998), 5-fluorouracil and nucleoside analogues (Li, Anticancer Res. 17(1A):21-27, 1997), cis- and trans-5-fluoro-5,6-dihydro-6-alkoxyuracil (Van der Wilt et al., Br. J. Cancer 68(4):702-7, 1993), cyclopentane 5-fluorouracil analogues (Hronowski & Szarek, Can. J. Chem. 70(4):1162-9, 1992), A-OT-fluorouracil (Zhang et al, Zongguo Yiyao Gongye Zazhi 20(11 ):513-15, 1989), N4-trimethoxybenzoyl-5′-deoxy-5-fluorocytidine and 5′-deoxy-5-fluorouridine (Miwa et al., Chem. Pharm. Bull. 38(4):998-1003, 1990), 1-hexylcarbamoyl-5-fluorouracil (Hoshi et al., J. Pharmacobio-Dun. 3(9)-:478-81, 1980; Maehara et al., Chemotherapy (Basel) 34(6):484-9, 1988), B-3839 (Prajda et al., In Vivo 2(2):151-4, 1988), uracil-1-(2-tetrahydrofuryl)-5-fluorouracil (Anai et al., Oncology 45(3):144-7, 1988), 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-fluorouracil (Suzuko et al., Mol. Pharmacol. 31(3):301-6, 1987), doxifluridine (Matuura et al., Oyo Yakuri 29(5):803-31, 1985), 5′-deoxy-5-fluorouridine (Bollag & Hartmann, Eur. J. Cancer 16(4):427-32, 1980), 1-acetyl-3-O-toluyl-5-fluorouracil (Okada, Hiroshima J. Med. Sci. 28(1): 49-66, 1979), 5-fluorouracil-m-formylbenzene-sulfonate (JP 55059173), N′-(2-furanidyl)-5-fluorouracil (JP 53149985) and 1-(2-tetrahydrofuryl)-57fluorouracil (JP 52089680).
  • These compounds are believed to function as therapeutic agents by serving as antimetabolites of pyrimidine. [0048]
  • C. Folic Acid Antagonists
  • In another aspect, the therapeutic agent is a folio acid antagonist, such as Methotrexate or derivatives or analogs thereof, including Edatrexate, Trimetrexate, Raltitrexed, Piritrexim, Denopterin, Tomudex, and Pteropterin. Methotrexate analogs have the following general structure: [0049]
    Figure US20040043052A1-20040304-C00013
  • The identity of the R group may be selected from organic groups, particularly those groups set forth in U.S. Pat. Nos. 5,166,149 and 5,382,582. For example, R[0050] 1 may be N, R2 may be N or C(CH3), R3 and R3′ may H or alkyl, e.g., CH3, R4 may be a single bond or NR, where R is H or alkyl group. R5,6,8 may be H, OCH3, or alternately they can be halogens or hydro groups. R7 is a side chain of the general structure:
    Figure US20040043052A1-20040304-C00014
  • wherein n=1 for methotrexate, n=3 for pteropterin. The carboxyl groups in the side chain may be esterified or form a salt such as a Zn[0051] 2+ salt. R9 and R10 can be NH2 or may be alkyl substituted.
  • Exemplary folic acid antagonist compounds have the structures: [0052]
    Figure US20040043052A1-20040304-C00015
    R0 R1 R2 R3 R4 R5 R6 R7 R8
    Methotrexate NH2 N N H N(CH3) H H A (n = 1) H
    Edatrexate NH2 N N H CH(CH2CH3) H H A (n = 1) H
    Trimetrexate NH2 CH C(CH3) H NH H OCH3 OCH3 OCH3
    Pteropterin OH N N H NH H H A (n = 3) H
    Denopterin OH N N CH3 N(CH3) H H A (n = 1) H
    Peritrexim NH2 N C(CH3) H single bond OCH3 H H OCH3
    A:
    Figure US20040043052A1-20040304-C00016
    Figure US20040043052A1-20040304-C00017
  • Other representative examples include 6-S-aminoacyloxymethyl mercaptopurine derivatives (Harada et al., [0053] Chem. Pharm. Bull. 43(10):793-6, 1995), 6-mercaptopurine (6-MP) (Kashida et al., Biol. Pharm. Bull. 18(11):1492-7, 1995), 7,8-polymethyleneimidazo-1,3,2-diazaphosphorines (Nilov et al., Mendeleev Commun. 2:67, 1995), azathioprine (Chifotides et al., J. Inorg. Biochem. 56(4): 249-64, 1994), methyl-D-glucopyranoside mercaptopurine derivatives (Da Silva et al., Eur. J. Med. Chem. 29(2):149-52, 1994) and s-alkynyl mercaptopurine derivatives (Ratsino et al., Khim.-Farm. Zh. 15(8):65-7, 1981); indoline ring and a modified ornithine or glutamic acid-bearing methotrexate derivatives (Matsuoka et al., Chem. Pharm. Bull. 45(7):1146-1150, 1997), alkyl-substituted benzene ring C bearing methotrexate derivatives (Matsuoka et al., Chem. Pharm. Bull. 44(12):2287-2293, 1996), benzoxazine or benzothiazine moiety-bearing methotrexate derivatives (Matsuoka et al., J. Med. Chem. 40(1):-105-111, 1997), 10-deazaaminopterin analogues (DeGraw et al., J. Med. Chem. 40(3):370-376, 1997), 5-deazaaminopterin and 5,10-dideazaaminopterin methotrexate analogues (Piper et al., J. Med. Chem. 40(3):377-384, 1997), indoline moiety-bearing methotrexate derivatives (Matsuoka et al., Chem. Pharm. Bull. 44(7):1332-1337, 1996), lipophilic amide methotrexate derivatives (Pignatello et al., World Meet. Pharm., Biopharm. Pharm. Technol., 563-4, 1995), L-threo-(2S,4S)-4-fluoroglutamic acid and DL-3,3-difluoroglutamic acid-containing methotrexate analogues (Hart et al., J. Med. Chem. 39(1):56-65, 1996), methotrexate tetrahydroquinazoline analogue (Gangjee, et al., J. Heterocycl. Chem. 32(1):243-8, 1995), N-(α-aminoacyl) methotrexate derivatives (Cheung et al., Pteridines 3(1-2):101-2, 1992), biotin methotrexate derivatives (Fan et al., Pteridines 3(1-2): 131-2, 1992), D-glutamic acid or D-erythrou, threo-4-fluoroglutamic acid methotrexate analogues (McGuire et al., Biochem. Pharmacol. 42(12):2400-3, 1991), β,γ-methano methotrexate analogues (Rosowsky et al., Pteridines 2(3): 133-9, 1991), 10-deazaaminopterin (10-EDAM) analogue (Braakhuis et al., Chem. Biol. Pteridines, Proc. Int. Symp. Pteridines Folic Acid Deriv., 1027-30, 1989), γ-tetrazole methotrexate analogue (Kalman et al., Chem. Biol. Pteridines, Proc. Int. Symp. Pteridines Folic Acid Deriv, 1154-7, 1989)-, N-(L-α-aminoacyl) methotrexate derivatives (Cheung et al., Heterocycles 28(2):751-8, 1989), meta and ortho isomers of aminopterin (Rosowsky et al., J. Med. Chem. 32(12):2582, 1989), hydroxymethylmethotrexate (DE 267495), γ-fluoromethotrexate (McGuire et al., Cancer Res. 49(16):4517-25, 1989), polyglutamyl methotrexate derivatives (Kumar et al., Cancer Res. 46(10):5020-3, 1986), gem-diphosphonate methotrexate analogues (WO 88/06158), α- and γ-substituted methotrexate analogues (Tsushima et al., Tetrahedron 44(17):5375-87, 1988), 5-methyl-5-deaza methotrexate analogues (4,725,687), Nδ-acyl-Nα-(4-amino-4-deoxypteroyl)-L-ornithine derivatives (Rosowsky et al., J. Med. Chem. 31(7):1332-7, 1988), 8-deaza methotrexate analogues (Kuehl et al., Cancer Res. 48(6):1481-8, 1988), acivicin methotrexate analogue (Rosowsky et al., J. Med. Chem. 30(8):1463-9, 1987), polymeric platinol methotrexate derivative (Carraher et al., Polym. Sci. Technol. (Plenum), 35(Adv. Biomed. Polym.):311-24, 1987), methotrexate-γ-dimyristoylphophatidylethanolamine (Kinsky et al., Biochim. Biophys. Acta 917(2):211-18, 1987), methotrexate polyglutamate analogues (Rosowsky et al., Chem. Biol. Pteridines, Pteridines Folid Acid Deriv., Proc. Int. Symp. Pteridines Folid Acid Deriv.: Chem., Biol. Clin. Aspects: 985-8, 1986), poly-γ-glutamyl methotrexate derivatives (Kisliuk et al., Chem. Biol. Pteridines, Pteridines Folid Acid Deriv., Proc. lnrt. Symp. Pteridines Folid Acid Deriv.: Chem., Biol. Clin. Aspects: 989-92, 1986), deoxyuridylate methotrexate derivatives (Webber et al., Chem. Biol. Pteridines, Pteridines Folid Acid Deriv., Proc. Int. Symp. Pteridines Folid Acid Deriv.: Chem., Biol. Clin. Aspects: 659-62, 1986), iodoacetyl lysine methotrexate analogue (Delcamp et al., Chem. Biol. Pteridines, Pteridines Folid Acid Deriv., Proc. Int. Symp. Pteridines Folid Acid Deriv.: Chem., Biol. Clin. Aspects: 807-9, 1986), 2, .omega.-diaminoalkanoid acid-containing methotrexate analogues (McGuire et al., Biochem. Pharmacol. 35(15):2607-13, 1986), polyglutamate methotrexate derivatives (Kamen & Winick, Methods Enzymol. 122(Vitam. Coenzymes, Pt. G):339-46, 1986), 5-methyl-5-deaza analogues (Piper et al., J. Med. Chem. 29(6):1080-7, 1986), quinazoline methotrexate analogue (Mastropaolo et al., J. Med. Chem. 29(1):155-8, 1986), pyrazine methotrexate analogue (Lever & Vestal, J. Heterocycl. Chem. 22(1):5-6, 1985), cysteic acid and homocysteic acid methotrexate analogues (4,490,529), γ-tert-butyl methotrexate esters (Rosowsky et al., J. Med. Chem. 28(5):660-7, 1985), fluorinated methotrexate analogues (Tsushima et al., Heterocycles 23(1):45-9, 1985), folate methotrexate analogue (Trombe, J. Bacteriol. 160(3):849-53, 1984), phosphonoglutamic acid analogues (Sturtz & Guillamot, Eur J. Med. Chem.—Chim. Ther. 19(3):267-73, 1984), poly (L-lysine) methotrexate conjugates (Rosowsky et al., J. Med. Chem. 27(7):888-93, 1984), dilysine and trilysine methotrexate derivates (Forsch & Rosowsky, J. Org. Chem. 49(7):1305-9, 1984), 7-hydroxymethotrexate (Fabre et al., Cancer Res. 43(10):4648-52, 1983), poly-γ-glutamyl methotrexate analogues (Piper & Montgomery, Adv. Exp. Med. Biol., 163(Folyl Antifolyl Polyglutamates): 95-100, 1983), 3′,5′-dichloromethotrexate (Rosowsky & Yu, J. Med. Chem. 26(10):1448-52, 1983), diazoketone and chloromethylketone methotrexate analogues (Gangjee et al., J. Pharm. Sci. 71(6):717-19, 1982), 10-propargylaminopterin and alkyl methotrexate homologs (Piper et al., J. Med. Chem. 25(7):877-80, 1982), lectin derivatives of methotrexate (Lin et al., JNCl 66(3):523-8, 1981), polyglutamate methotrexate derivatives (Galivan, Mol. Pharmacol. 17(1): 105-10, 1980), halogentated methotrexate; derivatives (Fox, JNCl 58(4):J955-8, 1977), 8-alkyl-7,8-dihydro analogues (Chaykovsky et al., J. Med. Chem. 20(10):J1323-7, 1977), 7-methyl methotrexate derivatives and dichloromethotrexate (Rosowsky & Chen, J. Med. Chem. 17(12):J1308-11, 1974), lipophilic methotrexate derivatives and 3′,5′-dichloromethotrexate (Rosowsky, J. Med. Chem. 16(10):J1190-3, 1973), deaza amethopterin analogues (Montgomery et al., Ann. N. Y Acad. Sci. 186:J227-34, 1971), MX068 (Pharma Japan, 1658:18, 1999) and cysteic acid and homocysteic acid methotrexate analogues (EPA 0142220);
  • These compounds are believed to act as antimetabolites of folic acid. [0054]
  • D. Podophyllotoxins
  • In another aspect, the therapeutic agent is a. Podophyllotoxin, or a derivative or an analog thereof. Exemplary compounds of this type are Etoposide or Teniposide, which have the following structures: [0055]
    Figure US20040043052A1-20040304-C00018
  • Other representative examples of podophyllotoxins include Cu(II)-VP-16 (etoposide) complex (Tawa et al., [0056] Bioorg. Med. Chem. 6(7):1003-1008, 1998), pyrrolecarboxamidino-bearing etoposide analogues (Ji et al., Bioorg. Med. Chem. Lett, 7(5):607-612, 1997), 4β-amino etoposide analogues (Hu, University of North Carolina Dissertation, 1992), γ-lactone ring-modified arylamino etoposide analogues (Zhou et al., J. Med. Chem. 37(2):287-92, 1994), N-glucosyl etoposide analogue (Allevi et al., Tetrahedron Lett. 34(45):7313-16, 1993), etoposide A-ring analogues (Kadow et al., Bioorg. Med. Chem. Lett. 2(1): 17-22, 1992), 4′-deshydroxy-4′-methyl etoposide (Saulnier et al., Bioorg. Med. Chem. Lett 2(10):1213-18, 1992), pendulum ring etoposide analogues (Sinha et al., Eur. J. Cancer 26(5):590-3, 1990) and E-ring desoxy etoposide analogues (Saulnier et al., J. Med. Chem. 32(7):1418-20, 1989).
  • These compounds are believed to act as Topoisomerase II Inhibitors and/or DNA cleaving agents. [0057]
  • E. Camptothecins
  • In another aspect, the therapeutic agent is Camptothecin, or an analog or derivative thereof. Camptothecins have the following general structure. [0058]
    Figure US20040043052A1-20040304-C00019
  • In this structure, X is typically O, but can be other groups, e.g., NH in the case of 21-lactam derivatives. R[0059] 1 is typically H or OH, but may be other groups, e.g., a terminally hydroxylated C1-3 alkane. R2 is typically H or an amino containing group such as (CH3)2NHCH2, but may be other groups e.g., NO2; NH2, halogen (as disclosed in, e.g., U.S. Pat. No. 5,552,156) or a short alkane containing these groups. R3 is typically H or a short alkyl such as C2H5. R4 is typically H but may be other groups, e.g., a methylenedioxy group with R1.
  • Exemplary camptothecin compounds include topotecan, irinotecan (CPT-11), 9-aminocamptothecin, 21 -lactam-20(S)-camptothecin, 10,11-methylenedioxycamptothecin, SN-38, 9-nitrocamptothecin, 10-hydroxycamptothecin. Exemplary compounds have the structures: [0060]
    Figure US20040043052A1-20040304-C00020
    R1 R2 R3
    Camptothecin: H H H
    Topotecan: OH (CH3)2NHCH2 H
    SN-38: OH H C2H5
  • Camptothecins have the five rings shown here. The ring labeled E must be intact (the lactone rather than carboxylate form) for maximum activity and minimum toxicity. [0061]
  • Camptothecins are believed to function as Topoisomerase I Inhibitors and/or DNA cleavage agents. [0062]
  • F. Hydroxyureas
  • The therapeutic agent of the present invention may be a hydroxyurea. Hydroxyureas have the following general structure: [0063]
    Figure US20040043052A1-20040304-C00021
  • Suitable hydroxyureas are disclosed in, for example, U.S. Pat. No. 6,080,874, wherein R[0064] 1 is:
    Figure US20040043052A1-20040304-C00022
  • and R[0065] 2 is an alkyl group having 1-4 carbons and R3 is one of H, acyl, methyl, ethyl, and mixtures thereof, such as a methylether.
  • Other suitable hydroxyureas are disclosed in. e.g., U.S. Pat. No. 5,665,768, wherein R[0066] 1 is a cycloalkenyl group, for example N-[3-[5-(4-fluorophenylthio)-furyl]-2-cyclopenten-1-yl]N-hydroxyurea; R2 is H or an alkyl group having 1 to 4 carbons and R3 is H; X is H or a cation.
  • Other suitable hydroxyureas are disclosed in, e.g., U.S. Pat. No. 4,299,778, wherein R[0067] 1 is a phenyl group substituted with one or more fluorine atoms; R2 is a cyclopropyl group; and R3 and X is H.
  • Other suitable hydroxyureas are disclosed in, e.g., U.S. Pat. No. 5,066,658, wherein R[0068] 2 and R3 together with the adjacent nitrogen form:
    Figure US20040043052A1-20040304-C00023
  • wherein m is 1 or 2, n is 0-2 and Y is an alkyl group. [0069]
  • In one aspect, the hydroxyurea has the structure: [0070]
    Figure US20040043052A1-20040304-C00024
  • These compounds are thought to function by inhibiting DNA synthesis. [0071]
  • G. Platinum Complexes
  • In another aspect, the therapeutic agent is a platinum compound. In general, suitable platinum complexes may be of Pt(lI) or Pt(IV) and have this basic structure: [0072]
    Figure US20040043052A1-20040304-C00025
  • wherein X and Y are anionic leaving groups such as sulfate, phosphate, carboxylate, and halogen; R[0073] 1 and R2 are alkyl, amine, amino alkyl any may be further substituted, and are basically inert or bridging groups. For Pt(II) complexes Z1 and Z2 are non-existent. For Pt(IV) Z1 and Z2 may be anionic groups such as halogen, hydroxy, carboxylate, ester, sulfate or phosphate. See, e.g., U.S. Pat. Nos. 4,588,831 and 4,250,189.
  • Suitable platinum complexes may contain multiple Pt atoms. See, e.g., U.S. Pat. Nos. 5,409,915 and 5,380,897. For example bisplatinum and triplatinum complexes of the type: [0074]
    Figure US20040043052A1-20040304-C00026
  • Exemplary platinum compounds are Cisplatin, Carboplatin, Oxaliplatin, and Miboplatin having the structures: [0075]
    Figure US20040043052A1-20040304-C00027
  • Other representative platinum compounds include (CPA)[0076] 2Pt[DOLYM] and (DACH)Pt[DOLYM] cisplatin (Choi et al., Arch. Pharmacal Res. 22(2):151-156, 1999), Cis-[PtCl2(4,7-H-5-methyl-7-oxo]1,2,4[triazolo[1,5-a]pyrimidine)2] (Navarro et al., J. Med. Chem. 41(3):332-338, 1998), [Pt(cis-1,4-DACH)(trans-Cl2)(CBDCA)]·½MeOH cisplatin (Shamsuddin et al., Inorg. Chem. 36(25):5969-5971, 1997), 4-pyridoxate diammine hydroxy platinum (Tokunaga et al., Pharm. Sci. 3(7):353-356, 1997), Pt(II) . . . Pt(II) (Pt2[NHCHN(C(CH2)(CH3))]4) (Navarro et al., Inorg. Chem. 35(26):7829-7835, 1996), 254-S cisplatin analogue (Koga et al., Neurol. Res. 18(3):244-247, 1996), o-phenylenediamine ligand bearing cisplatin analogues (Koeckerbauer & Bednarski, J. Inorg. Biochem. 62(4):281-298, 1996), trans, cis-[Pt(OAc)2l2(en)] (Kratochwil et al., J. Med. Chem. 39(13):2499-2507, 1996), estrogenic 1,2-diarylethylenediamine ligand (with sulfur-containing amino acids and glutathione) bearing cisplatin analogues (Bednarski, J. Inorg. Biochem. 62(1):75, 1996), cis-1,4-diaminocyclohexane cisplatin analogues (Shamsuddin et al., J. Inorg. Biochem. 61(4):291-301, 1996), 5′ orientational isomer of cis-[Pt(NH3)(4-aminoTEMP-O){d(GpG)}] (Dunham & Lippard, J. Am. Chem. Soc. 117(43): 10702-12, 1995), chelating diamine-bearing cisplatin analogues (Koeckerbauer & Bednarski, J. Pharm. Sci. 84(7):819-23, 1995), 1,2-diarylethyleneamine ligand-bearing cisplatin analogues (Otto et al., J. Cancer Res. Clin. Oncol. 121(1):31-8, 1995), (ethylenediamine)platinum(II) complexes (Pasini et al., J. Chem. Soc., Dalton Trans. 4:579-85, 1995), Cl-973 cisplatin analogue (Yang et al., Int. J. Oncol. 5(3):597-602, 1994), cis-diaminedichloroplatinum(II) and its analogues cis-1,1-cyclobutanedicarbosylato(2R)-2-methyl-1,4-butanediamineplatinum(II) and cis-diammine(glycolato)platinum (Claycamp & Zimbrick, J. Inorg. Biochem. 26(4):257-67, 1986; Fan et al., Cancer Res. 48(11):3135-9, 1988; Heiger-Bernays et al., Biochemistry 29(36):8461-6, 1990; Kikkawa et al., J. Exp. Clin. Cancer Res. 12(4):233-40, 1993; Murray et al., Biochemistry 31(47):11812-17, 1992; Takahashi et al., Cancer Chemother. Pharmacol. 33(1 ):31-5, 1993), cis-amine-cyclohexylamine-dichloroplatinum(II) (Yoshida et al., Biochem. Pharmacol. 48(4):793-9, 1994), gem-diphosphonate cisplatin analogues (FR 2683529), (meso-1,2-bis(2,6-dichloro-4-hydroxyplenyl)ethylenediamine) dichloroplatinum(II) (Bednarski et al., J. Med. Chem. 35(23):4479-85, 1992), cisplatin analogues containing a tethered dansyl group (Hartwig et al., J. Am. Chem. Soc. 114(21):8292-3, 1992), platinum(II) polyamines (Siegmann et al., Inorg. Met.-Containing Polym. Mater, (Proc. Am. Chem. Soc. Int. Symp.), 335-61, 1990), cis-(3H)dichloro(ethylenediamine)platinum(II) (Eastman, Anal. Biochem. 197(2):311 -15, 1991), trans-diamminedichloroplatinum(II) and cis-(Pt(NH3)2(N3-cytosine)Cl) (Bellon & Lippard, Biophys. Chem. 35(2-3):179-88, 1990), 3H-cis-1,2-diaminocyclohexanedichloroplatinum(II) and 3H-cis-1,2-diaminocyclohexane-malonatoplatinum (II) (Oswald et al., Res. Commun. Chem. Pathol. Pharmacol. 64(1):41-58, 1989), diaminocarboxylatoplatinum (EPA 296321), trans-(D,1)-1,2-diaminocyclohexane carrier ligand-bearing platinum analogues (Wyrick & Chaney, J. Labelled Compd. Radiopharm. 25(4):349-57, 1988), aminoalkylaminoanthraquinone-derived cisplatin analogues (Kitov et al., Eur. J. Med. Chem. 23(4):381-3, 1988), spiroplatin, carboplatin, iproplatin and JM40 platinum analogues (Schroyen et al., Eur. J. Cancer Clin. Oncol. 24(8):1309-12, 1988), bidentate tertiary diamine-containing cisplatinum derivatives (Orbell et al., Inorg. Chim. Acta 152(2):125-34, 1988), platinum(II), platinum(IV) (Liu & Wang, Shandong Yike Daxue Xuebao 24(1):35-41, 1986), cis-diammine(1,1-cyclobutanedicarboxylato-)platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(Il) (JM40) (Begg et al., Radiother. Oncol. 9(2):157-65, 1987), JM8 and JM9 cisplatin analogues (Harstrick et al., Int. J. Androl. 10(1); 139-45, 1987), (NPr4)2((PtCL4).cis-(PtC12-(NH2Me)2)) (Brammer et al., J. Chem. Soc., Chem. Commun. 6:443-5, 1987), aliphatic tricarboxylic acid platinum complexes (EPA 185225), and cis-dichloro(amino acid)(tert-butylamine)platinum(II) complexes (Pasini & Bersanetti, Inorg. Chim. Acta 107(4):259-67, 1985). These compounds are thought to function by binding to DNA, i.e., acting as alkylating agents of DNA.
  • II. COMPOSITIONS AND FORMULATIONS
  • As noted above, therapeutic agents described herein may be formulated in a variety of manners, and thus may additionally comprise a carrier. In this regard, a wide variety of carriers may be selected of either polymeric or non-polymeric origin. The polymers and non-polymer based carriers and formulations which are discussed in more detail below are provided merely by way of example, not by way of limitation. [0077]
  • Within one embodiment of the invention a wide variety of polymers can be utilized to contain and/or deliver one or more of the agents discussed above, including for example both biodegradable and non-biodegradable compositions. Representative examples of biodegradable compositions include albumin, collagen, gelatin, chitosan, hyaluronic acid, starch, cellulose and derivatives thereof (e.g., methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate), alginates, casein, dextrans, polysaccharides, fibrinogen, poly(L-lactide), poly(D,L lactide), poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide), poly(glycolide), poly(trimethylene carbonate), poly(hydroxyvalerate), poly(hydroxybutyrate), pbly(caprolactone), poly(alkylcarbonate) and poly(orthoesters), polyesters, poly(hydroxyvaleric acid), polydioxanone, poly(malic acid), poly(tartronic acid), polyanhydrides, polyphosphazenes, poly(amino acids), copolymers of such polymers and blends of such polymers (see generally, Illum, L., Davids, S. S. (eds.) “Polymers in Controlled Drug Delivery” Wright, Bristol, 1987; Arshady, [0078] J. Controlled Release 17:1-22, 1991; Pitt, Int. J. Phar 59:173-196, 1990; Holland et al., J. Controlled Release 4:155-0180, 1986). Representative examples of nondegradable polymers include poly(ethylene-co-vinyl acetate) (“EVA”) copolymers, silicone rubber, acrylic polymers (e.g., polyacrylic acid, polymethylacrylic acid, poly(hydroxyethylmethacrylate), polymethylmethacrylate, polyalkylcyanoacrylate), polyethylene, polyproplene, polyamides (e.g., nylon 6,6), polyurethane (e.g., poly(ester urethanes), poly(ether urethanes), poly(ester-urea), poly(carbonate urethanes)), polyethers (e.g., poly(ethylene oxide), poly(propylene oxide), Pluronics and poly(tetramethylene glycol)) and vinyl polymers [e.g., polyvinylpyrrolidone, poly(vinyl alcohol), poly(vinyl acetate phthalate)]. Polymers may also be developed which are either anionic (e.g., alginate, carrageenin, carboxymethyl cellulose and poly(acrylic acid), or cationic (e.g., chitosan, poly-L-lysine, polyethylenimine, and poly (allyl amine)) (see generally, Dunn et al., J. Applied Polymer Sci. 50:353-365, 1993; Cascone et al., J. Materials Sci.: Materials in Medicine 5:770-774, 1994; Shiraishi et al., Biol. Pharm. Bull. 16(11):1164-1168, 1993; Thacharodi and Rao, Int'l J. Pharm. 120:115-118, 1995; Miyazaki et al., Int'l J. Pharm. 118:257-263, 1995). Particularly preferred polymeric carriers include poly(ethylene-co-vinyl acetate), polyurethane, acid, poly(caprolactone), poly(valerolactone), polyanhydrides, copolymers of poly(caprolactone) or poly(lactic acid) with a polyethylene glycol (e.g., MePEG), and blends thereof.
  • Other representative polymers include carboxylic polymers, polyacetates, polyacrylamides, polycarbonates, polyethers, polyesters, polyethylenes, polyvinylbutyrals, polysilanes, polyureas, polyurethanes, polyoxides, polystyrenes, polysulfides, polysulfones, polysulfonides, polyvinylhalides, pyrrolidones, rubbers, thermal-setting polymers, cross-linkable acrylic and methacrylic polymers, ethylene acrylic acid copolymers, styrene acrylic copolymers, vinyl acetate polymers and copolymers, vinyl acetal polymers and copolymers, epoxy, melamine, other amino resins, phenolic polymers, and copolymers thereof, water-insoluble cellulose ester polymers (including cellulose acetate propionate, cellulose acetate, cellulose acetate butyrate, cellulose nitrate, cellulose acetate phthalate, and mixtures thereof), polyvinylpyrrolidone, polyethylene glycols, polyethylene oxide, polyvinyl alcohol, polyethers, polysaccharides, hydrophilic polyurethane, polyhydroxyacrylate, dextran, xanthan, hydroxypropyl cellulose, methyl cellulose, and homopolymers and copolymers of N-vinylpyrrolidone, N-vinyllactam, N-vinyl butyrolactam, N-vinyl caprolactam, other vinyl compounds having polar pendant groups, acrylate and methacrylate having hydrophilic esterifying groups, hydroxyacrylate, and acrylic acid, and combinations thereof; cellulose esters and ethers, ethyl cellulose, hydroxyethyl cellulose, cellulose nitrate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, polyurethane, polyacrylate, natural and synthetic elastomers, rubber, acetal, nylon, polyester, styrene polybutadiene, acrylic resin, polyvinylidene chloride, polycarbonate, homopolymers and copolymers of vinyl compounds, polyvinylchloride, polyvinylchloride acetate. [0079]
  • Representative examples of patents relating to polymers and their preparation include PCT Publication Nos. WO72827, 98/12243, 98/19713, 98/41154, 99/07417, 00/33764, 00/21842, 00/09190, 00/09088, 00/09087, 2001/17575 and 2001/15526 (as well as their corresponding U.S. applications), and U.S. Pat. Nos. 4,500,676, 4,582,865, 4,629,623, 4,636,524, 4,713,448, 4,795,741, 4,913,743, 5,069,899, 5,099,013, 5,128,326, 5,143,724, 5,153,174, 5,246,698, 5,266,563, 5,399,351, 5,525,348, 5,800,412, 5,837,226, 5,942,555, 5,997,517, 6,007,833, 6,071,447, 6,090,995, 6,099,563, 6,106,473, 6,110,483, 6,121,027, 6,156,345, 6,179,817, 6,197,051, 6,214,901, 6,335,029, 6,344,035, which, as noted above, are all incorporated by reference in their entirety. [0080]
  • Polymers can be fashioned in a variety of forms, with desired release characteristics and/or with specific desired properties. For example, polymers can be fashioned to release a therapeutic agent upon exposure to a specific triggering event such as pH (see, e.g., Heller et al., “Chemically Self-Regulated Drug Delivery Systems,” in [0081] Polymers in Medicine III, Elsevier Science.Publishers B.V., Amsterdam, 1988, pp. 175-188; Kang et al., J. Applied Polymer Sci. 48:343-354, 1993; Dong et al., J. Controlled Release 19:171-178, 1992; Dong and Hoffman, J. Controlled Release 15:141-152, 1991; Kim et al., J. Controlled Release 28:143-152, 1994; Cornejo-Bravo et al., J. Controlled Release 33:223-229, 1995; Wu and Lee, Pharm. Res. 10(10):1544-1547, 1993; Serres et al., Pharm. Res. 13(2):196-201, 1996; Peppas, “Fundamentals of pH- and Temperature-Sensitive Delivery Systems,” in Gurny et al. (eds.), Pulsatile Drug Delivery, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1993, pp.41-55; Doelker, “Cellulose Derivatives,” 1993, in Peppas and Langer (eds.), Biopolymers I, Springer-Verlag, Berlin). Representative examples of pH-sensitive polymers include poly(acrylic acid)-based polymers and derivatives (including, for example, homopolymers such as poly(aminocarboxylic acid), poly(acrylic acid), poly(methyl acrylic acid), copolymers of such homopolymers, and copolymers of poly(acrylic acid) and acrylmonomers such as those discussed above). Other pH sensitive polymers include polysaccharides such as carboxymethyl cellulose, hydroxypropylmethylcellulose phthalate, hydroxypropyl-methylcellu lose acetate succinate, cellulose acetate trimellilate, chitosan and alginates. Yet other pH sensitive polymers include any mixture of a pH sensitive polymer and a water soluble polymer.
  • Likewise, polymers can be fashioned which are temperature sensitive (see, e.g., Chen et al., “Novel Hydrogels of a Temperature-Sensitive Pluronic Grafted to a Bioadhesive Polyacrylic Acid Backbone for Vaginal Drug Delivery,” in [0082] Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22:167-168, Controlled Release Society, Inc., 1995; Okano, “Molecular Design of Stimuli-Responsive Hydrogels for Temporal Controlled Drug Delivery,” in Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22:111-112, Controlled Release Society, Inc., 1995; Johnston et al., Pharm. Res. 9(3):425-433, 1992; Tung, Int'l J. Pharm. 107:85-90, 1994;, Harsh and Gehrke, J. Controlled Release 17:175-186, 1991; Bae et al., Pharm. Res. 8(4):531-537, 1991; Dinarvand and D'Emanuele, J. Controlled Release 36:221-227, 1995; Yu and Grainger, “Novel Thermo-sensitive Amphiphilic Gels: Poly N-isopropylacrylamide-co-sodium acrylate-co-n-N-alkylacrylamide Network Synthesis and Physicochemical Characterization,” Dept. of Chemical & Biological Sci., Oregon Graduate Institute of Science & Technology, Beaverton, Oreg., pp. 820-821; Zhou and Smid, “Physical Hydrogels of Associative Star Polymers,” Polymer Research Institute, Dept. of Chemistry, College of Environmental Science and Forestry, State Univ. of New York, Syracuse, N.Y., pp. 822-823; Hoffman et al., “Characterizing Pore Sizes and Water ‘Structure’ in Stimuli-Responsive Hydrogels,” Center for Bioengineering, Univ. of Washington, Seattle, Wash., p. 828; Yu and Grainger, “Thermo-sensitive Swelling Behavior in Crosslinked N-isopropylacrylamide Networks: Cationic, Anionic and Ampholytic Hydrogels,” Dept. of Chemical & Biological Sci., Oregon Graduate Institute of Science & Technology, Beaverton, Oreg., pp. 829-830; Kim et al., Pharm. Res. 9(3):283-290, 1992; Bae et al., Pharm. Res. 8(5):624-628, 1991; Kono et al, J. Controlled Release 30:69-75, 1994; Yoshida et al., J. Controlled Release 32:97-102, 1994; Okano et al., J. Controlled Release 36:125-133, 1995; Chun and Kim, J. Controlled Release 38:39-47, 1996; D'Emanuele and Dinarvand, Int'l J. Pharm. 118:237-242, 1995; Katono et al., J. Controlled Release 16:215-228, 1991; Hoffman, “Thermally Reversible Hydrogels Containing Biologically Active Species,” in Migliaresi et al. (eds.), Polymers in Medicine III, Elsevier Science Publishers B.V., Amsterdam, 1988, pp.161-167; Hoffman, “Applications of Thermally Reversible Polymers and Hydrogels in Therapeutics and Diagnostics,” in Third International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, Feb. 24-27, 1987, pp. 297-305; Gutowska et al., J. Controlled Release 22:95-104, 1992; Palasis and Gehrke, J. Controlled Release 18:1-12, 1992; Paavola et al., Pharm. Res. 12(12):1997-2002, 1995).
  • Representative examples of thermogelling polymers include homopolymers such as poly(N-methyl-N-n-propylacrylamide), poly(N-n-propylacrylamide), poly(N-methyl-N-isopropylacrylamide), poly(N-n-propylmethacrylamide), poly(N-isopropylacrylamide), poly(N,n-diethylacrylamide), poly(N-isopropylmethacrylamide), poly(N-cyclopropylacrylam ide), poly(N-ethylmethyacrylamide), poly(N-methyl-N-ethylacrylam ide), poly(N-cyclopropylmethacrylamide) and poly(N-ethylacrylamide). Moreover thermogelling polymers may be made by preparing copolymers between (among) monomers of the above, or by combining such homopolymers with other water soluble polymers such as acrylmonomers (e.g., acrylic acid and derivatives thereof such as methylacrylic acid, acrylate and derivatives thereof such as butyl methacrylate, acrylamide, and N-n-butyl acrylamide). [0083]
  • Other representative examples of thermogelling cellulose ether derivatives such as hydroxypropyl cellulose, methyl cellulose, hydroxypropylmethyl cellulose, ethylhydroxyethyl cellulose, and Pluronics, such as F-127. [0084]
  • A wide variety of forms may be fashioned by the polymers of the present invention, including for example, rod-shaped devices, pellets, slabs, particulates, micelles, films, molds, sutures, threads, gels, creams, ointments, sprays or capsules (see, e.g., Goodell et al., [0085] Am. J. Hosp. Pharm. 43:1454-1461, 1986; Langer et al., “Controlled release of macromolecules from polymers”, in Biomedical Polymers, Polymeric Materials and Pharmaceuticals for Biomedical Use, Goldberg, E. P., Nakagim, A. (eds.) Academic Press, pp.113-137, 1980; Rhine et al, J. Pharm. Sci. 69:265-270, 1980; Brown et al., J. Pharm. Sci. 72:1181-1185, 1983; and Bawa et al., J. Controlled Release 1:259-267, 1985). Agents may be incorporated by dissolution in the polymer, occlusion in the matrices of the polymer, bound by covalent linkages, or encapsulated in microcapsules. Within certain preferred embodiments of the invention, therapeutic compositions are provided in non-capsular formulations, such as coatings microspheres (ranging from nanometers to micrometers in size), pastes, threads or sutures of various size, films and sprays.
  • Other compounds which can be utilized to carry and/or deliver the agents provided herein include vitamin-based compositions (e.g., based on vitamins A, D, E and/or K, see, e.g., PCT publication Nos. WO 98/30205 and WO 00/71163) and liposomes (see, U.S. Pat. Nos. 5,534,499, 5,683,715, 5,776,485, 5,882,679, 6,143,321, 6,146,659, 6,200,598, and PCT Publication Nos. WO 98/34597, WO 99/65466, WO 00/01366, WO 00/53231, WO 99/35162, WO 00/117508, WO 00/125223, WO 00/149,268, WO 00/1565438, and WO 00/158455). [0086]
  • Preferably, therapeutic compositions of the present invention are fashioned in a manner appropriate to the intended use. Within certain aspects of the present invention, the therapeutic composition should be biocompatible, and release one or more agents over a period of several days to months. Further, therapeutic compositions of the present invention should preferably be stable for several months and capable of being produced, and maintained under sterile conditions. [0087]
  • Within certain aspects of the present invention, therapeutic compositions may be fashioned in any size ranging from 50 nm to 500 μm, depending upon the particular use. Alternatively, such compositions may also be readily applied as a “spray” which solidifies into a film or coating. Such sprays may be prepared from microspheres of a wide array of sizes, including for example, from 0.1 μm to 9 μm, from 10 μm to 30 μm and from 30 μm to 100 μm. [0088]
  • Therapeutic compositions of the present invention may also be prepared in a variety of “paste” or gel forms. For example, within one embodiment of the invention, therapeutic compositions are provided which are liquid at one temperature (e.g., temperature greater than 37° C.) and solid or semi-solid at another temperature (e.g., ambient body temperature, or any temperature lower than 37° C.). Also included are polymers, such as Pluronic F-127, which are liquid at a low temperature (e.g., 4° C.) and a gel at body temperature. Such “thermopastes” may be readily made given the disclosure provided herein. [0089]
  • Within yet other aspects of the invention, the therapeutic compositions of the present invention may be formed as a film. Preferably, such films are generally less than 5, 4, 3, 2 or 1 mm thick, more preferably less than 0.75 mm or 0.5 mm thick, and most preferably less than 500 μm. Such films are preferably flexible with a good tensile strength (e.g., greater than 50, preferably greater than 100, and more preferably greater than 150 or 200 N/cm[0090] 2), good adhesive properties (i.e., readily adheres to moist or wet surfaces), and have controlled permeability.
  • Within certain embodiments of the invention, the therapeutic compositions can also comprise additional ingredients such as surfactants (e.g., Pluronics such as F-127, L-122, L-92, L-81, and L-61). [0091]
  • Within further aspects of the present invention, polymers are provided which are adapted to contain and release a hydrophobic compound, the carrier containing the hydrophobic compound in combination with a carbohydrate, protein or polypeptide. Within certain embodiments, the polymeric carrier contains or comprises regions, pockets or granules of one or more hydrophobic compounds. For example, within one embodiment of the invention, hydrophobic compounds may be incorporated within a matrix which contains the hydrophobic compound, followed by incorporation of the matrix within the polymeric carrier. A variety of matrices can be utilized in this regard, including for example, carbohydrates and polysaccharides, such as starch, cellulose, dextran, methylcellulose, and hyaluronic acid, proteins or polypeptides such as albumin, collagen and gelatin. Within alternative embodiments, hydrophobic compounds may be contained within a hydrophobic core, and this core contained within a hydrophilic shell. [0092]
  • Other carriers that may likewise be utilized to contain and deliver the agents described herein include: hydroxypropyl β-cyclodextrin (Cserhati and Hollo, [0093] Int. J. Pharm. 108:69-75, 1994), liposomes (see, e.g., Sharma et al., Cancer Res. 53:5877-5881, 1993; Sharma and Straubinger, Pharm. Res. 11(60):889-896, 1994; WO 93/18751; U.S. Pat. No. 5,242,073), liposome/gel (WO 94/26254), nanocapsules (Bartoli et al., J. Microencapsulation 7(2): 191-197, 1990), micelles (Alkan-Onyuksel et al, Pharm. Res. 11(2).206-212, 1994), implants (Jampel et al., Invest. Ophthalm. Vis. Science 34(11): 3076-3083, 1993; Walter et al., Cancer Res. 54:22017-2212,1994), nanoparticles (Violante and Lanzafame PAACR), nanoparticles—modified (U.S. Pat. No. 5,145,684), nanoparticles (surface modified) (U.S. Pat. No. 5,399,363), taxol emulsion/solution (U.S. Pat. No. 5,407,683), micelle (surfactant) (U.S. Pat. No. 5,403,858), synthetic phospholipid compounds (U.S. Pat. No. 4,534,899), gas borne dispersion (U.S. Pat. No. 5,301,664), foam, spray, gel, lotion, cream, ointment, dispersed vesicles, particles or droplets solid- or liquid- aerosols, microemulsions (U.S. Pat. No. 5,330,756), polymeric shell (nano- and micro- capsule) (U.S. Pat. No. 5,439,686), taxoid-based compositions in a surface-active agent (U.S. Pat. No. 5,438,072), liquid emulsions (Tarr et al., Pharm Res. 4:62-165, 1987), nanospheres (Hagan et al., Proc. Intern. Symp. Control Rel. Bioact. Mater 22, 1995; Kwon et al., Pharm Res. 12(2): 192-195; Kwon et al., Pharm Res. 10(7):970-974; Yokoyama et al., J. Contr. Rel. 32:269-277, 1994; Gref et al., Science 263:1600-1603, 1994; Bazile et al., J. Pharm. Sci. 84:493-498, 1994) and implants (U.S. Pat. No. 4,882,168).
  • The agents provided herein can also be formulated as a sterile composition (e.g., by treating the composition with ethylene oxide or by irradiation), packaged with preservatives or other suitable excipients suitable for administration to humans. Similarly, the devices provided herein (e.g., coated catheter) may be sterilized and prepared suitable for implantation into humans. [0094]
  • III. MEDICAL IMPLANTS A. Representative Medical Implants
  • A wide variety of implants or devices can be coated with or otherwise constructed to contain and/or release the therapeutic agents provided herein. Representative examples include cardiovascular devices (e.g., implantable venous catheters, venous ports, tunneled venous catheters, chronic infusion lines or ports, including hepatic artery infusion catheters, pacemakers and pacesmaker leads (see, e.g., U.S. Pat. Nos. 4,662,382, 4,782,836, 4,856,521, 4,860,751, 5,101,824, 5,261,419, 5,284,491, 6,055,454, 6,370,434, and 6,370,434), implantable defibrillators (see, e.g., U.S. Pat. Nos. 3,614,954, 3,614,955, 4,375,817, 5,314,430, 5,405,363, 5,607,385, 5,697,953, 5,776,165, 6,067,471, 6,169,923, and 6,152,955)); neurologic/neurosurgical devices (e.g., ventricular peritoneal shunts, ventricular atrial shunts, nerve stimulator devices, dural patches and implants to prevent epidural fibrosis post-laminectomy, devices for continuous subarachnoid infusions); gastrointestinal devices (e.g., chronic indwelling catheters, feeding tubes, portosystemic shunts, shunts for ascites, peritoneal implants for drug delivery, peritoneal dialysis catheters, and suspensions or solid implants to prevent surgical adhesions); genitourinary devices (e.g., uterine implants, including intrauterine devices (IUDs) and devices to prevent endometrial hyperplasia, fallopian tubal implants, including reversible sterilization devices, fallopian tubal stents, artificial sphincters and periurethral implants for incontinence, ureteric stents, chronic indwelling catheters, bladder augmentations, or wraps or splints for vasovasostomy, central venous catheters (see, e.g., U.S. Pat. Nos. 3,995,623, 4,072,146 4,096,860, 4,099,528, 4,134,402, 4,180,068, 4,385,631, 4,406,656, 4,568,329, 4,960,409, 5,176,661, 5,916,208), urinary catheters (see, e.g. U.S. Pat. Nos. 2,819,718, 4,227,533, 4,284,459, 4,335,723, 4,701,162, 4,571,241, 4,710,169, and 5,300,022,)); prosthetic heart valves (see, e.g., U.S. Pat. Nos. 3,656,185, 4,106,129, 4,892,540, 5,528,023, 5,772,694, 6,096,075, 6,176,877, 6,358,278, and 6,371,983), vascular grafts (see, e.g. 3,096,560, 3,805,301, 3,945,052, 4,140,126, 4,323,525, 4,355,426, 4,475,972, 4,530,113, 4,550,447, 4,562,596, 4,601,718, 4,647,416, 4,878,908, 5,024,671, 5,104,399, 5,116,360, 5,151,105, 5,197,977, 5,282,824, 5,405,379, 5,609,624, 5,693,088, and 5,910,168), ophthalmologic implants (e.g., multino implants and other implants for neovascular glaucoma, drug eluting contact lenses for pterygiums, splints for failed dacrocystalrhinostomy, drug eluting contact lenses for corneal neovascularity, implants for-diabetic retinopathy, drug eluting contact lenses for high risk corneal transplants); otolaryngology devices (e.g., ossicular implants, Eustachian tube splints or stents for glue ear or chronic otitis as an alternative to transtempanic drains); plastic surgery implants (e.g., breast implants or chin implants), catheter cuffs and orthopedic implants (e.g., cemented orthopedic prostheses). [0095]
  • B. Methods of Making Medical Implants having Therapeutic Agents
  • Implants and other surgical or medical devices may be covered, coated, contacted, combined, loaded, filled, associated with, or otherwise adapted to release therapeutic agents compositions of the present invention in a variety of manners, including for example: (a) by directly affixing to the implant or device a therapeutic agent or composition (e.g., by either spraying the implant or device with a polymer/drug film, or by dipping the implant or device into a polymer/drug solution, or by other covalent or noncovalent means); (b) by coating the implant or device with a substance, such as a hydrogel, which will in turn absorb the therapeutic composition (or therapeutic factor above); (c) by interweaving therapeutic composition coated thread (or the polymer itself formed into a thread) into the implant or device; (d) by inserting the implant or device into a sleeve or mesh which is comprised of or coated with a therapeutic composition; (e) constructing the implant or device itself with a therapeutic agent or composition; or (f) by otherwise adapting the implant or device to release the therapeutic agent. Within preferred embodiments of the invention, the composition should firmly adhere to the implant or device during storage and at the time of insertion. The therapeutic agent or composition should also preferably not degrade during storage, prior to insertion, or when warmed to body temperature after insertion inside the body (if this is required). In addition, it should preferably coat or cover the desired areas of the implant or device smoothly and evenly, with a uniform distribution of therapeutic agent. Within preferred embodiments of the invention, the therapeutic agent or composition should provide a uniform, predictable, prolonged release of the therapeutic factor into the tissue surrounding the implant or device once it has been deployed. For vascular stents, in addition to the above properties, the composition should not render the stent thrombogenic (causing blood clots to form), or cause significant turbulence in blood flow (more than the stent itself would be expected to cause if it was uncoated). [0096]
  • Within certain embodiments of the invention, a therapeutic agent can be deposited directly onto all or a portion of the device (see, e.g., U.S. Pat. Nos. 6,096,070 and 6,299,604), or admixed with a delivery system or carrier (e.g., a polymer, liposome, or vitamin as discussed above) which is applied to all or a portion of the device (see the patents, patent applications, and references listed above under “Compositions and Formulations.”[0097]
  • Within certain aspects of the invention, therapeutic agents can be attached to a medical implant using non-covalent attachments. For example, for compounds that are relatively sparingly water soluble or water insoluble, the compound can be dissolved in an organic solvent a specified concentration. The solvent chosen for this application would not result in dissolution or swelling of the polymeric device surface. The medical implant can then be dipped into the solution, withdrawn and then dried (air dry and/or vacuum dry). Alternatively, this drug solution can be sprayed onto the surface of the implant. This can be accomplished using current spray coating technology. The release duration for this method of coating would be relatively short and would be a function of the solubility of the drug in the body fluid in which it was placed. [0098]
  • In another aspect, a therapeutic agent can be dissolved in a solvent that has the ability to swell or partially dissolve the surface of a polymeric implant. Depending on the solvent/implant polymer combination, the implant could be dipped into the drug solution for a period of time such that the drug can diffuse into the surface layer of the polymeric device. Alternatively the drug solution can be sprayed onto all or a part of the surface of the implant. The release profile of the drug depends upon the solubility of the drug in the surface polymeric layer. Using this approach, one would ensure that the solvent does not result in a significant distortion or dimensional change of the medical implant. [0099]
  • If the implant is composed of materials that do not allow incorporation of a therapeutic agent into the surface layer using the above solvent method, one can treat the surface of the device with a plasma polymerization method such that a thin polymeric layer is deposited onto the device surface. Examples of such methods include parylene coating of devices, and the use of various monomers such hydrocyclosiloxane monomers, acrylic acid, acrylate monomers, methacrylic acid or methacrylate monomers. One can then use the dip coating or spray coating methods described above to incorporate the therapeutic agent into the coated surface of the implant. [0100]
  • For therapeutic agents that have some degree of water solubility, the retention of these compounds on a device are relatively short-term. For therapeutic agents that contain ionic groups, it is possible to tonically complex these agents to oppositely charged compounds that have a hydrophobic component. For example therapeutic agents containing amine groups can be complexed with compounds such as sodium dodecyl sulfate (SDS). Compounds containing carboxylic groups can be complexed with tridodecymethyammonium chloride (TDMAC). Mitoxantrone, for example, has two secondary amine groups and comes as a chloride salt. This compound can be added to sodium dodecyl sulfate in order to form a complex. This complex can be dissolved in an organic solvent which can then be dip coated or spray coated. Doxorubicin has an amine group and could thus also be complexed with SDS. This complex could then be applied to the device by dip coating or spray coating methods. Methotrexate, for example contains 2 carboxylic acid groups and could thus be complexed with TDMAC and then coated onto the medical implant. [0101]
  • For therapeutic agents that have the ability to form ionic complexes or hydrogen bonds, the release of these agents from the device can be modified by the use of organic compounds that have the ability to form ionic or hydrogen bonds with the therapeutic agent. As described above, a complex between the ionically charged therapeutic agent and an oppositely charged hydrophobic compound can be prepared prior to application of this complex to the medical implant. In another embodiment, a compound that has the ability to form ionic or hydrogen bond interactions with the therapeutic agent can be incorporated into the implant during the manufacture process, or during the coating process. Alternatively, this compound can be incorporated into a coating polymer that is applied to the implant or during the process of loading the therapeutic agent into or onto the implant. These agents can include fatty acids (e.g., palmitic acid, stearic acid, lauric acid), aliphatic acids, aromatic acids (e.g., benzoic acid, salicylic acid), cylcoaliphatic acids, aliphatic (stearyl alcohol, lauryl alcohol, cetyl alcohol) and aromatic alcohols alco multifunctional alcohols (e.g., citric acid, tartaric acid, pentaerithratol), lipids (e.g., phosphatidyl choline, phosphatidylethanolamine), carbohydrates, sugars, spermine, spermidine, aliphatic and aromatic amines, natural and synthetic amino acids, peptides or proteins. For example, a fatty acid such as palmitic acid can be used to modulate the release of 5-Fluoruracil from the implant. [0102]
  • For therapeutic agents that have the ability to form ionic complexes or hydrogen bonds, the release of these agents from the implant can be modified by the use of polymers that have the ability to form ionic or hydrogen bonds with the therapeutic agent. For example, therapeutic agents containing amine groups can form ionic complexes with sulfonic or carboxylic pendant groups or end-groups of a polymer. Examples of polymers that can be used for this application include, but are not limited to polymers and copolymers that are prepared using acrylic acid, methacrylic acid, sodium styrene sulfonate, styrene sulfonic acid, maleic acid or 2-acrylamido-2-methyl propane sulfonic acid. Polymers that have been modified by sulfonation post-polymerization can also be used in this application. The medical implant, for example, can be coated with, or prepared with, a polymer that comprises nafion, a sulfonated fluoropolymer. This medical device can then be dipped into a solution that comprises the amine-containing therapeutic agent. The amine-containing therapeutic agent can also be applied by a spray coating process. Methotrexate and doxorubicin are examples of therapeutic agents that can be used in this application. [0103]
  • It is known that the presence of bacteria on the implant surface can result in a localized decrease in pH. For polymers that comprise ionic exchange groups, for example, carboxylic groups, these polymers can have a localized increase in release of the therapeutic agent in response to the localized decrease in pH as a result of the presence of the bacteria. For therapeutic agents that contain carboxylic acid groups, polymers with pendant end-groups comprising primary, secondary, tertiary or quaternary amines can be used to modulate the release of the therapeutic agent. [0104]
  • Therapeutic agents with available functional groups can be covalently attached to the medical implant surface using several chemical methods. If the polymeric material used to manufacture the implant has available surface functional groups then these can be used for covalent attachment of the agent. For example, if the implant surface contains carboxylic acid groups, these groups can be converted to activated carboxylic acid groups (e.g acid chlorides, succinimidyl derivatives, 4-nitrophenyl ester derivatives etc). These activated carboxylic acid groups can then be reacted with amine functional groups that are present on the therapeutic agent (e.g., methotrexate, mitoxantrone). [0105]
  • For surfaces that do not contain appropriate functional groups, these groups can be introduced to the polymer surface via a plasma treatment regime. For example, carboxylic acid groups can be introduced via a plasma treatment process process (e.g., the use of O[0106] 2 and/or CO2 as a component in the feed gas mixture). The carboxylic acid groups can also be introduced using acrylic acid or methacrylic acid in the gas stream. These carboxylic acid groups can then be converted to activated carboxylic acid groups (e;g., acid chlorides, succinimidyl derivatives, 4-nitrophenyl ester derivatives, etc.) that can subsequently be reacted with amine functional groups that are present on the therapeutic agent.
  • In addition to direct covalent bonding to the implant surface, the therapeutic agents with available functional groups can be covalently attached to the medical implant via a linker. These linkers can be degradable or non-degradable. Linkers that are hydrolytically or enzymatically cleaved are preferred. These linkers can comprise azo, ester, amide, thioester, anhydride, or phosphoester bonds. [0107]
  • To further modulate the release of the therapeutic agent from the medical implant, portions of or the entire medical implant may be further coated with a polymer. The polymer coating can comprise the polymers described above. The polymer coating can be applied by a dip coating process, a spray coating process or a plasma deposition process. This coating can, if desired, be further crosslinked using thermal, chemical, or radiation (e.g., visible light, ultraviolet light, e-beam, gamma radiation, x-ray radiation) techniques in order to further modulate the release of the therapeutic agent from the medical implant. [0108]
  • This polymer coating can further contain agents that can increase the flexibility (e.g., plasticizer—glycerol, triethyl citrate), lubricity (e.g., hyaluronic acid), biocompatibility or hemocompatability,(e.g., heparin) of the coating. [0109]
  • The methods above describe methods for incorporation of a therapeutic agent into or onto a medical implant. Additional antibacterial or antifungal agents can also be incorporated into or onto the medical implant. These antibacterial or antifungal agents can be incorporated into or onto the medical implant prior to, simultaneously or after the incorporation of the therapeutic agents, described above, into or onto the medical implant. Agents that can be used include, but are not limited to silver compounds (e.g., silver chloride, silver nitrate, silver oxide), silver ions, silver particles, iodine, povidone/iodine, chlorhexidine, 2-p-sulfanilyanilinoethanol, 4,4′-sulfinyldianiline, 4-sulfanilamidosalicylic acid, acediasulfone, acetosulfone, amikacin, amoxicillin, amphotericin B, ampicillin, apalcillin, apicycline, apramycin, arbekacin, aspoxicillin, azidamfenicol, azithromycin, aztreonam, bacitracin, bambermycin(s), biapenem, brodimoprim, butirosin, capreomycin, carbenicillin, carbomycin, carumonam, cefadroxil, cefamandole, cefatrizine, cefbuperazone, cefclidin, cefdinir, cefditoren, cefepime, cefetamet, cefixime, cefinenoxime, cefminox, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotetan, cefotiam, cefozopran, cefpimizole, cefpiramide, cefpirome, cefprozil, cefroxadine, ceftazidime, cefteram, ceftibuten, ceftriaxone, cefuzonam, cephalexin, cephaloglycin, cephalosporin C, cephradine, chloramphenicol, chlortetracycline, ciprofloxacin, clarithromycin, clinafloxacin, clindamycin, clomocycline, colistin, cyclacillin, dapsone, demeclocycline, diathymosulfone, dibekacin, dihydrostreptomycin, dirithromycin, doxycycline, enoxacin, enviomycin, epicillin, erythromycin, flomoxef, fortimicin(s), gentamicin(s), glucosulfone solasulfone, gramicidin S, gramicidin(s), grepafloxacin, guamecycline, hetacillin, imipenem, isepamicin, josamycin, kanamycin(s), leucomycin(s), lincomycin, lomefloxacin, lucensomycin, lymecycline, meclocycline, meropenem, methacycline, micronomicin, midecamycin(s), minocycline, moxalactam, mupirocin, nadifloxacin, natamycin, neomycin, netilmicin, norfloxacin, oleandomycin, oxytetracycline, p-sulfanilylbenzylamine, panipenem, paromomycin, pazufloxacin, penicillin N, pipacycline, pipemidic acid, polymyxin, primycin, quinacillin, ribostamycin, rifamide, rifampin, rifamycin SV, rifapentine, rifaximin, ristocetin, ritipenem, rokitamycin, rolitetracycline, rosaramycin, roxithromycin, salazosulfadimidine, sancycline, sisomicin, sparfloxacin, spectinomycin, spiramycin, streptomycin, succisulfone, sulfachrysoidine, sulfaloxic acid, sulfamidochrysoidine, sulfanilic acid, sulfoxone, teicoplanin, temafloxacin, temocillin, tetracycline, tetroxoprim, thiamphenicol, thiazolsulfone, thiostrepton, ticarcillin, tigemonam, tobramycin, tosufloxacin, trimethoprim, trospectomycin, trovafloxacin, tuberactinomycin, vancomycin, azaserine, candicidin(s), chlorphenesin, dermostatin(s), filipin, fungichromin, mepartricin, nystatin, oligomycin(s), ciproflaxacin, norfloxacin, ofloxacin, pefloxacin, enoxacin, rosoxacin, amifloxacin, fleroxacin, temafloaxcin, lomefloxacin, perimycin A or tubercidin, and the like. [0110]
  • IV. CLINICAL APPLICATIONS
  • In order to further the understanding of the invention, discussed in more detail below are various clinical applications for the compositions, methods and devices provided herein. [0111]
  • Briefly, as noted above, within one aspect of the invention methods are provided for preventing, reducing, and/or inhibiting an infection associated with a medical device or implant, comprising the step of introducing into a patient a medical implant which releases a chemotherapeutic agent, wherein the chemotherapeutic agent reduces, inhibits, or prevents the growth or transmission of foreign organisms (e.g., bacteria, fungi, or viruses). As used herein, agents that reduce, inhibit, or prevent the growth or transmission of foreign organisms in a patient means that the growth or transmission of a foreign organism is reduced, inhibited, or prevented in a statistically significant manner in at least one clinical outcome, or by any measure routinely used by persons of ordinary skill in the art as a diagnostic criterion in determining the same. In a preferred embodiment, the medical implant has been covered or coated with an anthracycline (e.g., doxorubicin and mitoxantrone), fluoropyrimidine (e.g., 5-FU), folic acid antagonist (e.g., methotrexate), podophylotoxin (e.g., etoposide), camptothecin, hydroxyurea, and/or a platinum complexe (e.g., cisplatin). [0112]
  • Particularly preferred agents which are utilized within the context of the present invention should have an MIC of less than or equal to any one of 10[0113] −4M, 10−5M, 10−6M, or, 10−7M. Furthermore, particularly preferred agents are suitable for use at concentrations less than that 10%, 5%, or even 1% of the concentration-typically used in chemotherapeutic applications (Goodman and Gilman's The Pharmacological Basis of Therapeutics. Editors J. G. Hardman, L. L. Limbird. Consulting editor A. Goodman Gilman Tenth Edition. McGraw-Hill Medical publishing division. 10th edition, 2001, 2148 pp.). Finally, the devices should preferably be provided sterile, and suitable for use in humans.
  • A. Vascular Catheter-Associated Infections
  • More than 30 million patients receive infusion therapy annually in the United States. In fact, 30% of all hospitalized patients have at least one vascular catheter in place during their stay in hospital. A variety of medical devices are used for infusion therapy including, but not restricted to, peripheral intravenous catheters, central venous catheters, total parenteral nutrition catheters, peripherally inserted central venous catheters (PIC lines), totally implanted intravascular access devices, flow-directed balloon-tipped pulmonary artery catheters, arterial lines, and long-term central venous access catheters (Hickman lines, Broviac catheters). [0114]
  • Unfortunately, vascular access catheters are prone to infection by a variety of bacteria and are a common cause of bloodstream infection. Of the 100,000 bloodstream infections in US hospitals each year, many are related to the presence of an intravascular device. For example, 55,000 cases of bloodstream infections are caused by central venous catheters, while a significant percentage of the remaining cases are related to peripheral intravenous catheters and arterial lines. [0115]
  • Bacteremia related to the presence of intravascular devices is not a trivial clinical concern: 50% of all patients developing this type of infection will die as a result (over 23,000 deaths per year) and in those who survive, their hospitalization will be prolonged by an average of 24 days. Complications related to bloodstream infections include cellulites, the formation of abscesses, septic thrombophlebitis, and infective endocarditis. Therefore, there is a tremendous clinical need to reduce the morbidity and mortality associated with intravascular catheter infections. [0116]
  • The most common point of entry for the infection-causing bacteria is tracking along the device from the insertion site in the skin. Skin flora spread along the outside of the device to ultimately gain access to the bloodstream. Other possible sources of infection include a contaminated infusate, contamination of the catheter hub-infusion tubing junction, and hospital personnel. The incidence of infection increases the longer the catheter remains in place and any device remaining in situ for more than 72 hours is particularly susceptible. The most common infectious agents include common skin flora such as coagulase-negative staphylococci ([0117] S. epidermidis, S. saprophyticus) and Staphylococcus aureus (particularly MRSA—methicillin—resistant S. aureus) which account for ⅔ of all infections. Coagulase-negative staphylococci (CNS) is the most commonly isolated organism from the blood of hospitalized patients. CNS infections tend to be indolent; often occurring after a long latent period between contamination (i.e. exposure of the medical device to CNS bacteria from the skin during implantation) and the onset of clinical illness. Unfortunately, most clinically significant CNS infections are caused by bacterial strains that are resistant to multiple antibiotics, making them particularly difficult to treat. Other organisms known to cause vascular access catheter-related infections include Enterococci (e.g. E. coli, VRE—vancomycin-resistant enterococcci), Gram-negative aerobic bacilli, Pseudomonas aeruginosa, Klebsiella spp., Serratia marcescens, Burkholderia cepacia, Citrobacter freundii, Corynebacteria spp. and Candida species.
  • Most cases of vascular access catheter-related infection require removal of the catheter and treatment with systemic antibiotics (although few antibiotics are effective), with vancomycin being the drug of choice. As mentioned previously, mortality associated with vascular access catheter-related infection is high, while the morbidity and cost associated with treating survivors is also extremely significant. [0118]
  • It is therefore extremely important to develop vascular access catheters capable of reducing the incidence of bloodstream infections. Since it is impossible to predict in advance which catheters will become infected, any catheter expected to be in place longer than a couple of days would benefit from a therapeutic coating capable of reducing the incidence of bacterial colonization of the device. An ideal therapeutic coating would have one or more of the following characteristics: (a) the ability to kill, prevent, or inhibit colonization of a wide array of potential infectious agents including most or all of the species listed above; (b) the ability to kill, prevent, or inhibit colonization of bacteria (such as CNS and VRE) that are resistant to multiple antibiotics; (c) utilize a therapeutic agent unlikely to be used in the treatment of a bloodstream infection should one develop (i.e., one would not want to coat the device with a broad-acting antibiotic, for if a strain of bacteria resistant to the antibiotic were to develop on the device it would jeopardize systemic treatment of the patient since the infecting agent would be resistant to a potentially useful therapeutic). [0119]
  • Several classes of anticancer agents are particularly suitable for incorporation into coatings for vascular catheters, namely, anthracyclines (e.g., doxorubicin and mitoxantrone), fluoropyrimidines (e.g., 5-FU), folic acid antagonists (e.g., methotrexate), and podophylotoxins (e.g., etoposide). These agents have a high degree of antibacterial activity against CNS ([0120] S. epidermidis) and Staphylococcus aureus—the most common causes of vascular catheter infections. Particularly preferred agents are doxorubicin, mitoxantrone, 5-fluorouracil and analogues and derivatives thereof which also have activity against Escheridia coli and Pseudomonas aeruginosa. It is important to note that not all anticancer agents are suitable for the practice of the present invention as several agents, including 2-mercaptopurine, 6-mercaptopurine, hydroxyurea, cytarabine, cisplatinum, tubercidin, paclitaxel, and camptothecin did not have antibacterial activity against the organisms known to cause vascular access catheter-related infections.
  • 1. Central Venous Catheters [0121]
  • For the purposes of this invention, the term “Central Venous Catheters” should be understood to include any catheter or line that is used to deliver fluids to the large (central) veins of the body (e.g., jugular, pulmary, femoral, iliac, inferior vena cava, superior vena cava, axillary etc.). Examples of such catheters include central venous catheters, total parenteral nutrition catheters, peripherally inserted central venous catheters, flow-directed balloon-tipped pulmonary artery catheters, long-term central venous access catheters (such as Hickman lines and Broviac catheters). Representative examples of such catheters are described in U.S. Pat. Nos. 3,995,623, 4,072,146 4,096,860, 4,099,528, 4,134,402, 4,180,068, 4,385,631, 4,406,656, 4.568,329, 4,960,409, 5,176,661, 5,916,208. [0122]
  • As described previously, 55,000 cases of bloodstream infections are caused by central venous catheters every year in the United States resulting in 23,000 deaths. The risk of infection increases the longer the catheter remains in place, particularly if it is used beyond 72 hours. Severe complications of central venous catheter infection also include infective endocarditis and suppurative phlebitis of the great veins. If the device becomes infected, it must be replaced at a new site (over-the-wire exchange is not acceptable) which puts the patient at further risk to develop mechanical complications of insertion such as bleeding, pneumothorax and hemothorax. In addition, systemic antibiotic therapy is also required. An effective therapy would reduce the incidence of device infection, reduce the incidence of bloodstream infection, reduce the mortality rate, reduce the incidence of complications (such as endocarditis or suppurative phlebitis), prolong the effectiveness of the central venous catheter and/or reduce the need to replace the catheter. This would result in lower mortality and morbidity for patients with central venous catheters in place. [0123]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the vascular catheter. The drug(s) can be applied to the central venous catheter system in several manners: (a) as a coating applied to the exterior surface of the intravascular portion of the catheter and/or the segment of the catheter that traverses the skin; (b) as a coating applied to the interior and exterior surface of the intravascular portion of the catheter and/or the segment of the catheter that traverses the skin; (c) incorporated into the polymers which comprise the intravascular portion of the catheter; (d) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the catheter; (e) in solution in the infusate; (e incorporated into, or applied as a coating to, the catheter hub, junctions and/or infusion tubing; and (g) any combination of the aforementioned. [0124]
  • Drug-coating of, or drug incorporation into, the central venous catheter will allow bacteriocidal drug levels to be achieved locally on the catheter surface, thus reducing the incidence of bacterial colonization of the vascular catheter (and subsequent development of blood borne infection), while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the catheter surface, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g., poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g., poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0125]
  • As central venous catheters are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the central venous catheter, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0126]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the device, or applied without a polymer carrier, the total dose of doxorubicin applied to the central venous catheter (and the other components of the infusion system) should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied to the central venous catheter (and the other components of the infusion system) should be in the range of 1 μg to 5 mg. The dose per unit area of the device (i.e. the amount of drug as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0127] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the device surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the device surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the device surface. It is necessary to insure that drug concentrations on the device surface exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the device such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-30 days. It should be readily evident given the discussions provided herein that analogues and derivatives.of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the device, or applied without a carrier polymer, the total dose of mitoxantrone applied to the central venous catheter (and the other components of the infusion system) should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied to the central venous catheter (and the other components of the infusion system) should be in the range of 0.1 μg to 1 mg. The dose per unit area of the device (i.e. the amount of drug as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0128] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the device surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the device surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained on the device surface. It is necessary to insure that drug concentrations on the device surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the surface of the device such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the device, or applied without a carrier polymer, the total dose of 5-fluorouracil applied to the central venous catheter (and the other components of the infusion system) should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied to the central venous catheter (and the other components of the infusion system) should be in the range of 10 μg to 25 mg. The dose per unit area of the device (i.e. the amount of drug as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0129] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the device surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the device surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained on the device surface. It is necessary to insure that drug concentrations on the device surface exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the surface of the device such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-30 days. It should be readily evident given the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the device, or applied without a carrier polymer, the total dose of etoposide applied to the central venous catheter (and the other components of the infusion system) should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied to the central venous catheter (and the other components of the infusion system) should be in the range of 1 μg to 5 mg. The dose per unit area of the device (i.e. the amount of drug as a function of the surface area of the portion of the device to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0130] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the device surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the device surface such that a concentration of 10−5-10−6 M of etoposide is maintained on the device surface. It is necessary to insure that drug concentrations on the device surface exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e., are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the device such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-30 days. It should be readily evident based upon the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the central venous catheter coating. Similarly an anthracycline (e.g., doxorubicin or mitoxantrone), fluoropyrimidine (e.g., 5-fluorouracil), folic acid antagonist (e.g., methotrexate) and/or podophylotoxin (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. Since thrombogenicity of the catheter is associated with an increased risk of infection, combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be combined with antithrombotic and/or antiplatelet agents (for example, heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinase, and/or tissue plasminogen activator) to enhance efficacy. [0131]
  • 2. Peripheral Intravenous Catheters [0132]
  • For the purposes of this invention, the term “Peripheral Venous Catheters” should be understood to include any catheter or line that is used to deliver fluids to the smaller (peripheral) superficial veins of the body. [0133]
  • Peripheral venous catheters have a much lower rate of infection than do central venous catheters, particularly if they are in place for less than 72 hours. One exception is peripheral catheters inserted into the femoral vein (so called “femoral lines”) which have a significantly higher rate of infection. The organisms that cause infections in a peripheral venous catheter are identical to those described above (for central venous catheters). [0134]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the peripheral vascular catheter. The drug(s) can be applied to the peripheral venous catheter system in several manners: (a) as a coating applied to the exterior and/or interior surface of the intravascular portion of the catheter and/or the segment of the catheter that traverses the skin; (b) incorporated into the polymers which comprise the intravascular portion of the catheter; (c) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the catheter; (e) in solution in the infusate; (f incorporated into, or applied as a coating to, the catheter hub, junctions and/or infusion tubing; and (g) any combination of the aforementioned. [0135]
  • The formulation and dosing guidelines for this embodiment are identical to those described for central venous catheters. [0136]
  • 3. Arterial Lines and Transducers [0137]
  • Arterial lines are used to draw arterial blood gasses, obtain accurate blood pressure readings and to deliver fluids. They are placed in a peripheral artery (typically the radial artery) and often remain in place for several days. Arterial lines have a very high rate of infection (12-20% of arterial lines become infected) and the causative organisms are identical to those described above (for central venous catheters). [0138]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the arterial line in several manners: (a) as a coating applied to the exterior and/or interior surface of the intravascular portion of the catheter and/or the segment of the catheter that traverses the skin; (b) incorporated into the polymers which comprise the intravascular portion of the catheter; (c) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the catheter; (e) in solution in the infusate; (f) incorporated into, or applied as a coating to, the catheter hub, junctions and/or infusion tubing; and (g) any combination of the aforementioned. [0139]
  • The formulation and dosing guidelines for this embodiment are identical to those described for central venous catheters. [0140]
  • B. Prosthetic Heart Valve Endocarditis (PVE)
  • Prosthetic heart valves, mechanical and bioprosthetic, are at a significant risk for developing an infection. In fact, 3-6% of patients develop valvular infection within 5 years of valve replacement surgery and prosthetic valve endocarditis accounts for up to 15% of all cases of endocarditis. The risk of developing an infection is not uniform—the risk is greatest in the first year following surgery with a peak incidence between the second and third month postoperatively. Mechanical valves in particular are susceptible to infection in the 3 months following surgery and the microbiology is suggestive of nosocomial infection. Therefore, a drug coating designed to prevent colonization and infection of the valves in the months following surgery could be of great benefit in the prevention of this important medical problem. The incidence of prosthetic valve endocarditis has not changed in the last 40 years despite significant advances in surgical and sterilization technique. [0141]
  • Representative examples of prosthetic heart valves include those described in U.S. Pat. Nos. 3,656,185, 4,106,129, 4,892,540, 5,528,023, 5,772,694, 6,096,075, 6,176,877, 6,358,278, and 6,371,983 [0142]
  • Early after valve implantation, the prosthetic valve sewing ring and annulus are not yet endothelialized. The accumulation of platelets and thrombus at the site provide an excellent location for the adherence and colonization of microorganisms. Bacteria can be seeded during the surgical procedure itself or as a result of bacteremia arising in the early postoperative period (usually contamination from i.v. catheters, catheters to determine cardiac output, mediastinal tubes, chest tubes or wound infections). Common causes of PVE include Coagulase Negative Staphylococci (Staphylococcus epidermidis; 30%), Staphylococcus aureus (23%), Gram Negative Enterococci (Enterobacteriaceae, Pseudomonas arugenosa; 14%), Fungi (Candida albicans, Aspergillis: 12%), and Corynebacterium diptheriae. PVE of bioprosthetic valves is largely confined to the leaflets (and rarely the annulus), whereas the annulus is involved in the majority of cases of PVE in mechanical valves (82%). [0143]
  • Unfortunately, eradication of the infecting organism with antimicrobial therapy alone is often difficult or impossible. As a result, many patients who develop this complication require repeat open-heart surgery to replace the infected valve resulting in significant morbidity and mortality. Even if the infection is successfully treated medically, damage to the leaflets in bioprosthetic valves reduces the lifespan of the valve. Particularly problematic are patients who develop an infection caused by Staphylococcus aureus, as they have a 50-85% mortality rate and overall reoperation rate of 50-65%. Infections caused by [0144] Staphylococcus epidermidis are also difficult to treat as the majority are caused by organisms resistant to all currently available beta-lactam antibiotics. Other complications of prosthetic valve endocarditis include valve malfunction (stenosis, regurgitation), abscess formation, embolic complications (such as stroke, CNS hemorrhage, cerebritis), conduction abnormalities, and death (55-75% of patients who develop an infection in the first 2 months after surgery).
  • An effective therapeutic valve coating would reduce the incidence of prosthetic valve endocarditis, reduce the mortality rate, reduce the incidence of complications, prolong the effectiveness of the prosthetic valve and/or reduce the need to replace the valve. This would result in lower mortality and morbidity for patients with prosthetic heart valves. [0145]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the bioprosthetic or mechanical valve. The drug(s) can be applied to the prosthetic valve in several manners: (a) as a coating applied to the surface of the annular ring (particularly mechanical valves); (b) as a coating applied to the surface of the valve leaflets (particularly bioprosthetic valves); (c) incorporated into the polymers which comprise the annular ring; and/or (d) any combination of the aforementioned. [0146]
  • Drug-coating of, or drug incorporation into prosthetic heart valves will allow bacteriocidal drug levels to be achieved locally on the valvular surface, thus reducing the incidence of bacterial colonization and subsequent development of PVE, while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the valve annular ring and/or leaflets, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g., nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g., poly(ethylene-co-vinyl acetate)), as well as blends thereof. [0147]
  • As prosthetic heart valves are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the prosthetic heart valve, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0148]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the prosthetic heart valve, or applied without a carrier polymer, the total dose of doxorubicin applied to the prosthetic heart valve should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied to the prosthetic heart valve should be in the range of 1 μg to 5 mg. The dose per unit area of the valve (i.e., the amount of drug as a function of the surface area of the portion of the valve to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0149] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the valve surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the valve surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that drug concentrations on the valve surface exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the valve such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the prosthetic heart valve, or applied without a carrier polymer, the total dose of mitoxantrone applied to the prosthetic heart valve should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied to the prosthetic heart valve should be in the range of 0.1 μg to 1 mg. The dose per unit area of the valve (i.e. the amount of drug as a function of the surface area of the portion of the valve to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0150] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the valve surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the valve surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained on the valve surface. It is necessary to insure that drug concentrations on the valve surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the surface of the valve such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the prosthetic heart valve, or applied without a carrier polymer, the total dose of 5-fluorouracil applied to the prosthetic heart valve should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied to the prosthetic heart valve should be in the range of 10 μg to 25 mg. The dose per unit area of the valve (i.e. the amount of drug as a function of the surface area of the portion of the valve to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0151] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the valve surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the valve surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained on the valve surface. It is necessary to insure that drug concentrations on the prosthetic heart valve surface exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the surface of the valve such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the prosthetic heart valve, or applied without a carrier polymer, the total dose of etoposide applied to the prosthetic heart valve should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied to the prosthetic heart valve should be in the range of 1 μg to 5 mg. The dose per unit area of the valve (i.e., the amount of drug as a function of the surface area of the portion of the valve to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0152] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the prosthetic heart valve surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the valve surface such that a concentration of 10−5-10−6 M of etoposide is maintained on the valve surface. It is necessary to insure that drug concentrations on the valve surface exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e., are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the valve such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the prosthetic heart valve coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. Since thrombogenicity of the prosthetic heart valve is associated with an increased risk of infection, anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be combined with antithrombotic and/or antiplatelet agents (for example, heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinase, and/or tissue plasminogen activator) to enhance efficacy. [0153]
  • C. Cardiac Pacemaker Infections
  • Overall, slightly greater than 5% of cardiac pacemakers become infected following implantation. Cardiac pacemakers are subject to infection in two general manners: (a) infections involving the pulse generator pocket and/or subcutaneous portion of the lead, and (b) infections involving the transvenous intravascular electrode and/or the generator unit. Representative examples of patents which describe pacemakers and pacemaker leads include U.S. Pat. Nos. 4,662,382, 4,782,836, 4,856,521, 4,860,751, 5,101,824, 5,261,419, 5,284,491, 6,055,454, 6,370,434, and 6,370,434. [0154]
  • The most common type of pacemaker infection involves the subcutaneous generator unit or lead wires in the period shortly after placement. This type of infection is thought to be the result of contamination of the surgical site by skin flora at the time of placement. [0155] Staphylococcus epidermidis (65-75% of cases), Stapylococcus aureus, Streptococci, Corynebacterium, Proprionibacterium acnes, Enterobacteriaceae and Candida species are frequent causes of this type of infection. Treatment of the infection at this point is relatively straightforward, the infected portion of the device is removed, the patient is treated with antibiotics and a new pacemaker is inserted at a different site. Unfortunately, infections of the generator pocket can subsequently spread to the epicardial electrodes causing more severe complications such pericarditis, mediastinitis and bacteremia.
  • Infection of the intravascular portion of the tranvenous electrode poses a more significant clinical problem. This infection is thought to be caused by infection of the subcutaneous portion of the pacing apparatus that tracks along the device into the intravascular and intracardiac portions of the device. This infection tends to present at a later time (1-6 months post-procedure) and can result in sepsis, endocarditis, pneumonia, bronchitis, pulmonary embolism, cardiac vegetations and even death. Coagulase Negative Staphylococci (56% of infections), [0156] Staphylococcus aureus (27%), Enterobacteriaceae (6%), Pseudomonas arugenosa (3%) and Candida albicans (2%) are the most common cause of this serious form of pacemaker infection. Treatment of this form of infection is more complex. The generator and electrodes must be removed (often surgically), antibiotics are required for prolonged periods and an entire new pacemaker system must be inserted. Mortality rates associated with this condition can be quite high—41% if treated with antibiotics alone, 20% if treated with electrode removal and antibiotics.
  • An effective cardiac pacemaker coating would reduce the incidence of subcutaneous infection and subsequent tracking of infection to the pericardial and endocardial surfaces of the heart. Clinically, this would result in a reduction in the overall rate of infection and reduce the incidence of more severe complications such as sepsis, endocarditis, pneumonia, bronchitis, pulmonary embolism, cardiac vegetations and even death. An effective coating could also prolong the effectiveness of the pacemaker and decrease the number of pacemakers requiring replacement, resulting in lower mortality and morbidity for patients with these implants. [0157]
  • In a preferred embodiment, an anthracycline (e.g., doxorubicin and mitoxantrone), fluoropyrimidine (e.g., 5-FU), folic acid antagonist (e.g., methotrexate), and/or podophylotoxin (e.g., etoposide) is formulated into a coating applied to the surface of the components of the cardiac pacemaker. The drug(s) can be applied to the pacemaker in several manners: (a) as a coating applied to the surface of the generator unit; (b) as a coating applied to the surface of the subcutaneous portion of the lead wires; (c) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the subcutaneous insertion site; (d) as a coating applied to the surface of the epicardial electrodes; (e) as a coating applied to the surface of the transvenous electrode; and/or (f) any combination of the aforementioned. [0158]
  • Drug-coating of, or drug incorporation into cardiac pacemakers will allow bacteriocidal drug levels to be achieved locally on the pacemaker surface, thus reducing the incidence of bacterial colonization and subsequent development of infectious complications, while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the generator unit, leads and electrodes, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose. Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0159]
  • As cardiac pacemakers are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the pacemaker coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the cardiac pacemaker, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0160]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the pacemaker components, or applied without a carrier polymer, the total dose of doxorubicin applied to the pacemaker should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the pacemaker to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0161] 2of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the pacemaker surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the pacemaker surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the pacemaker such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the pacemaker, or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the pacemaker to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0162] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the pacemaker surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the pacemaker surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the pacemaker surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the surface of the pacemaker such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the pacemaker, or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the pacemaker to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0163] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the pacemaker surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the pacemaker surface such that a minimum concentration of 104-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the pacemaker surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the cardiac pacemaker, or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the pacemaker to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0164] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the pacemaker surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the pacemaker surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the pacemaker such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the pacemaker coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide). can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. Since thrombogenicity of the intravascular portion of the transvenous electrode is associated with an increased risk of infection, anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be combined with antithrombotic and/or antiplatelet agents (for example heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin,, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinase, and/or tissue plasminogen activator) to enhance efficacy. [0165]
  • D. Infections of Implantable Cardioverter-Defibrillators (ICD)
  • Overall, approximately 5-10% of implantable cardioverter-defibrillators become infected following implantation (the rate is highest if surgical placement is required). Like cardiac pacemakers, implantable defibrillators are subject to infection in two general manners: (a) infections involving the subcutaneous portion of the device (subcutaneous electrodes and pulse generator unit, and (b) infections involving the intrathoracic components (rate sensing electrode, SVC coil electrode and epicardial electrodes). Representative examples of ICD's and associated components are described in U.S. Pat. Nos. 3,614,954, 3,614,955, 4,375,817, 5,314,430, 5,405,363, 5,607,385, 5,697,953, 5,776,165, 6,067,471, 6,169,923, and 6,152,955. [0166]
  • Most infections present period shortly after placement and are thought to be the result of contamination of the surgical site by skin flora. [0167] Staphylococcus epidermidis, Stapylococcus aureus, Streptococci, Corynebacterium, Proprionibacterium acnes, Enterobacteriaceae and Candida species are frequent causes of this type of infection. Unfortunately, treatment frequently involves removal of the entire system and prolonged antibiotic therapy.
  • An effective ICD coating would reduce the incidence of infection-related side effects such subcutaneous infection, sepsis and pericarditis. An effective coating could also prolong the effectiveness of the ICD and decrease the number of patients requiring replacement, resulting in lower mortality and morbidity associated with these implants. [0168]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the ICD. The drug(s) can be applied in several manners: (a) as a coating applied to the surface of the pulse generator unit; (b) as a coating applied to the surface of the subcutaneous portion of the lead wires; (c) incorporated into, or applied to the surface of, a subcutaneous “cuff” around the subcutaneous insertion site; (d) as a coating applied to the surface of the SVC coil electrode; (e) as a coating applied to the surface of the epicardial electrode; and/or (f) any combination of the aforementioned. [0169]
  • Drug-coating of, or drug incorporation into prosthetic heart valves will allow bacteriocidal drug levels to be achieved locally on the ICD surface, thus reducing the incidence of bacterial colonization and subsequent development of infectious complications, while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the generator unit, leads and electrodes, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0170]
  • As implantable cardioverter-defibrillators have many design features similar to those found in cardiac pacemakers, the dosing guidelines for doxorubicin, mitoxantrone, 5-fluorouracil and etoposide in coating ICDs are identical to those described above for cardiac pacemakers. [0171]
  • E. Vascular Graft Infections
  • Infection rates for synthetic vascular grafts range from 1-5% and are highest in grafts that traverse the inguinal region (such as aorto-femoral grafts and femoral-popliteal grafts). Although infection can result from extension of an infection from an adjacent contaminated tissue or hematogenous seeding, the most common cause of infection is intraoperative contamination. In fact, more than half of all cases present within the first 3 months after surgery.. The most common causes of infection include [0172] Staphylococcus aureus (25-35% of cases), Enterobacteriaceae, Pseudomonas aerugenosa, and Coagulase Negative Staphylococci.
  • Complications arising from vascular graft infection include sepsis, subcutaneous infection, false aneurysm formation, graft thrombosis, haemorrhage, septic or thrombotic emboli and graft thrombosis. Treatment requires removal of the graft in virtually all cases combined with systemic antibiotics. Often the surgery must be performed in a staged manner (complete resection of the infected graft, debridement of adjacent infected tissues, development of a healthy arterial stump, reperfusion through an uninfected pathway) further adding to the morbidity and mortality associated with this condition. For example, if an aortic graft becomes infected there is a 37% mortality rate and a 21% rate of leg amputation in survivors; for infrainguinal grafts the rates are 18% and 40% respectively. [0173]
  • Representative examples of vascular grafts are described in U.S. Pat. Nos. 3,096,560, 3,805,301, 3,945,052, 4,140,126, 4,323,525, 4,355,426, 4,475,972, 4,530,113, 4,550,447, 4,562,596, 4,601,718, 4,647,416, 4,878,908, 5,024,671, 5,104,399, 5,116,360, 5,151,105, 5,197,977, 5,282,824, 5,405,379, 5,609,624, 5,693,088, and 5,910,168. [0174]
  • An effective vascular graft coating would reduce the incidence of complications such as sepsis, haemorrhage, thrombosis, embolism, amputation and even death. An effective coating would also decrease the number of vascular grafts requiring replacement, resulting in lower mortality and morbidity for patients with these implants. [0175]
  • In a preferred embodiment, an anthracycline (e.g., doxorubicin and mitoxantrone), fluoropyrimidine (e.g., 5-FU), folic acid antagonist (e.g., methotrexate), and/or podophylotoxin (e.g., etoposide) is formulated into a coating applied to the surface of the components of the vascular graft. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the graft; (b) as a coating applied to the internal (luminal) surface of the graft; and/or (c) as a coating applied to all or parts of both surfaces. [0176]
  • Drug-coating of, or drug incorporation into vascular grafts will allow bacteriocidal drug levels to be achieved locally on the graft surface, thus reducing the incidence of bacterial colonization and subsequent development of infectious complications, while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ (CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomateriais]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) collagen as well as blends thereof. [0177]
  • As vascular grafts are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the graft coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the vascular graft, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0178]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the vascular graft components (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the vascular graft to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0179] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the vascular graft surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the vascular graft surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the vascular graft such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the vascular graft (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the vascular graft to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0180] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the vascular graft surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the vascular graft surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the vascular graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the vascular graft (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the vascular graft to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0181] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the vascular graft surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the vascular graft surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the vascular graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the vascular graft (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the vascular graft to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0182] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the vascular graft surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the vascular graft surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the vascular graft such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the vascular graft coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. Since thrombogenicity of the vascular graft is associated with an increased risk of infection, anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate and/or podophylotoxins (e.g., etoposide) can be combined with antithrombotic and/or antiplatelet agents (for example heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinase, and/or tissue plasminogen activator) to enhance efficacy. [0183]
  • F. Infections Associated with Ear, Nose and Throat Implants
  • Bacterial infections involving the ear, nose and throat are common occurrences in both children and adults. For the management of chronic obstruction secondary to persistent infection, the use of implanted medical tubes is a frequent form of treatment. Specifically, chronic otitis media is often treated with the surgical implantation of tympanostomy tubes and chronic sinusitis is frequently treated with surgical drainage and the placement of a sinus stent. [0184]
  • Tympanostomy Tubes [0185]
  • Acute otitis media is the most common bacterial infection, the most frequent indication for surgical therapy, the leading cause of hearing loss and a common cause of impaired language development in children. The cost of treating this condition in children under the age of five is estimated at $5 billion annually in the United States alone. In fact, 85% of all children will have at least one episode of otitis media and 600,000 will require surgical therapy annually. The prevalence of otitis media is increasing and for severe cases surgical therapy is more cost effective than conservative management. [0186]
  • Acute otitis media (bacterial infection of the middle ear) is characterized by Eustachian tube dysfunction leading to failure of the middle ear clearance mechanism. The most common causes of otitis media are [0187] Streptococcus pneumoniae (30%), Haemophilus influenza (20%), Branhamella catarrhalis (12%), Streptococcus pyogenes (3%), and Staphylococcus aureus (1.5%). The end result is the accumulation of bacteria, white blood cells and fluid which, in the absence of an ability to drain through the Eustachian tube, results in increased pressure in the middle ear. For many cases antibiotic therapy is sufficient treatment and the condition resolves. However, for a significant number of patients the condition becomes frequently recurrent or does not resolve completely. In recurrent otitis media or chronic otitis media with effusion, there is a continuous build-up of fluid and bacteria that creates a pressure gradient across the tympanic membrane causing pain and impaired hearing. Fenestration of the tympanic membrane (typically with placement of a tympanostomy tube) relieves the pressure gradient and facilitates drainage of the middle ear (through the outer ear instead of through the Eustachian tube—a form of “Eustachian tube bypass”).
  • Surgical placement of tympanostomy tubes is the most widely used treatment for chronic otitis media because, although not curative, it improves hearing (which in turn improves language development) and reduces the incidence of acute otitis media. Tympanostomy tube placement is one of the most common surgical procedures in the United States with 1.3 million surgical placements per year. Nearly all younger children and a large percentage of older children require general anaesthesia for placement. Since general anaesthesia has a higher incidence of significant side effects in children (and represents the single greatest risk and cost associated with the procedure), it is desirable to limit the number of anaesthetics that the child is exposed to. Common complications of tympanostomy tube insertion include chronic otorrhea (often due to infection by [0188] S. pneumoniae, H. influenza, Pseudomonas aerugenosa, S.aureus, or Candida), foreign body reaction with the formation of granulation tissue and infection, plugging (usually obstructed by granulation tissue, bacteria and/or clot), tympanic membrane perforation, myringosclerosis, tympanic membrane atrophy (retraction, atelectasis), and cholesteatoma.
  • An effective tympanostomy tube coating would allow easy insertion, remain in place for as long as is required, be easily removed in the office without anaesthesia, resist infection and prevent the formation of granulation tissue in the tube (which can not only lead to obstruction, but also “tack down” the tube such that surgical removal of the tube under anaesthetic becomes necessary). An effective tympanostomy tube would also reduce the incidence of complications such as chronic otorrhea (often due to infection by [0189] S. pneumoniae, H. influenza, Pseudomonas aerugenosa, S. aureus, or Candida); maintain patency (prevent obstruction by granulation tissue, bacteria and/or clot); and/or reduce tympanic membrane perforation, myringoscierosis, tympanic membrane atrophy and cholesteatoma. Therefore, development of a tube which does not become obstructed by granulation tissue, does not scar in place and is less prone to infection (thereby reducing the need to remove/replace the tube) would be a significant medical advancement.
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the tympanostomy tube. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the tympanostomy tube; (b) as a coating applied to the internal (luminal) surface of the tympanostomy tube; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the tympanostomy tube. [0190]
  • Drug-coating of, or drug incorporation into, the tympanostomy tube will allow bacteriocidal drug levels to be achieved locally on the tube surface, thus reducing the incidence of bacterial colonization (and subsequent development of middle ear infection), while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the tympanostomy tube surface, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0191]
  • There are two general designs of tympanostomy tubes: grommet-shaped tubes, which tend to stay in place for less than 1 year but have a low incidence of permanent perforation of the tympanic membrane (1%), and T-tubes, which stay in place for several years but have a higher rate of permanent perforation (5%). As tympanostomy tubes are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the tympanostomy tube, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0192]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the tympanostomy tube components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the tympanostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0193] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the tympanostomy tube surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the tympanostomy tube surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the tympanostomy tube such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the tympanostomy tube, or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the tympanostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0194] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the tympanostomy tube surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the tympanostomy tube surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the tympanostomy tube surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident based upon the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the tympanostomy tube, or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the tympanostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0195] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the tympanostomy tube surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the tympanostomy tube surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the tympanostomy tube surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the tympanostomy tube, or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the tympanostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0196] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the tympanostomy tube surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the tympanostomy tube surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the tympanostomy tube such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the tympanostomy tube coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. [0197]
  • Sinus Stents [0198]
  • The sinuses are four pairs of hollow regions contained in the bones of the skull named after the bones in which they are located (ethmoid, maxillary, frontal and sphenoid). All are lined by respiratory mucosa which is directly attached to the bone. Following an inflammatory insult such as an upper respiratory tract infection or allergic rhinitis, a purulent form of sinusitis can develop. Occasionally secretions can be retained in the sinus due to altered ciliary function or obstruction of the opening (ostea) that drains the sinus. Incomplete drainage makes the sinus prone to infection typically with [0199] Haemophilus influenza, Streptococcus pneumoniae, Moraxella catarrhalis, Veillonella, Peptococcus, Corynebacterium acnes and certain species of fungi.
  • When initial treatment such as antibiotics, intranasal steroid sprays and decongestants are ineffective, it may become necessary to perform surgical drainage of the infected sinus. Surgical therapy often involves debridement of the ostea to remove anatomic obstructions and removal of parts of the mucosa. Occasionally a stent (a cylindrical tube which physically holds the lumen of the ostea open) is left in the osta to ensure drainage is maintained even in the presence of postoperative swelling. Stents, typically made of stainless steel or plastic, remain in place for several days or several weeks before being removed. [0200]
  • Unfortunately, the stents can become infected or overgrown by granulation tissue that renders them ineffective. An effective sinus stent coating would allow easy insertion, remain in place for as long as is required, be easily removed in the office without anaesthesia, resist infection and prevent the formation of granulation tissue in the stent (which can not only lead to obstruction, but also “tack down” the stent such that surgical removal becomes necessary). Therefore, development of a sinus stent which does not become obstructed by granulation tissue, does not scar in place and is less prone to infection would be beneficial. [0201]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the sinus stent. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the sinus stent; (b) as a coating applied to the internal (luminal) surface of the sinus stent; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the sinus stent. [0202]
  • Drug-coating of, or drug incorporation into, the sinus stent will allow bacteriocidal drug levels to be achieved locally on the tube surface, thus reducing the incidence of bacterial colonization (and subsequent development of sinusitis), while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the sinus stent surface, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640 ™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0203]
  • As sinus stents are prone to the same complications and infections from the same bacteria, the dosing guidelines for doxorubicin, mitoxantrone, 5-fluorouracil and etoposide in coating sinus stents are identical to those described above for tympanostomy tubes. [0204]
  • G. Infections Associated with Urological Implants
  • Implanted medical devices are used in the urinary tract with greater frequency than in any other body system and have some of the highest rates of infection. In fact, the great majority of urinary devices become infected if they remain in place for a prolonged period of time and are the most common cause of nosocomial infection. [0205]
  • Urinary (Foley) Catheters [0206]
  • Four-to-five million bladder catheters are inserted into hospitalized patients every year in the United States. The duration of catheterization is the important risk factor for patients developing a clinically significant infection—the rate of infection increases 5-10% per day that the patient is catheterized. Although simple cystitis can be treated with a short course of antibiotics (with or without removal of the catheter), serious complications are frequent and can be extremely serious. The infection can ascend to the kidneys causing acute pyelonephritis which can result in scarring and long term kidney damage. Perhaps of greatest concern is the 1-2% risk of developing gram negative sepsis (the risk is 3-times higher in catheterized patients and accounts for 30% of all cases) which can be extremely difficult to treat and can result in septic shock and death (up to 50% of patients). Therefore, there exists a significant medical need to produce improved urinary catheters capable of reducing the incidence of urinary tract infection in catheterized patients. [0207]
  • The most common cause of infection is bacteria typically found in the bowel or perineum that are able to track up the catheter to gain access to the normally sterile bladder. Bacteria can be carried into the bladder as the catheter is inserted, gain entry via the sheath of exudates that surrounds the catheter, and/or travel intraluminally inside the catheter tubing. Several species of bacteria are able to adhere to the catheter and form a biofilm that provides a protected site for growth. With short-term catheterization, single organism infections are most common and are typically due to [0208] Escherichia coli, Enterococci, Pseudomonas aeruginosa, Klebsiella, Proteus, Enterobacter, Staphylococcus epidermidis, Staphylococcus aureus and Staphylococcus saprophyticus. Patients who are catheterized for long periods of time are prone to polymicrobial infections caused by all of the organisms previously mentioned as well as Providencia stuartii, Morganella morganii and Candida. Antibiotic use either systemically or locally has been largely proven to be ineffective as it tends to result only in the selection of drug-resistant bacteria.
  • An effective urinary catheter coating would allow easy insertion into the bladder, resist infection and prevent the formation of biofilm in the catheter. An effective coating would prevent or reduce the incidence of urinary tract infection, pyelonephritis, and/or sepsis. In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the urinary catheter. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the urinary catheter; (b) as a coating applied to the internal (luminal) surface of the urinary catheter; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the urinary catheter. [0209]
  • Drug-coating of, or drug incorporation into, the urinary catheter will allow bacteriocidal drug levels to be achieved locally on the catheter surface, thus reducing the incidence of bacterial colonization (and subsequent development of urinary tract infection and bacteremia), while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the urinary catheter surface, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0210]
  • As urinary catheters (e.g. Foley catheters, suprapubic catheters) are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the urinary catheter, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0211]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the urinary catheter components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the urinary catheter to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0212] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the urinary catheter surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary catheter surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the urinary catheter such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 hour-1 month. It should be readily evident given the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the urinary catheter, or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the urinary catheter to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0213] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the urinary catheter surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary catheter surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the urinary catheter surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 hour-1 month. It should be readily evident given the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrim idines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the urinary catheter, or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the urinary catheter to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0214] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the urinary catheter surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary catheter surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the urinary catheter surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 hour-1 month. It should be readily evident given the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the urinary catheter, or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the urinary catheter to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0215] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the urinary catheter surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the urinary catheter surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the urinary catheter such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 hour-1 month. It should be readily evident given the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the urinary catheter coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. [0216]
  • Ureteral Stents [0217]
  • Ureteral stents are hollow tubes with holes along the sides and coils at either end to prevent migration. Ureteral stents are used to relieve obstructions (caused by stones or malignancy), to facilitate the passage of stones, or to allow healing of ureteral anastomoses or leaks following surgery or trauma. They are placed endoscopically via the bladder or percutaneously via the kidney. A microbial biofilm forms on up to 90% of ureteral stents and 30% develop significant bacteruria with the incidence increasing the longer the stent is in place. [0218] Pseudomonas aeruginosa is the most common pathogen, but Enterococci, Staphylococcus aureus and Candida also cause infection. Effective treatment frequently requires stent removal in addition to antibiotic therapy.
  • Unfortunately, ureteral stents can become infected or encrusted with urinary salts that render them ineffective. An effective ureteral stent coating would allow easy insertion, remain in place for as long as is required, be easily removed, resist infection and prevent the formation of urinary salts. Therefore, development of a ureteral stent which does not become obstructed by granulation tissue, does not scar in place and is less prone to infection would be beneficial. [0219]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the ureteral stent. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the ureteral stent; (b) as a coating applied to the internal (luminal) surface of the ureteral stent; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the ureteral stent. [0220]
  • Drug-coating of, or drug incorporation into, the ureteral stent will allow bacteriocidal drug levels to be achieved locally on the stent surface, thus reducing the incidence of bacterial colonization (and subsequent development of pyelonephritis and/or bacteremia), while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the ureteral stent surface, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0221]
  • As ureteral stents are prone to the same complications and infections from the same bacteria, the dosing guidelines for doxorubicin, mitoxantrone, 5-fluorouracil and etoposide in coating ureteral stents are identical to those described above for urinary catheters. However, unlike the formulations described for urinary catheters, drug release should occur over a 2 to 24 week period. [0222]
  • Urethral Stents [0223]
  • Urethral stents are used for the treatment of recurrent urethral strictures, detruso-external sphincter dyssynergia and bladder outlet obstruction due to benign prostatic hypertrophy. The stents are typically self-expanding and composed of metal superalloy, titanium, stainless steel or polyurethane. Infections are most often due to Coagulase Negative Staphylococci, [0224] Pseudomonas aeruginosa, Enterococci, Staphylococcus aureus, Serratia and Candida. Treatment of infected stents frequently requires systemic antibiotic therapy and removal of the device.
  • An effective urethral stent coating would allow easy insertion, remain in place for as long as is required, be easily removed, resist infection and prevent the formation of urinary salts. Therefore, development of a urethral stent which does not become obstructed by granulation tissue, does not scar in place and is less prone to infection would be beneficial. [0225]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the urethral stent. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the urethral stent; (b) as a coating applied to the internal (luminal) surface of the urethral stent; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the urethral stent. [0226]
  • Drug-coating of, or drug incorporation into, the urethral stent will allow bacteriocidal drug levels to be achieved locally on the stent surface, thus reducing the incidence of bacterial colonization (and subsequent development of pyelonephritis and/or bacteremia), while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the ureteral stent surface, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0227]
  • As urethral stents are prone to the same complications and infections from the same bacteria, the dosing guidelines for doxorubicin, mitoxantrone, 5-fluorouracil and etoposide in coating ureteral stents are identical to those described above for urinary catheters. However, unlike the formulations described for urinary catheters, drug release should occur over a 2 to 24 week period. [0228]
  • Prosthetic Bladder Sphincters [0229]
  • Prosthetic bladder sphincters are used to treat incontinence and generally consist of a periurethral implant. The placement of prosthetic bladder sphincters can be complicated by infection (usually in the first 6 months after surgery) with Coagulase Negative Staphylococci (including [0230] Staphylococcus epidermidis), Staphylococcus aureus, Pseudomonas aeruginosa, Enterococci, Serratia and Candida. Infection is characterized by fever, erythema, induration and purulent drainage from the operative site. The usual route of infection is through the incision at the time of surgery and up to 3% of prosthetic bladder sphincters become infected despite the best sterile surgical technique. To help combat this, intraoperative irrigation with antibiotic solutions is often employed.
  • Treatment of infections of prosthetic bladder sphincters requires complete removal of the device and antibiotic therapy; replacement of the device must often be delayed for 3-6 months after the infection has cleared. An effective prosthetic bladder sphincter coating would resist infection and reduce the incidence of re-intervention. [0231]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the prosthetic bladder sphincter. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the prosthetic bladder sphincter; and/or (b) incorporated into the polymers which comprise the prosthetic bladder sphincter. [0232]
  • Drug-coating of, or drug incorporation into, the prosthetic bladder sphincter will allow bacteriocidal drug levels to be achieved locally, thus reducing the incidence of bacterial colonization (and subsequent development of urethritis and/or wound infection), while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the prosthetic bladder sphincter surface, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0233]
  • As prosthetic bladder sphincters are prone to infections caused by the same bacteria as occur with urinary catheters, the dosing guidelines for doxorubicin, mitoxantrone, 5-fluorouracil and etoposide in coating prosthetic bladder sphincters are identical to those described above for urinary catheters. However, unlike the formulations described for urinary catheters, drug release should occur over a 2 to 24 week period. [0234]
  • Penile Implants [0235]
  • Penile implants are used to treat erectile dysfunction and are generally flexible rods, hinged rods or inflatable devices with a pump. The placement of penile implants can be complicated by infection (usually in the first 6 months after surgery) with Coagulase Negative Staphylococci (including [0236] Staphylococcus epidermidis), Staphylococcus aureus, Pseudomonas aeruginosa, Enterococci, Serratia and Candida. The type of device or route of insertion does not affect the incidence of infection. Infection is characterized by fever, erythema, induration and purulent drainage from the operative site. The usual route of infection is through the incision at the time of surgery and up to 3% of penile implants become infected despite the best sterile surgical technique. To help combat this, intraoperative irrigation with antibiotic solutions is often employed.
  • Treatment of infections of penile implants requires complete removal of the device and antibiotic therapy; replacement of the device must often be delayed for 3-6 months after the infection has cleared. An effective penile implant coating would resist infection and reduce the incidence of re-intervention. [0237]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the penile implant. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the penile implant; and/or (b) incorporated into the polymers which comprise the penile implant. [0238]
  • Drug-coating of, or drug incorporation into, the penile implant will allow bacteriocidal drug levels to be achieved locally, thus reducing the incidence of bacterial colonization (and subsequent development of local infection and device failure), while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the penile implant surface, several polymeric carriers are particularly suitable for use in this embodiment. [0239]
  • As penile implants are prone to infections caused by the same bacteria as occur with urinary catheters, the dosing guidelines for doxorubicin, mitoxantrone, 5-fluorouracil and etoposide in coating penile implants are identical to those described above for urinary catheters. However, unlike the formulations described for urinary catheters, drug release should occur over a 2 to 24 week period. [0240]
  • H. Infections Associated with Endotracheal and Tracheostomy Tubes
  • Endotracheal tubes and tracheostomy tubes are used to maintain the airway when ventilatory assistance is required. Endotracheal tubes tend to be used to establish an airway in the acute setting, while tracheostomy tubes are used when prolonged ventilation is required or when there is a fixed obstruction in the upper airway. In hospitalized patients, nosocomial pneumonia occurs 300,000 times per year and is the second most common cause of hospital-acquired infection (after urinary tract infection) and the most common infection in ICU patients. In the intensive care unit, nosocomial pneumonia is a frequent cause death with fatality rates over 50%. Survivors spend on average 2 weeks longer in hospital and the annual cost of treatment is close to $2 billion. [0241]
  • Bacterial pneumonia is the most common cause of excess morbidity and mortality in patients who require intubation. In patients who are intubated electively (i.e. for elective surgery), less than 1% will develop a nosocomial pneumonia. However, patients who are severely ill with ARDS (Adult Respiratory Distress Syndrome) have a greater than 50% chance of developing a nosocomial pneumonia. It is thought that new organisms colonize the oropharynx in intubated patients, are swallowed to contaminate the stomach, are aspirated to inoculate the lower airway and eventually contaminate the endotracheal tube. Bacteria adhere to the tube, form a biolayer and multiply serving as a source for bacteria that can aerosolize and be carried distally into the lungs. Chronic tracheostomy tubes also frequently become colonized with pathogenic bacteria known to cause pneumonia. The most common causes of pneumonia in ventilated patients are [0242] Staphylococcus aureus (17%), Pseudomonas aeruginosa (18%), Klebsiella pneumoniae (9%), Enterobacter (9%) and Haemophilus influenza (5%). Treatment requires aggressive therapy with antibiotics.
  • An effective endotracheal tube or tracheostomy tube coating would resist infection and prevent the formation of biofilm in the tube. An effective coating would prevent or reduce the incidence of pneumonia, sepsis and death. In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the endotracheal tube or tracheostomy tube. Due to its activity against [0243] Klebsiella pneumoniae, methotrexate can also be useful for this embobiment. As cisplatin and hydroxyurea have some activity against Pseudomonas aeruginosa, they can also be of some utility in the practice of this embodiment. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the endotracheal tube or tracheostomy tube; (b) as a coating applied to the internal (luminal) surface of the endotracheal tube or tracheostomy tube; (c) as a coating applied to all or parts of both surfaces; and/or (d) incorporated into the polymers which comprise the endotracheal tube or tracheostomy tube.
  • Drug-coating of, or drug incorporation into, the endotracheal tube or tracheostomy tube will allow bacteriocidal drug levels to be achieved locally on the catheter surface, thus reducing the incidence of bacterial colonization (and subsequent development of pneumonia and sepsis), while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug to the endotracheal tube or tracheostomy tube surface, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0244]
  • As endotracheal tube and tracheostomy tubes are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area and design. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the endotracheal tube or tracheostomy tube, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0245]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the endotracheal tube or tracheostomy tube components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the endotracheal tube or tracheostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0246] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the endotracheal tube or tracheostomy tube surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the endotracheal tube or tracheostomy tube surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the endotracheal tube or tracheostomy tube such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations from the endotracheal tube for a period ranging from 1 hour to 1 month, while release from a tracheostomy tube would range from 1 day to 3 months. It should be readily evident given the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the endotracheal tube or tracheostomy tube, or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the endotracheal tube or tracheostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0247] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the endotracheal tube or tracheostomy tube surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the endotracheal tube or tracheostomy tube surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the endotracheal tube or tracheostomy tube surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment, the drug is released in effective concentrations from the endotracheal tube for a period ranging from 1 hour to 1 month, while release from a tracheostomy tube would range from 1 day to 3 months. It should be readily evident given the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the endotracheal tube or tracheostomy tube, or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the endotracheal tube or tracheostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0248] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the endotracheal tube or tracheostomy tube surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the endotracheal tube or tracheostomy tube surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e. are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the endotracheal tube or tracheostomy tube surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment, the drug is released in effective concentrations from the endotracheal tube for a period ranging from 1 hour to 1 month, while release from a tracheostomy tube would range from 1 day to 3 months. It should be readily evident given the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the endotracheal tube or tracheostomy tube, or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the endotracheal tube or tracheostomy tube to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0249] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the endotracheal tube or tracheostomy tube surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the endotracheal tube or tracheostomy tube surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of ptoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the endotracheal tube or tracheostomy tube such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred, embodiment the drug is released in effective concentrations from the endotracheal tube for a period ranging from 1 hour to 1 month, while release from a tracheostomy tube would range from 1 day to 3 months. It should be readily evident given the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the endotracheal tube or tracheostomy tube coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. [0250]
  • I. Infections Associated with Dialysis Catheters
  • In 1997, there were over 300,000 patients in the United States with end-stage renal disease. Of these, 63% were treated with hemodialysis, 9% with peritoneal dialysis and 38% with renal transplantation. Hemodialysis requires reliable access to the vascular system typically as a surgically created arteriovenous fistula (AVF; 18%), via a synthetic bridge graft (usually a PTFE arteriovenous interposition graft in the forearm or leg; 50%) or a central venous catheter (32%). Peritoneal dialysis requires regular exchange of dialysate through the peritoneum via a double-cuffed and tunnelled peritoneal dialysis catheter. Regardless of the form of dialysis employed, infection is the second leading cause of death in renal failure patients (15.5% of all deaths) after heart disease. A significant number of those infections are secondary to the dialysis procedure itself. [0251]
  • Hemodialysis Access Grafts [0252]
  • Kidney failure patients have a dysfunctional immune response that makes them particularly susceptible to infection. Infections of hemodialysis access grafts are characterized as either being early (within month; thought to be a complication of surgery) and late (after 1 month; thought to be related to access care). Over a 2 year period, approximately 2% of AVF's become infected while 11-16% of PTFE grafts will become infected on at least one occasion. Although infection can result from extension of an infection from an adjacent contaminated tissue or hematogenous seeding, the most common cause of infection is intraoperative contamination. The most common causes of infection include [0253] Staphylococcus aureus, Enterobacteriaceae, Pseudomonas aerugenosa, and Coagulase Negative Staphylococci.
  • Complications arising from hemodialysis access graft infection include sepsis, subcutaneous infection, false aneurysm formation, endocarditis, osteomyelitis, septic arthritis, haemorrhage, septic or thrombotic emboli, graft thrombosis and septic dealth (2-4% of all infections). Treatment often requires removal of part or all of the graft combined with systemic antibiotics. [0254]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the synthetic hemodialysis access graft. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the graft; (b) as a coating applied to the internal (luminal) surface of the graft; and/or (c) as a coating applied to all or parts of both surfaces. For an AVF, the drug would be formulated into a surgical implant placed around the outside of the fistula at the time of surgery. [0255]
  • Drug-coating of, or drug incorporation into hemodialysis access grafts will allow bacteriocidal drug levels to be achieved locally on the graft surface, thus reducing the incidence of bacterial colonization and subsequent development of infectious complications, while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) , collagen, PLG as well as blends thereof. [0256]
  • An effective hemodialysis access graft coating would reduce the incidence of complications such as sepsis, haemorrhage, thrombosis, embolism, endocarditis, osteomyelitis and even death. An effective coating would also decrease the number of hemodialysis access grafts requiring replacement, resulting in lower mortality and morbidity for patients with these implants. [0257]
  • As hemodialysis access grafts are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the graft coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the hemodialysis access graft, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0258]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the hemodialysis access graft components (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the hemodialysis access graft to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0259] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the hemodialysis access graft surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hemodialysis access graft surface such that a minimum concentration of 10−7 -10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the hemodialysis access graft such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the hemodialysis access graft (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the hemodialysis access graft to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0260] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the hemodialysis access graft surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hemodialysis access graft surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the hemodialysis access graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the hemodialysis access graft (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the hemodialysis access graft to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0261] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the hemodialysis access graft surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hemodialysis access graft surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the hemodialysis access graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the hemodialysis access graft (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the hemodialysis access graft to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0262] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the hemodialysis access graft surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the hemodialysis access graft surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the hemodialysis access graft such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the hemodialysis access graft coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. Since thrombogenicity of the hemodialysis access graft is associated with an increased risk of infection, anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and/or podophylotoxins (e.g., etoposide) can be combined with antithrombotic and/or antiplatelet agents (for example heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinase, and/or tissue plasminogen activator) to enhance efficacy. [0263]
  • Central Venous Catheters [0264]
  • A variety of central venous catheters are available for use in hemodialysis including, but not restricted to, catheters which are totally implanted such as the Lifesite (Vasca Inc., Tewksbury, Mass.) and the Dialock (Biolink Corp., Middleboro, Mass.). Central venous catheters are, prone to infection and embodiments for that purpose are described above. [0265]
  • Peritoneal Dialysis Catheters [0266]
  • Peritoneal dialysis catheters are typically double-cuffed and tunnelled catheters that provide access to the peritoneum. The most common peritoneal dialysis catheter designs are the Tenckhoff catheter, the Swan Neck Missouri catheter and the Toronto Western catheter. In peritoneal dialysis, the peritoneum acts as a semipermeable membrane across which solutes can be exchanged down a concentration gradient. [0267]
  • Peritoneal dialysis infections are typically classified as either peritonitis or exit-site/tunnel infections (i.e. catheter infections). Exit-site/tunnel infections are characterized by redness, induration or purulent discharge from the exit site or subcutaneous portions of the catheter. Peritonitis is more a severe infection that causes abdominal pain, nausea, fever and systemic evidence of infection. Unfortunately, the peritoneal dialysis catheter likely plays a role in both types of infection. In exit-site/tunnel infections, the catheter itself becomes infected. In peritonitis, the infection is frequently the result of bacteria tracking from the skin through the catheter lumen or migrating on the outer surface (pericatheter route) of the catheter into the peritoneum. Peritoneal catheter-related infections are typically caused by [0268] Staphylococcus aureus, Coagulase Negative Staphylococci, Escherichia coli, Viridans group streptococci, Enterobacteriacae, Corynebacterium, Branhamella, Actinobacter, Serratia, Proteus, Pseudomonas aeruginosa and Fungi.
  • Treatment of peritonitis involves rapid in-and-out exchanges of dialysate, systemic antibiotics (intravenous and/or intraperitoneal administration) and often requires removal of the catheter. Complications include hospitalization, the need to switch to another form of dialysis (30%) and mortality (2%; higher if the infection is due to Enterococci, [0269] S. aureus or polymicrobial).
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the synthetic peritoneal dialysis graft. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the graft; (b) as a coating applied to the internal (luminal) surface of the graft; (c) as a coating applied to the superficial cuff; (d) as a coating applied to the deep cuff; (e) incorporated into the polymers that comprise the graft; and/or (f) as a coating applied to a combination of these surfaces. [0270]
  • Drug-coating of, or drug incorporation into peritoneal dialysis grafts will allow bacteriocidal drug levels to be achieved locally on the graft surface, thus reducing the incidence of bacterial colonization and subsequent development of infectious complications, while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0271]
  • An effective peritoneal dialysis graft coating would reduce the incidence of complications such as hospitalization, peritonoitis, sepsis, and even death. An effective coating would also decrease the number of peritoneal dialysis grafts requiring replacement, resulting in lower mortality and morbidity for patients with these implants. [0272]
  • As peritoneal dialysis grafts are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the graft coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the peritoneal dialysis graft, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0273]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the peritoneal dialysis graft components (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the peritoneal dialysis graft to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0274] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the peritoneal dialysis graft surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the peritoneal dialysis graft surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the peritoneal dialysis graft such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the peritoneal dialysis graft (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the peritoneal dialysis graft to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0275] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the peritoneal dialysis graft surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the peritoneal dialysis graft surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the peritoneal dialysis graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the peritoneal dialysis graft (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the peritoneal dialysis graft to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0276] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the peritoneal dialysis graft surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the peritoneal dialysis graft surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the peritoneal dialysis graft surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the peritoneal dialysis graft (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the peritoneal dialysis graft to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0277] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the peritoneal dialysis graft surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the peritoneal dialysis graft surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the peritoneal dialysis graft such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1 week-6 months. It should be readily evident given the discussions provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the peritoneal dialysis graft coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. [0278]
  • J. Infections of Central Nervous System (CNS) Shunts
  • Hydocephalus, or accumulation of cerebrospinal fluid (CSF) in the brain, is a frequently encountered neurosurgical condition arising from congenital malformations, infection, hemmorrhage, or malignancy. The incompressible fluid exerts pressure on the brain leading to brain damage or even death if untreated. CNS shunts are conduits placed in the ventricles of the brain to divert the flow of CSF from the brain to other body compartments and relieve the fluid pressure. Ventricular CSF is diverted via a prosthetic shunt to a number of drainage locations including the pleura (ventriculopleural shunt), jugular vein, vena cava (VA shunt), gallbladder and peritoneum (VP shunt; most common). [0279]
  • Unfortunately, CSF shunts are relatively prone to developing infection, although the incidence has declined from 25% twenty years ago to 10% at present as a result of improved surgical technique. Approximately 25% of all shunt complications are due to the development of infection of the shunt and these can lead to significant clinical problems such as ventriculitis, ventricular compartmentalization, meningitis, subdural empyema, nephritis (with VA shunts), seizures, cortical mantle thinning, mental retardation or death. Most infections present with fever, nausea, vomiting, malaise, or signs of increased intracranial pressure such as headache or altered consciousness. The most common organisms causing CNS shunt infections are Coagulase Negative Staphylococci (67%; [0280] Staphylococcus epidermidis is the most frequently isolated organism), Staphylococcus aureus (10-20%), viridans streptococci, Streptococcus pyogenes, Enterococcus, Corynebacterium, Escherichia coli, Klebsiella, Proteus and Pseudomonas aeruginosa. It is thought that the majority of infections are due to inoculation of the organism during surgery, or during manipulation of the shunt in the postoperative period. As a result, most infections present clinically in the first few weeks following surgery.
  • Since many of the infections are caused by [0281] S. epidermidis, it is not uncommon to find that the catheter becomes coated with a bacterial-produced “slime” that protects the organism from the immune system and makes eradication of the infection difficult. Therefore, the treatments of most infections require shunt removal (and often placement of a temporary external ventricular shunt to relieve hydrocephalus) in addition to systemic and/or intraventricular antibiotic therapy. Poor therapeutic results tend to occur if the shunt is left in place during treatment. Antibiotic therapy is complicated by the fact that many antibiotics do not cross the blood-brain barrier effectively.
  • An effective CNS shunt coating would reduce the incidence of complications such as ventriculitis, ventricular compartmentalization, meningitis, subdural empyema, nephritis (with VA shunts), seizures, cortical mantle thinning, mental retardation or death. An effective coating would also decrease the number of CNS shunts requiring replacement, resulting in lower mortality and morbidity for patients with these implants. [0282]
  • In a preferred embodiment, an anthracycline (e.g., doxorubicin and mitoxantrone), fluoropyrimidine (e.g., 5-FU), folic acid antagonist (e.g., methotrexate), and/or podophylotoxin (e.g., etoposide) is formulated into a coating applied to the surface of the components of the CNS shunt. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the shunt; (b) as a coating applied to the internal (luminal) surface of the shunt; and/or (c) as a coating applied to all or parts of both surfaces. [0283]
  • Drug-coating of, or drug incorporation into CNS shunts will allow bacteriocidal drug levels to be achieved locally on the shunt surface, thus reducing the incidence of bacterial colonization and subsequent development of infectious complications, while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0284]
  • As CNS shunts are made in a variety of configurations and sizes, the exact dose administered will vary with device size, surface area, design and portions of the shunt coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the device being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the CNS shunt, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0285]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the CNS shunt components (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the CNS shunt to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0286] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the CNS shunt surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the CNS shunt surface such that a minimum concentration of 10−7 -10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e.. are in excess of 10−4 M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the CNS shunt such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-12 weeks. It should be readily evident given the discussions provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the CNS shunt (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the CNS shunt to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0287] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the CNS shunt surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the CNS shunt surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the CNS shunt surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-12 weeks. It should be readily evident based upon the discussion provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the CNS shunt (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the CNS shunt to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0288] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the CNS shunt surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the CNS shunt surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the CNS shunt surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-12 weeks. It should be readily evident based upon the discussion provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the CNS shunt (such as Dacron or Teflon), or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the CNS shunt to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0289] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the CNS shunt surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the CNS shunt surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the CNS shunt such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-12 weeks. It should be readily evident based upon the discussion provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the CNS shunt coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. [0290]
  • (g) External Ventricular Drainage (EVD) Device and Intracranial Pressure (ICP) Monitoring Devices
  • EVD and ICP monitoring devices are also used in the management of hydrocephalus. The therapeutic agents, doses, coatings and release kinetics for the development of drug-coated EVD's and drug-coated ICP monitoring devices are identical to those described for CNS shunts. [0291]
  • K. Infections of Orthopedic Implants
  • Implanted orthopedic devices such as prosthetic joints such as hip, knee, elbow, shoulder, wrist, metacarpal, and metatarsal prosthetics are subject to complications as a result of infection of the implant. Orthopedic implant infection has a variety of sequela including pain, immobility, failure of the prosthetic itself, loss/removal the of prosthetic, reoperation, loss of the affected limb or even death. The cost of treating each infection exceeds the cost of the primary joint arthroplasty itself by 3 or 4-fold (in excess of $50,000/case). Other orthopedic implant hardware such as internal and external fixation devices, plates and screws are also subject to such infection and infection-related complications. The present treatment includes multiple operations to remove infected prosthetics, with its own inherent risks, combined with antibiotic use. [0292]
  • The rate of orthopedic prosthetic infection is highest in the first month post operatively then declines continuously there after. As an example, the combined incidence of rate of prosthetic joint infection for 2 years is approximately 5.9% per 1,000 joints; the rate then drops to 2.3% per 1,000 joints from [0293] year 2 to 10. The rate of infection also varies depending on the joint. Knee prosthetics are infected twice as frequently as hips. Shoulder prosthetic infections range from 0.5% to 3%, elbows up to 12%, wrists 1.5% to 5.0% and ankles 1.4% to 2.4%.
  • There are three main mechanisms of infection. The most common is colonization of the implant (prosthetic, fixation plate, screws—any implantable orthopedic device) at the time of implant, either directly or through airborne contamination of the wound. The second method is spread from an adjacent focus of infection, such as wound infection, abscess or sinus tract. The third is hematogenous seeding during a systemic bacteremia, likely accounting for approximately 7% of all implant infections. [0294]
  • Risk factors are multiple. The host may be compromised as a result of a systemic condition, an illness, a local condition, or as a result of medications that decrease the host defence capability. There is also a predisposition to infections if the patient has had prior surgery, perioperative wound compilations, or rheumatoid arthritis. Repeat surgical procedures increase the likelihood of infection as there is a reported 8-fold elevated risk of infection as compared to the primary prosthetic replacement procedure. The presence of a deep infection increases the risk of prosthetic infection 6-fold. Various diseases also increase the risk of infection. For example, rheumatoid arthritis patients have a higher risk of infection possibly as a result of medications that compromising their immunocompetency, while psoriatic patients have a higher rate possibly mediated by a compromised skin barrier that allows entry of microbes. [0295]
  • The implant itself, and the cements that secure it in place, can cause a local immunocompromised condition that is poorly understood. Different implant materials have their own inherent rate of infection. For example, a metal-to-metal hinged prosthetic knee has 20-times the risk of infection of a metal-to-plastic knee. [0296]
  • An implanted device is most susceptible to infection early on. Rabbit models have shown that only a few [0297] Staphylococcus aureus inoculated at the time of implant are required to cause an infection, but bacteremic (hematogenous) seeding at 3 weeks postoperatively is substantially more difficult and requires significantly more bacteria. This emphasizes the importance of an antimicrobial strategy initiated early at the time of implantation.
  • Sixty five percent of all prosthetic joint infections are caused by gram positive cocci, ([0298] Staphylococcus aureus, Coagulase Negative Staphylococci, Beta-Hemolytic Streptococcus, Viridans Group Streptococci) and enterococci. Often multiple strains of staphylococcus can be present in a single prosthetic infection. Other organisms include aerobic gram negative bacilli, Enterobacteriacea, Pseudomonas aeruginosa and Anaerobes (such as Peptostreptococcus and Bacteroides species). Polymicrobial infections account for 12% of infections.
  • The diagnosis of an infected implant is difficult due to the highly variable presentation; fever, general malaise, swelling, erythema, joint pain, loosening of the implant, or even acute septicemia. Fulminate presentations are typically caused by more virulent organisms such as [0299] Stapylococcus arureus and pyogneic beta-hemolytic streptococci. Chronic indolent courses are more typical of coagulase-negative staphylococci.
  • Management of an infected orthopedic implant usually requires prolonged use of antibiotics and surgery to remove the infected device. Surgery requires debridement of the infected tissue, soft tissue, bone, cement, and removal of the infected implant. After a period of prolonged antibiotic use (weeks, months and sometimes a year to ensure microbial eradication), it is possible to implant a replacement prosthesis. Some authors advocate the use of antibiotic impregnated cement, but cite concerns regarding the risk of developing antibiotic resistance; especially methecillin resistance. If bone loss is extensive, an arthrodesis is often performed and amputation is necessary in some cases. Even when an infection is eradicated, the patient can be left severely compromised physically, have significant pain and carry a high risk of re-infection. [0300]
  • It is therefore extremely clinically important to develop orthopedic implants capable of resisting or reducing the rate of infection. An effective orthopedic implant coating would reduce the incidence of joint and hardware infection; lower the incidence of prosthetic failure, sepsis, amputation and even death; and also decrease the number of orthopedic implants requiring replacement, resulting in lower morbidity for patients with these implants. [0301]
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the orthopedic implant. The drug(s) can be applied in several manners: (a) as a coating applied to the external intraosseous surface of the prosthesis; (b) as a coating applied to the external (articular) surface of the prosthesis; (c) as a coating applied to all or parts of both surfaces; (d) as a coating applied to the surface of the orthopedic hardware (plates, screws, etc); (e) incorporated into the polymers which comprise the prosthetic joints (e.g. articular surfaces and other surface coatings) and hardware (e.g. polylactic acid screws and plates); and/or (f) incorporated into the components of the cements used to secure the orthopedic implants in place. [0302]
  • Drug-coating of, or drug incorporation into orthopedic implant will allow bacteriocidal drug levels to be achieved locally on the implant surface, thus reducing the incidence of bacterial colonization and subsequent development of infectious complications, while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0303]
  • The drugs of interest can also be incorporated into calcium phosphate or hydroxyapatite coatings on the medical devices. [0304]
  • As orthopedic implants are made in a variety of configurations and sizes, the exact dose administered will vary with implant size, surface area, design and portions of the implant coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the implant being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the orthopedic implant, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0305]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the orthopedic implant components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the orthopedic implant to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the orthopedic implant surface at a dose of 0.1 μg/mm[0306] 2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the orthopedic implant surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria. and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the orthopedic implant such that anti-infective activity is maintained for a period ranging from several hours to several months. As described previously, the risk of infectious contamination of the implant is greatest over the first 3 days. Therefore, in a particularly preferred embodiment, the majority (or all) of the drug is released over the first 72 hours to prevent infection while allowing normal healing to occur thereafter. It should be readily evident based upon the discussion provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g., a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the orthopedic implant, or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the orthopedic implant to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0307] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the orthopedic implant surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the orthopedic implant surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the orthopedic implant surface such that anti-infective activity is maintained for a period ranging from several hours to several months. As described previously, the risk of infectious contamination of the implant is greatest over the first 3 days. Therefore, in one embodiment, the majority (or all) of the drug is released over the first 72 hours to prevent infection while allowing normal healing to occur thereafter. It should be readily evident based upon the discussion provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the orthopedic implant, or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the orthopedic implant to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0308] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the orthopedic implant surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the orthopedic implant surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (ie., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the orthopedic implant surface such that anti-infective activity is maintained for a period ranging from several hours to several months. As described previously, the risk of infectious contamination of the implant is greatest over the first 3 days. Therefore, in a particularly preferred embodiment, the majority (or all) of the drug is released over the first 72 hours to prevent infection while allowing normal healing to occur thereafter. It should be readily evident based upon the discussion provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the orthopedic implant, or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the orthopedic implant to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0309] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the orthopedic implant surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the orthopedic implant surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the orthopedic implant such that anti-infective activity is maintained for a period ranging from several hours to several months. As described previously, the risk of infectious contamination of the implant is greatest over the first 3 days. Therefore, in a particularly preferred embodiment, the majority (or all) of the drug is released over the first 72 hours to prevent infection while allowing normal healing to occur thereafter. It should be readily evident based upon the discussion provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the orthopedic implant coating. Similarly anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. [0310]
  • L. Infections Associated with Other Medical Devices and Implants
  • Implants are commonly used in the practice of medicine and surgery for a wide variety of purposes. These include implants such as drainage tubes, biliary T-tubes, clips, sutures, meshes, barriers (for the prevention of adhesions), anastomotic devices, conduits, irrigation fluids, packing agents, stents, staples, inferior vena cava filters, embolization agents, pumps (for the delivery of therapeutics), hemostatic implants (sponges), tissue fillers, cosmetic implants (breast implants, facial implants, prostheses), bone grafts, skin grafts, intrauterine devices (IUD), ligatures, titanium implants (particularly in dentistry), chest tubes, nasogastric tubes, percutaneous feeding tubes, colostomy devices, bone wax, and Penrose drains, hair plugs, ear rings, nose rings, and other piercing-associated implants, as well as anaesthetic solutions to name a few. Any foreign body when placed into the body is at risk for developing an infection—particularly in the period immediately following implantation. [0311]
  • The drug-coating, dosing, surface concentrations and release kinetics of these implants is identical to the embodiment described above for orthopedic implants. In addition, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide can be added to solutions used in medicine (storage solutions, irrigation fluids, saline, mannitol, glucose solutions, lipids, nutritional fluids, and anaesthetic solutions) to prevent infection transmitted via infected solutions/fluids used in patient management. [0312]
  • M. Infections Associated with Ocular Implants
  • The principle infections of medical device implants in the eye are endophthalmitis associated with intraocular lens implantation for cataract surgery and corneal infections secondary to contact lens use. [0313]
  • Infections of Intraocular Lenses [0314]
  • The number of intraocular lenses implanted in the United States has grown exponentially over the last decade. Currently, over 1 million intraocular lenses are implanted annually, with the vast majority (90%) being placed in the posterior chamber of the eye. Endophthalmitis is the most common infectious complication of intraocular lens placement and occurs in approximately 0.3% of surgeries (3,000 cases per year). The vast majority are due to surgical contamination and have an onset within 48 hours of the procedure. [0315]
  • The most common causes of endophthalmitis are Coagulase Negative Staphylococci (principally [0316] Staphylococcus epidermidis), Staphylococcus aureus, Enterococci, and Proteus mirabilis. Symptoms of the condition include blurred vision, ocular pain, headache, photophobia, and corneal edema. The treatment of endophthalmitis associated with cataract surgery includes vitrectomy and treatment with systemic and/or intravitreal antibiotic therapy. Although most cases do not require removal of the lens, in complicated cases, visual acuity can be permanently affected and/or the lens must be removed and replaced at a later date. An effective intraocular lens coating would reduce the incidence of endophthalmitis and also decrease the number of intraocular lens requiring replacement, resulting in lower morbidity for patients with these implants.
  • In a preferred embodiment, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide are formulated into a coating applied to the surface of the components of the intraocular lens. The drug(s) can be applied in several manners: (a) as a coating applied to the external surface of the lens; (b) as a coating applied to the internal (luminal) surface of the lens; (c) as a coating applied to all or parts of both surfaces of the lens; and/or (d) incorporated into the polymers which comprise the lens. [0317]
  • Drug-coating of, or drug incorporation into intraocular lenses will allow bacteriocidal drug levels to be achieved locally on the lens surface, thus reducing the incidence of bacterial colonization and subsequent development of infectious complications, while producing negligible systemic exposure to the drugs. Although for some agents polymeric carriers are not required for attachment of the drug, several polymeric carriers are particularly suitable for use in this embodiment. Of particular interest are polymeric carriers such as polyurethanes (e.g., ChronoFlex AL 85A [CT Biomaterials], HydroMed640™ [CT Biomaterials], HYDROSLIP C™ [CT Biomaterials], HYDROTHANE™ [CT Biomaterials]), acrylic or methacrylic copolymers (e.g. poly(ethylene-co-acrylic acid), cellulose-derived polymers (e.g. nitrocellulose, Cellulose Acetate Butyrate, Cellulose acetate propionate), acrylate and methacrylate copolymers (e.g. poly(ethylene-co-vinyl acetate)) as well as blends thereof. [0318]
  • As intraocular lenses are made in a variety of configurations and sizes, the exact dose administered will vary with lens size, surface area, design and portions of the lens coated. However, certain principles can be applied in the application of this art. Drug dose can be calculated as a function of dose per unit area (of the portion of the lens being coated), total drug dose administered can be measured and appropriate surface concentrations of active drug can be determined. Regardless of the method of application of the drug to the intraocular lens, the preferred anticancer agents, used alone or in combination, should be administered under the following dosing guidelines: [0319]
  • (a) Anthracyclines. Utilizing the anthracycline doxorubicin as an example, whether applied as a polymer coating, incorporated into the polymers which make up the intraocular lens components, or applied without a carrier polymer, the total dose of doxorubicin applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the intraocular lens to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0320] 2 of surface area. In a particularly preferred embodiment, doxorubicin should be applied to the intraocular lens surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release doxorubicin at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the intraocular lens surface such that a minimum concentration of 10−7-10−4 M of doxorubicin is maintained on the surface. It is necessary to insure that surface drug concentrations exceed concentrations of doxorubicin known to be lethal to multiple species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower concentrations are sufficient). In a preferred embodiment, doxorubicin is released from the surface of the intraocular lens such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-12 weeks. It should be readily evident based upon the discussion provided herein that analogues and derivatives of doxorubicin (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as doxorubicin is administered at half the above parameters, a compound half as potent as doxorubicin is administered at twice the above parameters, etc.).
  • Utilizing mitoxantrone as another example of an anthracycline, whether applied as a polymer coating, incorporated into the polymers which make up the intraocular lens, or applied without a carrier polymer, the total dose of mitoxantrone applied should not exceed 5 mg (range of 0.01 μg to 5 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 0.1 μg to 1 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the intraocular lens to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-20 μg per mm[0321] 2 of surface area. In a particularly preferred embodiment, mitoxantrone should be applied to the intraocular lens surface at a dose of 0.05 μg/mm2-3 μg/mm2. As different polymer and non-polymer coatings will release mitoxantrone at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the intraocular lens surface such that a minimum concentration of 10−5-10−6 M of mitoxantrone is maintained. It is necessary to insure that drug concentrations on the surface exceed concentrations of mitoxantrone known to be lethal to multiple species of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, mitoxantrone is released from the intraocular lens surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-12 weeks. It should be readily evident based upon the discussion provided herein that analogues and derivatives of mitoxantrone (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as mitoxantrone is administered at half the above parameters, a compound half as potent as mitoxantrone is administered at twice the above parameters, etc.).
  • (b) Fluoropyrimidines Utilizing the fluoropyrimidine 5-fluorouracil as an example, whether applied as a polymer coating, incorporated into the polymers which make up the intraocular lens, or applied without a carrier polymer, the total dose of 5-fluorouracil applied should not exceed 250 mg (range of 1.0 μg to 250 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 10 μg to 25 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the intraocular lens to which drug is applied and/or incorporated) should fall within the range of 0.1 μg-1 mg per mm[0322] 2 of surface area. In a particularly preferred embodiment, 5-fluorouracil should be applied to the intraocular lens surface at a dose of 1.0 μg/mm2-50 μg/mm2. As different polymer and non-polymer coatings will release 5-fluorouracil at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the intraocular lens surface such that a minimum concentration of 10−4-10−7 M of 5-fluorouracil is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of 5-fluorouracil known to be lethal to numerous species of bacteria and fungi (i.e., are in excess of 10−4 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, 5-fluorouracil is released from the intraocular lens surface such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-12 weeks. It should be readily evident based upon the discussion provided herein that analogues and derivatives of 5-fluorouracil (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as 5-fluorouracil is administered at half the above parameters, a compound half as potent as 5-fluorouracil is administered at twice the above parameters, etc.).
  • (c) Podophylotoxins Utilizing the podophylotoxin etoposide as an example, whether applied as a polymer coating, incorporated into the polymers which make up the intraocular lens, or applied without a carrier polymer, the total dose of etoposide applied should not exceed 25 mg (range of 0.1 μg to 25 mg). In a particularly preferred embodiment, the total amount of drug applied should be in the range of 1 μg to 5 mg. The dose per unit area (i.e. the amount of drug as a function of the surface area of the portion of the intraocular lens to which drug is applied and/or incorporated) should fall within the range of 0.01 μg-100 μg per mm[0323] 2 of surface area. In a particularly preferred embodiment, etoposide should be applied to the intraocular lens surface at a dose of 0.1 μg/mm2-10 μg/mm2. As different polymer and non-polymer coatings will release etoposide at differing rates, the above dosing parameters should be utilized in combination with the release rate of the drug from the intraocular lens surface such that a concentration of 10−5-10−6 M of etoposide is maintained. It is necessary to insure that surface drug concentrations exceed concentrations of etoposide known to be lethal to a variety of bacteria and fungi (i.e. are in excess of 10−5 M; although for some embodiments lower drug levels will be sufficient). In a preferred embodiment, etoposide is released from the surface of the intraocular lens such that anti-infective activity is maintained for a period ranging from several hours to several months. In a particularly preferred embodiment the drug is released in effective concentrations for a period ranging from 1-12 weeks. It should be readily evident based upon the discussion provided herein that analogues and derivatives of etoposide (as described previously) with similar functional activity can be utilized for the purposes of this invention; the above dosing parameters are then adjusted according to the relative potency of the analogue or derivative as compared to the parent compound (e.g. a compound twice as potent as etoposide is administered at half the above parameters, a compound half as potent as etoposide is administered at twice the above parameters, etc.).
  • (d) Combination therapy. It should be readily evident based upon the discussions provided herein that combinations of anthracyclines (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and podophylotoxins (e.g., etoposide) can be utilized to enhance the antibacterial activity of the intraocular lens coating. Similarly anthracyclihes (e.g., doxorubicin or mitoxantrone), fluoropyrimidines (e.g., 5-fluorouracil), folic acid antagonists (e.g., methotrexate) and/or podophylotoxins (e.g., etoposide) can be combined with traditional antibiotic and/or antifungal agents to enhance efficacy. [0324]
  • Corneal Infections Secondary to Contact Lens Use [0325]
  • Contact lenses are primarily used for the correction of refractive errors, but are also used after cataract surgery (Aphakie lenses) and “bandage” lenses are used following corneal trauma. Over 24 million people wear contact lenses and many of them will suffer from ulcerative keratitis resulting from contact lens-associated infection. These infections are typically bacterial in nature, are secondary to corneal damage/defects, and are caused primarily by Gram Positive Cocci and [0326] Pseudomonas aeruginosa.
  • The drug-coating of contact lenses is identical to the embodiment described above for intraocular lenses. In addition, doxorubicin, mitoxantrone, 5-fluorouracil and/or etoposide can be added to contact lens storage solution to prevent infection transmitted via infected cleaning/storage solutions. [0327]
  • It should be readily evident to one of skill in the art that any of the previously mentioned agents, or derivatives and analogues thereof, can be utilized to create variation of the above compositions without deviating from the spirit and scope of the invention. [0328]
  • EXAMPLES Example 1 MIC Determination by Microtitre Broth Dilution Method
  • A. MIC Assay of Various Gram Negative and Positive Bacteria [0329]
  • MIC assays were conducted essentially as described by Amsterdam, D. 1996. Susceptibility testing of antimicrobials in liquid media, p.52-111. In Loman, V., ed. Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, Md. Briefly, a variety of compounds were tested for antibacterial activity against isolates of [0330] P. aeruginosa, K. pneumoniae, E. coli. S. epidermidus and S. aureus in the MIC (minimum inhibitory concentration assay under aerobic conditions using 96 well polystyrene microtitre plates (Falcon 1177), and Mueller Hinton broth at 37° C. incubated for 24 h. (MHB was used for most testing except C721 (S. pyogenes), which used Todd Hewitt broth, and Haemophilus influenzae, which used Haemophilus test medium (HTM)) Tests were conducted in triplicate. The results are provided below in Table 1.
    TABLE 1
    Minimum Inhibitory Concentrations of Therapeutic Agents
    Against Various Gram Negative and Positive Bacteria
    Bactrial Strain
    P. K.
    aeruginosa pneumoniae E. coli S. aureus S. S.
    PAE/K799 ATCC13883 UB1005 ATCC25923 epidermidis pyogenes
    H187 C238 C498 C622 C621 C721
    Wt wt wt wt wt wt
    Drug Gram − Gram − Gram − Gram + Gram + Gram +
    doxorubicin 10−5 10−6 10−4 10−5 10−6 10−7
    mitoxantrone 10−5 10−6 10−5 10−5 10−5 10−6
    5-fluorouracil 10−5 10−6 10−6 10−7 10−7 10−4
    methotrexate N 10−6 N 10−5 N 10−6
    etoposide N 10−5 N 10−5 10−6 10−5
    camptothecin N N N N 10−4 N
    hydroxyurea 10−4 N N N N 10−4
    cisplatin 10−4 N N N N N
    tubercidin N N N N N N
    2-mercaptopurine N N N N N N
    6-mercaptopurine N N N N N N
    Cytarabine N N N N N N
  • B. MIC of Antibiotic-resistant Bacteria [0331]
  • Various concentrations of the following compounds, mitoxantrone, cisplatin, tubercidin, methotrexate, 5-fluorouracil, etoposide, 2-mercaptopurine, doxorubicin, 6-mercaptopurine, camptothecin, hydroxyurea and cytarabine were tested for antibacterial activity against clinical isolates of a methicillin resistant [0332] S. aureus and a vancomycin resistant pediocoocus clinical isolate in an MIC assay as described above. Compounds which showed inhibition of growth (MIC value of <1.0×10-3) included: mitoxantrone (both strains), methotrexate (vancomycin resistant pediococcus), 5-fluorouracil (both strains), etoposide (both strains), and 2-mercaptopurine (vancomycin resistant pediococcus).
  • Example 2 Catheter—Dip Coating—Non-degradable Polymer
  • A coating solution is prepared by dissolving 20 g ChronoFlex Al 85A (CT Biomaterials) in 100 mL DMAC:THF (40:60) at 50° C. with stirring. Once dissolved, the polymer solution is cooled to room temperature. 20 mg mitoxantrone is added to 2 mL of the polyurethane solution. The solution is stirred until a homogenious mixture is obtained. [0333] Polyurethane 7 French tubing is dipped into the polymer/drug solution and then withdrawn. The coated tube is air dried (80° C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • Example 3 Catheter—Dip Coating—Degradable Polymer
  • A coating solution is prepared by dissolving 2 g PLG (50:50) in 10 mL dichloromethane:methanol (70:30). Once dissolved, 20mg mitoxantrone is added to the polymer solution. Once the solution is a homogeneous solution, [0334] polyurethane 7 French tubing is dipped into the solution and then withdrawn. The coated tube is air dried. The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • Example 4 Catheter—Dip Coating—Drug Only
  • 1 mL methanol is added to 20 mg mitoxantrone. [0335] Polyurethane 7 French tubing is dipped into the solution and then withdrawn. The coated tube is air dried. The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • Example 5 Catheter—Dip Coating—Drug Impregnation
  • 0.6 mL methanol is added to 20 mg mitoxantrone. 1.4 mL DMAC is added slowly. [0336] Polyurethane 7 French tubing is dipped into the solution. After various periods of time (2 min, 5 min, 10 min, 20 min, 30 min) the tube was withdrawn. The coated tube is air dried (80° C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • Example 6 Tympanostomy Tubes—Dip Coating—Non-degradable Polymer
  • A coating solution is prepared by dissolving 20 g ChronoFlex Al 85A (CT Biomaterials) in 100 mL DMAC:THF (50:50) at 50° C. with stirring. Once dissolved, the polymer solution is cooled to room temperature. 20 mg mitoxantrone is added to 2 mL of the polyurethane solution. The solution is stirred until a homogenious mixture is obtained. A stainless steel tympanostomy tube is dipped into the polymer/drug solution and then withdrawn. The coated tube is air dried (80° C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating. [0337]
  • Example 7 Catheter—Dip Coating—Non-degradable Polymer
  • A coating solution is prepared by dissolving 20 g ChronoFlex Al 85A (CT Biomaterials) in 100 mL THF at 50° C. with stirring. Once dissolved, the polymer solution is cooled to room temperature. 20 mg etoposide is added to 2 mL of the polyurethane solution. The solution is stirred until a homogenious mixture is obtained. [0338] Polyurethane 7 French tubing is dipped into the polymer/drug solution and then withdrawn. The coated tube is air dried (80 C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • Example 8 Catheter—Dip Coating—Degradable Polymer
  • A coating solution is prepared by dissolving 2 g PLG (50:50) in 10 mL dichloromethane:methanol (70:30). Once dissolved, 20 mg etoposide is added to the polymer solution. Once the solution is a homogeneous solution, [0339] polyurethane 7 French tubing is dipped into the solution and then withdrawn. The coated tube is air dried. The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • Example 9 Catheter—Dip Coating—Drug Only
  • 1 mL THF is added to 20 mg etoposide. [0340] Polyurethane 7 French tubing is dipped into the solution and then withdrawn. The coated tube is air dried. The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • Example 10 Catheter—Dip Coating—Drug Impregnation
  • 0.6 mL methanol is added to 1.4 mL DMAC which contains 20 mg etoposide. [0341] Polyurethane 7 French tubing is dipped into the solution. After various periods of time (2 min, 5 min, 10 min. 20 min, 30 min) the tube was withdrawn. The coated tube is air dried (80° C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating.
  • Example 11 Tympanostomy Tubes—Dip Coating—Non-degradable Polymer
  • A coating solution is prepared by dissolving 20 g ChronoFlex Al 85A (CT Biomaterials) in 100 mL DMAC:THF (50:50) at 50° C. with stirring. Once dissolved, the polymer solution is cooled to room temperature. 20 mg etoposide is added to 2 mL of the polyurethane solution. The solution is stirred until a homogenious mixture is obtained. A stainless steel tympanostomy tube is dipped into the polymer/drug solution and then withdrawn. The coated tube is air dried (80° C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating. [0342]
  • Example 12 Covalent Attachment of Doxorubicin to a Polymer Coated Device
  • A piece of [0343] polyurethane 7 French tubing, with and without an oxygen plasma pretreatment step, is dipped into a solution of 5% (w/w) poly(ethylene-co acrylic acid) in THF. The sample was dried at 45° C. for 3 hours. The coated tubing was then dipped into a water:methanol (30:70) solution that contained 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 20 mg/mL Doxorubicin. After various times (15 min, 30 min, 60 min 120 min) the tubing is removed from the solution and dried at 60° C. for 2 hours followed by vacuum drying for 24 hours.
  • Example 13 Covalent Attachment of Doxorubicin to a Device Surface
  • A piece of [0344] polyurethane 7 French tubing that has undergone a oxygen plasma pretreatment step is dipped into a water:methanol (30:70) solution that contained 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 20 mg/mL Doxorubicin. After various times (15 min, 30 min, 60 min 120 min) the tubing is removed from the solution and dried at 60° C. for 2 hours followed by vacuum drying for 24 hours.
  • Example 14 Impregnation of 5-Fluorouracil into Polyurethane Catheter
  • A solution was prepared by dissolving 100 mg of 5-Fluorouracil into 20 ml anhydrous methanol. Polyurethane catheter tubing was immersed in this solution for 16 hours. The catheter tubing was vacuum dried at 50° C. for 16 hours. [0345]
  • Example 15 Impregnation of Mitoxantrone into Polyurethane Catheter
  • A solution was prepared by dissolving 20 mg of Mitoxantrone-2HCl into 20 ml anhydrous methanol. Polyurethane catheter tubing was immersed in this solution for 16 hours. The catheter tubing was vacuum dried at 50° C. for 16 hours. [0346]
  • Example 16 Impregnation of Doxorubicin into Polyurethane Catheter
  • A solution was prepared by dissolving 20 mg of Doxorubicin-HCl into 20 ml anhydrous methanol. Polyurethane catheter tubing was immersed in this solution for 16 hours. The catheter tubing was vacuum dried at 50° C. for 16 hours. [0347]
  • Example 17 Polyurethane Dip Coating With 5-Fluorouracil
  • A solution was prepared by dissolving 125 mg 5-Fluorouracil and 2.5 g of Chronoflex AL85A (CT Biomaterials) in 50 ml of THF at 55° C. The solution was cooled to room temperature. Polyurethane catheters were weighted at one end and dipped in solution and then removed immediately. This process was repeated three times with 1 minute drying time interval between each dipping process. The catheter tubing was vacuum dried at 50° C. for 16 hours. [0348]
  • Example 18 Polyurethane Dip Coating With 5-Fluorouracil and Palmitic Acid
  • A solution was prepared by dissolving 125 mg 5-Fluorouracil, 62.5 mg of palmitic acid, and 2.437 g of ChronoflexAL85A (CT Biomaterials) in 50 ml of THF at 55° C. The solution was cooled to room temperature. Polyurethane catheters were weighted at one end and dipped in solution and then removed immediately. This process was repeated three times with a 1 minute drying time interval between each dipping process. The catheter tubing was vacuum dried at 50° C. for 16 hours. [0349]
  • Example 19 Catheter Dip Coating With Nafion and Mitoxantrone
  • Catheters are weighted at one end and dipped into 5% Nafion solution (Dupont) and then removed immediately. This process was repeated three times with a 1 minute drying time interval between each dipping process. The catheter tubing was dried at room temperature for 2 hours. A solution was prepared with 1 mg of mitoxantrone-2HCl in 40 ml of deionized water. The catheter tubing was immersed in the solution for 5 minutes, and then was washed with deionized water and dried at room temperature. [0350]
  • Example 20 Catheter Dip Coating With Nafion and Doxorubicin
  • Catheters are weighted at one end and dipped into 5% Nafion solution (Dupont) and then removed immediately. This process was repeated three times with a 1 minute drying time interval between each dipping process. The catheter tubing was dried at room temperature for 2 hours. A solution was prepared with 1 mg of doxorubicin-HCl in 40 ml of deionized water. The catheter tubing was immersed in the solution for 5 minutes, and then was washed with deionized water and dried at room temperature. [0351]
  • Example 21 Preparation of Release Buffer
  • The release buffer was prepared by adding 8.22 g sodium chloride, 0.32 g sodium phosphate monobasic (monohydrate) and 2.60 g sodium phosphate dibasic (anhydrous) to a beaker. 1 L HPLC grade water was added and the solution was stirred until all the salts were dissolved. If required, the pH of the solution was adjusted to pH 7.4±0.2 using either 0.1N NaOH or 0.1N phosphoric acid. [0352]
  • Example 22 Release Study to Determine Release Profile of the Therapeutic Agent From a Catheter
  • A sample of the therapeutic agent-loaded catheter was placed in a 15 mL culture tube. 15 mL release buffer (Example 21) was added to the culture tube. The tube was sealed with a Teflon lined screw cap and was placed on a rotating wheel in a 37° C. oven. At various time point, the buffer is withdrawn from the culture tube and is replaced with fresh buffer. The withdrawn buffer is then analysed for the amount of therapeutic agent contained in this buffer solution. [0353]
  • Example 23 HPLC Analysis of Therapeutic Agents in Release Buffer
  • The following chromatographic conditions were used to quantify the amount of the therapeutic agent in the release medium: [0354]
    Run Injection Detection
    Therapeutic Flow Rate Time Volume Wavelength
    Agent Column Mobile Phase (mL/min) (min) (μL) (nm)
    5-Fluorouracil YMC ODS-AQ 150 × 4.6 mm, 5 μm PBS, pH 6.8 1 8 100 268
    Doxorubicin ACE 5 (V02-742) 150 × 4 mm 20% CAN, 26% Methanol, 54%
    PBS (pH 3.6) 1 10 10 254
    Mitoxantrone ACE 5 C18, 150 × 4 mm, 5 μm Phosphate buffer (pH 2.3) 1 4 10 658
  • Example 24 Effect of Palmitic Acid on the Release Profile of 5-Fluorouracil From a Polyurethane Film
  • A 25%(w/v) Chronoflex AL 85A (CT Biomaterials) solution was prepared in THF. 50 mg 5-fluorouracil was weighed into each of 4 glass scintillation vials. Various amount of palmitic acid were added to each vial. 20 mL of the polyurethane solution was added to each scintillation vial. The samples were rotated at 37° C. until the solids had all dissolved. Samples were then cast as films using a casting knife on a piece of release liner. Samples were air dried and then dried overnight under vacuum. A portion of these samples were used to perform release studies (Example 22). FIG. 1 show the effect of palmitic acid on the release profile of 5-fluorouracil. [0355]
  • Example 25 Radial Diffusion Assay for Testing Drug Impregnated Catheters Against Various Strains of Bacteria
  • An overnight bacterial culture was diluted 1 to 5 to a final volume of 5 mls fresh Mueller Hinton broth. Then 100 μl of the diluted bacterial culture were spread onto Mueller Hinton agar plates. A test material (e.g., catheter tubing), with or without drug, was placed on the center of the plate. For example, catheters are typically 1 cm long and about 3 mm in diameter (which may be made of polyurethane, silicon or other suitable material) and are loaded with drug either through dip-coating or through use of a drug-impregnated coating. The plates were incubated at 37° C. for 16-18 hours. The zone of clearing around a test material was then measured (e.g., the distance from the catheter to where bacterial growth is inhibited), which indicated the degree of bacterial growth prevention. Various bacterial strains that may be tested include, but are not limited to, the following: [0356] E. coli C498 UB1005, P. aeruginosa H187, S. aureus C622 ATCC 25923, and S. epidermidis C621.
  • One cm polyurethane catheters coated with 5-fluorouracil at several concentrations (2.5 mg/mL and 5.0 mg/mL) were examined for their effect against [0357] S. aureus. The zone of inhibition around the catheters coated in a solution of 2.5 mg/mL 5-Fluorouracil and placed on Mueller Hinton agar plates as described above was 35×39 mm, and for the catheters coated in a solution of 5.0 mg/mL 5-Fluorouracil was 30×37 mm. Catheters without drug showed no zone of inhibition. These results demonstrate the efficacy of 5-fluorouracil coated on a catheter at inhibiting the growth of S. aureus.
  • From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims. [0358]

Claims (23)

We claim:
1. A medical implant which releases an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
2. The medical implant according to claim 1 wherein said implant is covered or coated in whole or in part with a composition comprising an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
3. The medical implant according to claim 1 or 2 wherein said anthracycline is doxorubicin or mitoxantrone.
4. The medical implant according to claim 1 or 2 wherein said fluoropyrimidine is 5-fluorouracil.
5. The medical implant according to claim 1 or 2 wherein said folic acid antagonist is methotrexate.
6. The medical implant according to claim 1 or 2 wherein said podophylotoxin is etoposide.
7. The medical implant according to claim 2 wherein said composition further comprises a polymer.
8. The medical implant according to claim 7 wherein said polymer is a biodegrable or a non-biodegradable polymer.
9. The medical implant according to claim 7 wherein said polymer is a polyurethane.
10. The medical implant according to claim 7 wherein said polymer is a poly(lactide-co-glycolide).
11. The medical implant according to any one of claims 7 to 10 wherein said fluoropyrimidine is 5-fluorouracil.
12. The medical implant according to claim 1 or 2 wherein said medical implant is a vascular catheter, prosthetic heart valve, cardiac pacemaker, implantable cardioverter defibrillator, vascular graft, ear, nose, or throat implant, urological implant, endotracheal or tracheostomy tube, dialysis catheter, CNS shunt, orthopedic implant, or ocular implant.
13. A composition, comprising a polymer and an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex, wherein said anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex is present in said composition at a concentration of less than 10−4 M.
14. The composition according to claim 13 wherein said anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex, wherein said anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex is present in said composition at a concentration of less than any one of 10−5 M, 10−6 M, or 10−7 M.
15. The composition according to claim 13 wherein said polymer is a biodegrable or a non-biodegradable polymer.
16. The medical implant according to claim 13 wherein said polymer is a polyurethane.
17. The medical implant according to claim 13 wherein said polymer is a poly(lactide-co-glycolide).
18. The composition according to any one of claims 13 to 17 wherein said fluoropyrimidine is 5-fluorouracil.
19. A method for reducing or inhibiting infection associated with a medical implant, comprising the step of introducing into a patient a medical implant which has been covered or coated with an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
20. The method according to claim 19 wherein said fluoropyrimidine is 5-fluorouracil.
21. A method for making medical implants, comprising covering or coating a medical implant with an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.
22. The method according to claim 21 wherein said fluoropyrimidine is 5-fluorouracil.
23. The method according to claim 21 wherein said medical implant covered or coated by dipping or by impregnation.
US10/447,309 2002-05-24 2003-05-27 Compositions and methods for coating medical implants Abandoned US20040043052A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US10/447,309 US20040043052A1 (en) 2002-05-24 2003-05-27 Compositions and methods for coating medical implants
US11/343,714 US20060127438A1 (en) 2002-05-24 2006-01-31 Compositions and methods for coating medical implants
US11/888,674 US20080089952A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,511 US20070270447A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,615 US20080145514A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,624 US20080113000A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US12/035,772 US20080241217A1 (en) 2002-05-24 2008-02-22 Compositions and methods for coating medical implants
US12/107,629 US8313760B2 (en) 2002-05-24 2008-04-22 Compositions and methods for coating medical implants
US12/553,744 US8372420B2 (en) 2002-05-24 2009-09-03 Compositions and methods for coating medical implants
US12/939,565 US8425927B2 (en) 2002-05-24 2010-11-04 Compositions and methods for coating medical implants
US13/663,254 US20130115263A1 (en) 2002-05-24 2012-10-29 Compositions and methods for coating medical implants
US13/846,396 US20130224276A1 (en) 2002-05-24 2013-03-18 Compositions and methods for coating medical implants
US14/334,326 US20140328891A1 (en) 2002-05-24 2014-07-17 Compositions and methods for coating medical implants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38341902P 2002-05-24 2002-05-24
US10/447,309 US20040043052A1 (en) 2002-05-24 2003-05-27 Compositions and methods for coating medical implants

Related Child Applications (8)

Application Number Title Priority Date Filing Date
US11/343,714 Continuation US20060127438A1 (en) 2002-05-24 2006-01-31 Compositions and methods for coating medical implants
US11/888,674 Division US20080089952A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,615 Continuation US20080145514A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,624 Continuation US20080113000A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,511 Division US20070270447A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US12/035,772 Continuation US20080241217A1 (en) 2002-05-24 2008-02-22 Compositions and methods for coating medical implants
US12/107,629 Continuation-In-Part US8313760B2 (en) 2002-05-24 2008-04-22 Compositions and methods for coating medical implants
US12/553,744 Continuation US8372420B2 (en) 2002-05-24 2009-09-03 Compositions and methods for coating medical implants

Publications (1)

Publication Number Publication Date
US20040043052A1 true US20040043052A1 (en) 2004-03-04

Family

ID=29584566

Family Applications (10)

Application Number Title Priority Date Filing Date
US10/447,309 Abandoned US20040043052A1 (en) 2002-05-24 2003-05-27 Compositions and methods for coating medical implants
US11/343,714 Abandoned US20060127438A1 (en) 2002-05-24 2006-01-31 Compositions and methods for coating medical implants
US11/888,624 Abandoned US20080113000A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,511 Abandoned US20070270447A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,674 Abandoned US20080089952A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,615 Abandoned US20080145514A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US12/035,772 Abandoned US20080241217A1 (en) 2002-05-24 2008-02-22 Compositions and methods for coating medical implants
US12/553,744 Expired - Fee Related US8372420B2 (en) 2002-05-24 2009-09-03 Compositions and methods for coating medical implants
US12/939,565 Expired - Fee Related US8425927B2 (en) 2002-05-24 2010-11-04 Compositions and methods for coating medical implants
US13/846,396 Abandoned US20130224276A1 (en) 2002-05-24 2013-03-18 Compositions and methods for coating medical implants

Family Applications After (9)

Application Number Title Priority Date Filing Date
US11/343,714 Abandoned US20060127438A1 (en) 2002-05-24 2006-01-31 Compositions and methods for coating medical implants
US11/888,624 Abandoned US20080113000A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,511 Abandoned US20070270447A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,674 Abandoned US20080089952A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US11/888,615 Abandoned US20080145514A1 (en) 2002-05-24 2007-07-31 Compositions and methods for coating medical implants
US12/035,772 Abandoned US20080241217A1 (en) 2002-05-24 2008-02-22 Compositions and methods for coating medical implants
US12/553,744 Expired - Fee Related US8372420B2 (en) 2002-05-24 2009-09-03 Compositions and methods for coating medical implants
US12/939,565 Expired - Fee Related US8425927B2 (en) 2002-05-24 2010-11-04 Compositions and methods for coating medical implants
US13/846,396 Abandoned US20130224276A1 (en) 2002-05-24 2013-03-18 Compositions and methods for coating medical implants

Country Status (20)

Country Link
US (10) US20040043052A1 (en)
EP (2) EP1509256B1 (en)
JP (2) JP2005527302A (en)
KR (1) KR20100110378A (en)
CN (2) CN100341589C (en)
AT (1) ATE515277T1 (en)
AU (2) AU2003234670B2 (en)
BR (1) BR0311285A (en)
CA (1) CA2484761C (en)
DE (1) DE60328486D1 (en)
DK (1) DK1509256T3 (en)
ES (2) ES2330326T3 (en)
HK (1) HK1082435A1 (en)
IL (1) IL165120A (en)
MX (1) MXPA04011651A (en)
NZ (2) NZ575452A (en)
PT (1) PT1509256E (en)
RU (1) RU2341296C2 (en)
WO (1) WO2003099346A2 (en)
ZA (1) ZA200409291B (en)

Cited By (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146546A1 (en) * 2002-09-26 2004-07-29 Angiotech Pharmaceuticals, Inc. Perivascular wraps
WO2004082525A2 (en) 2003-03-14 2004-09-30 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US20050142162A1 (en) * 2003-11-20 2005-06-30 Angiotech International Ag Soft tissue implants and anti-scarring agents
US20050147643A1 (en) * 2003-11-10 2005-07-07 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20050181117A1 (en) * 2003-03-14 2005-08-18 Medtronic Vascular, Inc. Stent coating method
US20050209664A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Electrical devices and anti-scarring agents
US20060020328A1 (en) * 2004-07-23 2006-01-26 Tan Sharon M L Composite vascular graft having bioactive agent
US20060051392A1 (en) * 2004-09-03 2006-03-09 Medtronic, Inc. Porous coatings for drug release from medical devices
US20060127438A1 (en) * 2002-05-24 2006-06-15 Angiotech International Ag Compositions and methods for coating medical implants
US20060149310A1 (en) * 2002-09-30 2006-07-06 Becker Bruce B Balloon catheters and methods for treating paranasal sinuses
US20060164680A1 (en) * 2005-01-25 2006-07-27 Hyuck Kim Printing system and method of printing data on a designated paper
US20060165739A1 (en) * 2005-01-06 2006-07-27 Mary Kay Inc. Alcohol-free microemulsion composition
US20060205789A1 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
US20060241000A1 (en) * 2005-04-22 2006-10-26 Cardiac Pacemakers, Inc. Lubricious compound and medical device made of the same
US20060240059A1 (en) * 2005-04-22 2006-10-26 Cardiac Pacemakers, Inc. Lubricious eluting polymer blend and coating made from the same
US20060240060A1 (en) * 2005-04-22 2006-10-26 Cardiac Pacemakers, Inc. Lubricious compound and medical device made of the same
US20060240253A1 (en) * 2005-04-22 2006-10-26 Cardiac Pacemakers, Inc. Guidewire and tube with lubricious coating
US20060246105A1 (en) * 2005-04-28 2006-11-02 Fred Molz Coatings on medical implants to guide soft tissue healing
US20060247793A1 (en) * 2005-04-28 2006-11-02 Sdgi Holdings, Inc. Surface treatments for promoting selective tissue attachment to medical implants
US20060251694A1 (en) * 2002-12-20 2006-11-09 Nielsen Bo R Hydrophilic coating and a method for the preparation thereof
WO2006107957A3 (en) * 2005-04-04 2006-11-16 Sinexus Inc Device and methods for treating paranasal sinus conditions
US20070026043A1 (en) * 2003-11-20 2007-02-01 Angiotech International Ag Medical devices combined with diblock copolymer compositions
US20070134287A1 (en) * 2005-12-09 2007-06-14 Biomet Manufacturing Corp Method for coating biocompatible substrates with antibiotics
US20070150036A1 (en) * 2005-12-27 2007-06-28 Advanced Bionics Corporation Stimulator leads and methods for lead fabrication
US20070150007A1 (en) * 2005-12-27 2007-06-28 Advanced Bionics Corporation Non-linear electrode array
US20070198040A1 (en) * 2006-02-08 2007-08-23 Tyrx Pharma Inc. Temporarily Stiffened Mesh Prostheses
US20070292478A1 (en) * 2004-08-30 2007-12-20 Popowski Youri Medical Implant Provided with Inhibitors of Atp Synthesis
US20070292468A1 (en) * 2006-06-14 2007-12-20 Joel Studin Coated jewelry articles to reduce skin irritation
US20070299409A1 (en) * 2004-11-09 2007-12-27 Angiotech Biocoatings Corp. Antimicrobial Needle Coating For Extended Infusion
WO2008011125A2 (en) * 2006-07-20 2008-01-24 Neurosystec Corporation Devices, systems and methods for ophthalmic drug delivery
US20080075628A1 (en) * 2006-09-27 2008-03-27 Medtronic, Inc. Sterilized minocycline and rifampin-containing medical device
US20080091270A1 (en) * 2005-01-14 2008-04-17 Miller Timothy R Expandable osteoimplant
US20080097154A1 (en) * 2004-04-21 2008-04-24 Acclarent, Inc. Methods and Apparatus for Treating Disorders of the Ear Nose and Throat
US20080125728A1 (en) * 2006-09-27 2008-05-29 Medtronic, Inc. Two part antimicrobial boot
US20080133027A1 (en) * 2006-12-01 2008-06-05 Hodges Steve J Urologic devices incorporating collagen inhibitors
US20080132922A1 (en) * 2006-02-08 2008-06-05 Tyrx Pharma, Inc. Mesh Pouches for Implantable Medical Devices
US20080145439A1 (en) * 2006-07-31 2008-06-19 Neurosystec Corporation Nanoparticle drug formulations
US20080163870A1 (en) * 2004-10-05 2008-07-10 Takao Kusunoki Tracheostomy Tube
US20080241212A1 (en) * 2007-03-29 2008-10-02 Tyrx Pharma, Inc. Biodegradable, Polymer Coverings for Breast Implants
US20080255492A1 (en) * 2004-08-19 2008-10-16 Jens Hoeg Truelsen Absorbent Fiber Material and Use Thereof in Wound Dressings
US20080319424A1 (en) * 2004-04-21 2008-12-25 Acclarent, Inc. Devices and Methods for Delivering Therapeutic Substances for the Treatment of Sinusitis and Other Disorders
US20090017090A1 (en) * 2006-07-10 2009-01-15 Arensdorf Patrick A Devices and methods for delivering active agents to the osteomeatal complex
US20090060973A1 (en) * 2002-05-24 2009-03-05 Angiotech International Ag Compositions and methods for coating medical implants
US20090177272A1 (en) * 2007-12-18 2009-07-09 Abbate Anthony J Self-expanding devices and methods therefor
US20090192439A1 (en) * 2005-05-20 2009-07-30 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US20090196248A1 (en) * 2004-01-09 2009-08-06 Interdigital Technology Corporation Transport format combination selection in a wireless transmit/receive unit
US20090203632A1 (en) * 2004-01-30 2009-08-13 Angiotech International Ag Compositions and methods for treating contracture
US7645272B2 (en) 2004-04-21 2010-01-12 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US20100030052A1 (en) * 2008-07-31 2010-02-04 Bommakanti Balasubrahmanya S Analyte sensors comprising plasticizers
US7766923B2 (en) 2005-05-20 2010-08-03 Neotract, Inc. Integrated handle assembly for anchor delivery system
US7780682B2 (en) 2005-05-20 2010-08-24 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US7803148B2 (en) 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
US20100249783A1 (en) * 2009-03-24 2010-09-30 Warsaw Orthopedic, Inc. Drug-eluting implant cover
US7815655B2 (en) 2005-05-20 2010-10-19 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US20100266657A1 (en) * 2009-04-15 2010-10-21 Warsaw Orthopedic, Inc. Preformed drug-eluting device to be affixed to an anterior spinal plate
US20110015667A1 (en) * 2009-06-05 2011-01-20 Entrigue Surgical, Inc. Systems, Devices and Methods for Providing Therapy to an Anatomical Structure
US20110040312A1 (en) * 2005-05-20 2011-02-17 Neotract, Inc. Deforming anchor device
US7909836B2 (en) 2005-05-20 2011-03-22 Neotract, Inc. Multi-actuating trigger anchor delivery system
US20110077579A1 (en) * 2005-03-24 2011-03-31 Harrison William V Cochlear implant with localized fluid transport
US20110125091A1 (en) * 2009-05-15 2011-05-26 Abbate Anthony J Expandable devices and methods therefor
US20110264213A1 (en) * 2008-12-19 2011-10-27 Demiranda Jose Maria Silicone implant with expandable compartment
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8142422B2 (en) 2004-04-21 2012-03-27 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8172828B2 (en) 2004-04-21 2012-05-08 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US8216254B2 (en) 2005-05-20 2012-07-10 Neotract, Inc. Anchor delivery system with replaceable cartridge
US20120220518A1 (en) * 2009-06-03 2012-08-30 Case Western Reserve University Therapeutic agent delivery system and method
US8267905B2 (en) 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US8333776B2 (en) 2005-05-20 2012-12-18 Neotract, Inc. Anchor delivery system
US8388642B2 (en) 2005-01-18 2013-03-05 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US8394113B2 (en) 2005-05-20 2013-03-12 Neotract, Inc. Coiled anchor device
US20130079809A1 (en) * 2011-09-23 2013-03-28 Cook Medical Technologies, LLD Introducer placement system
US8414473B2 (en) 2004-04-21 2013-04-09 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8425535B2 (en) 2005-05-20 2013-04-23 Neotract, Inc. Multi-actuating trigger anchor delivery system
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8454655B2 (en) 2002-03-14 2013-06-04 Neotract, Inc. Method for anchoring suture and approximating tissue
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US20130183435A1 (en) * 2012-01-13 2013-07-18 Hongmin Sun Low temperature plasma coating for anti-biofilm formation
US8491606B2 (en) 2005-05-20 2013-07-23 Neotract, Inc. Median lobe retraction apparatus and method
US8529584B2 (en) 2005-05-20 2013-09-10 Neotract, Inc. Median lobe band implant apparatus and method
US8603106B2 (en) 2005-05-20 2013-12-10 Neotract, Inc. Integrated handle assembly for anchor delivery system
US8628542B2 (en) 2005-05-20 2014-01-14 Neotract, Inc. Median lobe destruction apparatus and method
US8668705B2 (en) 2005-05-20 2014-03-11 Neotract, Inc. Latching anchor device
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8715169B2 (en) 2004-04-21 2014-05-06 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8740929B2 (en) 2001-02-06 2014-06-03 Acclarent, Inc. Spacing device for releasing active substances in the paranasal sinus
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8758366B2 (en) 2007-07-09 2014-06-24 Neotract, Inc. Multi-actuating trigger anchor delivery system
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US8763222B2 (en) 2008-08-01 2014-07-01 Intersect Ent, Inc. Methods and devices for crimping self-expanding devices
US8834492B2 (en) 2005-05-20 2014-09-16 Neotract, Inc. Continuous indentation lateral lobe apparatus and method
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8909339B2 (en) * 2012-08-15 2014-12-09 National Tsing Hua University Glucose powered implantable device to collect blood ingredients
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US8945152B2 (en) 2005-05-20 2015-02-03 Neotract, Inc. Multi-actuating trigger anchor delivery system
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
US9034001B2 (en) 2005-05-20 2015-05-19 Neotract, Inc. Slotted anchor device
US9039657B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US9107574B2 (en) 2004-04-21 2015-08-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
WO2015157512A1 (en) * 2014-04-11 2015-10-15 Drexel University Novel methods and kits for detecting a rifamycin, or derivative or analogue thereof
US9161749B2 (en) 2011-04-14 2015-10-20 Neotract, Inc. Method and apparatus for treating sexual dysfunction
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US9364212B2 (en) 2005-05-20 2016-06-14 Neotract, Inc. Suture anchoring devices and methods for use
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US9414864B2 (en) 2009-04-15 2016-08-16 Warsaw Orthopedic, Inc. Anterior spinal plate with preformed drug-eluting device affixed thereto
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9504461B2 (en) 2005-05-20 2016-11-29 Neotract, Inc. Anchor delivery system
US9549739B2 (en) 2005-05-20 2017-01-24 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US10130353B2 (en) 2012-06-29 2018-11-20 Neotract, Inc. Flexible system for delivering an anchor
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US10195014B2 (en) 2005-05-20 2019-02-05 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US10232152B2 (en) 2013-03-14 2019-03-19 Intersect Ent, Inc. Systems, devices, and method for treating a sinus condition
US10292801B2 (en) 2012-03-29 2019-05-21 Neotract, Inc. System for delivering anchors for treating incontinence
US10524814B2 (en) 2009-03-20 2020-01-07 Acclarent, Inc. Guide system with suction
US10925587B2 (en) 2005-05-20 2021-02-23 Neotract, Inc. Anchor delivery system
US20210052782A1 (en) * 2018-01-15 2021-02-25 Technion Research & Development Foundation Limited Electrospun-coated medical devices
US11065061B2 (en) 2004-04-21 2021-07-20 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US11179298B2 (en) * 2008-01-09 2021-11-23 Innovative Health Technologies, Llc Implant pellets and methods for performing bone augmentation and preservation
US11298115B2 (en) 2020-08-03 2022-04-12 Teleflex Life Sciences Limited Handle and cartridge system for medical interventions
US11529502B2 (en) 2004-04-21 2022-12-20 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US11672520B2 (en) 2017-12-23 2023-06-13 Teleflex Life Sciences Limited Expandable tissue engagement apparatus and method

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992127B2 (en) * 2002-11-25 2006-01-31 Ast Products, Inc. Polymeric coatings containing a pH buffer agent
JP2007525429A (en) * 2003-03-11 2007-09-06 キューエルティー ユーエスエー,インコーポレイテッド. Formulations for cell schedule dependent anticancer agents
US8518097B2 (en) 2003-04-25 2013-08-27 Medtronic Vascular, Inc. Plasticized stent coatings
JP2007516740A (en) * 2003-11-10 2007-06-28 アンジオテック インターナショナル アーゲー Medical implants and scarring inhibitors
AU2006214100B2 (en) * 2005-02-18 2012-05-31 Abraxis Bioscience, Llc Drugs with improved hydrophobicity for incorporation in medical devices
FR2896165B1 (en) * 2006-01-13 2012-08-03 Centre Nat Rech Scient PREPARATION OF AN INORGANIC SUBSTRATE HAVING ANTI-MICROBIAL PROPERTIES
EP1832289A3 (en) * 2006-03-08 2007-12-12 Sahajanand Medical Technologies PVT. ltd Compositions and coatings for implantable medical devices
BRPI0722412B8 (en) * 2006-07-03 2021-06-22 Hemoteq Ag use of a composition consisting of rapamycin or rapamycin and paclitaxel and balloon catheter
US20080102122A1 (en) * 2006-10-31 2008-05-01 Shivkumar Mahadevan Antimicrobial polymeric articles, processes to prepare them and methods of their use
US20080221533A1 (en) * 2007-03-09 2008-09-11 Anthem Orthopaedics Llc Implantable device with bioabsorbable layer, kit and method for use therewith, and apparatus for preparing same
EP2152078B8 (en) 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
DE102007036685A1 (en) 2007-08-03 2009-02-05 Innora Gmbh Improved drug-coated medical devices their manufacture and use
CA2719033C (en) 2007-12-07 2014-07-08 Zimmer Orthopaedic Surgical Products, Inc. Spacer mold and methods therefor
US8444579B2 (en) * 2007-12-21 2013-05-21 St. Jude Medical, Atrial Fibrillation Division, Inc. System for delivering acoustic energy in connection with therapeutic ultrasound systems and catheters
US8784356B2 (en) * 2007-12-21 2014-07-22 St. Jude Medical, Atrial Fibrillation Division, Inc. Ultrasonic endovascular clearing device
EP2254640A4 (en) * 2008-02-22 2013-10-23 Angiotech Int Ag Anti-infective catheters
CN102548510B (en) 2008-10-29 2015-04-01 捷迈骨科手术产品公司 Spacer molds with releasable securement
JP2010187910A (en) * 2009-02-18 2010-09-02 Nippon Sherwood Medical Industries Ltd Antibacterial medical device and manufacturing method thereof
US20120150093A1 (en) * 2009-03-30 2012-06-14 Jointech Med. Ltd. Synovial shunts
BRPI1007676A2 (en) * 2009-05-08 2020-10-13 3M Innovative Properties Company hydration methods, kits for oral treatment and method for hydration of oral tissues
CN104606681B (en) 2009-05-13 2018-08-21 锡德克斯药物公司 Include the pharmaceutical composition and its preparation and application of prasugrel and cyclodextrine derivatives
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2011031548A2 (en) 2009-08-27 2011-03-17 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
US10265435B2 (en) 2009-08-27 2019-04-23 Silver Bullet Therapeutics, Inc. Bone implant and systems and coatings for the controllable release of antimicrobial metal ions
US9821094B2 (en) 2014-06-11 2017-11-21 Silver Bullet Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US8927004B1 (en) 2014-06-11 2015-01-06 Silver Bullet Therapeutics, Inc. Bioabsorbable substrates and systems that controllably release antimicrobial metal ions
US9114197B1 (en) 2014-06-11 2015-08-25 Silver Bullett Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
US8951577B2 (en) 2010-08-03 2015-02-10 Teleflex Medical Incorporated Antimicrobial hydrochloric acid catheter lock solution and method of use
WO2012064402A1 (en) 2010-11-12 2012-05-18 Silver Bullet Therapeutics, Inc. Bone implant and systems that controllably releases silver
US8894613B2 (en) 2011-01-22 2014-11-25 Hideo Koike Catheter attachment and method
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9120040B2 (en) * 2011-05-26 2015-09-01 The University Of Akron Anti-fouling materials based on poly(β-peptoid)s
EP2714747B1 (en) 2011-06-02 2020-08-05 Massachusetts Institute of Technology Modified alginates for cell encapsulation and cell therapy
US20130085451A1 (en) * 2011-09-29 2013-04-04 Tyco Healthcare Group Lp Plasma-treated dialysis catheter cuff
WO2013158773A2 (en) * 2012-04-17 2013-10-24 The Research Institute At Nationwide Children's Hospital Rnase 7 antimicrobial peptides
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
NL2010040C2 (en) * 2012-12-21 2014-06-24 Internat Inst For Diagnostic And Analitical Affairs B V Cleavable coating material having microbial functionality.
US9445884B2 (en) * 2013-01-30 2016-09-20 Boston Scientific Scimed, Inc. Ureteral stent with drug-releasing structure
US9308137B2 (en) 2013-03-28 2016-04-12 Kimberly-Clark Worldwide, Inc. Transitional absorbent pad and pantiliner
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
RU2530568C1 (en) * 2013-04-24 2014-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Саратовский государственный технический университет имени Гагарина Ю.А." (СГТУ имени Гагарина Ю.А.) Method for making endosseous implant with ion beam modification
CN103301513B (en) * 2013-06-09 2015-02-04 诸辉 Preparation method of intravascular stent with pharmaceutical enzyme coating
CN110731838A (en) 2013-06-23 2020-01-31 威廉·L·亨特 Devices, systems, and methods for monitoring knee replacements
US9579205B2 (en) 2013-09-12 2017-02-28 Ronen Shavit Liners for medical joint implants with improved wear-resistance
RU2568917C1 (en) * 2014-04-17 2015-11-20 Государственное автономное учреждение здравоохранения "Республиканская клиническая больница Министерства здравоохранения Республики Татарстан" Method for producing bone-cement spacer
US9452242B2 (en) 2014-06-11 2016-09-27 Silver Bullet Therapeutics, Inc. Enhancement of antimicrobial silver, silver coatings, or silver platings
EP3751574A3 (en) 2014-06-25 2021-04-21 Canary Medical Inc. Devices, systems and methods for using and monitoring orthopedic hardware
EP4212113A1 (en) 2014-06-25 2023-07-19 Canary Medical Switzerland AG Devices monitoring spinal implants
RU2558089C1 (en) * 2014-06-27 2015-07-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ КПССЗ" СО РАМН) Method for pre-implantation preparation of biological prostheses for cardiovascular surgery
RU2551938C1 (en) * 2014-07-14 2015-06-10 Общество с ограниченной ответственностью "Инновационная компания "Современные технологии" Multipurpose vascular implant
AU2015316252A1 (en) * 2014-09-10 2017-03-09 Double Bond Pharmaceuticals Ab Targeted delivery of hydrophilic drugs
EP3195138A4 (en) 2014-09-17 2019-03-06 Canary Medical Inc. Devices, systems and methods for using and monitoring medical devices
RU2581824C1 (en) * 2014-11-12 2016-04-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный технический университет имени Гагарина Ю.А." (СГТУ имени Гагарина Ю.А.) Method for bioceramic coating deposition on implants
NL2013786B1 (en) * 2014-11-13 2016-10-07 Original G B V Quenched coating.
EP3393537A1 (en) 2015-12-22 2018-10-31 Access Vascular, Inc. High strength biomedical materials
JP7006940B2 (en) 2016-01-29 2022-01-24 ニオバスク ティアラ インコーポレイテッド Artificial valve to avoid blockage of outflow
EP3419682A4 (en) 2016-02-24 2019-11-13 Innovative Surface Technologies, Inc. Crystallization inhibitor compositions for implantable urological devices
EP3426228A1 (en) * 2016-03-07 2019-01-16 Double Bond Pharmaceutical AB Targeted delivery of hydrophilic drugs to lung
IL294630B2 (en) 2016-03-23 2023-12-01 Canary Medical Inc Implantable reporting processor for an alert implant
EP3469008A1 (en) 2016-06-13 2019-04-17 Massachusetts Institute Of Technology Biocompatible zwitterionic polymer coatings and hydrogels for reducing foreign body response and fibrosis
RU2630464C1 (en) * 2016-07-29 2017-09-08 Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт лекарственных и ароматических растений (ФГБНУ ВИЛАР) Combined method for bone implants sterilisation
RU2626896C1 (en) * 2016-11-11 2017-08-02 Общество с ограниченной ответственностью "ЭЛЕСТИМ-КАРДИО" Endocardial electrode system for left heart departments stimulation
WO2018090148A1 (en) 2016-11-21 2018-05-24 Neovasc Tiara Inc. Methods and systems for rapid retraction of a transcatheter heart valve delivery system
SG11201906845PA (en) * 2017-02-09 2019-08-27 Ixom Operations Pty Ltd Polymer beads and application thereof
AU2018290246A1 (en) 2017-06-21 2020-01-30 Access Vascular, Inc High strength porous materials incorporating water soluble polymers
EP3672530A4 (en) 2017-08-25 2021-04-14 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US11318231B2 (en) 2017-11-06 2022-05-03 Massachusetts Institute Of Technology Anti-inflammatory coatings to improve biocompatibility of neurological implants
WO2019147188A1 (en) * 2018-01-26 2019-08-01 Huang ying ying Method of selectively modifying the abluminal surface and coating the luminal surface of polymeric stent grafts
CN108310460B (en) * 2018-02-02 2021-08-03 武汉大学 Injectable high-strength temperature-sensitive modified chitin-based hydrogel and preparation method and application thereof
CN108451553A (en) * 2018-03-21 2018-08-28 成都康拓邦科技有限公司 Cerebral apoplexy operation device and system
CN108742950A (en) * 2018-05-11 2018-11-06 上海长海医院 The production method of individuation breast prosthesis based on strong side breast MRI image data
CN109223253A (en) * 2018-08-16 2019-01-18 河南科技大学第附属医院 A kind of breast prosthesis
JP7260930B2 (en) 2018-11-08 2023-04-19 ニオバスク ティアラ インコーポレイテッド Ventricular deployment of a transcatheter mitral valve prosthesis
KR102219852B1 (en) * 2018-12-07 2021-02-25 주식회사 메디팹 Biocompatible structure comprising a hollow cage and method for manufacturing the same
EP3946163A4 (en) 2019-04-01 2022-12-21 Neovasc Tiara Inc. Controllably deployable prosthetic valve
WO2020210652A1 (en) 2019-04-10 2020-10-15 Neovasc Tiara Inc. Prosthetic valve with natural blood flow
CN110038159A (en) * 2019-04-22 2019-07-23 哈尔滨工业大学 The preparation method of flexible composite implant material
CA3140925A1 (en) 2019-05-20 2020-11-26 Neovasc Tiara Inc. Introducer with hemostasis mechanism
WO2020257643A1 (en) 2019-06-20 2020-12-24 Neovasc Tiara Inc. Low profile prosthetic mitral valve
EP4221645A1 (en) * 2020-10-01 2023-08-09 Lyra Therapeutics, Inc. Osmotic drug delivery implants
CN114425101B (en) * 2022-01-21 2022-07-22 北京大学口腔医学院 Micro-nano double-layer structure antibacterial bracket and preparation method and application thereof
CN114533955B (en) * 2022-02-16 2023-07-28 苏州英诺科医疗科技有限公司 Medical magnesium alloy surface coating with strong binding force and preparation method thereof
US20230321326A1 (en) * 2022-04-11 2023-10-12 Becton, Dickinson And Company Catheter with inherent antimicrobial properties

Citations (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55666A (en) * 1866-06-19 Edwaed b
US65546A (en) * 1867-06-11 Improved machine foe draining sugar
US216758A (en) * 1879-06-24 Improvement in friction-clutches
US4017626A (en) * 1974-01-14 1977-04-12 Robugen Gmbh, Pharmazeutische Fabrik Fungicidally active uracil derivatives
US4033962A (en) * 1975-06-26 1977-07-05 Hoffman-La Roche Inc. 2,4-Diamino-pyrimidine derivatives and processes
US4215062A (en) * 1978-05-22 1980-07-29 University Of Kansas Endowment Association Anthracycline synthesis
US4500676A (en) * 1983-12-15 1985-02-19 Biomatrix, Inc. Hyaluronate modified polymeric articles
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4590270A (en) * 1983-04-14 1986-05-20 Hoffmann-La Roche Inc. 2,4-diamino-[4-piperidinyl]pyrimidines useful as antibacterial agents, antimalarial agents, antitumors agents
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4649198A (en) * 1983-07-12 1987-03-10 Kyorin Pharmaceutical Co., Ltd. Imidazo(1,5-a)pyrimidine derivatives and their use as antimycotic agents
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US4814182A (en) * 1983-07-22 1989-03-21 National Research Development Corporation Controlled release device
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4925668A (en) * 1989-01-18 1990-05-15 Becton, Dickinson And Company Anti-infective and lubricious medical articles and method for their preparation
US4999210A (en) * 1989-01-18 1991-03-12 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5013306A (en) * 1989-01-18 1991-05-07 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5015238A (en) * 1989-06-21 1991-05-14 Becton, Dickinson And Company Expandable obturator and catheter assembly including same
US5091442A (en) * 1988-09-07 1992-02-25 Smith And Nephew Plc Tubular articles
US5130126A (en) * 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
US5207648A (en) * 1990-12-14 1993-05-04 The Kendall Company Multilumen catheter
US5221256A (en) * 1992-02-10 1993-06-22 Mahurkar Sakharam D Multiple-lumen catheter
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
US5322520A (en) * 1992-11-12 1994-06-21 Implemed, Inc. Iontophoretic structure for medical devices
US5330756A (en) * 1990-10-18 1994-07-19 Steuart Gary M Polyphase fluid extraction process, resulting products and methods of use
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5399351A (en) * 1990-07-09 1995-03-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5403858A (en) * 1991-07-08 1995-04-04 Rhone-Poulenc Rorer, S.A. New compositions containing taxane derivatives
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
US5512055A (en) * 1991-02-27 1996-04-30 Leonard Bloom Anti-infective and anti-inflammatory releasing systems for medical devices
US5520664A (en) * 1991-03-01 1996-05-28 Spire Corporation Catheter having a long-lasting antimicrobial surface treatment
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
US5594158A (en) * 1990-06-22 1997-01-14 The Board Of Regents Of The University Of Nebraska Processes for producing doxorubicin, daunomycinone, and derivatives of doxorubicin
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5616119A (en) * 1994-10-07 1997-04-01 Lathrotec, Inc. Medicated polymeric apparatus
US5620419A (en) * 1994-10-14 1997-04-15 Cook Pacemaker Corporation Port stabilizer ring
US5624704A (en) * 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US5707366A (en) * 1989-01-18 1998-01-13 Becton Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5709672A (en) * 1995-11-01 1998-01-20 Texas Tech University Health Sciences Center Silastic and polymer-based catheters with improved antimicrobial/antifungal properties
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5725553A (en) * 1996-02-29 1998-03-10 Moenning; Stephen P. Apparatus and method for protecting a port site opening in the wall of a body cavity
US5741224A (en) * 1996-04-16 1998-04-21 Implemed, Inc. Iontophoretic material
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
US5752941A (en) * 1994-02-15 1998-05-19 Gruppo Lepetit S.P.A. Central venous catheters loaded with antibiotics of the ramoplanin group preventing development of catheter related infections
US5759564A (en) * 1996-04-16 1998-06-02 Implemed, Inc. Iontophoretic material
US5861191A (en) * 1996-02-26 1999-01-19 Technology Licensing Company Bacteriostatic coating of polymeric conduit
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5879697A (en) * 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US5895419A (en) * 1996-09-30 1999-04-20 St. Jude Medical, Inc. Coated prosthetic cardiac device
US5912225A (en) * 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US6060000A (en) * 1992-11-12 2000-05-09 Implemed, Inc. Iontophoretic material containing carbon and metal granules
US6059816A (en) * 1996-02-29 2000-05-09 Moenning; Stephen P. Apparatus and method for protecting a port site opening in the wall of a body cavity utilizing a sealing member and a biologically active compound
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6071447A (en) * 1990-06-14 2000-06-06 Integra Lifescineces I, Ltd. Method of making a polyurethane-biopolymer composite
US6179817B1 (en) * 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US6197051B1 (en) * 1997-06-18 2001-03-06 Boston Scientific Corporation Polycarbonate-polyurethane dispersions for thromobo-resistant coatings
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6206849B1 (en) * 1987-12-22 2001-03-27 Vas-Cath Incorporated Multiple lumen catheter
US6214901B1 (en) * 1998-04-27 2001-04-10 Surmodics, Inc. Bioactive agent release coating
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US20020001629A1 (en) * 2000-03-23 2002-01-03 Voellmy Richard W. Compositions and methods relating to prevention of chemotherapy-induced alopecia
US6338904B1 (en) * 1996-11-25 2002-01-15 Scimed Life Systems Polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents
US6340465B1 (en) * 1999-04-12 2002-01-22 Edwards Lifesciences Corp. Lubricious coatings for medical devices
US20020018795A1 (en) * 2000-04-13 2002-02-14 Whitbourne Richard J. Targeted therapeutic agent release devices and methods of making and using the same
US6355001B1 (en) * 1991-01-29 2002-03-12 Edwards Lifesciences Corporation Thermodilution catheter method using a safe, flexible heating element
US6361526B1 (en) * 1993-11-01 2002-03-26 Medtronic Xomed, Inc. Antimicrobial tympanostomy tube
US20020049349A1 (en) * 2000-08-08 2002-04-25 Degussa Ag Low monomer 1:1-monoadducts from hydroxy (meth) acrylates and diisocyanates and a process for their manufacture
US6383144B1 (en) * 2000-01-18 2002-05-07 Edwards Lifesciences Corporation Devices and methods for measuring temperature of a patient
US20020055666A1 (en) * 1999-11-12 2002-05-09 Hunter William L. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
US6409764B1 (en) * 1998-12-03 2002-06-25 Charles F. White Methods and articles for regenerating bone or peridontal tissue
US6409723B1 (en) * 1999-04-02 2002-06-25 Stuart D. Edwards Treating body tissue by applying energy and substances
US6506411B2 (en) * 1993-07-19 2003-01-14 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US6518426B1 (en) * 1991-04-08 2003-02-11 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
US6530951B1 (en) * 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US20030055053A1 (en) * 1999-12-29 2003-03-20 Linde Robert G. 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives
US6559881B1 (en) * 2001-07-17 2003-05-06 Nokia Corporation Video telecommunications device, and camera for same
US6685672B1 (en) * 2000-07-13 2004-02-03 Edwards Lifesciences Corporation Multi-balloon drug delivery catheter for angiogenesis
US6730064B2 (en) * 1998-08-20 2004-05-04 Cook Incorporated Coated implantable medical device
US6730313B2 (en) * 2000-01-25 2004-05-04 Edwards Lifesciences Corporation Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
US6740333B2 (en) * 2000-07-07 2004-05-25 Anestic Aps Suppository and composition comprising at least one polyethylene glycol
US6744278B1 (en) * 2000-09-02 2004-06-01 Actel Corporation Tileable field-programmable gate array architecture
US20040117007A1 (en) * 2001-03-16 2004-06-17 Sts Biopolymers, Inc. Medicated stent having multi-layer polymer coating
US6753071B1 (en) * 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US6756428B2 (en) * 1999-02-25 2004-06-29 Seefar Technologies, Incorporated Degradable plastics possessing a microbe-inhibiting quality
US20050042240A1 (en) * 2002-01-28 2005-02-24 Utterberg David S. High viscosity antibacterials
US6997894B2 (en) * 2002-07-02 2006-02-14 Caresio Joseph F Vascular access catheter having a curved tip and method
US7201745B2 (en) * 2003-05-13 2007-04-10 Boston Scientific Scimed, Inc. Anti-infective central venous catheter with diffusion barrier layer
US7335228B2 (en) * 2002-10-08 2008-02-26 Cook Incorporated Stent with ring architecture and axially displaced connector segments
US7344599B2 (en) * 2002-09-27 2008-03-18 Labcoat, Ltd. Contact coating of prostheses

Family Cites Families (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US65481A (en) * 1867-06-04 Hen by c
US65483A (en) * 1867-06-04 Improvement in rotary steam engines
US43052A (en) * 1864-06-07 photo-lithographer
US167531A (en) * 1875-09-07 Improvement in dumping-wagons
US165342A (en) * 1875-07-06 Improvement in potato-diggers
US271024A (en) * 1883-01-23 Poison for squirrels
US42240A (en) * 1864-04-05 Improvement in heat-governors for stoves
US63627A (en) * 1867-04-09 Obadiah v
US244453A (en) * 1881-07-19 hammeestein
US259013A (en) * 1882-06-06 Vania
US147690A (en) * 1874-02-17 Improvement in belt-fastenings
US175323A (en) * 1876-03-28 Improvement in circular sawing machines
US1629A (en) * 1840-06-10 Horse-power eor driving machinery
US244459A (en) * 1881-07-19 Permutation-lock
US65482A (en) * 1867-06-04 Hugh m
US276894A (en) * 1883-05-01 Berge
US55053A (en) * 1866-05-29 Improved apparatus for lowering shipsj boats
US73207A (en) * 1868-01-07 stbele
US256502A (en) * 1882-04-18 William w
US106261A (en) * 1870-08-09 Improvement in lubricators
US255142A (en) * 1882-03-21 Jambs oastell
US89539A (en) * 1869-04-27 Improvement in lighting railway-cars
US259913A (en) * 1882-06-20 Fourth to henry reinheimer
US52452A (en) * 1866-02-06 Improvement in steam gage-cocks
US24372A (en) * 1859-06-14 Improvement in self-priming gun-locks
US80008A (en) * 1868-07-14 Isbandf
US45894A (en) * 1865-01-10 Improvement in calipers
US195156A (en) * 1877-09-11 Improvement in harvester-elevators
US216324A (en) * 1879-06-10 Improvement in steam-radiators
US271000A (en) * 1883-01-23 Combination-tool for housekeepers
US198868A (en) * 1878-01-01 Improvement in methods of attaching sweat-leathers to hat-bodies
US147491A (en) * 1874-02-17 Improvement in crutches
US281857A (en) * 1883-07-24 Snap for harness
DE267495C (en) 1913-09-07 1913-11-20 Max Schreiber SECURITY LOCK FOR JEWELRY
US2819718A (en) 1953-07-16 1958-01-14 Isidore H Goldman Drainage tube
US3096560A (en) 1958-11-21 1963-07-09 William J Liebig Process for synthetic vascular implants
NL143127B (en) 1969-02-04 1974-09-16 Rhone Poulenc Sa REINFORCEMENT DEVICE FOR A DEFECTIVE HEART VALVE.
US3614955A (en) 1970-02-09 1971-10-26 Medtronic Inc Standby defibrillator and method of operation
US3614954A (en) 1970-02-09 1971-10-26 Medtronic Inc Electronic standby defibrillator
BE793253A (en) 1971-12-23 1973-04-16 Lepetit Spa NEW BACTERICIDE COMPOSITIONS AND THEIR USE
US3945052A (en) 1972-05-01 1976-03-23 Meadox Medicals, Inc. Synthetic vascular graft and method for manufacturing the same
US3980650A (en) * 1972-05-05 1976-09-14 N.V. Koninklijke Pharmaceutische Fabrieken V/H Brocades-Stheeman En Pharmacia 4-Amino-pyrimidine derivatives
US3805301A (en) 1972-07-28 1974-04-23 Meadox Medicals Inc Tubular grafts having indicia thereon
GB1527592A (en) 1974-08-05 1978-10-04 Ici Ltd Wound dressing
US3995623A (en) 1974-12-23 1976-12-07 American Hospital Supply Corporation Multipurpose flow-directed catheter
US4281669A (en) 1975-05-09 1981-08-04 Macgregor David C Pacemaker electrode with porous system
US4096860A (en) 1975-10-08 1978-06-27 Mclaughlin William F Dual flow encatheter
JPS5289680A (en) 1976-01-22 1977-07-27 Mitsui Toatsu Chem Inc Preparation of 1-(2-tetrahydrofuryl)-5-flurouracil
CA1069652A (en) 1976-01-09 1980-01-15 Alain F. Carpentier Supported bioprosthetic heart valve with compliant orifice ring
US4134402A (en) 1976-02-11 1979-01-16 Mahurkar Sakharam D Double lumen hemodialysis catheter
GB1546937A (en) 1976-07-29 1979-05-31 Beecham Group Ltd 2,4-diaminopyrimidine derivatives
US4072146A (en) 1976-09-08 1978-02-07 Howes Randolph M Venous catheter device
US4335723A (en) 1976-11-26 1982-06-22 The Kendall Company Catheter having inflatable retention means
US4099528A (en) 1977-02-17 1978-07-11 Sorenson Research Co., Inc. Double lumen cannula
US4140126A (en) 1977-02-18 1979-02-20 Choudhury M Hasan Method for performing aneurysm repair
JPS53149985A (en) 1977-05-31 1978-12-27 Asahi Chem Ind Co Ltd Preparation of 5-fluorouracil derivatives
US4180068A (en) 1978-04-13 1979-12-25 Motion Control, Incorporated Bi-directional flow catheter with retractable trocar/valve structure
DE2960875D1 (en) 1978-04-19 1981-12-10 Ici Plc A method of preparing a tubular product by electrostatic spinning
SE7903361L (en) 1978-04-20 1979-10-21 Johnson Matthey Co Ltd COMPOSITIONS CONTAINING PLATINUM
US4284459A (en) 1978-07-03 1981-08-18 The Kendall Company Method for making a molded catheter
US4296105A (en) 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
JPS5559173A (en) 1978-10-27 1980-05-02 Kaken Pharmaceut Co Ltd Novel fluorouracil derivative
US4227533A (en) 1978-11-03 1980-10-14 Bristol-Myers Company Flushable urinary catheter
US4375817A (en) 1979-07-19 1983-03-08 Medtronic, Inc. Implantable cardioverter
DE3010841A1 (en) 1980-03-21 1981-10-08 Ulrich Dr.med. 6936 Haag Uthmann CATHEDER
US4299778A (en) 1980-07-21 1981-11-10 Shell Oil Company N'Cyclopropyl-N-(fluorophenyl)-N-hydroxyureas
US4301277A (en) 1980-10-20 1981-11-17 Sri International 3-Deamino-3-(4-morpholinyl) derivatives of daunorubicin and doxorubicin
US4314054A (en) 1981-03-23 1982-02-02 Sri International 3'-Deamino-3'-(4-methoxy-1-piperidinyl) derivatives of daunorubicin and doxorubicin
US4406656A (en) 1981-06-01 1983-09-27 Brack Gillium Hattler Venous catheter having collapsible multi-lumens
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4475972A (en) 1981-10-01 1984-10-09 Ontario Research Foundation Implantable material
US4568329A (en) 1982-03-08 1986-02-04 Mahurkar Sakharam D Double lumen catheter
US4546499A (en) 1982-12-13 1985-10-15 Possis Medical, Inc. Method of supplying blood to blood receiving vessels
EP0117485A3 (en) 1983-02-28 1985-01-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyridine, pyrazine and pyrimidine derivatives and their use as fungicides
US4888176A (en) 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4530113A (en) 1983-05-20 1985-07-23 Intervascular, Inc. Vascular grafts with cross-weave patterns
US4585859A (en) 1983-05-24 1986-04-29 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
DE3323025A1 (en) * 1983-06-25 1985-01-10 Hoechst Ag, 6230 Frankfurt ANTHRACYCLINE DERIVATIVES, A MICROBIOLOGICAL METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS CYTOSTATICS
US4647416A (en) 1983-08-03 1987-03-03 Shiley Incorporated Method of preparing a vascular graft prosthesis
US4550447A (en) 1983-08-03 1985-11-05 Shiley Incorporated Vascular graft prosthesis
US4490529A (en) 1983-09-06 1984-12-25 Dana-Farber Cancer Institute, Inc. Cysteic acid and homocysteic acid analogues of methotrexate and aminopterin
US5104399A (en) 1986-12-10 1992-04-14 Endovascular Technologies, Inc. Artificial graft and implantation method
US4571241A (en) 1983-12-16 1986-02-18 Christopher T Graham Urinary catheter with collapsible urethral tube
US4710169A (en) 1983-12-16 1987-12-01 Christopher T Graham Urinary catheter with collapsible urethral tube
US5197977A (en) 1984-01-30 1993-03-30 Meadox Medicals, Inc. Drug delivery collagen-impregnated synthetic vascular graft
US4562596A (en) 1984-04-25 1986-01-07 Elliot Kornberg Aortic graft, device and method for performing an intraluminal abdominal aortic aneurysm repair
US4782836A (en) 1984-05-24 1988-11-08 Intermedics, Inc. Rate adaptive cardiac pacemaker responsive to patient activity and temperature
US4629623A (en) 1984-06-11 1986-12-16 Biomatrix, Inc. Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof
US5266563A (en) 1984-06-11 1993-11-30 Biomatrix, Inc. Hyakyribate-poly (ethylene oxide) mixtures
JPS6143191A (en) 1984-08-07 1986-03-01 Kyorin Pharmaceut Co Ltd Imidazo(1,5-a)pyrimidine derivative
US4588831A (en) 1984-11-09 1986-05-13 Natec Platinum complex compounds of substituted 5,8-dihydroxyl-1,4-naphthoquinone, and process for their production and use
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4662382A (en) 1985-01-16 1987-05-05 Intermedics, Inc. Pacemaker lead with enhanced sensitivity
US4860751A (en) 1985-02-04 1989-08-29 Cordis Corporation Activity sensor for pacemaker control
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5099013A (en) 1985-03-12 1992-03-24 Biomatrix, Inc, Hylan preparation and method of recovery thereof from animal tissues
US4714703A (en) * 1985-09-11 1987-12-22 Burckhalter Joseph H Method of inhibiting herpetic lesions
US4701162A (en) 1985-09-24 1987-10-20 The Kendall Company Foley catheter assembly
DE3780374D1 (en) 1986-07-31 1992-08-20 Irnich Werner FREQUENCY ADAPTING HEART PACEMAKER.
US4882168A (en) 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
US4960409A (en) 1986-09-11 1990-10-02 Catalano Marc L Method of using bilumen peripheral venous catheter with adapter
US5004606A (en) 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
JPS63112530A (en) * 1986-10-29 1988-05-17 Kyushu Kogyo Univ Production of 1,4,5,8-tetramethoxynaphthalene
GB8701381D0 (en) 1987-01-22 1987-02-25 Erba Farmitalia Antitumor agent
FR2611203B1 (en) 1987-02-20 1989-06-09 Sturtz Georges GEM-DIPHOSPHONIC ANALOGS OF AMETHOPTERIN (METHOTREXATE) AND DEAZA-N-10 AMETHOPTERINE DERIVATIVES. THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US4913743A (en) 1987-04-15 1990-04-03 Biomatrix, Inc. Processes for managing keratinous material using glycosaminoglycan and cationic polymer combinations
US5019096A (en) * 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5059186A (en) 1988-03-07 1991-10-22 Vitaphore Corporation Percutaneous access device
US4892540A (en) 1988-04-21 1990-01-09 Sorin Biomedica S.P.A. Two-leaflet prosthetic heart valve
US5176661A (en) 1988-09-06 1993-01-05 Advanced Cardiovascular Systems, Inc. Composite vascular catheter
US5024671A (en) 1988-09-19 1991-06-18 Baxter International Inc. Microporous vascular graft
US5066658A (en) 1988-11-10 1991-11-19 Ortho Pharmaceutical Corporation Substituted hydroxyureas
IE64997B1 (en) * 1989-01-18 1995-10-04 Becton Dickinson Co Anti-infection and antithrombogenic medical articles and method for their preparation
US6261271B1 (en) 1989-01-18 2001-07-17 Becton Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5041100A (en) * 1989-04-28 1991-08-20 Cordis Corporation Catheter and hydrophilic, friction-reducing coating thereon
US5242073A (en) 1989-08-23 1993-09-07 Aluminum Company Of America Resealable container closure
US5166149A (en) 1989-09-08 1992-11-24 Chemex Pharmaceuticals, Inc. Methotrexate compositions and methods of treatment using same
WO1991003990A1 (en) 1989-09-15 1991-04-04 Chiron Ophthalmics, Inc. Method for achieving epithelialization of synthetic lenses
US4976697A (en) 1989-10-26 1990-12-11 Becton, Dickinson And Company Catheter obturator with automatic feed and control
US5064415A (en) 1989-10-26 1991-11-12 Becton, Dickinson And Company Catheter obturator with automatic feed and control
US5153174A (en) 1989-10-30 1992-10-06 Union Carbide Chemicals & Plastics Inc. Polymer mixtures useful in skin care
US5069899A (en) 1989-11-02 1991-12-03 Sterilization Technical Services, Inc. Anti-thrombogenic, anti-microbial compositions containing heparin
DK0434960T3 (en) 1989-12-19 1996-10-14 Pharmacia Spa Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates
US5101824A (en) 1990-04-16 1992-04-07 Siemens-Pacesetter, Inc. Rate-responsive pacemaker with circuitry for processing multiple sensor inputs
GB2243838A (en) * 1990-05-09 1991-11-13 Learonal Process for metallising a through-hole printed circuit board by electroplating
US5143724A (en) 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5405379A (en) 1990-07-26 1995-04-11 Lane; Rodney J. Self expanding vascular endoprosthesis for aneurysms
AU646299B2 (en) 1990-08-23 1994-02-17 Novartis Vaccines And Diagnostics, Inc. Uses of recombinant colony stimulating factor-1
PH31064A (en) * 1990-09-07 1998-02-05 Nycomed As Of Nycoveten Polymers containing diester units.
CA2052981C (en) 1990-10-09 1995-08-01 Cesare Gianturco Percutaneous stent assembly
DE59008908D1 (en) 1990-12-19 1995-05-18 Osypka Peter Pacemaker lead with an inner channel and with an electrode head.
US5116360A (en) 1990-12-27 1992-05-26 Corvita Corporation Mesh composite graft
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5405363A (en) 1991-03-15 1995-04-11 Angelon Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5238926A (en) * 1991-08-20 1993-08-24 Schering Corporation Anti-fungal agents
US5346898A (en) * 1992-06-18 1994-09-13 Schering Corporation Anti-fungal uracil compounds
US5151105A (en) 1991-10-07 1992-09-29 Kwan Gett Clifford Collapsible vessel sleeve implant
JPH07500113A (en) 1991-10-16 1995-01-05 リチャードソン、ビックス、インコーポレーテッド High skin penetration system for improved local delivery of drugs
FR2683529B1 (en) 1991-11-12 1994-02-04 Bretagne Occidentale Universite PHARMACEUTICAL COMPOUNDS GEM-DIPHOSPHONATES ANALOGUE OF CIS-PLATINUM.
EP0615458B1 (en) 1991-12-06 1997-08-06 North Shore University Hospital Research Corporation Method of reducing medical device related infections
US5284491A (en) 1992-02-27 1994-02-08 Medtronic, Inc. Cardiac pacemaker with hysteresis behavior
GB9204918D0 (en) 1992-03-06 1992-04-22 Nycomed As Chemical compounds
PT706373E (en) 1992-03-23 2000-11-30 Univ Georgetown TAXOL ENCAPSULATED IN A LIPOSOM AND A METHOD
US5461223A (en) 1992-10-09 1995-10-24 Eastman Kodak Company Bar code detecting circuitry
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5300022A (en) 1992-11-12 1994-04-05 Martin Klapper Urinary catheter and bladder irrigation system
US6287484B1 (en) 1992-11-12 2001-09-11 Robert Hausslein Iontophoretic material
US5496362A (en) 1992-11-24 1996-03-05 Cardiac Pacemakers, Inc. Implantable conformal coil patch electrode with multiple conductive elements for cardioversion and defibrillation
FR2698543B1 (en) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa New taxoid-based compositions.
US5716395A (en) 1992-12-11 1998-02-10 W.L. Gore & Associates, Inc. Prosthetic vascular graft
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5697953A (en) 1993-03-13 1997-12-16 Angeion Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5382582A (en) 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5380897A (en) 1993-05-25 1995-01-10 Hoeschele; James D. Tri(platinum) complexes
US5314430A (en) 1993-06-24 1994-05-24 Medtronic, Inc. Atrial defibrillator employing transvenous and subcutaneous electrodes and method of use
JPH0767895A (en) 1993-06-25 1995-03-14 Sumitomo Electric Ind Ltd Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
CA2167715C (en) 1993-07-20 1998-10-06 Akiyoshi Kawai Heteroaryl cycloalkenyl hydroxyureas
JPH0763933A (en) * 1993-08-25 1995-03-10 Ricoh Co Ltd Optical integrated circuit
US5409915A (en) 1993-09-14 1995-04-25 The University Of Vermont And State Agricultural College Bis-platinum (IV) complexes as chemotherapeutic agents
US5609624A (en) 1993-10-08 1997-03-11 Impra, Inc. Reinforced vascular graft and method of making same
AU1091095A (en) 1993-11-08 1995-05-29 Harrison M. Lazarus Intraluminal vascular graft and method
WO1995015748A1 (en) 1993-12-08 1995-06-15 Vitaphore Corporation Microsphere drug delivery system
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5554106A (en) * 1994-10-13 1996-09-10 Quinton Instrument Company Hydrocolloid exit site dressing
US5569207A (en) 1994-10-13 1996-10-29 Quinton Instrument Company Hydrocolloid dressing
US5869127A (en) 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US6468649B1 (en) 1995-02-22 2002-10-22 Scimed Life Systems, Inc. Antimicrobial adhesion surface
GB9506769D0 (en) * 1995-03-28 1995-05-24 Aortech Europ Ltd Device
US5627187A (en) * 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
US5772694A (en) 1995-05-16 1998-06-30 Medical Carbon Research Institute L.L.C. Prosthetic heart valve with improved blood flow
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
EP0753523A1 (en) 1995-07-10 1997-01-15 Gador S.A. Amino-substituted bisphosphonic acids
US5607385A (en) 1995-08-17 1997-03-04 Medtronic, Inc. Device and algorithm for a combined cardiomyostimulator and a cardiac pacer-carioverter-defibrillator
FR2740978B1 (en) 1995-11-10 1998-01-02 Ela Medical Sa IMPLANTABLE DEFIBRILLATOR / CARDIOVERVER ACTIVE MEDICAL DEVICE
CA2189097A1 (en) * 1995-11-15 1997-05-16 Pin-Fang Lin Composition and method of treating retroviral infection
US5843903A (en) 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
CA2171073A1 (en) 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
JPH09319097A (en) * 1996-01-16 1997-12-12 Sumitomo Chem Co Ltd Method for forming resist pattern
EP0874643B1 (en) * 1996-02-15 2001-11-21 J. Paul Santerre Bioresponsive pharmacologically-active polymers and articles made therefrom
US5942555A (en) 1996-03-21 1999-08-24 Surmodics, Inc. Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
US6117125A (en) * 1996-05-02 2000-09-12 Cook Incorporated Method for predetermining uniform flow rate of a fluid from a tubular body and device therefrom
US5921954A (en) * 1996-07-10 1999-07-13 Mohr, Jr.; Lawrence G. Treating aneurysms by applying hardening/softening agents to hardenable/softenable substances
US6419673B1 (en) * 1996-05-06 2002-07-16 Stuart Edwards Ablation of rectal and other internal body structures
WO1997046268A1 (en) * 1996-06-04 1997-12-11 Cook Incorporated Implantable medical device
US5913848A (en) 1996-06-06 1999-06-22 Luther Medical Products, Inc. Hard tip over-the-needle catheter and method of manufacturing the same
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
CA2266478C (en) 1996-09-23 2002-11-12 Focal, Inc. Polymerizable biodegradable polymers including carbonate or dioxanone linkages
US6566406B1 (en) 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
US5800412A (en) 1996-10-10 1998-09-01 Sts Biopolymers, Inc. Hydrophilic coatings with hydrating agents
ATE279213T1 (en) 1996-11-06 2004-10-15 Sts Biopolymers Inc COATING WITH GAS-CONTAINING CAVITIES TO AMPLIFY ULTRASONIC ECHOS
US6106473A (en) 1996-11-06 2000-08-22 Sts Biopolymers, Inc. Echogenic coatings
US7229413B2 (en) 1996-11-06 2007-06-12 Angiotech Biocoatings Corp. Echogenic coatings with overcoat
US5783689A (en) * 1996-11-12 1998-07-21 University Of Notre Dame Antibacterial and antifungal nucleosides
WO1998024483A2 (en) * 1996-12-03 1998-06-11 Osteobiologics, Inc. Biodegradable polymeric film
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5997517A (en) 1997-01-27 1999-12-07 Sts Biopolymers, Inc. Bonding layers for medical device surface coatings
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
AU6769098A (en) 1997-03-20 1998-10-12 Focal, Inc. Biodegradable tissue retractor
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
UA54505C2 (en) 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Biodegradable polymers, bound by phosphates, compositions, products and pocesses for manufacturing and using thereof
ATE279461T1 (en) 1997-04-03 2004-10-15 Guilford Pharm Inc BIODEGRADABLE TEREPHTHALATE POLYESTER POLYPHOSPHATE POLYMERS, COMPOSITIONS, ARTICLES AND METHODS FOR THEIR PRODUCTION AND USE
DE19718430A1 (en) * 1997-04-30 1999-01-14 Stemberger Axel Dr Anti=infective treatment of bio=material, e.g. prosthesis
WO1998048859A1 (en) * 1997-04-30 1998-11-05 Guilford Pharmaceuticals Inc. Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds, articles, and methods for using the same
JPH10328293A (en) * 1997-06-04 1998-12-15 Unitika Ltd Medical instrument and manufacture therefor
US6110483A (en) 1997-06-23 2000-08-29 Sts Biopolymers, Inc. Adherent, flexible hydrogel and medicated coatings
US5921965A (en) * 1997-07-07 1999-07-13 New York University Tubing device for antibiotic administration through central venous catheters
ZA987019B (en) 1997-08-06 1999-06-04 Focal Inc Hemostatic tissue sealants
US6067471A (en) 1998-08-07 2000-05-23 Cardiac Pacemakers, Inc. Atrial and ventricular implantable cardioverter-defibrillator and lead system
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
US6121027A (en) 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
US6316522B1 (en) * 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US5854382A (en) * 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US6080874A (en) 1997-09-25 2000-06-27 Abbott Laboratories Synthesis and isolation of N-(aryl or heteroaryl)-alkyl-N-hydroxyurea
US6149574A (en) 1997-12-19 2000-11-21 Radiance Medical Systems, Inc. Dual catheter radiation delivery system
WO1999035162A1 (en) 1998-01-07 1999-07-15 Jenner Biotherapies, Inc. Therapeutic liposome-encapsulated immunomodulators
US6096075A (en) 1998-01-22 2000-08-01 Medical Carbon Research Institute, Llc Prosthetic heart valve
WO1999044997A1 (en) 1998-03-06 1999-09-10 Ube Industries, Ltd. 6-(α-FLUOROALKYL)-4-PYRIMIDONES AND PROCESS FOR PRODUCING THE SAME
US6007833A (en) 1998-03-19 1999-12-28 Surmodics, Inc. Crosslinkable macromers bearing initiator groups
US6176877B1 (en) 1998-04-20 2001-01-23 St. Jude Medical, Inc. Two piece prosthetic heart valve
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6055454A (en) 1998-07-27 2000-04-25 Cardiac Pacemakers, Inc. Cardiac pacemaker with automatic response optimization of a physiologic sensor based on a second sensor
US6514534B1 (en) 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6152943A (en) 1998-08-14 2000-11-28 Incept Llc Methods and apparatus for intraluminal deposition of hydrogels
US6273875B1 (en) * 1998-08-17 2001-08-14 Edwards Lifesciences Corporation Medical devices having improved antimicrobial/antithrombogenic properties
US20050147690A1 (en) 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
US6153212A (en) 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
DE69924749T2 (en) 1998-11-20 2006-04-27 The University Of Connecticut, Farmington Generically integrated implantable potentiostat remote sensing device for electrochemical probes
WO2000033895A1 (en) 1998-12-07 2000-06-15 Baylor College Of Medicine Preventing and removing biofilm from the surface of medical devices
ES2187112T3 (en) * 1998-12-21 2003-05-16 Lonza Ag PROCEDURE FOR THE PREPARATION OF N- (AMINO-4,6-DIHALOGENOPIRIMIDIN) -FORMAMIDS.
US20020065546A1 (en) * 1998-12-31 2002-05-30 Machan Lindsay S. Stent grafts with bioactive coatings
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
RU2001127313A (en) 1999-03-09 2003-09-20 Протарга, Инк. (Us) CONJUGATES FATTY ACID-ANTI-CANCER AGENT AND THEIR APPLICATION
US6169923B1 (en) 1999-04-23 2001-01-02 Pacesetter, Inc. Implantable cardioverter-defibrillator with automatic arrhythmia detection criteria adjustment
AU5273200A (en) 1999-05-24 2000-12-12 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6425853B1 (en) * 1999-06-23 2002-07-30 Stuart D. Edwards Treating body tissue by applying energy and substances with a retractable catheter and contained cooling element
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6309660B1 (en) 1999-07-28 2001-10-30 Edwards Lifesciences Corp. Universal biocompatible coating platform for medical devices
US6368611B1 (en) 1999-08-31 2002-04-09 Sts Biopolymers, Inc. Anti-infective covering for percutaneous and vascular access device and coating method
DE60027730T2 (en) 1999-09-09 2007-03-29 The Regents Of The University Of California, Oakland ADMINISTRATION OF TAXANES TO ANGIOGENIC BLOOD VESSELS BY CATIONIC LIPOSOMES
US6358557B1 (en) * 1999-09-10 2002-03-19 Sts Biopolymers, Inc. Graft polymerization of substrate surfaces
US6358278B1 (en) 1999-09-24 2002-03-19 St. Jude Medical, Inc. Heart valve prosthesis with rotatable cuff
US6371983B1 (en) 1999-10-04 2002-04-16 Ernest Lane Bioprosthetic heart valve
WO2001025223A1 (en) 1999-10-06 2001-04-12 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
CA2395132A1 (en) 2000-01-05 2001-07-12 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7296577B2 (en) 2000-01-31 2007-11-20 Edwards Lifescience Ag Transluminal mitral annuloplasty with active anchoring
DE60123583T2 (en) 2000-02-04 2007-08-09 Lipoxen Technologies Ltd. DEHYDRATISATION / REHYDRATISATION PROCESS FOR THE PREPARATION OF LIPOSOME
GB0003201D0 (en) 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
US6403618B1 (en) * 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
US6206749B1 (en) * 2000-02-24 2001-03-27 Dale L. Bell Yo-yo
US6370434B1 (en) 2000-02-28 2002-04-09 Cardiac Pacemakers, Inc. Cardiac lead and method for lead implantation
US20010049422A1 (en) 2000-04-14 2001-12-06 Phaneuf Matthew D. Methods of applying antibiotic compounds to polyurethane biomaterials using textile dyeing technology
US6423050B1 (en) * 2000-06-16 2002-07-23 Zbylut J. Twardowski Method and apparatus for locking of central-vein catheters
CA2771263A1 (en) 2000-07-27 2002-02-07 Rutgers, The State University Therapeutic polyesters and polyamides
US7304122B2 (en) * 2001-08-30 2007-12-04 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
JP4583756B2 (en) * 2000-10-31 2010-11-17 クック インコーポレイテッド Medical instruments
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
WO2002069949A2 (en) 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
EP1383504A1 (en) 2001-04-26 2004-01-28 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
US7175873B1 (en) * 2001-06-27 2007-02-13 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
JP4426285B2 (en) * 2001-06-28 2010-03-03 クック・バイオテック・インコーポレーテッド Graft prosthesis device containing renal capsule collagen
IN2014DN10834A (en) * 2001-09-17 2015-09-04 Psivida Inc
US20030229390A1 (en) 2001-09-17 2003-12-11 Control Delivery Systems, Inc. On-stent delivery of pyrimidines and purine analogs
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
US20030144362A1 (en) 2002-01-28 2003-07-31 Utterberg David S. High viscosity antibacterials for cannulae
US6942633B2 (en) 2002-03-22 2005-09-13 Twin Star Medical, Inc. System for treating tissue swelling
CN100341589C (en) * 2002-05-24 2007-10-10 血管技术国际股份公司 Compositions and methods for coating medical implants
US7622146B2 (en) * 2002-07-18 2009-11-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US7255891B1 (en) * 2003-02-26 2007-08-14 Advanced Cardiovascular Systems, Inc. Method for coating implantable medical devices
US6926919B1 (en) * 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
US7306580B2 (en) 2003-04-16 2007-12-11 Cook Incorporated Medical device with therapeutic agents
US7311697B2 (en) 2003-07-02 2007-12-25 Cook Critical Care Incorporated Central venous catheter
EP1660013A4 (en) 2003-08-26 2011-07-20 Gel Del Technologies Inc Protein biomaterials and biocoacervates and methods of making and using thereof
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US7004176B2 (en) * 2003-10-17 2006-02-28 Edwards Lifesciences Ag Heart valve leaflet locator
US20070249986A1 (en) 2004-03-15 2007-10-25 Smego Douglas R Arteriovenous access for hemodialysis employing a vascular balloon catheter and an improved hybrid endovascular technique
CA2560507C (en) 2004-03-26 2011-08-16 Surmodics, Inc. Composition and method for preparing biocompatible surfaces
US7550443B2 (en) 2004-03-26 2009-06-23 Surmodics, Inc. Process and systems for biocompatible surfaces
CA2561496A1 (en) 2004-04-02 2005-10-20 Baylor College Of Medicine Novel modification of medical prostheses
US20050244459A1 (en) 2004-04-06 2005-11-03 Dewitt David M Coating compositions for bioactive agents
US20060083772A1 (en) 2004-04-06 2006-04-20 Dewitt David M Coating compositions for bioactive agents
WO2005113034A1 (en) 2004-05-12 2005-12-01 Surmodics, Inc. Natural biodegradable polysaccharides coatings for medical articles
US20050281857A1 (en) 2004-05-25 2005-12-22 Heyer Toni M Methods and reagents for preparing biomolecule-containing coatings
US20060024372A1 (en) 2004-07-29 2006-02-02 Utterberg David S High viscosity antibacterials
US7807750B2 (en) 2004-08-06 2010-10-05 Surmodics, Inc. Thermally-reactive polymers
US8198326B2 (en) 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US20060051384A1 (en) 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US9028852B2 (en) 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060198868A1 (en) 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US20060147491A1 (en) 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US8105666B2 (en) 2005-03-15 2012-01-31 Finley Michael J Compliant polymeric coatings for insertable medical articles
US7611505B2 (en) 2005-05-10 2009-11-03 Baxa Corporation Sterile docking apparatus and method
JP2008541950A (en) 2005-06-02 2008-11-27 サーモディクス,インコーポレイティド Hydrophilic polymer coating for medical products
US8512736B2 (en) 2005-09-21 2013-08-20 Surmodics, Inc. Coatings including natural biodegradable polysaccharides and uses thereof
US20070259913A1 (en) 2006-05-04 2007-11-08 David Deitchman Prophylaxis of thromboembolic events in cancer patients
US7947019B2 (en) 2006-08-18 2011-05-24 Angio Dynamics, Inc Catheter retention assembly and method of use
US20080063627A1 (en) 2006-09-12 2008-03-13 Surmodics, Inc. Tissue graft materials containing biocompatible agent and methods of making and using same

Patent Citations (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55666A (en) * 1866-06-19 Edwaed b
US65546A (en) * 1867-06-11 Improved machine foe draining sugar
US216758A (en) * 1879-06-24 Improvement in friction-clutches
US4017626A (en) * 1974-01-14 1977-04-12 Robugen Gmbh, Pharmazeutische Fabrik Fungicidally active uracil derivatives
US4033962A (en) * 1975-06-26 1977-07-05 Hoffman-La Roche Inc. 2,4-Diamino-pyrimidine derivatives and processes
US4215062A (en) * 1978-05-22 1980-07-29 University Of Kansas Endowment Association Anthracycline synthesis
US4590270A (en) * 1983-04-14 1986-05-20 Hoffmann-La Roche Inc. 2,4-diamino-[4-piperidinyl]pyrimidines useful as antibacterial agents, antimalarial agents, antitumors agents
US4649198A (en) * 1983-07-12 1987-03-10 Kyorin Pharmaceutical Co., Ltd. Imidazo(1,5-a)pyrimidine derivatives and their use as antimycotic agents
US4814182A (en) * 1983-07-22 1989-03-21 National Research Development Corporation Controlled release device
US4500676A (en) * 1983-12-15 1985-02-19 Biomatrix, Inc. Hyaluronate modified polymeric articles
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US6206849B1 (en) * 1987-12-22 2001-03-27 Vas-Cath Incorporated Multiple lumen catheter
US5091442A (en) * 1988-09-07 1992-02-25 Smith And Nephew Plc Tubular articles
US4925668A (en) * 1989-01-18 1990-05-15 Becton, Dickinson And Company Anti-infective and lubricious medical articles and method for their preparation
US5013306A (en) * 1989-01-18 1991-05-07 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US4999210A (en) * 1989-01-18 1991-03-12 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5707366A (en) * 1989-01-18 1998-01-13 Becton Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5015238A (en) * 1989-06-21 1991-05-14 Becton, Dickinson And Company Expandable obturator and catheter assembly including same
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
US6071447A (en) * 1990-06-14 2000-06-06 Integra Lifescineces I, Ltd. Method of making a polyurethane-biopolymer composite
US5594158A (en) * 1990-06-22 1997-01-14 The Board Of Regents Of The University Of Nebraska Processes for producing doxorubicin, daunomycinone, and derivatives of doxorubicin
US5130126A (en) * 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
US5399351A (en) * 1990-07-09 1995-03-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5330756A (en) * 1990-10-18 1994-07-19 Steuart Gary M Polyphase fluid extraction process, resulting products and methods of use
US5207648A (en) * 1990-12-14 1993-05-04 The Kendall Company Multilumen catheter
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6355001B1 (en) * 1991-01-29 2002-03-12 Edwards Lifesciences Corporation Thermodilution catheter method using a safe, flexible heating element
US6387052B1 (en) * 1991-01-29 2002-05-14 Edwards Lifesciences Corporation Thermodilution catheter having a safe, flexible heating element
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5512055A (en) * 1991-02-27 1996-04-30 Leonard Bloom Anti-infective and anti-inflammatory releasing systems for medical devices
US5520664A (en) * 1991-03-01 1996-05-28 Spire Corporation Catheter having a long-lasting antimicrobial surface treatment
US6518426B1 (en) * 1991-04-08 2003-02-11 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
US5403858A (en) * 1991-07-08 1995-04-04 Rhone-Poulenc Rorer, S.A. New compositions containing taxane derivatives
US5221256A (en) * 1992-02-10 1993-06-22 Mahurkar Sakharam D Multiple-lumen catheter
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
US5322520A (en) * 1992-11-12 1994-06-21 Implemed, Inc. Iontophoretic structure for medical devices
US5725817A (en) * 1992-11-12 1998-03-10 Implemed, Inc. Iontophoretic structure for medical devices
US6060000A (en) * 1992-11-12 2000-05-09 Implemed, Inc. Iontophoretic material containing carbon and metal granules
US5498248A (en) * 1992-11-12 1996-03-12 Implemed, Inc. Iontophoretic structure for medical devices
US6506411B2 (en) * 1993-07-19 2003-01-14 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6361526B1 (en) * 1993-11-01 2002-03-26 Medtronic Xomed, Inc. Antimicrobial tympanostomy tube
US5752941A (en) * 1994-02-15 1998-05-19 Gruppo Lepetit S.P.A. Central venous catheters loaded with antibiotics of the ramoplanin group preventing development of catheter related infections
US5616119A (en) * 1994-10-07 1997-04-01 Lathrotec, Inc. Medicated polymeric apparatus
US5620419A (en) * 1994-10-14 1997-04-15 Cook Pacemaker Corporation Port stabilizer ring
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6179817B1 (en) * 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US5624704A (en) * 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US5902283A (en) * 1995-04-24 1999-05-11 Baylor College Of Medicine Board Of Regents Antimicrobial impregnated catheters and other medical implants
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5709672A (en) * 1995-11-01 1998-01-20 Texas Tech University Health Sciences Center Silastic and polymer-based catheters with improved antimicrobial/antifungal properties
US5861191A (en) * 1996-02-26 1999-01-19 Technology Licensing Company Bacteriostatic coating of polymeric conduit
US5725553A (en) * 1996-02-29 1998-03-10 Moenning; Stephen P. Apparatus and method for protecting a port site opening in the wall of a body cavity
US6059816A (en) * 1996-02-29 2000-05-09 Moenning; Stephen P. Apparatus and method for protecting a port site opening in the wall of a body cavity utilizing a sealing member and a biologically active compound
US5741224A (en) * 1996-04-16 1998-04-21 Implemed, Inc. Iontophoretic material
US5759564A (en) * 1996-04-16 1998-06-02 Implemed, Inc. Iontophoretic material
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
US5895419A (en) * 1996-09-30 1999-04-20 St. Jude Medical, Inc. Coated prosthetic cardiac device
US6530951B1 (en) * 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US6338904B1 (en) * 1996-11-25 2002-01-15 Scimed Life Systems Polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents
US5912225A (en) * 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US5879697A (en) * 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US6197051B1 (en) * 1997-06-18 2001-03-06 Boston Scientific Corporation Polycarbonate-polyurethane dispersions for thromobo-resistant coatings
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6344035B1 (en) * 1998-04-27 2002-02-05 Surmodics, Inc. Bioactive agent release coating
US6214901B1 (en) * 1998-04-27 2001-04-10 Surmodics, Inc. Bioactive agent release coating
US6730064B2 (en) * 1998-08-20 2004-05-04 Cook Incorporated Coated implantable medical device
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6409764B1 (en) * 1998-12-03 2002-06-25 Charles F. White Methods and articles for regenerating bone or peridontal tissue
US6756428B2 (en) * 1999-02-25 2004-06-29 Seefar Technologies, Incorporated Degradable plastics possessing a microbe-inhibiting quality
US6409723B1 (en) * 1999-04-02 2002-06-25 Stuart D. Edwards Treating body tissue by applying energy and substances
US6340465B1 (en) * 1999-04-12 2002-01-22 Edwards Lifesciences Corp. Lubricious coatings for medical devices
US20020055666A1 (en) * 1999-11-12 2002-05-09 Hunter William L. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
US20030055053A1 (en) * 1999-12-29 2003-03-20 Linde Robert G. 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives
US6383144B1 (en) * 2000-01-18 2002-05-07 Edwards Lifesciences Corporation Devices and methods for measuring temperature of a patient
US6991804B2 (en) * 2000-01-25 2006-01-31 Edwards Lifesciences Corporation Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
US6730313B2 (en) * 2000-01-25 2004-05-04 Edwards Lifesciences Corporation Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
US20020001629A1 (en) * 2000-03-23 2002-01-03 Voellmy Richard W. Compositions and methods relating to prevention of chemotherapy-induced alopecia
US20020018795A1 (en) * 2000-04-13 2002-02-14 Whitbourne Richard J. Targeted therapeutic agent release devices and methods of making and using the same
US6740333B2 (en) * 2000-07-07 2004-05-25 Anestic Aps Suppository and composition comprising at least one polyethylene glycol
US6997898B2 (en) * 2000-07-13 2006-02-14 Edwards Lifesciences Corporation Multi-balloon drug delivery catheter for angiogenesis
US6685672B1 (en) * 2000-07-13 2004-02-03 Edwards Lifesciences Corporation Multi-balloon drug delivery catheter for angiogenesis
US20020049349A1 (en) * 2000-08-08 2002-04-25 Degussa Ag Low monomer 1:1-monoadducts from hydroxy (meth) acrylates and diisocyanates and a process for their manufacture
US6744278B1 (en) * 2000-09-02 2004-06-01 Actel Corporation Tileable field-programmable gate array architecture
US20040117007A1 (en) * 2001-03-16 2004-06-17 Sts Biopolymers, Inc. Medicated stent having multi-layer polymer coating
US6559881B1 (en) * 2001-07-17 2003-05-06 Nokia Corporation Video telecommunications device, and camera for same
US6753071B1 (en) * 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US20050042240A1 (en) * 2002-01-28 2005-02-24 Utterberg David S. High viscosity antibacterials
US6997894B2 (en) * 2002-07-02 2006-02-14 Caresio Joseph F Vascular access catheter having a curved tip and method
US7344599B2 (en) * 2002-09-27 2008-03-18 Labcoat, Ltd. Contact coating of prostheses
US7335228B2 (en) * 2002-10-08 2008-02-26 Cook Incorporated Stent with ring architecture and axially displaced connector segments
US7201745B2 (en) * 2003-05-13 2007-04-10 Boston Scientific Scimed, Inc. Anti-infective central venous catheter with diffusion barrier layer
US20070106261A1 (en) * 2003-05-13 2007-05-10 Dimatteo Kristian Anti-infective central venous catheter with diffusion barrier layer

Cited By (384)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8740929B2 (en) 2001-02-06 2014-06-03 Acclarent, Inc. Spacing device for releasing active substances in the paranasal sinus
US8777992B2 (en) 2002-03-14 2014-07-15 Neotract, Inc. Methods for anchoring suture and approximating tissue
US8454655B2 (en) 2002-03-14 2013-06-04 Neotract, Inc. Method for anchoring suture and approximating tissue
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20110129513A1 (en) * 2002-05-24 2011-06-02 Angiotech International Ag Compositions and methods for coating medical implants
US8372420B2 (en) 2002-05-24 2013-02-12 Angiotech International Ag Compositions and methods for coating medical implants
US20080113000A1 (en) * 2002-05-24 2008-05-15 Angiotech International Ag Compositions and methods for coating medical implants
US8425927B2 (en) 2002-05-24 2013-04-23 Angiotech International Ag Compositions and methods for coating medical implants
US20080241217A1 (en) * 2002-05-24 2008-10-02 Angiotech International Ag Compositions and methods for coating medical implants
US20090060973A1 (en) * 2002-05-24 2009-03-05 Angiotech International Ag Compositions and methods for coating medical implants
US20060127438A1 (en) * 2002-05-24 2006-06-15 Angiotech International Ag Compositions and methods for coating medical implants
US20080085855A1 (en) * 2002-09-26 2008-04-10 Angiotech International Ag Perivascular wraps
US20040146546A1 (en) * 2002-09-26 2004-07-29 Angiotech Pharmaceuticals, Inc. Perivascular wraps
US20080208243A1 (en) * 2002-09-30 2008-08-28 Becker Bruce B Method for treating obstructed paranasal ethmoid sinuses
US7740642B2 (en) * 2002-09-30 2010-06-22 Acclarent, Inc. Method for treating naturally obstructed paranasal sinuses
US20090125046A1 (en) * 2002-09-30 2009-05-14 Becker Bruce B Method for treating obstructed paranasal frontal sinuses
US20080281349A2 (en) * 2002-09-30 2008-11-13 Bruce Becker Balloon catheters and methods for treating paranasal sinuses
US7717933B2 (en) * 2002-09-30 2010-05-18 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US20080215082A1 (en) * 2002-09-30 2008-09-04 Becker Bruce B Method for treating obstructed paranasal sphenoid sinuses
US20080215083A1 (en) * 2002-09-30 2008-09-04 Becker Bruce B Method for treating obstructed paranasal maxillary sinuses
US8317816B2 (en) 2002-09-30 2012-11-27 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US20080208242A1 (en) * 2002-09-30 2008-08-28 Becker Bruce B Method for treating naturally obstructed paranasal sinuses
US8100933B2 (en) * 2002-09-30 2012-01-24 Acclarent, Inc. Method for treating obstructed paranasal frontal sinuses
US20060149310A1 (en) * 2002-09-30 2006-07-06 Becker Bruce B Balloon catheters and methods for treating paranasal sinuses
US7753930B2 (en) * 2002-09-30 2010-07-13 Acclarent, Inc. Method for treating obstructed paranasal maxillary sinuses
US7753929B2 (en) * 2002-09-30 2010-07-13 Acclarent, Inc. Method for treating obstructed paranasal sphenoid sinuses
US9457175B2 (en) 2002-09-30 2016-10-04 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8764786B2 (en) 2002-09-30 2014-07-01 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US7854744B2 (en) * 2002-09-30 2010-12-21 Acclarent, Inc. Method for treating obstructed paranasal ethmoid sinuses
US20060251694A1 (en) * 2002-12-20 2006-11-09 Nielsen Bo R Hydrophilic coating and a method for the preparation thereof
US8728508B2 (en) * 2002-12-20 2014-05-20 Coloplast A/S Hydrophilic coating and a method for the preparation thereof
US20110004193A1 (en) * 2003-03-14 2011-01-06 Eaton Donald J Sinus delivery of sustained release therapeutics
US7662142B2 (en) 2003-03-14 2010-02-16 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US20090192490A1 (en) * 2003-03-14 2009-07-30 Eaton Donald J Sinus delivery of sustained release therapeutics
US20090192492A1 (en) * 2003-03-14 2009-07-30 Eaton Donald J Sinus delivery of sustained release therapeutics
US20090192491A1 (en) * 2003-03-14 2009-07-30 Eaton Donald J Sinus delivery of sustained release therapeutics
US20090192488A1 (en) * 2003-03-14 2009-07-30 Eaton Donald J Sinus delivery of sustained release therapeutics
US7544192B2 (en) 2003-03-14 2009-06-09 Sinexus, Inc. Sinus delivery of sustained release therapeutics
WO2004082525A2 (en) 2003-03-14 2004-09-30 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US7951135B2 (en) 2003-03-14 2011-05-31 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US7951134B2 (en) 2003-03-14 2011-05-31 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US7951132B2 (en) 2003-03-14 2011-05-31 Intersect, ENT, Inc. Sinus delivery of sustained release therapeutics
US20090047327A1 (en) * 2003-03-14 2009-02-19 Eaton Donald J Sinus delivery of sustained release therapeutics
US7951133B2 (en) 2003-03-14 2011-05-31 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US20090047326A1 (en) * 2003-03-14 2009-02-19 Eaton Donald J Sinus delivery of sustained release therapeutics
US7951131B2 (en) 2003-03-14 2011-05-31 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US11291812B2 (en) 2003-03-14 2022-04-05 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US7951130B2 (en) 2003-03-14 2011-05-31 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US20110066135A1 (en) * 2003-03-14 2011-03-17 Eaton Donald J Sinus delivery of sustained release therapeutics
US20110004196A1 (en) * 2003-03-14 2011-01-06 Eaton Donald J Sinus delivery of sustained release therapeutics
US20090238859A1 (en) * 2003-03-14 2009-09-24 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US7662141B2 (en) 2003-03-14 2010-02-16 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US20110004195A1 (en) * 2003-03-14 2011-01-06 Eaton Donald J Sinus delivery of sustained release therapeutics
US8109918B2 (en) 2003-03-14 2012-02-07 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US7686798B2 (en) 2003-03-14 2010-03-30 Sinexus, Inc. Sinus delivery of sustained release therapeutics
EP1605863A4 (en) * 2003-03-14 2010-12-08 Sinexus Inc Sinus delivery of sustained release therapeutics
US7691094B2 (en) 2003-03-14 2010-04-06 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US7713255B2 (en) 2003-03-14 2010-05-11 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
EP3103422A1 (en) * 2003-03-14 2016-12-14 Intersect ENT, Inc. Sinus delivery of sustained release therapeutics
EP1605863A2 (en) * 2003-03-14 2005-12-21 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US20090192489A1 (en) * 2003-03-14 2009-07-30 Eaton Donald J Sinus delivery of sustained release therapeutics
US20050181117A1 (en) * 2003-03-14 2005-08-18 Medtronic Vascular, Inc. Stent coating method
US20050147643A1 (en) * 2003-11-10 2005-07-07 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20050158274A1 (en) * 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
US7166570B2 (en) 2003-11-10 2007-01-23 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20050277577A1 (en) * 2003-11-10 2005-12-15 Angiotech International Ag Compositions and methods for treating diverticular disease
US7241736B2 (en) 2003-11-10 2007-07-10 Angiotech International Ag Compositions and methods for treating diverticular disease
US20070254833A1 (en) * 2003-11-10 2007-11-01 Angiotech International Ag Compositions and methods for treating diverticular disease
US20050152944A1 (en) * 2003-11-20 2005-07-14 Angiotech International Ag Soft tissue implants and anti-scarring agents
US20070026043A1 (en) * 2003-11-20 2007-02-01 Angiotech International Ag Medical devices combined with diblock copolymer compositions
US20050209664A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Electrical devices and anti-scarring agents
US20050182496A1 (en) * 2003-11-20 2005-08-18 Angiotech International Ag Soft tissue implants and anti-scarring agents
US20050182467A1 (en) * 2003-11-20 2005-08-18 Angiotech International Ag Electrical devices and anti-scarring agents
US20050187600A1 (en) * 2003-11-20 2005-08-25 Angiotech International Ag Electrical devices and anti-scarring agents
US20050186246A1 (en) * 2003-11-20 2005-08-25 Angiotech International Ag Soft tissue implants and anti-scarring agents
US20050209666A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Electrical devices and anti-scarring agents
US20050142162A1 (en) * 2003-11-20 2005-06-30 Angiotech International Ag Soft tissue implants and anti-scarring agents
US20100268288A1 (en) * 2003-11-20 2010-10-21 Angiotech International Ag Electrical devices and anti-scarring agents
US20050192647A1 (en) * 2003-11-20 2005-09-01 Angiotech International Ag Electrical devices and anti-scarring agents
US20050182450A1 (en) * 2003-11-20 2005-08-18 Angiotech International Ag Electrical devices and anti-scarring agents
US20050152948A1 (en) * 2003-11-20 2005-07-14 Angiotech International Ag Soft tissue implants and anti-scarring agents
US20050182468A1 (en) * 2003-11-20 2005-08-18 Angiotech International Ag Electrical devices and anti-scarring agents
US20050152941A1 (en) * 2003-11-20 2005-07-14 Angiotech International Ag Soft tissue implants and anti-scarring agents
US20060282123A1 (en) * 2003-11-20 2006-12-14 Angiotech International Ag Electrical devices and anti-scarring agents
US20090196248A1 (en) * 2004-01-09 2009-08-06 Interdigital Technology Corporation Transport format combination selection in a wireless transmit/receive unit
US20090203632A1 (en) * 2004-01-30 2009-08-13 Angiotech International Ag Compositions and methods for treating contracture
US11202644B2 (en) 2004-04-21 2021-12-21 Acclarent, Inc. Shapeable guide catheters and related methods
US11864725B2 (en) 2004-04-21 2024-01-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US10492810B2 (en) 2004-04-21 2019-12-03 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8715169B2 (en) 2004-04-21 2014-05-06 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US10098652B2 (en) 2004-04-21 2018-10-16 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US8721591B2 (en) 2004-04-21 2014-05-13 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US10500380B2 (en) 2004-04-21 2019-12-10 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US10034682B2 (en) 2004-04-21 2018-07-31 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US7645272B2 (en) 2004-04-21 2010-01-12 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9826999B2 (en) 2004-04-21 2017-11-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US10631756B2 (en) 2004-04-21 2020-04-28 Acclarent, Inc. Guidewires for performing image guided procedures
US10695080B2 (en) 2004-04-21 2020-06-30 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US9649477B2 (en) 2004-04-21 2017-05-16 Acclarent, Inc. Frontal sinus spacer
US20080319424A1 (en) * 2004-04-21 2008-12-25 Acclarent, Inc. Devices and Methods for Delivering Therapeutic Substances for the Treatment of Sinusitis and Other Disorders
US10702295B2 (en) 2004-04-21 2020-07-07 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US20100121308A1 (en) * 2004-04-21 2010-05-13 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US10779752B2 (en) 2004-04-21 2020-09-22 Acclarent, Inc. Guidewires for performing image guided procedures
US9610428B2 (en) 2004-04-21 2017-04-04 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US10806477B2 (en) 2004-04-21 2020-10-20 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US10856727B2 (en) 2004-04-21 2020-12-08 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8764709B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9554691B2 (en) 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US10874838B2 (en) 2004-04-21 2020-12-29 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US11019989B2 (en) 2004-04-21 2021-06-01 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US11020136B2 (en) 2004-04-21 2021-06-01 Acclarent, Inc. Deflectable guide catheters and related methods
US9370649B2 (en) 2004-04-21 2016-06-21 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US11065061B2 (en) 2004-04-21 2021-07-20 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US20080103361A1 (en) * 2004-04-21 2008-05-01 Acclarent, Inc. Methods and Apparatus for Treating Disorders of the Ear Nose and Throat
US8764726B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US20080097154A1 (en) * 2004-04-21 2008-04-24 Acclarent, Inc. Methods and Apparatus for Treating Disorders of the Ear Nose and Throat
US8425457B2 (en) 2004-04-21 2013-04-23 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorder of the ears, nose and/or throat
US8414473B2 (en) 2004-04-21 2013-04-09 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8777926B2 (en) 2004-04-21 2014-07-15 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasel or paranasal structures
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US8828041B2 (en) 2004-04-21 2014-09-09 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9241834B2 (en) 2004-04-21 2016-01-26 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9220879B2 (en) 2004-04-21 2015-12-29 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9167961B2 (en) 2004-04-21 2015-10-27 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8852143B2 (en) 2004-04-21 2014-10-07 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9107574B2 (en) 2004-04-21 2015-08-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8858586B2 (en) 2004-04-21 2014-10-14 Acclarent, Inc. Methods for enlarging ostia of paranasal sinuses
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8870893B2 (en) 2004-04-21 2014-10-28 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US11511090B2 (en) 2004-04-21 2022-11-29 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US11529502B2 (en) 2004-04-21 2022-12-20 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US11589742B2 (en) 2004-04-21 2023-02-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US10441758B2 (en) 2004-04-21 2019-10-15 Acclarent, Inc. Frontal sinus spacer
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8905922B2 (en) 2004-04-21 2014-12-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US8945088B2 (en) 2004-04-21 2015-02-03 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US9055965B2 (en) 2004-04-21 2015-06-16 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8172828B2 (en) 2004-04-21 2012-05-08 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8080000B2 (en) * 2004-04-21 2011-12-20 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8090433B2 (en) * 2004-04-21 2012-01-03 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8088101B2 (en) 2004-04-21 2012-01-03 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8961398B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8142422B2 (en) 2004-04-21 2012-03-27 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8114062B2 (en) 2004-04-21 2012-02-14 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US8961495B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8123722B2 (en) 2004-04-21 2012-02-28 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US20060020328A1 (en) * 2004-07-23 2006-01-26 Tan Sharon M L Composite vascular graft having bioactive agent
US9039657B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9039680B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9084876B2 (en) 2004-08-04 2015-07-21 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US20080255492A1 (en) * 2004-08-19 2008-10-16 Jens Hoeg Truelsen Absorbent Fiber Material and Use Thereof in Wound Dressings
US20070292478A1 (en) * 2004-08-30 2007-12-20 Popowski Youri Medical Implant Provided with Inhibitors of Atp Synthesis
US20060051392A1 (en) * 2004-09-03 2006-03-09 Medtronic, Inc. Porous coatings for drug release from medical devices
US8186349B2 (en) 2004-10-05 2012-05-29 Covidien Ag Tracheostomy tube
US20080163870A1 (en) * 2004-10-05 2008-07-10 Takao Kusunoki Tracheostomy Tube
US20070299409A1 (en) * 2004-11-09 2007-12-27 Angiotech Biocoatings Corp. Antimicrobial Needle Coating For Extended Infusion
US20060165739A1 (en) * 2005-01-06 2006-07-27 Mary Kay Inc. Alcohol-free microemulsion composition
US20080091270A1 (en) * 2005-01-14 2008-04-17 Miller Timothy R Expandable osteoimplant
US9308361B2 (en) 2005-01-18 2016-04-12 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US8388642B2 (en) 2005-01-18 2013-03-05 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US20060164680A1 (en) * 2005-01-25 2006-07-27 Hyuck Kim Printing system and method of printing data on a designated paper
US20060205789A1 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
US20110136870A1 (en) * 2005-03-04 2011-06-09 Neurosystec Corporation Gacyclidine formulations
US20110077579A1 (en) * 2005-03-24 2011-03-31 Harrison William V Cochlear implant with localized fluid transport
US11123091B2 (en) 2005-04-04 2021-09-21 Intersect Ent, Inc. Device and methods for treating paranasal sinus conditions
US8858974B2 (en) 2005-04-04 2014-10-14 Intersect Ent, Inc. Device and methods for treating paranasal sinus conditions
US8337454B2 (en) 2005-04-04 2012-12-25 Intersect Ent, Inc. Device and methods for treating paranasal sinus conditions
WO2006107957A3 (en) * 2005-04-04 2006-11-16 Sinexus Inc Device and methods for treating paranasal sinus conditions
US20090227945A1 (en) * 2005-04-04 2009-09-10 Eaton Donald J Device and methods for treating paranasal sinus conditions
US8740839B2 (en) * 2005-04-04 2014-06-03 Intersect Ent, Inc. Device and methods for treating paranasal sinus conditions
US20110004194A1 (en) * 2005-04-04 2011-01-06 Eaton Donald J Device and methods for treating paranasal sinus conditions
US8025635B2 (en) * 2005-04-04 2011-09-27 Intersect Ent, Inc. Device and methods for treating paranasal sinus conditions
AU2006231506B2 (en) * 2005-04-04 2012-08-30 Intersect Ent, Inc. Device and methods for treating paranasal sinus conditions
US20110004192A1 (en) * 2005-04-04 2011-01-06 Eaton Donald J Device and methods for treating paranasal sinus conditions
US20090156980A1 (en) * 2005-04-04 2009-06-18 Sinexus, Inc. Device and methods for treating paranasal sinus conditions
US9585681B2 (en) 2005-04-04 2017-03-07 Intersect Ent, Inc. Device and methods for treating paranasal sinus conditions
US20070005094A1 (en) * 2005-04-04 2007-01-04 Eaton Donald J Device and methods for treating paranasal sinus conditions
US20060240060A1 (en) * 2005-04-22 2006-10-26 Cardiac Pacemakers, Inc. Lubricious compound and medical device made of the same
US20060241000A1 (en) * 2005-04-22 2006-10-26 Cardiac Pacemakers, Inc. Lubricious compound and medical device made of the same
US20060240059A1 (en) * 2005-04-22 2006-10-26 Cardiac Pacemakers, Inc. Lubricious eluting polymer blend and coating made from the same
US20060240253A1 (en) * 2005-04-22 2006-10-26 Cardiac Pacemakers, Inc. Guidewire and tube with lubricious coating
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US20060247793A1 (en) * 2005-04-28 2006-11-02 Sdgi Holdings, Inc. Surface treatments for promoting selective tissue attachment to medical implants
US20060246105A1 (en) * 2005-04-28 2006-11-02 Fred Molz Coatings on medical implants to guide soft tissue healing
US8529584B2 (en) 2005-05-20 2013-09-10 Neotract, Inc. Median lobe band implant apparatus and method
US8043309B2 (en) 2005-05-20 2011-10-25 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US8628542B2 (en) 2005-05-20 2014-01-14 Neotract, Inc. Median lobe destruction apparatus and method
US11504149B2 (en) 2005-05-20 2022-11-22 Teleflex Life Sciences Limited Median lobe destruction apparatus and method
US8663243B2 (en) 2005-05-20 2014-03-04 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8668705B2 (en) 2005-05-20 2014-03-11 Neotract, Inc. Latching anchor device
US11471148B2 (en) 2005-05-20 2022-10-18 Teleflex Life Sciences Limited Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US11090036B2 (en) 2005-05-20 2021-08-17 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10945719B2 (en) 2005-05-20 2021-03-16 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US8715239B2 (en) 2005-05-20 2014-05-06 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8715298B2 (en) 2005-05-20 2014-05-06 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US10925587B2 (en) 2005-05-20 2021-02-23 Neotract, Inc. Anchor delivery system
US10575844B2 (en) 2005-05-20 2020-03-03 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10492792B2 (en) 2005-05-20 2019-12-03 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8734468B2 (en) 2005-05-20 2014-05-27 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8491606B2 (en) 2005-05-20 2013-07-23 Neotract, Inc. Median lobe retraction apparatus and method
US20090192439A1 (en) * 2005-05-20 2009-07-30 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US10426509B2 (en) 2005-05-20 2019-10-01 Neotract, Inc. Median lobe destruction apparatus and method
US10299780B2 (en) 2005-05-20 2019-05-28 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US10265061B2 (en) 2005-05-20 2019-04-23 Neotract, Inc. Latching anchor device
US10195014B2 (en) 2005-05-20 2019-02-05 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8425535B2 (en) 2005-05-20 2013-04-23 Neotract, Inc. Multi-actuating trigger anchor delivery system
US10143461B2 (en) 2005-05-20 2018-12-04 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US10105132B2 (en) 2005-05-20 2018-10-23 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8394110B2 (en) 2005-05-20 2013-03-12 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US8394113B2 (en) 2005-05-20 2013-03-12 Neotract, Inc. Coiled anchor device
US7758594B2 (en) 2005-05-20 2010-07-20 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8343187B2 (en) 2005-05-20 2013-01-01 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8834492B2 (en) 2005-05-20 2014-09-16 Neotract, Inc. Continuous indentation lateral lobe apparatus and method
US8333776B2 (en) 2005-05-20 2012-12-18 Neotract, Inc. Anchor delivery system
US7766923B2 (en) 2005-05-20 2010-08-03 Neotract, Inc. Integrated handle assembly for anchor delivery system
US9549739B2 (en) 2005-05-20 2017-01-24 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US7780682B2 (en) 2005-05-20 2010-08-24 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US9504461B2 (en) 2005-05-20 2016-11-29 Neotract, Inc. Anchor delivery system
US9486203B2 (en) 2005-05-20 2016-11-08 Neotract, Inc. Latching anchor device
US9402711B2 (en) 2005-05-20 2016-08-02 Neotract, Inc. Median lobe band implant apparatus and method
US8888799B2 (en) 2005-05-20 2014-11-18 Neotract, Inc. Coiled anchor device
US8216254B2 (en) 2005-05-20 2012-07-10 Neotract, Inc. Anchor delivery system with replaceable cartridge
US8900252B2 (en) 2005-05-20 2014-12-02 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US8211118B2 (en) 2005-05-20 2012-07-03 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US7815655B2 (en) 2005-05-20 2010-10-19 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US9364212B2 (en) 2005-05-20 2016-06-14 Neotract, Inc. Suture anchoring devices and methods for use
US9320511B2 (en) 2005-05-20 2016-04-26 Neotract, Inc. Multi-actuating trigger anchor delivery system
US8936609B2 (en) 2005-05-20 2015-01-20 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US8940001B2 (en) 2005-05-20 2015-01-27 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US8939996B2 (en) 2005-05-20 2015-01-27 Neotract, Inc. Anchor delivery System
US20110040312A1 (en) * 2005-05-20 2011-02-17 Neotract, Inc. Deforming anchor device
US8945152B2 (en) 2005-05-20 2015-02-03 Neotract, Inc. Multi-actuating trigger anchor delivery system
US8603106B2 (en) 2005-05-20 2013-12-10 Neotract, Inc. Integrated handle assembly for anchor delivery system
US8157815B2 (en) 2005-05-20 2012-04-17 Neotract, Inc. Integrated handle assembly for anchor delivery system
US7896891B2 (en) 2005-05-20 2011-03-01 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US7905889B2 (en) 2005-05-20 2011-03-15 Neotract, Inc. Integrated handle assembly for anchor delivery system
US9149266B2 (en) 2005-05-20 2015-10-06 Neotract, Inc. Deforming anchor device
US7909836B2 (en) 2005-05-20 2011-03-22 Neotract, Inc. Multi-actuating trigger anchor delivery system
US7914542B2 (en) 2005-05-20 2011-03-29 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US9034001B2 (en) 2005-05-20 2015-05-19 Neotract, Inc. Slotted anchor device
US7951158B2 (en) 2005-05-20 2011-05-31 Neotract, Inc. Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures
US8007503B2 (en) 2005-05-20 2011-08-30 Neotract, Inc. Apparatus and method for manipulating or retracting tissue and anatomical structure
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US10842978B2 (en) 2005-06-10 2020-11-24 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US10124154B2 (en) 2005-06-10 2018-11-13 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US9050440B2 (en) 2005-09-23 2015-06-09 Acclarent, Inc. Multi-conduit balloon catheter
US10639457B2 (en) 2005-09-23 2020-05-05 Acclarent, Inc. Multi-conduit balloon catheter
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US8968269B2 (en) 2005-09-23 2015-03-03 Acclarent, Inc. Multi-conduit balloon catheter
US9999752B2 (en) 2005-09-23 2018-06-19 Acclarent, Inc. Multi-conduit balloon catheter
US20070134287A1 (en) * 2005-12-09 2007-06-14 Biomet Manufacturing Corp Method for coating biocompatible substrates with antibiotics
US9421361B2 (en) 2005-12-27 2016-08-23 Boston Scientific Neuromodulation Corporation Methods for fabricating stimulator leads
US7672734B2 (en) 2005-12-27 2010-03-02 Boston Scientific Neuromodulation Corporation Non-linear electrode array
US20070150036A1 (en) * 2005-12-27 2007-06-28 Advanced Bionics Corporation Stimulator leads and methods for lead fabrication
US20100152818A1 (en) * 2005-12-27 2010-06-17 Boston Scientific Neuromodulation Corporation Non-linear electrode array
US8700178B2 (en) * 2005-12-27 2014-04-15 Boston Scientific Neuromodulation Corporation Stimulator leads and methods for lead fabrication
US20070150007A1 (en) * 2005-12-27 2007-06-28 Advanced Bionics Corporation Non-linear electrode array
US9987116B2 (en) 2006-02-08 2018-06-05 Tyrx, Inc. Temporarily stiffened mesh prostheses
US10765500B2 (en) 2006-02-08 2020-09-08 Medtronic, Inc. Temporarily stiffened mesh prostheses
US20070198040A1 (en) * 2006-02-08 2007-08-23 Tyrx Pharma Inc. Temporarily Stiffened Mesh Prostheses
US8636753B2 (en) 2006-02-08 2014-01-28 Tyrx, Inc. Temporarily stiffened mesh prostheses
US9457129B2 (en) 2006-02-08 2016-10-04 Tyrx, Inc. Temporarily stiffened mesh prostheses
US20080132922A1 (en) * 2006-02-08 2008-06-05 Tyrx Pharma, Inc. Mesh Pouches for Implantable Medical Devices
US8591531B2 (en) 2006-02-08 2013-11-26 Tyrx, Inc. Mesh pouches for implantable medical devices
US8267905B2 (en) 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US9629656B2 (en) 2006-05-17 2017-04-25 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9198736B2 (en) 2006-05-17 2015-12-01 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US7803148B2 (en) 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
US8298176B2 (en) 2006-06-09 2012-10-30 Neurosystec Corporation Flow-induced delivery from a drug mass
US20070292468A1 (en) * 2006-06-14 2007-12-20 Joel Studin Coated jewelry articles to reduce skin irritation
US20090017090A1 (en) * 2006-07-10 2009-01-15 Arensdorf Patrick A Devices and methods for delivering active agents to the osteomeatal complex
US8802131B2 (en) 2006-07-10 2014-08-12 Intersect Ent, Inc. Devices and methods for delivering active agents to the osteomeatal complex
US20090306624A1 (en) * 2006-07-10 2009-12-10 Sinexus, Inc. Devices and methods for delivering active agents to the osteomeatal complex
US8535707B2 (en) 2006-07-10 2013-09-17 Intersect Ent, Inc. Devices and methods for delivering active agents to the osteomeatal complex
US20080152694A1 (en) * 2006-07-20 2008-06-26 Neurosystec Corporation Devices, Systems and Methods for Ophthalmic Drug Delivery
WO2008011125A2 (en) * 2006-07-20 2008-01-24 Neurosystec Corporation Devices, systems and methods for ophthalmic drug delivery
WO2008011125A3 (en) * 2006-07-20 2008-10-16 Neurosystec Corp Devices, systems and methods for ophthalmic drug delivery
US20080145439A1 (en) * 2006-07-31 2008-06-19 Neurosystec Corporation Nanoparticle drug formulations
US10716629B2 (en) 2006-09-15 2020-07-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9572480B2 (en) 2006-09-15 2017-02-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9603506B2 (en) 2006-09-15 2017-03-28 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9179823B2 (en) 2006-09-15 2015-11-10 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US8298564B2 (en) 2006-09-27 2012-10-30 Medtronic, Inc. Two part antimicrobial boot
US20080075628A1 (en) * 2006-09-27 2008-03-27 Medtronic, Inc. Sterilized minocycline and rifampin-containing medical device
US20080125728A1 (en) * 2006-09-27 2008-05-29 Medtronic, Inc. Two part antimicrobial boot
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
US8883190B2 (en) * 2006-12-01 2014-11-11 Wake Forest University Health Sciences Urologic devices incorporating collagen inhibitors
US20080133027A1 (en) * 2006-12-01 2008-06-05 Hodges Steve J Urologic devices incorporating collagen inhibitors
US8883183B2 (en) * 2006-12-01 2014-11-11 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
US20080132941A1 (en) * 2006-12-01 2008-06-05 Sullivan Christopher A Medical devices incorporating collagen inhibitors
US8668703B2 (en) 2006-12-01 2014-03-11 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
US20090028914A1 (en) * 2006-12-01 2009-01-29 Wake Forest University Health Science Medical devices incorporating collagen inhibitors
US20090028920A1 (en) * 2006-12-01 2009-01-29 Wake Forest University Health Sciences Urological devices incorporating collagen inhibitors
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8911765B2 (en) 2007-03-29 2014-12-16 Tyrx, Inc. Biodegradable, polymer coverings for breast implants
US20080241212A1 (en) * 2007-03-29 2008-10-02 Tyrx Pharma, Inc. Biodegradable, Polymer Coverings for Breast Implants
US9615775B2 (en) 2007-04-30 2017-04-11 Acclarent, Inc. Methods and devices for ostium measurements
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US9463068B2 (en) 2007-05-08 2016-10-11 Acclarent, Inc. Methods and devices for protecting nasal turbinates
US8758366B2 (en) 2007-07-09 2014-06-24 Neotract, Inc. Multi-actuating trigger anchor delivery system
US8585731B2 (en) 2007-12-18 2013-11-19 Intersect Ent, Inc. Self-expanding devices and methods therefor
US20090220571A1 (en) * 2007-12-18 2009-09-03 Eaton Donald J Self-expanding devices and methods therefor
US20090198179A1 (en) * 2007-12-18 2009-08-06 Abbate Anthony J Delivery devices and methods
US11826494B2 (en) 2007-12-18 2023-11-28 Intersect Ent, Inc. Self-expanding devices and methods therefor
US11654216B2 (en) 2007-12-18 2023-05-23 Intersect Ent, Inc. Self-expanding devices and methods therefor
US11497835B2 (en) 2007-12-18 2022-11-15 Intersect Ent, Inc. Self-expanding devices and methods therefor
US8986341B2 (en) 2007-12-18 2015-03-24 Intersect Ent, Inc. Self-expanding devices and methods therefor
US11110210B2 (en) 2007-12-18 2021-09-07 Intersect Ent, Inc. Self-expanding devices and methods therefor
US8585730B2 (en) 2007-12-18 2013-11-19 Intersect Ent, Inc. Self-expanding devices and methods therefor
US10010651B2 (en) 2007-12-18 2018-07-03 Intersect Ent, Inc. Self-expanding devices and methods therefor
US20090177272A1 (en) * 2007-12-18 2009-07-09 Abbate Anthony J Self-expanding devices and methods therefor
US10471185B2 (en) 2007-12-18 2019-11-12 Intersect Ent, Inc. Self-expanding devices and methods therefor
US11311419B2 (en) 2007-12-20 2022-04-26 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US11850120B2 (en) 2007-12-20 2023-12-26 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US11179298B2 (en) * 2008-01-09 2021-11-23 Innovative Health Technologies, Llc Implant pellets and methods for performing bone augmentation and preservation
US11872293B2 (en) 2008-01-09 2024-01-16 Innovative Health Technologies, Llc Implant pellets and methods for performing bone augmentation and preservation
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US9861793B2 (en) 2008-03-10 2018-01-09 Acclarent, Inc. Corewire design and construction for medical devices
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
US10271719B2 (en) 2008-07-30 2019-04-30 Acclarent, Inc. Paranasal ostium finder devices and methods
US11116392B2 (en) 2008-07-30 2021-09-14 Acclarent, Inc. Paranasal ostium finder devices and methods
US9750401B2 (en) 2008-07-30 2017-09-05 Acclarent, Inc. Paranasal ostium finder devices and methods
US20100030052A1 (en) * 2008-07-31 2010-02-04 Bommakanti Balasubrahmanya S Analyte sensors comprising plasticizers
US8763222B2 (en) 2008-08-01 2014-07-01 Intersect Ent, Inc. Methods and devices for crimping self-expanding devices
US9782283B2 (en) 2008-08-01 2017-10-10 Intersect Ent, Inc. Methods and devices for crimping self-expanding devices
US20110264213A1 (en) * 2008-12-19 2011-10-27 Demiranda Jose Maria Silicone implant with expandable compartment
US10524814B2 (en) 2009-03-20 2020-01-07 Acclarent, Inc. Guide system with suction
US11207087B2 (en) 2009-03-20 2021-12-28 Acclarent, Inc. Guide system with suction
US20100249783A1 (en) * 2009-03-24 2010-09-30 Warsaw Orthopedic, Inc. Drug-eluting implant cover
US9636258B2 (en) 2009-03-31 2017-05-02 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US10376416B2 (en) 2009-03-31 2019-08-13 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9414864B2 (en) 2009-04-15 2016-08-16 Warsaw Orthopedic, Inc. Anterior spinal plate with preformed drug-eluting device affixed thereto
US20100266657A1 (en) * 2009-04-15 2010-10-21 Warsaw Orthopedic, Inc. Preformed drug-eluting device to be affixed to an anterior spinal plate
US9078712B2 (en) 2009-04-15 2015-07-14 Warsaw Orthopedic, Inc. Preformed drug-eluting device to be affixed to an anterior spinal plate
US11484693B2 (en) 2009-05-15 2022-11-01 Intersect Ent, Inc. Expandable devices and methods for treating a nasal or sinus condition
US10357640B2 (en) 2009-05-15 2019-07-23 Intersect Ent, Inc. Expandable devices and methods for treating a nasal or sinus condition
US20110125091A1 (en) * 2009-05-15 2011-05-26 Abbate Anthony J Expandable devices and methods therefor
US10045937B2 (en) * 2009-06-03 2018-08-14 Case Western Reserve University Therapeutic agent delivery system and method
US20120220518A1 (en) * 2009-06-03 2012-08-30 Case Western Reserve University Therapeutic agent delivery system and method
US20110015667A1 (en) * 2009-06-05 2011-01-20 Entrigue Surgical, Inc. Systems, Devices and Methods for Providing Therapy to an Anatomical Structure
US20110022172A1 (en) * 2009-06-05 2011-01-27 Entrigue Surgical, Inc. Disposable Medical Device for Engaging with Reusable Medical Instrument and Methods of Use
US20110015734A1 (en) * 2009-06-05 2011-01-20 Entrigue Surgical, Inc. Methods for Providing Therapy to an Anatomical Structure
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
US9161749B2 (en) 2011-04-14 2015-10-20 Neotract, Inc. Method and apparatus for treating sexual dysfunction
US9089672B2 (en) * 2011-09-23 2015-07-28 Cook Medical Technologies Llc Introducer placement system
US20130079809A1 (en) * 2011-09-23 2013-03-28 Cook Medical Technologies, LLD Introducer placement system
US20130183435A1 (en) * 2012-01-13 2013-07-18 Hongmin Sun Low temperature plasma coating for anti-biofilm formation
US10292801B2 (en) 2012-03-29 2019-05-21 Neotract, Inc. System for delivering anchors for treating incontinence
US11331093B2 (en) 2012-06-29 2022-05-17 Teleflex Life Sciences Limited Flexible system for delivering an anchor
US10130353B2 (en) 2012-06-29 2018-11-20 Neotract, Inc. Flexible system for delivering an anchor
US8909339B2 (en) * 2012-08-15 2014-12-09 National Tsing Hua University Glucose powered implantable device to collect blood ingredients
US11672960B2 (en) 2013-03-14 2023-06-13 Intersect Ent, Inc. Systems, devices, and method for treating a sinus condition
US10406332B2 (en) 2013-03-14 2019-09-10 Intersect Ent, Inc. Systems, devices, and method for treating a sinus condition
US10232152B2 (en) 2013-03-14 2019-03-19 Intersect Ent, Inc. Systems, devices, and method for treating a sinus condition
US10912637B2 (en) 2013-03-14 2021-02-09 Neotract, Inc. Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US11850140B2 (en) 2013-03-14 2023-12-26 Teleflex Life Sciences Limited Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US10349932B2 (en) 2013-03-15 2019-07-16 Neotract, Inc. Anchor delivery system
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US10524869B2 (en) 2013-03-15 2020-01-07 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US11129608B2 (en) 2013-03-15 2021-09-28 Neotract, Inc. Anchor delivery system
WO2015157512A1 (en) * 2014-04-11 2015-10-15 Drexel University Novel methods and kits for detecting a rifamycin, or derivative or analogue thereof
US11672520B2 (en) 2017-12-23 2023-06-13 Teleflex Life Sciences Limited Expandable tissue engagement apparatus and method
US20210052782A1 (en) * 2018-01-15 2021-02-25 Technion Research & Development Foundation Limited Electrospun-coated medical devices
US11801041B2 (en) 2020-08-03 2023-10-31 Teleflex Life Sciences Limited Handle and cartridge system for medical interventions
US11298115B2 (en) 2020-08-03 2022-04-12 Teleflex Life Sciences Limited Handle and cartridge system for medical interventions

Also Published As

Publication number Publication date
US20130224276A1 (en) 2013-08-29
AU2003234670B2 (en) 2010-06-10
ATE515277T1 (en) 2011-07-15
EP2075014A3 (en) 2009-08-12
NZ575452A (en) 2010-03-26
IL165120A (en) 2010-05-31
CN101134119A (en) 2008-03-05
ES2369640T3 (en) 2011-12-02
US20100082003A1 (en) 2010-04-01
US20080089952A1 (en) 2008-04-17
US8372420B2 (en) 2013-02-12
JP2010158545A (en) 2010-07-22
JP2005527302A (en) 2005-09-15
DE60328486D1 (en) 2009-09-03
DK1509256T3 (en) 2009-11-23
US20110129513A1 (en) 2011-06-02
CN100341589C (en) 2007-10-10
MXPA04011651A (en) 2005-03-07
NZ536308A (en) 2009-01-31
EP2075014B9 (en) 2012-02-01
US20080241217A1 (en) 2008-10-02
CA2484761A1 (en) 2003-12-04
CA2484761C (en) 2010-11-09
ZA200409291B (en) 2010-04-28
US20080145514A1 (en) 2008-06-19
RU2341296C2 (en) 2008-12-20
HK1082435A1 (en) 2006-06-09
US20070270447A1 (en) 2007-11-22
EP1509256A2 (en) 2005-03-02
BR0311285A (en) 2007-04-27
US20060127438A1 (en) 2006-06-15
ES2330326T3 (en) 2009-12-09
WO2003099346A3 (en) 2004-03-18
EP1509256B1 (en) 2009-07-22
CN1688349A (en) 2005-10-26
PT1509256E (en) 2009-10-15
US8425927B2 (en) 2013-04-23
AU2010201996A1 (en) 2010-06-10
EP2075014B1 (en) 2011-07-06
WO2003099346A2 (en) 2003-12-04
KR20100110378A (en) 2010-10-12
AU2003234670A1 (en) 2003-12-12
IL165120A0 (en) 2005-12-18
US20080113000A1 (en) 2008-05-15
RU2004137816A (en) 2005-06-27
EP2075014A2 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
US8372420B2 (en) Compositions and methods for coating medical implants
US8313760B2 (en) Compositions and methods for coating medical implants
CA2715269C (en) Anti-infective catheters
KR20050023270A (en) Compositions and methods for coating medical implants

Legal Events

Date Code Title Description
AS Assignment

Owner name: ANGIOTECH PHARMACEUTICALS, INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUNTER, WILLIAM L.;GRAVETT, DAVID M.;TOLEIKIS, PHILIP M.;AND OTHERS;REEL/FRAME:014570/0901

Effective date: 20030627

Owner name: ANGIOTECH INTERNATIONAL GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANGIOTECH PHARMACEUTICALS, INC.;REEL/FRAME:014571/0479

Effective date: 20030627

AS Assignment

Owner name: ANGIOTECH INTERNATIONAL AG, SWITZERLAND

Free format text: CHANGE OF NAME;ASSIGNOR:ANGIOTECH INTERNATIONAL GMBH;REEL/FRAME:014907/0641

Effective date: 20040510

AS Assignment

Owner name: ANGIOTECH INTERNATIONAL AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANGIOTECH PHARMACEUTICALS, INC.;REEL/FRAME:015043/0933

Effective date: 20040803

Owner name: ANGIOTECH INTERNATIONAL AG, SWITZERLAND

Free format text: CHANGE OF NAME;ASSIGNOR:ANGIOTECH INTERNATIONAL GMBH;REEL/FRAME:015043/0879

Effective date: 20040510

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATI

Free format text: SECURITY INTEREST;ASSIGNOR:ANGIOTECH PHARMACEUTICALS, INC.;REEL/FRAME:049288/0184

Effective date: 20190507

AS Assignment

Owner name: ANGIOTECH PHARMACEUTICALS, INC., CANADA

Free format text: RELEASE OF SECURITY INTEREST : RECORDED AT REEL/FRAME - 049288/0184;ASSIGNOR:CAPITAL ONE, NATIONAL ASSOCIATION;REEL/FRAME:055171/0634

Effective date: 20210129